<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Electronic cigarettes for smoking cessation - Lindson, N - 2025 | Cochrane Library</title> <meta content="Electronic cigarettes for smoking cessation - Lindson, N - 2025 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub9/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Electronic cigarettes for smoking cessation - Lindson, N - 2025 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub9/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010216.pub9" name="dc.identifier" scheme="DOI"/> <meta content="Electronic cigarettes for smoking cessation" name="citation_title"/> <meta content="Nicola Lindson" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Ailsa R Butler" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Hayden McRobbie" name="citation_author"/> <meta content="University of New South Wales" name="citation_author_institution"/> <meta content="Chris Bullen" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Peter Hajek" name="citation_author"/> <meta content="Barts &amp; The London School of Medicine and Dentistry, Queen Mary University of London" name="citation_author_institution"/> <meta content="Angela Difeng Wu" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Rachna Begh" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Annika Theodoulou" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Caitlin Notley" name="citation_author"/> <meta content="University of East Anglia" name="citation_author_institution"/> <meta content="Nancy A Rigotti" name="citation_author"/> <meta content="Massachusetts General Hospital and Harvard Medical School" name="citation_author_institution"/> <meta content="Tari Turner" name="citation_author"/> <meta content="School of Public Health &amp; Preventive Medicine, Monash University" name="citation_author_institution"/> <meta content="Jonathan Livingstone-Banks" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Tom Morris" name="citation_author"/> <meta content="University of Leicester" name="citation_author_institution"/> <meta content="Jamie Hartmann-Boyce" name="citation_author"/> <meta content="University of Massachusetts" name="citation_author_institution"/> <meta content="jhartmannboy@umass.edu" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD010216.pub9" name="citation_doi"/> <meta content="2025" name="citation_date"/> <meta content="2025/01/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub9/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub9/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub9/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Electronic Nicotine Delivery Systems; Network Meta-Analysis; Nicotine [adverse effects]; Nicotine Replacement Therapy; Randomized Controlled Trials as Topic; *Smoking Cessation" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010216.pub9&amp;doi=10.1002/14651858.CD010216.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6zFwvAqw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010216\x2epub9\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010216\x2epub9\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","fr"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD010216.pub9",title:"Electronic cigarettes for smoking cessation",firstPublishedDate:"Jan 29, 2025 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Central Editorial Service",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010216.pub9&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010216.pub9';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010216.pub9/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010216.pub9/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010216.pub9%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010216.PUB9" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010216.pub9/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010216.PUB9" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010216.pub9/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010216.pub9/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2869 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010216.pub9" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-sec-0121"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-sec-0013"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-sec-0014"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-sec-0113"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/appendices#CD010216-sec-0127"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/supinfo/CD010216-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/supinfo/CD010216-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2025 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Electronic cigarettes for smoking cessation</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#CD010216-cr-0004">Nicola Lindson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#CD010216-cr-0005">Ailsa R Butler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#CD010216-cr-0006">Hayden McRobbie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#CD010216-cr-0007">Chris Bullen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#CD010216-cr-0008">Peter Hajek</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#CD010216-cr-0009">Angela Difeng Wu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#CD010216-cr-0010">Rachna Begh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#CD010216-cr-0011">Annika Theodoulou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#CD010216-cr-0012">Caitlin Notley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#CD010216-cr-0013">Nancy A Rigotti</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#CD010216-cr-0014">Tari Turner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#CD010216-cr-0015">Jonathan Livingstone-Banks</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#CD010216-cr-0016">Tom Morris</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information#CD010216-cr-0017"><i class="icon corresponding-author fa fa-envelope"></i>Jamie Hartmann-Boyce</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information/en#CD010216-sec-0142">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 January 2025 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010216.pub9">https://doi.org/10.1002/14651858.CD010216.pub9</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010216-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010216-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010216-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010216-abs-0005">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010216-abs-0001" lang="en"> <section id="CD010216-sec-0001"> <h3 class="title" id="CD010216-sec-0001">Background</h3> <p>Electronic cigarettes (ECs) are handheld electronic vaping devices that produce an aerosol by heating an e‐liquid. People who smoke, healthcare providers, and regulators want to know if ECs can help people quit smoking, and if they are safe to use for this purpose. This is a review update conducted as part of a living systematic review. </p> </section> <section id="CD010216-sec-0002"> <h3 class="title" id="CD010216-sec-0002">Objectives</h3> <p>To examine the safety, tolerability, and effectiveness of using EC to help people who smoke tobacco achieve long‐term smoking abstinence, in comparison to non‐nicotine EC, other smoking cessation treatments, and no treatment. </p> </section> <section id="CD010216-sec-0003"> <h3 class="title" id="CD010216-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and PsycINFO to 1 February 2024 and the Cochrane Tobacco Addiction Group's Specialized Register to 1 February 2023, reference‐checked, and contacted study authors. </p> </section> <section id="CD010216-sec-0004"> <h3 class="title" id="CD010216-sec-0004">Selection criteria</h3> <p>We included trials randomizing people who smoke to an EC or control condition. We included uncontrolled intervention studies in which all participants received an EC intervention. Studies had to report an eligible outcome. </p> </section> <section id="CD010216-sec-0005"> <h3 class="title" id="CD010216-sec-0005">Data collection and analysis</h3> <p>We followed standard Cochrane methods for screening and data extraction. We used the risk of bias tool (RoB 1) and GRADE to assess the certainty of evidence. Critical outcomes were abstinence from smoking after at least six months, adverse events (AEs), and serious adverse events (SAEs). Important outcomes were biomarkers, toxicants/carcinogens, and longer‐term EC use. We used a fixed‐effect Mantel‐Haenszel model to calculate risk ratios (RRs) with a 95% confidence interval (CI) for dichotomous outcomes. For continuous outcomes, we calculated mean differences. Where appropriate, we pooled data in pairwise and network meta‐analyses (NMA). </p> </section> <section id="CD010216-sec-0006"> <h3 class="title" id="CD010216-sec-0006">Main results</h3> <p>We included 90 completed studies (two new to this update), representing 29,044 participants, of which 49 were randomized controlled trials (RCTs). Of the included studies, we rated 10 (all but one contributing to our main comparisons) at low risk of bias overall, 61 at high risk overall (including all non‐randomized studies), and the remainder at unclear risk. </p> <p>Nicotine EC results in increased quit rates compared to nicotine replacement therapy (NRT) (high‐certainty evidence) (RR 1.59, 95% CI 1.30 to 1.93; I<sup>2</sup> = 0%; 7 studies, 2544 participants). In absolute terms, this might translate to an additional four quitters per 100 (95% CI 2 to 6 more). The rate of occurrence of AEs is probably similar between groups (moderate‐certainty evidence (limited by imprecision)) (RR 1.03, 95% CI 0.91 to 1.17; I<sup>2</sup> = 0%; 5 studies, 2052 participants). SAEs were rare, and there is insufficient evidence to determine whether rates differ between groups due to very serious imprecision (RR 1.20, 95% CI 0.90 to 1.60; I<sup>2</sup> = 32%; 6 studies, 2761 participants; low‐certainty evidence). </p> <p>Nicotine EC probably results in increased quit rates compared to non‐nicotine EC (moderate‐certainty evidence, limited by imprecision) (RR 1.46, 95% CI 1.09 to 1.96; I<sup>2</sup> = 4%; 6 studies, 1613 participants). In absolute terms, this might lead to an additional three quitters per 100 (95% CI 1 to 7 more). There is probably little to no difference in the rate of AEs between these groups (moderate‐certainty evidence) (RR 1.01, 95% CI 0.91 to 1.11; I<sup>2</sup> = 0%; 5 studies, 840 participants). There is insufficient evidence to determine whether rates of SAEs differ between groups, due to very serious imprecision (RR 1.00, 95% CI 0.56 to 1.79; I<sup>2</sup> = 0%; 9 studies, 1412 participants; low‐certainty evidence). </p> <p>Compared to behavioural support only/no support, quit rates may be higher for participants randomized to nicotine EC (low‐certainty evidence due to issues with risk of bias) (RR 1.96, 95% CI 1.66 to 2.32; I<sup>2</sup> = 0%; 11 studies, 6819 participants). In absolute terms, this represents an additional four quitters per 100 (95% CI 3 to 5 more). There was some evidence that (non‐serious) AEs may be more common in people randomized to nicotine EC (RR 1.18, 95% CI 1.10 to 1.27; I<sup>2</sup> = 6%; low‐certainty evidence; 6 studies, 2351 participants) and, again, insufficient evidence to determine whether rates of SAEs differed between groups (RR 0.93, 95% CI 0.68 to 1.28; I<sup>2</sup> = 0%; 12 studies, 4561 participants; very low‐certainty evidence). </p> <p>Results from the NMA were consistent with those from pairwise meta‐analyses for all critical outcomes. There was inconsistency in the AE network, which was explained by a single outlying study contributing the only direct evidence for one of the nodes. </p> <p>Data from non‐randomized studies were consistent with RCT data. The most commonly reported AEs were throat/mouth irritation, headache, cough, and nausea, which tended to dissipate with continued EC use. Very few studies reported data on other outcomes or comparisons; hence, evidence for these is limited, with CIs often encompassing both clinically significant harm and benefit. </p> </section> <section id="CD010216-sec-0007"> <h3 class="title" id="CD010216-sec-0007">Authors' conclusions</h3> <p>There is high‐certainty evidence that ECs with nicotine increase quit rates compared to NRT and moderate‐certainty evidence that they increase quit rates compared to ECs without nicotine. Evidence comparing nicotine EC with usual care or no treatment also suggests benefit, but is less certain due to risk of bias inherent in the study design. Confidence intervals were, for the most part, wide for data on AEs, SAEs, and other safety markers, with no evidence for a difference in AEs between nicotine and non‐nicotine ECs nor between nicotine ECs and NRT, but low‐certainty evidence for increased AEs compared with behavioural support/no support. Overall incidence of SAEs was low across all study arms. We did not detect evidence of serious harm from nicotine EC, but longer, larger studies are needed to fully evaluate EC safety. Our included studies tested regulated nicotine‐containing EC; illicit products and/or products containing other active substances (e.g. tetrahydrocannabinol (THC)) may have different harm profiles. </p> <p>The main limitation of the evidence base remains imprecision due to the small number of RCTs, often with low event rates. Further RCTs are underway. To ensure the review continues to provide up‐to‐date information to decision‐makers, this is a living systematic review. We run searches monthly, with the review updated when relevant new evidence becomes available. Please refer to the <i>Cochrane Database of Systematic Reviews</i> for the review's current status. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010216-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010216-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010216-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010216-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010216-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010216-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010216-abs-0002" lang="en"> <h3>Can electronic cigarettes help people stop smoking, and do they have any unwanted effects when used for this purpose? </h3> <p><b>What are electronic cigarettes?</b> </p> <p>Electronic cigarettes (e‐cigarettes) are handheld devices that work by heating a liquid that usually contains nicotine and flavourings. E‐cigarettes allow users to inhale nicotine in a vapour rather than smoke. Because they do not burn tobacco, e‐cigarettes, in general, do not expose users to the same levels of chemicals that can cause diseases in people who use conventional cigarettes. </p> <p>Using an e‐cigarette is commonly known as 'vaping'. Many people use e‐cigarettes to help them to stop smoking tobacco. In this review we focus primarily on e‐cigarettes containing nicotine. </p> <p><b>Why did we do this Cochrane review?</b> </p> <p>Stopping smoking lowers the risk of many diseases. Many people find it difficult to stop smoking. We wanted to find out if using e‐cigarettes could help people to stop smoking, and if people using them for this purpose experience any unwanted effects. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that looked at the use of e‐cigarettes for stopping smoking.</p> <p>We looked for randomized controlled trials, in which the treatments people received were decided at random. This type of study usually gives the most reliable evidence about treatment effects. We also looked for studies in which everyone received e‐cigarette treatment. We also included studies that gave e‐cigarettes to people who smoked and monitored their health even if there was no randomized group, because such studies can contribute to our understanding of health effects. </p> <p>We were interested in:</p> <p>· how many people stopped smoking for at least six months; and</p> <p>· how many people had unwanted effects, reported on after at least one week of use.</p> <p><b>Search date</b> </p> <p>We included evidence published up to 1 February 2024.</p> <p><b>What we found</b> </p> <p>We found 90 studies, which included 29,044 adults who smoked. The studies compared nicotine e‐cigarettes with: </p> <p>· nicotine replacement therapy, such as patches or gum;</p> <p>· varenicline (a medicine to help people stop smoking);</p> <p>· e‐cigarettes without nicotine;</p> <p>· heated tobacco (products designed to heat tobacco to a high enough temperature to release vapour, without burning it or producing smoke; these differ from e‐cigarettes because they heat tobacco leaf/sheet rather than a liquid); </p> <p>· other types of nicotine‐containing e‐cigarettes (e.g. pod devices, newer devices);</p> <p>· behavioural support, such as advice or counselling; or</p> <p>· no support for stopping smoking.</p> <p>Most studies took place in the USA (39 studies), the UK (20), and Italy (9).</p> <p><b>What are the results of our review?</b> </p> <p>People are more likely to stop smoking for at least six months using nicotine e‐cigarettes than using nicotine replacement therapy (7 studies, 2544 people), or e‐cigarettes without nicotine (6 studies, 1613 people). </p> <p>Nicotine e‐cigarettes may help more people to stop smoking than no support or behavioural support only (11 studies, 6819 people). </p> <p>For every 100 people using nicotine e‐cigarettes to stop smoking, 8 to 10 might successfully stop, compared with only 6 of 100 people using nicotine‐replacement therapy, 7 of 100 using e‐cigarettes without nicotine, or 4 of 100 people having no support or behavioural support only. </p> <p>We are uncertain if there is a difference between how many unwanted effects occur using nicotine e‐cigarettes compared with nicotine replacement therapy, no support or behavioural support only. There was some evidence that non‐serious unwanted effects were more common in groups receiving nicotine e‐cigarettes compared to no support or behavioural support only. Low numbers of unwanted effects, including serious unwanted effects, were reported in studies comparing nicotine e‐cigarettes to nicotine replacement therapy. There is probably no difference in how many non‐serious unwanted effects occur in people using nicotine e‐cigarettes compared to e‐cigarettes without nicotine. </p> <p>The unwanted effects reported most often with nicotine e‐cigarettes were throat or mouth irritation, headache, cough, and feeling sick. These appeared similar to those people experience when using NRT. These effects were reduced over time as people continued using nicotine e‐cigarettes. </p> <p><b>How reliable are these results?</b> </p> <p>Our results are based on few studies for most outcomes and, for some outcomes, the data varied widely. </p> <p>We found evidence that nicotine e‐cigarettes help more people to stop smoking than nicotine replacement therapy. Nicotine e‐cigarettes probably help more people to stop smoking than e‐cigarettes without nicotine, but more studies are still needed to confirm this. </p> <p>Studies comparing nicotine e‐cigarettes with behavioural or no support also showed higher quit rates in people using nicotine e‐cigarettes, but provide less certain data because of issues with study design. </p> <p>Most of our results for the unwanted effects could change when more evidence becomes available. </p> <p><b>Key messages</b> </p> <p>Nicotine e‐cigarettes can help people to stop smoking for at least six months. Evidence shows they work better than nicotine replacement therapy, and probably better than e‐cigarettes without nicotine. </p> <p>They may work better than no support, or behavioural support alone, and they may not be associated with serious unwanted effects. </p> <p>However, we still need more evidence, particularly about the effects of newer types of e‐cigarettes that have better nicotine delivery than older types of e‐cigarettes, as better nicotine delivery might help more people quit smoking. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010216-sec-0121" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010216-sec-0121"></div> <h3 class="title" id="CD010216-sec-0122">Implications for practice</h3> <section id="CD010216-sec-0122"> <p>Evidence suggesting that nicotine electronic cigarettes (EC) can aid in smoking cessation is consistent across several comparisons. There is high‐certainty evidence that EC with nicotine increases quit rates at six months or longer compared to nicotine replacement therapy (NRT), and moderate‐certainty evidence (limited by imprecision) that EC with nicotine increases quit rates at six months or longer compared to non‐nicotine EC. There is also low‐certainty evidence (limited by risk of bias) that EC with nicotine may increase quit rates compared to behavioural support alone or to no support. </p> <p>Issues with risk of bias, few studies, and differences between studies preclude strong conclusions regarding the effect of nicotine EC when added to NRT, but the data available suggest a benefit. </p> <p>None of the evidence synthesized provides a clear indication that serious adverse events are increased by EC use. However, more long‐term data are needed, and this conclusion relates specifically to people using EC to quit smoking and not to people who have never smoked. The most commonly reported adverse effects are throat/mouth irritation, headache, cough, and nausea, which tend to dissipate with continued use. In some studies, reduced toxin concentrations and biomarkers of harm were observed in people who smoked and switched to vaping, consistent with reductions seen in people who stopped smoking without EC. </p> </section> <h3 class="title" id="CD010216-sec-0123">Implications for research</h3> <section id="CD010216-sec-0123"> <p>Further randomized controlled trials of nicotine EC are needed. All studies (including uncontrolled intervention cohort studies) should aim to assess the safety profile of EC for as long as possible (the current review only includes data up to two years), and ideally be powered to detect differences in safety outcomes, particularly serious adverse events. Safety results should be presented in both absolute and relative risk terms (in comparison to the risks of continuing to smoke tobacco). </p> <p>Studies with active comparators (i.e. comparing nicotine EC to frontline smoking cessation pharmacotherapies, particularly those other than NRT) are likely to be of particular use to decision‐makers, as are those testing EC as an adjunct to existing stop‐smoking pharmacotherapies; in particular, those testing combinations of traditional NRTs with e‐cigarettes (e.g. patch plus e‐cigarettes). </p> <p>Studies should offer recent devices with good nicotine delivery to participants to be most representative of what will be on the market at the time results are released. Studies should also monitor and collect data on participants switching use of other devices during trials, and use of different flavours and nicotine strengths. Protocols and statistical analysis plans should be registered in advance and openly available. </p> <p>Further RCTs need to be adequately powered. Further trials of pod and newer disposable devices would be of particular value, as would RCTs providing ECs in a way that would be used in real‐world settings (e.g. taking into account individual preferences for strengths and flavours of e‐liquids and even EC devices, and also allowing for changes in preferences over time). Further studies directly comparing nicotine ECs based on characteristics including nicotine content and delivery, flavour, and device type, and reporting outcomes including cessation at six months or longer, would also be particularly useful. </p> <p>Further reviews, using the best available methods, need to be conducted to evaluate the possible relationships between EC use and availability and youth uptake of EC and conventional cigarettes (such as <a href="./references#CD010216-bbs2-0242" title="Hartmann-BoyceJ , BeghR , LindsonN , Livingstone-BanksJ , FanshaweTR , McNeillA , et al. Electronic cigarettes and subsequent cigarette smoking in young people. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD015170. [DOI: 10.1002/14651858.CD015170]">Hartmann‐Boyce 2022b</a>), as well as the safety of EC use in people who have never smoked. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010216-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010216-sec-0008"></div> <div class="table" id="CD010216-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Nicotine EC compared to NRT for smoking cessation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Nicotine EC compared to NRT for smoking cessation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke cigarettes, aged 18 or older<br/><b>Setting:</b> various settings in New Zealand, UK, USA<br/><b>Intervention:</b> nicotine EC<br/><b>Comparison:</b> NRT </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events with NRT</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events with Nicotine EC</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Smoking cessation at 6 months to 1 year</p> <p>Assessed with biochemical validation</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.59<br/>(1.30 to 1.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2544<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 100<br/>(8 to 12) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events at 4 weeks to 6 to 9 months</p> <p>Assessed by self‐report</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/>(0.91 to 1.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2052<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 100<br/>(21 to 27) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events at 4 weeks to 1 year</p> <p>Assessed via self‐report and medical records</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.20<br/>(0.90 to 1.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2761<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 studies reported no events; effect estimate based on the 4 studies in which events were reported </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100<br/>(4 to 6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The estimated number of events in the intervention group</b> (and its 95% confidence interval) is based on the assumed number of events in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). For cessation, the assumed number of events in the control group is based on assumed quit rates for NRT assuming receipt of limited behavioural stop‐smoking support (as per <a href="./references#CD010216-bbs2-0238" title="Hartmann-BoyceJ , ChepkinSC , YeW , BullenC , LancasterT . Nicotine replacement therapy versus control for smoking cessation. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD000146. [DOI: 10.1002/14651858.CD000146.pub5]">Hartmann‐Boyce 2018a</a>). The assumed risk for adverse events and serious adverse events is a weighted mean average of quit rates across control groups in contributing studies.<br/><br/><b>CI:</b> confidence interval; <b>EC</b> : electronic cigarette; <b>NRT</b> : nicotine replacement therapy; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to imprecision; CIs consistent with benefit and harm.<br/><sup>b</sup>Downgraded two levels due to imprecision; fewer than 300 events and CIs encompass clinically important harm and clinically important benefit. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010216-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Nicotine EC compared to non‐nicotine EC for smoking cessation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Nicotine EC compared to non‐nicotine EC for smoking cessation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke cigarettes, aged 18 or older<br/><b>Setting:</b> various settings in Canada, Italy, New Zealand, UK, USA<br/><b>Intervention:</b> nicotine EC<br/><b>Comparison:</b> non‐nicotine EC </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events with non‐nicotine EC</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events with nicotine EC</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Smoking cessation at 6 to 12 months</p> <p>Assessed with biochemical validation</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.46<br/>(1.09 to 1.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1613<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 100<br/>(8 to 14) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events at 1 week to 6 months</p> <p>Assessed via self‐report</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.91 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>840<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100<br/>(8 to 10) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events at 1 week to 1 year</p> <p>Assessed via self‐report and medical records</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.00<br/>(0.56 to 1.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1412<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5 studies reported no events; effect estimate based on the 4 studies in which events were reported </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100<br/>(2 to 6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The estimated number of events in the intervention group</b> (and its 95% confidence interval) is based on the assumed number of events in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). For cessation, the assumed number of events in the control group is based on assumed quit rates for NRT assuming receipt of limited behavioural stop‐smoking support (as per <a href="./references#CD010216-bbs2-0238" title="Hartmann-BoyceJ , ChepkinSC , YeW , BullenC , LancasterT . Nicotine replacement therapy versus control for smoking cessation. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD000146. [DOI: 10.1002/14651858.CD000146.pub5]">Hartmann‐Boyce 2018a</a>). The assumed risk for adverse events and serious adverse events is a weighted mean average of quit rates across control groups in contributing studies.<br/><br/><b>CI:</b> confidence interval; <b>EC</b> : electronic cigarette; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for risk of bias. One of four studies considered high risk of bias; removing this study increased the direction of the effect in favour of the intervention.<br/><sup>b</sup>Downgraded one level due to imprecision; &lt; 300 events overall.<br/><sup>c</sup>Downgraded two levels due to imprecision: confidence intervals encompass clinically significant harm as well as clinically significant benefit; &lt; 300 events overall. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010216-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Nicotine EC compared to behavioural support only/no support for smoking cessation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Nicotine EC compared to behavioural support only/no support for smoking cessation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke cigarettes, aged 18 or older<br/><b>Setting:</b> various settings in Canada, Italy, Switzerland, UK, USA<br/><b>Intervention:</b> nicotine EC<br/><b>Comparison:</b> behavioural support only/no support </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events with behavioural support only/no support</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events with nicotine EC</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Smoking cessation at 6 to 12 months</p> <p>Assessed using biochemical validation</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.96<br/>(1.66 to 2.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6819<br/>(11 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 100<br/>(7 to 9) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events at 12 weeks to 6 months</p> <p>Assessed via self‐report</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/>(1.10 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2351<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 100<br/>(54 to 62) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events at 4 weeks to 8 months</p> <p>Assessed via self‐report and medical records</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/>(0.68 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4561<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5 of the 12 studies reported no SAEs; MA is based on pooled results from 7 studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100<br/>(3 to 5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The estimated number of events in the intervention group</b> (and its 95% confidence interval) is based on the assumed number of events in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). For cessation, the assumed number of events in the control group is based on assumed quit rates assuming receipt of limited behavioural stop‐smoking support (as per <a href="./references#CD010216-bbs2-0238" title="Hartmann-BoyceJ , ChepkinSC , YeW , BullenC , LancasterT . Nicotine replacement therapy versus control for smoking cessation. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD000146. [DOI: 10.1002/14651858.CD000146.pub5]">Hartmann‐Boyce 2018a</a>). The assumed risk for adverse events and serious adverse events is a weighted mean average of quit rates across control groups in contributing studies.<br/><br/><b>CI:</b> confidence interval; <b>EC</b> : electronic cigarette; <b>MA:</b> meta‐analysis; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to risk of bias. Due to lack of blinding and differential support between arms, judged to be at high risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision. Confidence intervals incorporate clinically significant benefit and clinically significant harm; &lt; 300 events overall. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010216-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010216-sec-0009"></div> <p>Throughout this review, we discuss (1) conventional cigarettes and (2) electronic cigarettes, defined as hand‐held and producing for inhalation an aerosol formed by heating an e‐liquid using a battery‐powered heating coil. In this review, all mention of smoking, smoking cessation, cigarette use, smoke intake, etc. concerns combustible tobacco cigarettes. When the text concerns electronic cigarettes, we use the abbreviation 'ECs'. EC users are sometimes described as 'vapers', and EC use as 'vaping'. We refer to ECs that do not contain nicotine as non‐nicotine ECs; these can also be conceptualized as placebo ECs, but we are using the term non‐nicotine EC, as they can be conceptualized as an intervention in themselves. This review does not address the use of vaping devices to inhale substances other than nicotine, such as cannabis. </p> <section id="CD010216-sec-0010"> <h3 class="title" id="CD010216-sec-0010">Description of the condition</h3> <p>Stopping smoking tobacco is associated with large health benefits. Despite most people who smoke wanting to quit, many find it difficult to succeed in the long term. Almost half who try to quit without support will not manage to stop for even a week, and fewer than five per cent remain abstinent one year after quitting (<a href="./references#CD010216-bbs2-0249" title="HughesJR , KeelyJ , NaudS . Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction2004;99(1):29-38.">Hughes 2004</a>). </p> <p>Behavioural support and medications such as nicotine patches or gum increase the chances of quitting through providing nicotine to help alleviate withdrawal symptoms, but even with such support, long‐term quit rates remain low (<a href="./references#CD010216-bbs2-0239" title="Hartmann-BoyceJ , HongB , Livingstone-BanksJ , WheatH , FanshaweTR . Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database of Systematic Reviews2019, Issue 6. Art. No: CD009670. [DOI: 10.1002/14651858.CD009670.pub4]">Hartmann‐Boyce 2019</a>; <a href="./references#CD010216-bbs2-0240" title="Hartmann-BoyceJ , Livingstone-BanksJ , Ordonez-MenaJ , FanshaweTR , LindsonN , FreemanSC , et al. Behavioural interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database of Systematic Reviews2021, Issue 1. Art. No: CD013229. [DOI: 10.1002/14651858.CD013229.pub2]">Hartmann‐Boyce 2021b</a>; <a href="./references#CD010216-bbs2-0257" title="Livingstone-BanksJ , FanshaweTR , ThomasKH , TheodoulouA , HajizadehA , HartmanL , et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews2023, Issue 6. Art. No: CD006103. [DOI: 10.1002/14651858.CD006103.pub9]">Livingstone‐Banks 2023</a>). One of the limitations of current treatments is that, apart from providing nicotine more slowly and at lower levels than smoking, none adequately addresses the sensory, behavioural, and/or social aspects of smoking that ex‐smokers miss when they stop smoking (e.g. holding a cigarette in their hands, taking a puff, enjoyment of smoking, feeling part of a group). ECs may offer a way to overcome these limitations (<a href="./references#CD010216-bbs2-0267" title="NotleyC , WardE , DawkinsL , HollandR . The unique contribution of e-cigarettes for tobacco harm reduction in supporting smoking relapse prevention. Harm Reduction Journal2018;15(1):31.">Notley 2018b</a>), and have become a popular consumer choice for smoking cessation support where regulations allow (<a href="./references#CD010216-bbs2-0206" title="BussB , KockL , WesrR , BeardE , KaleD , BrownJ . Trends in electronic cigarette use in England, Smoking in England. https://smokinginengland.info/graphs/e-cigarettes-latest-trends; July 2023 (accessed 27 September 2023).">Buss 2023</a>). </p> <p>There is no doubt that people become dependent on tobacco, and many find it difficult to stop smoking, primarily because of nicotine and its actions on the brain's reward system (<a href="./references#CD010216-bbs2-0194" title="BalfourD . The neurobiology of tobacco dependence: a preclinical perspective on the role of dopamine projections to the nucleus. Nicotine &amp; Tobacco Research2004;6(6):899-912.">Balfour 2004</a>). However, developing dependence on tobacco smoking is a complex biopsychosocial process (<a href="./references#CD010216-bbs2-0200" title="BenowitzNL . Nicotine addiction. New England Journal of Medicine2010;362(24):2295-303.">Benowitz 2010</a>; <a href="./references#CD010216-bbs2-0285" title="RoseJE . Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology2006;184(3-4):274-85.">Rose 2006</a>). Other tobacco chemicals, such as acetaldehyde and monoamine oxidase (MAO) inhibitors, seem to potentiate the effects of nicotine (<a href="./references#CD010216-bbs2-0285" title="RoseJE . Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology2006;184(3-4):274-85.">Rose 2006</a>). In addition, sensory and behavioural cues provide additional reinforcement of smoking behaviour (<a href="./references#CD010216-bbs2-0282" title="RoseJE , BehmFM , LevinED . Role of nicotine dose and sensory cues in the regulation of smoke intake. Pharmacology Biochemistry &amp; Behavior1993;44(4):891-900.">Rose 1993</a>; <a href="./references#CD010216-bbs2-0284" title="RoseJE , BehmFM , WestmanEC , JohnsonM . Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacology Biochemistry &amp; Behavior2000;67(1):71-81.">Rose 2000</a>) and may over time become almost as rewarding as nicotine. There are several lines of evidence to support this. Firstly, people who smoke appear to have a preference for cigarette smoke compared to other forms of nicotine delivery. This is partly related to the speed of nicotine delivery through smoke inhalation. However, even when nicotine is administered intravenously, it does not provide the same level of satisfaction or reward as smoking (<a href="./references#CD010216-bbs2-0284" title="RoseJE , BehmFM , WestmanEC , JohnsonM . Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacology Biochemistry &amp; Behavior2000;67(1):71-81.">Rose 2000</a>; <a href="./references#CD010216-bbs2-0305" title="WestmanEC , BehmFM , RoseJE . Dissociating the nicotine and airway sensory effects of smoking. Pharmacology Biochemistry &amp; Behavior1996;53(2):309-15.">Westman 1996</a>). Secondly, the local sensory effects of smoking (e.g. the ‘scratch’ in the back of the throat) may be important for enjoyment and reward. Numbing the sensations of cigarette smoke by anaesthetizing the upper and lower respiratory tract leads to less enjoyment of smoking (<a href="./references#CD010216-bbs2-0281" title="RoseJE , TashkinDP , ErtleA , ZinserMC , LaferR . Sensory blockade of smoking satisfaction. Pharmacology Biochemistry &amp; Behavior1985;23(2):289-93.">Rose 1985</a>). Conversely, products that mimic the sensory effects of smoking on the mouth and throat (such as citric acid, black pepper, and ascorbic acid) reduce craving and some withdrawal symptoms, at least in the short term (<a href="./references#CD010216-bbs2-0252" title="LevinED , BehmF , CarnahanE , LeClairR , ShipleyR , RoseJE . Clinical trials using ascorbic acid aerosol to aid smoking cessation. Drug and Alcohol Dependence1993;33(3):211-23.">Levin 1993</a>; <a href="./references#CD010216-bbs2-0283" title="RoseJE , BehmFM . Inhalation of vapor from black pepper extract reduces smoking withdrawal symptoms. Drug and Alcohol Dependence1994;34(3):225-9.">Rose 1994</a>; <a href="./references#CD010216-bbs2-0304" title="WestmanEC , BehmFM , RoseJE . Airway sensory replacement combined with nicotine replacement for smoking cessation. A randomized, placebo-controlled trial using a citric acid inhaler. Chest1995;107(5):1358-64.">Westman 1995</a>). Thirdly, very low nicotine content cigarettes (VLNCs), which have e.g. 0.08 mg instead of the normal 1 mg, and so have negligible or no central effects, have also been investigated for their role in aiding smoking cessation (<a href="./references#CD010216-bbs2-0275" title="PrzuljD , McRobbieH , HajekP . The effect of sensorimotor replacement on smoking cessation and craving. Open Addiction Journal2013;5:41-50.">Przulj 2013</a>). Despite delivering low levels of nicotine, VLNCs are satisfying over the initial few days of abstinence from nicotine (<a href="./references#CD010216-bbs2-0218" title="DonnyEC , HoutsmullerE , StitzerML . Smoking in the absence of nicotine: behavioral, subjective and physiological effects over 11 days. Addiction2007;102(2):324-34.">Donny 2007</a>; <a href="./references#CD010216-bbs2-0220" title="DonnyEC , DenlingerRL , TideyJW , KoopmeinersJS , BenowitzNL , VandreyRG , et al. Randomized trial of reduced-nicotine standards for cigarettes. New England Journal of Medicine2015;373(14):1340-9.">Donny 2015</a>; <a href="./references#CD010216-bbs2-0272" title="PickworthWB , FantRV , NelsonRA , RohrerMS , HenningfieldJE . Pharmacodynamic effects of new de-nicotinized cigarettes. Nicotine &amp; Tobacco Research1999;1(4):357-64.">Pickworth 1999</a>; <a href="./references#CD010216-bbs2-0284" title="RoseJE , BehmFM , WestmanEC , JohnsonM . Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacology Biochemistry &amp; Behavior2000;67(1):71-81.">Rose 2000</a>). They also reduce tobacco withdrawal symptoms, including urges to smoke and low mood (<a href="./references#CD010216-bbs2-0198" title="BarrettSP . The effects of nicotine, denicotinized tobacco, and nicotine-containing tobacco on cigarette craving, withdrawal, and self-administration in male and female smokers. Behavorial Pharmacology2010;21(2):144-52.">Barrett 2010</a>; <a href="./references#CD010216-bbs2-0219" title="DonnyEC , JonesM . Prolonged exposure to denicotinized cigarettes with or without transdermal nicotine. Drug and Alcohol Dependence2009;104(1-2):23-33.">Donny 2009</a>; <a href="./references#CD010216-bbs2-0262" title="McRobbieH , PrzuljD , SmithKM , CornwallD . Complementing the standard multicomponent treatment for smokers with denicotinized cigarettes: a randomized trial. Nicotine &amp; Tobacco Research2016;18(5):1134-41.">McRobbie 2016</a>; <a href="./references#CD010216-bbs2-0271" title="PerkinsKA , KarelitzJL , ConklinCA , SayetteMA , GiedgowdGE . Acute negative affect relief from smoking depends on the affect situation and measure but not on nicotine. Biological Psychology2010;67(8):707-14.">Perkins 2010</a>; <a href="./references#CD010216-bbs2-0284" title="RoseJE , BehmFM , WestmanEC , JohnsonM . Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacology Biochemistry &amp; Behavior2000;67(1):71-81.">Rose 2000</a>), and have been shown to improve long‐term continuous abstinence rates in one study (<a href="./references#CD010216-bbs2-0302" title="WalkerN , HoweC , BullenC , GriggM , GloverM , McRobbieH , et al. The combined effect of very low nicotine content cigarettes, used as an adjunct to usual Quitline care (nicotine replacement therapy and behavioural support), on smoking cessation: a randomized controlled trial. Addiction2012;107(10):1857-67.">Walker 2012</a>). Social aspects of smoking, such as feeling part of a like‐minded group, or including smoking behaviour as part of one's social identity, are also elements of cigarette smoking that some people who smoke report to be drivers of cigarette use (<a href="./references#CD010216-bbs2-0266" title="NotleyC , ColllinsR . Redefining smoking relapse as recovered social identity - secondary qualitative analysis of relapse narratives. Journal of Substance Use2018;23(6):660-6.">Notley 2018a</a>). </p> <p>Considering the other factors that contribute to tobacco dependence, there is interest in developing smoking‐cessation products that not only help relieve the unpleasant effects of nicotine withdrawal, but that also act as effective substitutes for smoking behaviour and the rituals and sensations that accompany smoking, without the health risks associated with the inhalation of tobacco smoke. The only pharmaceutical treatment with some of these characteristics is the nicotine inhalator. However, these do not have greater cessation efficacy than other nicotine replacement therapy (NRT) products (<a href="./references#CD010216-bbs2-0232" title="HajekP , WestR , FouldsJ , NilssonF , BurrowsS , MeadowA . Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Archives of Internal Medicine1999;159(17):2033-8.">Hajek 1999</a>; <a href="./references#CD010216-bbs2-0238" title="Hartmann-BoyceJ , ChepkinSC , YeW , BullenC , LancasterT . Nicotine replacement therapy versus control for smoking cessation. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD000146. [DOI: 10.1002/14651858.CD000146.pub5]">Hartmann‐Boyce 2018a</a>). This may in part be due to the considerable effort (e.g. 20 minutes of continuous puffing) needed to provide nicotine blood concentrations consistent with other NRT products (<a href="./references#CD010216-bbs2-0286" title="SchneiderNG , OlmsteadRE , FranzonMA , LunellE . The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clinical Pharmcokinetics2001;40(9):661-84.">Schneider 2001</a>). Adherence to correct use of the inhalator is low compared to other types of NRT (<a href="./references#CD010216-bbs2-0232" title="HajekP , WestR , FouldsJ , NilssonF , BurrowsS , MeadowA . Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Archives of Internal Medicine1999;159(17):2033-8.">Hajek 1999</a>). It is therefore possible that any advantage of sensorimotor replacement is diminished by low nicotine delivery and limited similarities between inhalator use and sensations of smoking (<a href="./references#CD010216-bbs2-0205" title="BullenC , McRobbieH , ThornleyS , GloverM , LinR , LaugesenM , . Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tobacco Control 20102010;19(2):98-103. [DOI: 10.1136/tc.2009.031567]">Bullen 2010</a>). </p> </section> <section id="CD010216-sec-0011"> <h3 class="title" id="CD010216-sec-0011">Description of the intervention</h3> <p>ECs are devices that produce, for inhalation, an aerosol formed by heating a solution (an e‐liquid) using a battery‐powered heating coil (<a href="./references#CD010216-bbs2-0222" title="Anonymous. E-cigarette v1. www.qeios.com/read/0WX80U (accessed prior to 3 November 2022). [URL: www.qeios.com/read/0WX80U]">E‐cigarette ontology 2021</a>). The e‐liquid, usually comprising propylene glycol and glycerol, with or without nicotine and flavours, is stored in disposable or refillable cartridges or a reservoir or 'pod'. The commonly used term for this aerosol is vapour, which we use throughout the review. ECs are marketed as consumer products. Although routes are in place for licencing them as medicine or medical devices in some areas, no country yet has a licenced medicinal EC. </p> <p>ECs provide sensations similar to smoking a cigarette. They provide taste and throat sensations that are closer to smoking than those provided by the nicotine inhalator (<a href="./references#CD010216-bbs2-0197" title="BarbeauAM , BurdaJ , SiegelM . Perceived efficacy of e-cigarettes versus nicotine replacement therapy among successful e-cigarette users: a qualitative approach. Addiction: Science &amp; Clinical Practice2013;8(1):5.">Barbeau 2013</a>). The aerosol, typically referred to as vapour, looks like tobacco smoke, but is only visible when the user exhales after drawing on the mouthpiece, not when the device is being held. In qualitative studies, users report a sense of shared identity with other users, similar to tobacco‐smoking identity, and also report pleasure and enjoyment of use, suggesting that ECs may be viewed less as medical cessation aids but rather as acceptable alternatives to tobacco smoking (<a href="./references#CD010216-bbs2-0213" title="CoxS , JakesS . Nicotine and e-cigarettes: rethinking addiction in the context of reduced harm. International Journal of Drug Policy2017;44:84-5.">Cox 2017</a>; <a href="./references#CD010216-bbs2-0266" title="NotleyC , ColllinsR . Redefining smoking relapse as recovered social identity - secondary qualitative analysis of relapse narratives. Journal of Substance Use2018;23(6):660-6.">Notley 2018a</a>). </p> <p>There are many different brands and models of EC available. Variation exists both in the device ('product') and consumable (e‐liquid used). There is a wide variation in the composition of e‐liquids (nicotine content, flavours, and other components) (<a href="./references#CD010216-bbs2-0227" title="GoniewiczML , KumaT , GawronM , KnysakJ , KosmiderL . Nicotine levels in electronic cigarettes. Nicotine &amp; Tobacco Research2012;15(1):158-66.">Goniewicz 2012</a>; <a href="./references#CD010216-bbs2-0228" title="GoniewiczML , HajekP , McRobbieH . Nicotine content of electronic cigarettes, its release in vapour and its consistency across batches: regulatory implications. Addiction2014;109(3):500-7.">Goniewicz 2014</a>), with some users choosing to mix their own e‐liquids (<a href="./references#CD010216-bbs2-0214" title="CoxS , LeighNJ , VanderbushTS , ChooE , GoniewiczML , DawkinsL . An exploration into &quot;do-it-yourself&quot; (DIY) e-liquid mixing: sers' motivations, practices and product laboratory analysis. Addictive Behaviors Reports2019;9:100151.">Cox 2019b</a>). Initial studies showed that early models of EC delivered very low amounts of nicotine to naïve users (<a href="./references#CD010216-bbs2-0205" title="BullenC , McRobbieH , ThornleyS , GloverM , LinR , LaugesenM , . Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tobacco Control 20102010;19(2):98-103. [DOI: 10.1136/tc.2009.031567]">Bullen 2010</a>; <a href="./references#CD010216-bbs2-0223" title="EissenbergT . Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration. Tobacco Control2010;19(1):87-8. [DOI: 10.1136/tc.2009.033498]">Eissenberg 2010</a>; <a href="./references#CD010216-bbs2-0299" title='VansickelAR , CobbCO , WeaverMF , EissenbergTE . A clinical laboratory model for evaluating the acute effects of electronic "cigarettes": nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiology, Biomarkers &amp; Prevention2010;19(8):1945-53. [DOI: 10.1158/1055-9965.EPI-10-0288]'>Vansickel 2010</a>). Later studies that have measured nicotine pharmacokinetics in both experienced and naïve EC users have found that some EC users can achieve blood nicotine levels similar to those achieved with smoking, albeit more slowly, and that their ability to do so often improves over time (<a href="./references#CD010216-bbs2-0234" title="HajekP , GoniewiczML , PhillipsA , Myers SmithK , WestO , McRobbieH . Nicotine intake from electronic cigarettes on initial use and after 4 weeks of regular use. Nicotine &amp; Tobacco Research2015;17(2):175-9.">Hajek 2015b</a>; <a href="./references#CD010216-bbs2-0300" title="VansickelAR , WeaverMF , EissenbergT . Clinical laboratory assessment of the abuse liability of an electronic cigarette. Addiction2012;107(8):1483-500. [DOI: 10.1111/j.1360-0443.2012.03791.x]">Vansickel 2012</a>; <a href="./references#CD010216-bbs2-0301" title="VansickelAR , EissenbergT . Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine &amp; Tobacco Research2013;15(1):267-70. [DOI: 10.1093/ntr/ntr316]">Vansickel 2013</a>; <a href="./references#CD010216-bbs2-0307" title="YingstJM , FouldsJ , VeldheerS , HrabovskyS , TrushinN , EissenbergTT , et al. Nicotine absorption during electronic cigarette use among regular users. PLOS One2019;14(7):e0220300.">Yingst 2019a</a>; <a href="./references#CD010216-bbs2-0308" title="YingstJM , HrabovskyS , HobkirkA , TrushinN , Richie JP Jr, FouldsJ . Nicotine absorption profile among regular users of a pod-based electronic nicotine delivery system. JAMA Network Open2019;2(11):e1915494.">Yingst 2019b</a>). </p> <p>Early in their development, ECs were designed to look like cigarettes and used disposable cartridges. These models were often called 'cig‐a‐likes'. The nicotine delivery from these products was low (<a href="./references#CD010216-bbs2-0235" title="HajekP , PrzuljD , PhillipsA , AndersonR , McRobbieH . Nicotine delivery to users from cigarettes and from different types of e-cigarettes. Psychopharmacology (Berl)2017;234(5):773-9.">Hajek 2017</a>). The later refillable, or 'tank', products had a larger battery and a transparent container that users fill with an e‐liquid of their choice, and usually provide faster and more efficient nicotine delivery, allowing a wider choice of flavours and nicotine concentrations, and were typically used by experienced vapers who reportedly managed to switch to vaping completely (<a href="./references#CD010216-bbs2-0191" title="Action on Smoking and Health. Use of electronic cigarettes (vapourisers) among adults in Great Britain. ash.org.uk/information-and-resources/fact-sheets/statistical/use-of-e-cigarettes-among-adults-in-great-britain-2019/ (accessed 21 July 2020).">ASH 2019</a>; <a href="./references#CD010216-bbs2-0211" title="ChenC , ZhuangYL , ZhuSH . E-cigarette design preference and smoking cessation: a U.S. population study. American Journal of Preventive Medicine2016;51(3):356-63. [DOI: 10.1016/j.amepre.2016.02.002]">Chen 2016</a>; <a href="./references#CD010216-bbs2-0215" title="DawkinsL , TurnerJ , RobertsA , SoarK . 'Vaping' profiles and preferences: an online survey of electronic cigarette users. Addiction2013;108(6):1115-25.">Dawkins 2013b</a>; <a href="./references#CD010216-bbs2-0226" title="FarsalinosKE , PolosaR . Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Therapeutic Advances in Drug Safety2014;5(2):67-86.">Farsalinos 2014</a>). More recently, smaller 'pod' devices that use nicotine salt solutions have become available. This nicotine formulation reduces irritant effects and allows the delivery of higher nicotine levels that closely mimic the pharmacokinetic profile of nicotine delivery from cigarettes, despite the low battery power of the devices (<a href="./references#CD010216-bbs2-0236" title="HajekP , PittaccioK , PesolaF , Myers SmithK , Phillips-WallerA , PrzuljD . Nicotine delivery and users' reactions to Juul compared with cigarettes and other e-cigarette products. Addiction2020;115(6):1141-8.">Hajek 2020</a>). In qualitative studies, pod devices have been highly rated by users in terms of satisfaction, usability (simple to use), affordability, and availability (<a href="./references#CD010216-bbs2-0199" title="BeldersonP , WardE , PopeI , NotleyC . Selecting an e-cigarette for use in smoking cessation interventions and healthcare services: findings from patient and public consultation for the COSTED trial. BMJ Open2024;14(3):e078677. [DOI: 10.1136/bmjopen-2023-078677] [PMID: 38443079]">Belderson 2024</a>). The nicotine salts used in pods allow for high nicotine delivery; this may increase the likelihood that adult smokers are able to transition completely from conventional cigarettes (<a href="./references#CD010216-bbs2-0274" title="ProchaskaJJ , VogelEA , BenowitzN . Nicotine delivery and cigarette equivalents from vaping a JUULpod. Tobacco Control2022;31(e1):e88-93. [DOI: 10.1136/tobaccocontrol-2020-056367]">Prochaska 2022</a>). Average nicotine concentrations in EC sold in the United States increased overall during 2013‐2018, for all flavour categories, and for rechargeable ECs (<a href="./references#CD010216-bbs2-0280" title="RombergAR , Miller LoEJ , CucciaAF , WillettJG , XiaoH , HairEC , et al. Patterns of nicotine concentrations in electronic cigarettes sold in the United States, 2013-2018. Drug and Alcohol Dependence2019;203:1-7. [DOI: 10.1016/j.drugalcdep.2019.05.029]">Romberg 2019</a>). The EU Tobacco Products Directive (<a href="./references#CD010216-bbs2-0225" title="European Parliament and Council of the European Union. Directive 2014/40/EU of the European Parliament and of the Council of 3 April 2014 on the approximation of the laws, regulations and administrative provisions of the Member States concerning the manufacture, presentation and sale of tobacco and related products and repealing Directive 2001/37/EC. EUR-Lex - 32014L0040 - EN - EUR-Lex (europa.eu) 2014 (accessed 25 November 2014).">European Parliament 2014</a>) does not allow sales of e‐liquids with nicotine content higher than 20 mg/mL, and so the US version of the Juul pod device (59 mg/nl nicotine) is not legally available within the EU (<a href="./references#CD010216-bbs2-0248" title="HuangJ , DuanZ , KwokJ , BinnsS , VeraLE , KimY , et al. Vaping versus JUULing: how the extraordinary growth and marketing of JUUL transformed the US retail e-cigarette market. Tobacco Control2019;28(2):146-51.">Huang 2019</a>; <a href="./references#CD010216-bbs2-0289" title="TalihS , SalmanR , El-HageR , KaramE , SalamS , KaraoghlanianN , et al. A comparison of the electrical characteristics, liquid composition, and toxicant emissions of JUUL USA and JUUL UK e-cigarettes. Scientific Reports2020;10(1):7322.">Talih 2020</a>). Most recently, there has been rapid growth in the use of disposable and single‐use devices (<a href="./references#CD010216-bbs2-0291" title="Tattan-BirchH , JacksonSE , KockL , DockrellM , BrownJ . Rapid growth in disposable e-cigarette vaping among young adults in Great Britain from 2021 to 2022: a repeat cross-sectional survey. Addiction2023;118(2):382-6. [DOI: 10.1111/add.16044]">Tattan‐Birch 2022</a>; <a href="./references#CD010216-bbs2-0292" title="Tattan-BirchH , BrownJ , ShahabL , BeardE , JacksonS . Trends in vaping and smoking following the rise of disposable e-cigarettes: a repeat cross-sectional study in England between 2016 and 2023. The Lancet Regional Health – Europe2024;42:100924. [DOI: 10.1016/j.lanepe.2024.100924]">Tattan‐Birch 2024</a>). These are available in a range of attractive flavours, generally have a high nicotine content, are low cost, and have a closed system that is designed to be disposed of following use. According to <a href="./references#CD010216-bbs2-0193" title="Action on Smoking and Health. Use of vapes (e-cigarettes) among adults in Great Britain. https://ash.org.uk/resources/view/use-of-e-cigarettes-among-adults-in-great-britain August 2024. [WEB: https://ash.org.uk/resources/view/use-of-e-cigarettes-among-adults-in-great-britain]">ASH 2024</a>, for adults in Great Britain, tank‐style devices are the most popular. For young people, the <a href="./references#CD010216-bbs2-0193" title="Action on Smoking and Health. Use of vapes (e-cigarettes) among adults in Great Britain. https://ash.org.uk/resources/view/use-of-e-cigarettes-among-adults-in-great-britain August 2024. [WEB: https://ash.org.uk/resources/view/use-of-e-cigarettes-among-adults-in-great-britain]">ASH 2024</a> report shows that disposables are now the most popular type of device. The different device types may differ significantly in their efficacy in helping people who smoke to quit, as they differ in delivery of nicotine. Nicotine itself, when delivered through mechanisms and doses similar to that delivered in traditional NRT, is not considered harmful (<a href="./references#CD010216-bbs2-0238" title="Hartmann-BoyceJ , ChepkinSC , YeW , BullenC , LancasterT . Nicotine replacement therapy versus control for smoking cessation. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD000146. [DOI: 10.1002/14651858.CD000146.pub5]">Hartmann‐Boyce 2018a</a>). The safety profile of the different types of nicotine EC may be similar as they use the same constituents, although within the generic range of EC types there is some evidence to suggest EC providing less nicotine may pose higher risks. This is because low‐nicotine delivery devices need to be puffed with higher intensity to provide users with the nicotine levels that they seek, and more intensive puffing is accompanied by increased inhalation of potential toxicants (<a href="./references#CD010216-bbs2-0216" title="DawkinsLE , KimberCF , DoigM , FeyerabendC , CorcoranO . Self-titration by experienced e-cigarette users: blood nicotine delivery and subjective effects. Psychopharmacology (Berl)2016;233(14-16):2933-41. [DOI: 10.1007/s00213-016-4338-2]">Dawkins 2016</a>; <a href="./references#CD010216-bbs2-0217" title="DawkinsL , CoxS , GoniewiczM , McRobbieH , KimberC , DoigM , et al. 'Real-world' compensatory behaviour with low nicotine concentration e-liquid: subjective effects and nicotine, acrolein and formaldehyde exposure. Addiction2018;113(10):1874-82.">Dawkins 2018</a>; <a href="./references#CD010216-bbs2-0288" title="SmetsJ , BaeyensF , ChaumontM , AdriaensK , Van GuchtD . When less is more: vaping low-nicotine vs. high-nicotine e-liquid is compensated by increased wattage and higher liquid consumption. International Journal of Environmental Research and Public Health2019;16(5):723.">Smets 2019</a>). Throughout this review, we refer to a nicotine‐containing EC as ‘nicotine EC’ and to nicotine‐free EC as 'non‐nicotine EC', which can also be considered 'placebo EC'. The 'placebo' comparison is a test just of the nicotine effect and not of the potential sensorimotor or behavioural and social replacement that the EC may provide. </p> <p>There is no one agreed classification system for EC devices, and product development has moved so quickly that the definitions used within trials of the devices tested may no longer necessarily be fit for purpose. In this review, the definitions used are based on those drawn from the included trials. We currently label three different types of EC as 'cartridges' for devices with disposable cartridges and ‐ typically, but not always ‐ low nicotine delivery (e.g. cig‐a‐likes); refillable ECs for devices that people fill with their own choice of e‐liquids; and pods for the small devices with disposable pods that commonly use nicotine salts. To date, there are no trials of disposable devices, so we do not include this category in the current review. We may review this categorization system in future versions of the review as new trials and devices emerge. </p> </section> <section id="CD010216-sec-0012"> <h3 class="title" id="CD010216-sec-0012">Why it is important to do this review</h3> <p>Since ECs appeared on the market in 2006, there has been a steady increase in their use. In Great Britain, only 27% of people who smoke have never tried vaping according to a recent survey (<a href="./references#CD010216-bbs2-0192" title="Action on Smoking and Health. Use of e-cigarettes (vapes) among adults in Great Britain. Use-of-e-cigarettes-among-adults-in-Great-Britain-2023.pdf (ash.org.uk) August 2023 (accessed 27 September 2023).">ASH 2023</a>). EC use is most prevalent in people who currently (27%) and have previously (15%) smoked (<a href="./references#CD010216-bbs2-0192" title="Action on Smoking and Health. Use of e-cigarettes (vapes) among adults in Great Britain. Use-of-e-cigarettes-among-adults-in-Great-Britain-2023.pdf (ash.org.uk) August 2023 (accessed 27 September 2023).">ASH 2023</a>). Only 1.1% of adults who have never smoked report currently using ECs (<a href="./references#CD010216-bbs2-0192" title="Action on Smoking and Health. Use of e-cigarettes (vapes) among adults in Great Britain. Use-of-e-cigarettes-among-adults-in-Great-Britain-2023.pdf (ash.org.uk) August 2023 (accessed 27 September 2023).">ASH 2023</a>). Prevalence data from the USA in 2019 showed that 4.4% of adults were current EC users (<a href="./references#CD010216-bbs2-0221" title="DuY , LiuB , XuG , RongS , SunY , WuY , et al. Association of electronic cigarette regulations with electronic cigarette use among adults in the United States. JAMA Network Open2020;3(1):e1920255.">Du 2020</a>). Data from lower‐income countries suggest similar levels of EC use and awareness (<a href="./references#CD010216-bbs2-0201" title="BesaratiniaA , TommasiS . Vaping: a growing global health concern. EClinicalMedicine2019;17:100208.">Besaratinia 2019</a>; <a href="./references#CD010216-bbs2-0250" title="JiangN , ChenJ , WangMP , McGheeSM , KwongAC , LaiVW , et al. Electronic cigarette awareness and use among adults in Hong Kong. Addictive Behaviors2016;52:34-8.">Jiang 2016</a>; <a href="./references#CD010216-bbs2-0269" title="PalipudiKM , MbuloL , MortonJ , BunnellR , Blutcher-NelsonG , KosenS , et al. Awareness and current use of electronic cigarettes in Indonesia, Malaysia, Qatar, and Greece: findings from 2011–2013 global adult tobacco surveys. Nicotine &amp; Tobacco Research2016;18(4):501-7.">Palipudi 2016</a>). </p> <p>Regulatory approaches being used for ECs currently vary widely, from no regulation to partial and complete bans (<a href="./references#CD010216-bbs2-0261" title="McNeillA , SimonavičiusE , BroseLS , TaylorE , EastK , ZuikovaE , et al. Nicotine vaping in England: an evidence update including health risks and perceptions. A report commissioned by the Office for Health Improvement and Disparities. London: Office for Health Improvement and Disparities. assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1107701/Nicotine-vaping-in-England-2022-report.pdf (accessed prior to 3 November 2022).">McNeill 2022</a>). Within the USA, for example, the Food and Drug Administration (FDA) has classified EC as tobacco products and laws include prohibition of EC use indoors, a requirement for retailers to have a license to sell, and prohibition of sales to minors. Laws prohibiting sales to minors apply nationwide, but other laws vary by state (<a href="./references#CD010216-bbs2-0221" title="DuY , LiuB , XuG , RongS , SunY , WuY , et al. Association of electronic cigarette regulations with electronic cigarette use among adults in the United States. JAMA Network Open2020;3(1):e1920255.">Du 2020</a>). The European Union includes ECs in their Tobacco Products Directive, except where therapeutic claims are made or in instances where they contain over 20 mg/nl of nicotine (<a href="./references#CD010216-bbs2-0225" title="European Parliament and Council of the European Union. Directive 2014/40/EU of the European Parliament and of the Council of 3 April 2014 on the approximation of the laws, regulations and administrative provisions of the Member States concerning the manufacture, presentation and sale of tobacco and related products and repealing Directive 2001/37/EC. EUR-Lex - 32014L0040 - EN - EUR-Lex (europa.eu) 2014 (accessed 25 November 2014).">European Parliament 2014</a>). </p> <p>Categorical statements about the toxicity of ECs are not possible because of the large number of devices and liquids available and the frequent addition of new products to the market. In 2019, cases of severe lung injury associated with EC use were reported in the USA and, by February 2020, there were around 2800 hospitalized cases and 68 deaths (<a href="./references#CD010216-bbs2-0208" title="Centres for Disease Control and Prevention. Outbreak of lung injury associated with the use of e-cigarette, or vaping, products. www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html#latest-outbreak-information; February 2020 (accessed 12 August 2020).">CDC 2020</a>). This illness, which was termed E‐cigarette or Vaping‐Associated Lung Injury (EVALI), caused concern throughout the world (<a href="./references#CD010216-bbs2-0237" title="HallW , GartnerC , BonevskiB . Lessons from the public health responses to the US outbreak of vaping-related lung injury. Addiction 2020 [Epub ahead of print].">Hall 2020</a>) and a negative change in people's perception of the risks of EC use compared to smoking (<a href="./references#CD010216-bbs2-0290" title="Tattan-BirchH , BrownJ , ShahabL , JacksonSE . Association of the US outbreak of vaping-associated lung injury with perceived harm of e-cigarettes compared with cigarettes. JAMA Network Open2020;3(6):e206981.">Tattan‐Birch 2020</a>). These cases were somewhat at odds with data from trials and cohort studies, and it was later found that these injuries were related to use of tetrahydrocannabinol (THC)‐containing products adulterated with vitamin E acetate (<a href="./references#CD010216-bbs2-0203" title="BlountBC , KarwowskiMP , ShieldsPG , Morel-EspinosaM , Valentin-BlasiniL , GardnerM , et al. Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI. New England Journal of Medicine2020;382(8):697-705.">Blount 2020</a>; <a href="./references#CD010216-bbs2-0244" title="HartnettKP , Kite-PowellA , PatelMT , HaagBL , SheppardMJ , DiasTP , et al. Syndromic surveillance for e-cigarette, or vaping, product use-associated lung injury. New England Journal of Medicine2020;382(8):766-72.">Hartnett 2020</a>). </p> <p>Amongst those brands of nicotine EC that have been tested, levels of toxins have been found to be substantially lower than in cigarettes (<a href="./references#CD010216-bbs2-0233" title="HajekP , Etter J-F, BenowitzN , EissenbergT , McRobbieH . Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction2014;109(11):1801-10.">Hajek 2014</a>; <a href="./references#CD010216-bbs2-0261" title="McNeillA , SimonavičiusE , BroseLS , TaylorE , EastK , ZuikovaE , et al. Nicotine vaping in England: an evidence update including health risks and perceptions. A report commissioned by the Office for Health Improvement and Disparities. London: Office for Health Improvement and Disparities. assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1107701/Nicotine-vaping-in-England-2022-report.pdf (accessed prior to 3 November 2022).">McNeill 2022</a>). Long‐term effects beyond 12 months are unclear, although based on what is known about liquid and vapour constituents and patterns of use, a report from the UK's Royal College of Physicians has concluded that using an EC is likely to be considerably safer than smoking (<a href="./references#CD010216-bbs2-0277" title="Tobacco Advisory Group of the Royal College of Physicians. Nicotine Without Smoke—Tobacco Harm Reduction. London: Royal College of Physicians, 2016.">RCP 2016</a>). The US National Academies of Sciences, Engineering, and Medicine (NASEM) concluded that ECs are likely to be far less harmful than continuing to smoke cigarettes, with the caveat that the long‐term health effects of e‐cigarette use are not yet known (<a href="./references#CD010216-bbs2-0264" title="National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice. Public Health Consequences of E-Cigarettes. Washington (DC): National Academies Press (US), 2018.">NASEM 2018</a>). </p> <p>Despite general acknowledgement that EC use exposes the user to fewer toxicants and at lower levels than smoking cigarettes (<a href="./references#CD010216-bbs2-0260" title="McNeillA , BroseLS , CalderR , BauldL , RobsonD . Vaping in England: an evidence update including vaping for smoking cessation, February 2021: a report commissioned by Public Health England London, UK: Public Health England. assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/962221/Vaping_in_England_evidence_update_February_2021.pdf (accessed prior to 3 November 2022).">McNeill 2021</a>; <a href="./references#CD010216-bbs2-0261" title="McNeillA , SimonavičiusE , BroseLS , TaylorE , EastK , ZuikovaE , et al. Nicotine vaping in England: an evidence update including health risks and perceptions. A report commissioned by the Office for Health Improvement and Disparities. London: Office for Health Improvement and Disparities. assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1107701/Nicotine-vaping-in-England-2022-report.pdf (accessed prior to 3 November 2022).">McNeill 2022</a>; <a href="./references#CD010216-bbs2-0264" title="National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice. Public Health Consequences of E-Cigarettes. Washington (DC): National Academies Press (US), 2018.">NASEM 2018</a>; <a href="./references#CD010216-bbs2-0278" title="Royal College of Physicians. E-cigarettes and harm reduction: An evidence review, 2024. https://www.rcp.ac.uk/policy-and-campaigns/policy-documents/e-cigarettes-and-harm-reduction-an-evidence-review (accessed 1 August 2024).">RCP 2024</a>), in some countries and settings there remains hesitancy in making these products available to people who smoke as a harm‐reduction tool or smoking‐cessation aid (e.g. <a href="./references#CD010216-bbs2-0259" title="McDonaldCF , JonesS , BeckertL , BonevskiB , BuchananT , BozierJ , et al. Electronic cigarettes: a position statement from the Thoracic Society of Australia and New Zealand. Respirology 2020 [Epub ahead of print].">McDonald 2020</a>). Concerns include that the long‐term effects of EC use on health are not yet known, the possible harms of second‐hand EC vapour inhalation, the lack of quality control measures, and that ECs may undermine smoke‐free legislation if used in smoke‐free spaces (<a href="./references#CD010216-bbs2-0261" title="McNeillA , SimonavičiusE , BroseLS , TaylorE , EastK , ZuikovaE , et al. Nicotine vaping in England: an evidence update including health risks and perceptions. A report commissioned by the Office for Health Improvement and Disparities. London: Office for Health Improvement and Disparities. assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1107701/Nicotine-vaping-in-England-2022-report.pdf (accessed prior to 3 November 2022).">McNeill 2022</a>). Of concern is also the involvement of the tobacco industry and that ECs may be a gateway to smoking initiation or nicotine dependence amongst nicotine‐naïve users or may prolong continued dual use of tobacco amongst cigarette smokers (<a href="./references#CD010216-bbs2-0261" title="McNeillA , SimonavičiusE , BroseLS , TaylorE , EastK , ZuikovaE , et al. Nicotine vaping in England: an evidence update including health risks and perceptions. A report commissioned by the Office for Health Improvement and Disparities. London: Office for Health Improvement and Disparities. assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1107701/Nicotine-vaping-in-England-2022-report.pdf (accessed prior to 3 November 2022).">McNeill 2022</a>). A report from the US Preventive Services Taskforce concluded "that the current evidence is insufficient to assess the balance of benefits and harms of electronic cigarettes (e‐cigarettes) for tobacco cessation in adults" (<a href="./references#CD010216-bbs2-0297" title="US Preventive Services Task Force. Interventions for tobacco smoking cessation in adults,including pregnant persons. www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions (accessed prior to 3 November 2022).">USPFTS 2021</a>). However, others suggest that potential benefits outweigh potential disadvantages (<a href="./references#CD010216-bbs2-0226" title="FarsalinosKE , PolosaR . Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Therapeutic Advances in Drug Safety2014;5(2):67-86.">Farsalinos 2014</a>; <a href="./references#CD010216-bbs2-0233" title="HajekP , Etter J-F, BenowitzN , EissenbergT , McRobbieH . Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction2014;109(11):1801-10.">Hajek 2014</a>; <a href="./references#CD010216-bbs2-0260" title="McNeillA , BroseLS , CalderR , BauldL , RobsonD . Vaping in England: an evidence update including vaping for smoking cessation, February 2021: a report commissioned by Public Health England London, UK: Public Health England. assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/962221/Vaping_in_England_evidence_update_February_2021.pdf (accessed prior to 3 November 2022).">McNeill 2021</a>; <a href="./references#CD010216-bbs2-0261" title="McNeillA , SimonavičiusE , BroseLS , TaylorE , EastK , ZuikovaE , et al. Nicotine vaping in England: an evidence update including health risks and perceptions. A report commissioned by the Office for Health Improvement and Disparities. London: Office for Health Improvement and Disparities. assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1107701/Nicotine-vaping-in-England-2022-report.pdf (accessed prior to 3 November 2022).">McNeill 2022</a>; <a href="./references#CD010216-bbs2-0264" title="National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice. Public Health Consequences of E-Cigarettes. Washington (DC): National Academies Press (US), 2018.">NASEM 2018</a>; <a href="./references#CD010216-bbs2-0278" title="Royal College of Physicians. E-cigarettes and harm reduction: An evidence review, 2024. https://www.rcp.ac.uk/policy-and-campaigns/policy-documents/e-cigarettes-and-harm-reduction-an-evidence-review (accessed 1 August 2024).">RCP 2024</a>). </p> <p>People who smoke, healthcare providers, and regulators are interested in knowing if ECs can help people to quit and if it is safe to use them to do so. In particular, healthcare providers have an urgent need to know what they should recommend to people to help them to stop smoking. The largest health gains are achieved from stopping smoking completely, as opposed to reducing cigarette consumption and, as such, this review focuses on the effectiveness of ECs in aiding complete smoking cessation. </p> <p>This review was first published in 2014, and updated in 2016, 2020, 2021, 2022, and 2024. We published an update to the protocol in 2023 (see <a href="./references#CD010216-bbs2-0256" title="LindsonN , ButlerA , McRobbieH , BullenC , BeghR , Theodoulou A et al. Update to protocol of the Cochrane review of electronic cigarettes for smoking cessation. OSF 2023;July:1-3. [DOI: 10.17605/OSF.IO/ZWGSK]">Lindson 2023b</a>). </p> <p>Following publication of the 2020 update of this review, we are maintaining it as a living systematic review (<a href="./references#CD010216-bbs2-0204" title="BrookerJ , SynnotA , McDonaldS , ElliottJ , TurnerT , et al. Guidance for the production and publication of Cochrane living systematic reviews: Cochrane Reviews in living mode; December 2019. community.cochrane.org/sites/default/files/uploads/inline-files/Transform/201912_LSR_Revised_Guidance.pdf (accessed 30 July 2020).">Brooker 2019</a>). This means we are continually running searches and incorporating new evidence into the review. For more information about the living systematic review methods being used, see <a href="./appendices#CD010216-sec-0128">Appendix 1</a>. A living systematic review approach is appropriate for this review for three reasons. First, the review addresses an important public health issue: the role of ECs in enabling people who smoke to stop smoking, with the potential for substantial ongoing individual and societal benefits, depending on the extent of effectiveness. Secondly, there remains uncertainty in the existing evidence; more studies are needed to confirm the degree of benefit for different comparisons and product types, and there is considerable uncertainty about adverse events and other markers of safety. Thirdly, we are aware of multiple ongoing trials that are likely to have an important impact on the conclusions of the review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010216-sec-0013" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010216-sec-0013"></div> <p>To examine the safety, tolerability, and effectiveness of using electronic cigarettes (ECs) to help people who smoke tobacco achieve long‐term smoking abstinence, in comparison to non‐nicotine EC, other smoking cessation treatments, and no treatment. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010216-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010216-sec-0014"></div> <section id="CD010216-sec-0015"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010216-sec-0016"> <h4 class="title">Types of studies</h4> <p>We include randomized controlled trials (RCTs) and randomized cross‐over trials in which people who smoke are randomized to ECs or to a control condition. RCTs are the best available primary evidence; we also include uncontrolled intervention studies in which all participants are given an EC intervention. These studies have the potential to provide information on harms and longer‐term use. </p> <p>We include studies regardless of their publication status or language of publication.</p> </section> <section id="CD010216-sec-0017"> <h4 class="title">Types of participants</h4> <p>Participants are people defined as currently smoking cigarettes at enrolment into the studies. Participants could be motivated or unmotivated to quit. We include studies that recruited pregnant people and include their data in our pairwise meta‐analyses and narrative syntheses; however, we will not include their data in our network meta‐analyses (NMA) (described in our <a href="#CD010216-sec-0035">Data synthesis</a> section) as some of the comparisons eligible for inclusion are unlikely to be offered to this population (e.g. varenicline). </p> <p>Should a study meet all other criteria but include only a subset of eligible participants (e.g. a study on people who currently smoke and people who formerly smoked), we would only include data on the subgroup of participants who met our inclusion criteria. If these data were not available, we would include the study if at least 80% of participants met our inclusion criteria and would test the exclusion of the study in a sensitivity analysis. </p> <p>We include participants regardless of age.</p> </section> <section id="CD010216-sec-0018"> <h4 class="title">Types of interventions</h4> <p>Any type of EC or intervention intended to promote EC use for smoking cessation, including studies that did not measure smoking cessation but provided ECs with the instruction that they be used as a complete substitute for cigarette use. ECs may or may not contain nicotine. For the purpose of the NMA, we assume that the interventions were jointly randomizable for all participants except those who were pregnant. </p> <section id="CD010216-sec-0019"> <h5 class="title">Types of comparators</h5> <p>We compare nicotine ECs with alternative smoking cessation aids, including NRT or no intervention, with ECs without nicotine, and ECs added to standard smoking cessation treatment (behavioural or pharmacological or both) with standard treatment alone. We compare different types of EC (refillable, cartridge, nicotine salt, free‐base), different nicotine doses, and different flavours. </p> </section> </section> <section id="CD010216-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD010216-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010216-list-0001"> <li> <p>Cessation at the longest follow‐up point, at least six months from the start of the intervention, measured on an intention‐to‐treat basis using the strictest definition of abstinence, preferring biochemically validated results where reported </p> </li> <li> <p>Number of participants reporting any type of adverse event(s) at one week or longer (as defined by study authors) </p> </li> <li> <p>Number of participants reporting any type of serious adverse event(s) at one week or longer (as defined by study authors) </p> </li> </ul> </p> </section> <section id="CD010216-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>Number of people still using study product (EC or pharmacotherapy) at longest follow‐up (at least six months). The product could be that provided by the study, or could be the same product type but bought independently by the participant. </p> <p>Changes in the following measures at longest follow‐up (one week or longer):</p> <p> <ul id="CD010216-list-0002"> <li> <p>Carbon monoxide (CO), as measured through breath or blood</p> </li> <li> <p>Blood pressure</p> </li> <li> <p>Heart rate</p> </li> <li> <p>Blood oxygen saturation</p> </li> <li> <p>Lung function measures</p> </li> <li> <p>Known toxins/carcinogens, as measured through blood, urine or saliva (toxicant names and abbreviations are listed in <a href="./appendices#CD010216-sec-0136">Appendix 2</a>) </p> </li> </ul> </p> <p>Studies had to set out to measure one of the primary or secondary outcomes above to be eligible for inclusion. If a study set out to measure an eligible outcome but did not measure and/or report results on this outcome, we would still include this study and flag its missing data in the results section. </p> <p>In addition, we set out to include any measure of an association between withdrawal symptoms and smoking cessation at six months or longer, as long as withdrawal was measured using a validated scale designed explicitly to investigate smoking withdrawal or craving. We added this because British guidelines now specify that efforts should be made to provide EC in a way that will reduce symptoms of withdrawal in people who smoke (<a href="./references#CD010216-bbs2-0265" title="NICE, National Institute for Health and Care Excellence. Tobacco: preventing uptake, promoting quitting and treating dependence. NICE Guideline 2021, updated 2023;NG209(London):UK.">NICE 2021</a>). However, no studies provided data on this. </p> </section> </section> </section> <section id="CD010216-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010216-sec-0024"> <h4 class="title">Electronic searches</h4> <p>Searches are conducted monthly. This update includes results from searches conducted up to 1 February 2024: </p> <p> <ul id="CD010216-list-0003"> <li> <p>Cochrane Tobacco Addiction Group Specialized Register (CRS‐Web up to 1 February 2023);</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2024, Issue 1) via CRS‐Web;</p> </li> <li> <p>MEDLINE (OVID SP; 1 January 2004 to 1 February 2024);</p> </li> <li> <p>Embase (OVID SP; 1 January 2004 to 1 February 2024);</p> </li> <li> <p>PsycINFO (OVID SP; 1 January 2004 to 1 February 2024);</p> </li> <li> <p><a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> (via CENTRAL; 2024, Issue 1); </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP: <a href="https://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>, via CENTRAL; 2024, Issue 1). </p> </li> </ul> </p> <p>We did not search the Cochrane Tobacco Addiction Group Specialized Register beyond 1 February 2023 as it ceased to be maintained. At the time of the last search, the Register included the results of searches of MEDLINE (via OVID) to update 20221222; Embase (via OVID) to week 202251; and PsycINFO (via OVID) to update 20221219. See the <a href="https://tobacco.cochrane.org/resources/cochrane-tag-specialised-register" target="_blank">Tobacco Addiction Group website</a> for full search strategies and a list of other resources searched. </p> <p>For the first version of the review, we also searched CINAHL (EBSCO Host) (2004 to July 2014). We did not search this database from 2016 onwards, as it did not contribute additional search results to the first version of the review. The search terms were broad and included 'e‐cig$' OR 'elect$ cigar$' OR 'electronic nicotine'. The search for the 2016 update added the terms 'vape' or 'vaper' or 'vapers' or 'vaping'. The 2020 searches added further terms, including the MESH heading 'Electronic Nicotine Delivery Systems' and terms to limit by study design. All current search strategies are listed in <a href="./appendices#CD010216-sec-0137">Appendix 3</a>. The previously used search strategy is shown in <a href="./appendices#CD010216-sec-0138">Appendix 4</a>. The search date parameters of the original searches were limited to 2004 to the present, due to the fact that ECs were not available before 2004. </p> </section> <section id="CD010216-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of eligible studies found in the literature search and contacted authors of known trials and other published EC studies. We also searched abstracts from the Society for Research on Nicotine and Tobacco (SRNT) Annual Meetings up to 1 February 2024. </p> </section> </section> <section id="CD010216-sec-0026"> <h3 class="title" id="CD010216-sec-0026">Data collection and analysis</h3> <section id="CD010216-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (for this update from: ARB, JHB, NL, AT) independently pre‐screened all titles and abstracts obtained from the search, using a screening checklist, and then independently screened full‐text versions of the potentially relevant papers for inclusion. We resolved any disagreements by discussion or with a third review author. </p> </section> <section id="CD010216-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>One review author extracted data on study characteristics (ARB), whereas two review authors (for this update: ARB and ADW) independently extracted outcome data, effect modifiers, and the information needed to make risk of bias judgements. We used a pre‐piloted data extraction form, and checked the forms for inconsistencies. We resolved any disagreements by discussion or with a third review author (NL). We extracted data on the following: </p> <p> <ul id="CD010216-list-0004"> <li> <p>Author</p> </li> <li> <p>Date and place of publication</p> </li> <li> <p>Study dates</p> </li> <li> <p>Study design</p> </li> <li> <p>Inclusion and exclusion criteria</p> </li> <li> <p>Setting</p> </li> <li> <p>Summary of study participant characteristics</p> </li> <li> <p>Summary of intervention and control conditions</p> </li> <li> <p>Number of participants in each arm</p> </li> <li> <p>Smoking cessation outcomes</p> </li> <li> <p>Type of biochemical validation (if any)</p> </li> <li> <p>Adverse events (AEs), serious adverse events (SAEs), number of people still using study product, and relevant biomarkers </p> </li> <li> <p>Continued EC use or pharmaceutical intervention (PI) use at longest follow‐up</p> </li> <li> <p>Data investigating the association between withdrawal and smoking cessation</p> </li> <li> <p>Assessment time points</p> </li> <li> <p>Study funding source</p> </li> <li> <p>Author declarations of interest</p> </li> <li> <p>Risk of bias in the domains specified below</p> </li> <li> <p>Additional comments</p> </li> </ul> </p> <p>We adopted a broad focus to detect a variety of adverse events.</p> <p>There were no papers that required translation<i>;</i> should there be in the future, we would seek a translator to assist us. </p> <p>For studies that received tobacco or EC industry funding the study name is followed by an asterisk (*). </p> <p>One review author (NL for this update) then entered the data contributing to pairwise network meta‐analysis (NMA) into <a href="./references#CD010216-bbs2-0279" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">Review Manager 2022</a> software for analyses, and another checked them (JHB for this update). Data for the NMA were collated by one author (ARB) and checked by NL and JHB. </p> </section> <section id="CD010216-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (for this update: ARB and ADW) independently assessed the risks of bias for each included study, using the Cochrane risk of bias tool (RoB 1) (<a href="./references#CD010216-bbs2-0246" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We resolved any disagreements by discussion or with a third review author (NL). This approach uses a domain‐based evaluation that addresses seven different areas: random sequence generation; allocation concealment; blinding of participants and providers; blinding of outcome assessment; incomplete outcome data; selective outcome reporting; and other potential sources of bias. We assigned a grade (low, high, or unclear) for risk of bias for each domain. We resolved disagreements by discussion or by consulting a third review author. </p> <p>Specific considerations about judgements for individual domains in this review are outlined below: </p> <p> <ul id="CD010216-list-0005"> <li> <p>Random sequence generation/allocation concealment: We rated all non‐randomized studies at high risk in these domains. </p> </li> <li> <p>Blinding of participants and personnel: We did not evaluate this domain for non‐randomized studies, as we considered it not to be applicable. For randomized studies that did not use blinding, we considered studies to be at low risk in this domain if the intervention was compared to an active control of similar intensity, as we judged performance bias to be unlikely in this circumstance. If studies were unblinded and the comparator group was a minimal‐intervention control or of lower intensity than the intervention group, we considered the study to be at high risk of bias in this domain. </p> </li> <li> <p>Following the standard methods of the Cochrane Tobacco Addiction Group, we considered studies to be at low risk of detection bias (blinding of outcome assessment) if our primary outcome was objectively measured or if the intensity of the intervention was similar between groups, or both. For studies where cessation was measured, our judgement was based on whether cessation was biochemically verified. Where cessation was not measured, we judged this domain based on adverse or serious adverse events. </p> </li> <li> <p>Again, following the standard methods of the Cochrane Tobacco Addiction Group, we rated studies at high risk of attrition bias if loss to follow‐up was greater than 50% overall or if there was a difference in follow‐up rates of more than 20% between study arms. </p> </li> </ul> </p> <p>We judged studies to be at high risk of bias overall if they were rated at high risk in at least one domain, and at low risk of bias overall if they were judged to be at low risk across all domains evaluated. We judged the remaining studies to be at unclear risk of bias overall. </p> </section> <section id="CD010216-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We analyzed dichotomous data by calculating the risk ratio (RR). For cessation, we calculated the RR as (number of events in intervention condition/intervention denominator)/(number of events in control condition/control denominator) with a 95% confidence interval (CI), using data at the longest follow‐up period reported. </p> <p>We analyzed continuous data (other measures of tobacco exposure) by comparing the difference between the mean change from baseline to follow‐up in the intervention and comparator groups, or by comparing absolute data at follow‐up where insufficient data were available on mean change. For outcomes other than cessation where data were reported at multiple time points, we used data at the longest follow‐up point at which ECs were still being provided, or their use was encouraged. </p> </section> <section id="CD010216-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>In the case of trials with multiple arms, we do not combine data between arms unless this is the way it has been presented by study authors, or there is no evidence of difference between similar trial arms for the outcome of interest. We note in our analyses where this is the case. </p> <p>For all but one study, the unit of assignment was the individual. <a href="./references#CD010216-bbs2-0016" title="DawkinsL , BauldL , FordA , RobsonD , HajekP , ParrottS , et al. A cluster feasibility trial to explore the uptake and use of e-cigarettes versus usual care offered to smokers attending homeless centres in Great Britain. PLOS One2020;15(10):e0240968. [ISRCTN14140672]ISRCTN14140672. Exploring the use and uptake of e-cigarettes for homeless smokers. www.isrctn.com/ISRCTN14140672 (first received 7 November 2018). ">Dawkins 2020</a> assigned the condition based on homeless support service; this was a small pilot study with very few events and hence we judged clustering to have very little impact on our overall result. If larger cluster‐randomized trials are eligible in the future, we will assess whether the study authors have adjusted for this clustering, and whether this had an impact on the overall result. When clustering appears to have had little impact on the results, we will use unadjusted quit‐rate data; however, when clustering does appear to have an impact on results, we will adjust for this using the intraclass correlation (ICC). </p> <p>For randomized cross‐over trials, we report results at the end of the first assignment period where available and where sufficiently long to meet our inclusion criteria for outcomes. All other outcomes from randomized cross‐over trials are reported narratively. We offer a narrative synthesis of data from non‐randomized studies and outcomes from comparative trials that are not reported with sufficient data for meta‐analysis, using effect direction plots as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i> where possible (<a href="./references#CD010216-bbs2-0247" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>). </p> </section> <section id="CD010216-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>For smoking cessation, we use a conservative approach, as is standard for the Cochrane Tobacco Addiction Group, treating participants with missing data as still smoking. We base the proportion of people affected by adverse events on the number of people available for follow‐up, and not the number randomized. For other outcomes, we use complete‐case data and do not attempt to impute missing values. </p> </section> <section id="CD010216-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the clinical and methodological diversity between studies to guide our decision about whether data should be pooled. We were also guided by the degree of statistical heterogeneity, assessed by calculating the I<sup>2</sup> statistic (<a href="./references#CD010216-bbs2-0245" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>), and considering a value greater than 50% as evidence of substantial heterogeneity. We did not present pooled results where I<sup>2</sup> values exceeded 75%. </p> <p>For our NMA, we assessed global inconsistency using scatterplots of residual deviance in the NMA model against residual deviance in the Unrelated Mean Effects (UME) model. The UME model does not assume transitivity of treatment effects, so a smaller deviance in this model in comparison to the main NMA indicates inconsistency within the network. We also used scatterplots of leverage versus deviance to check the general model fit. We assessed local inconsistency using node‐split models for the main analyses of each outcome. We did not formally assess potential participant‐level effect moderators as a way to evaluate transitivity in our NMA, as previous work has shown these to be inconsistently reported in this body of studies (<a href="./references#CD010216-bbs2-0240" title="Hartmann-BoyceJ , Livingstone-BanksJ , Ordonez-MenaJ , FanshaweTR , LindsonN , FreemanSC , et al. Behavioural interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database of Systematic Reviews2021, Issue 1. Art. No: CD013229. [DOI: 10.1002/14651858.CD013229.pub2]">Hartmann‐Boyce 2021b</a>; <a href="./references#CD010216-bbs2-0243" title="Hartmann-BoyceJ , Ordonez-MenaJ , Livingstone-BanksJ , FanshaweT , LindsonN , FreemanS , et al. Behavioural programmes for cigarette smoking cessation: investigating interactions between behavioural, motivational and delivery components in a systematic review and component network meta-analysis. Addiction2022;117(8):2145-56. [DOI: org/10.1111/add.15791]">Hartmann‐Boyce 2022c</a>; <a href="./references#CD010216-bbs2-0255" title="LindsonN , TheodoulouA , Ordóñez-MenaJM , FanshaweTR , SuttonAJ , Livingstone-BanksJ , et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses. Cochrane Database of Systematic Reviews2023, Issue 9. Art. No: CD015226. [DOI: 10.1002/14651858.CD015226.pub2]">Lindson 2023a</a>). </p> </section> <section id="CD010216-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting bias can be assessed using funnel plots, where 10 or more RCTs contribute to an outcome. Where studies were included in an analysis but did not contribute data to the pooled effect (as zero events were reported), these were not included in the count of included studies when deciding whether to generate funnel plots. Therefore, there were only two analyses with sufficient studies to support this approach. </p> <p>Had it been appropriate for our NMA, we would have adapted existing methods for assessing publication bias in standard systematic reviews by generating a funnel plot for each of the comparisons of interest and overlaying these plots on top of one another, while aligning the reference lines (representing the overall component effect). This is called a 'comparison adjusted funnel plot'. We would have considered studies distributed asymmetrically as potential evidence of publication bias. However, there were insufficient studies for each comparison to make this approach appropriate. </p> </section> <section id="CD010216-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We provide a narrative summary of the included studies.</p> <section id="CD010216-sec-0036"> <h5 class="title">Pairwise meta‐analyses</h5> <p>Where appropriate, we have pooled data from RCTs in pairwise meta‐analyses, grouping studies by comparison type and outcome. Data from single‐armed intervention studies are summarized narratively. Where presented per type of AE, rather than for all types together, these data were summarized narratively rather than meta‐analyzed. </p> <p>For dichotomous data, we used a fixed‐effect Mantel‐Haenszel model to calculate the RR with a 95% CI, in accord with the standard methods of the Cochrane Tobacco Addiction Group for cessation studies. </p> <p>For continuous outcomes, we pooled mean differences (or standardized mean differences for studies using different measures for the same construct), using the inverse variance approach (also with a 95% CI). </p> </section> <section id="CD010216-sec-0037"> <h5 class="title">Network meta‐analyses</h5> <p>We also carried out three network meta‐analyses (NMA), as these can give further insight into comparative effects by drawing on data from both direct and indirect comparisons. NMA produces estimates of the relative effects between any pair of interventions in the network, usually providing more precise estimates than a single direct estimate (<a href="./references#CD010216-bbs2-0209" title="ChaimaniA , CaldwellDM , LiT , HigginsJPT , SalantiG . Chapter 11: Undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org/handbook.">Chaimani A</a>). Our three NMAs are as follows: one for each of our three primary outcomes: smoking cessation at six months follow‐up or longer; AEs at one‐week follow‐up or longer; and SAEs at one‐week follow‐up or longer. All NMAs were run using MetaInsight (<a href="./references#CD010216-bbs2-0268" title="OwenRK , BradburyN , XinY , CooperN , SuttonA . MetaInsight: An interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta. Research Synthesis Methods2019;10(4):569-81.">Owen 2019</a>). The models were Bayesian generalized linear models with non‐informative prior distributions on all parameters. Fixed effects were assumed in each case. MCMC simulations were run for 25,000 iterations, with the first 5,000 discarded, on four chains. Convergence was assessed through Gelman plots. Bayesian models were chosen because they are more flexible and have become the most common choice for NMA in recent years. </p> <p>Our NMAs only included RCTs and excluded studies carried out on pregnant people, as specified in the <a href="#CD010216-sec-0017">Types of participants</a> section. Interventions were classified as nodes as per our primary comparisons, but only including nodes where two or more studies contributed data. In addition, NRT was split into combined and single forms because evidence indicates there is a clinically significant difference in smoking cessation outcomes between them (<a href="./references#CD010216-bbs2-0294" title="TheodoulouA , ChepkinSC , YeW , FanshaweTR , BullenC , Hartmann-BoyceJ , et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews2023, Issue 6. Art. No: CD013308. [DOI: 10.1002/14651858.CD013308.pub2]">Theodoulou 2023</a>). In this update, the following interventions were eligible nodes (further nodes may be added as additional comparisons are added): </p> <p> <ul id="CD010216-list-0006"> <li> <p>Nicotine EC</p> </li> <li> <p>Non‐nicotine EC</p> </li> <li> <p>NRT (single form)</p> </li> <li> <p>NRT (combined fast‐acting form and patch)</p> </li> <li> <p>Nicotine EC plus single‐form NRT</p> </li> <li> <p>Non‐nicotine EC plus single‐form NRT</p> </li> <li> <p>Advice to use nicotine e‐cigarettes in a quit attempt (but no e‐cigarettes provided)</p> </li> <li> <p>No e‐cigarettes or pharmacotherapy</p> </li> </ul> </p> <p>Studies that provided an additional intervention component, such as behavioural support, were included only if the additional component was matched between intervention arms and comparator arms, as is the case for this review overall. </p> <p>Studies with no outcome events in any study arm were excluded. In contrast, studies with no outcome events in some but not all arms were included. </p> <p>We did not conduct any ranking of interventions in the NMA.</p> </section> </section> <section id="CD010216-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>For our pairwise analyses, we had planned to undertake subgroup analyses to investigate differences between studies, such as the following: </p> <p> <ul id="CD010216-list-0007"> <li> <p>Intensity of behavioural support used (as this could potentially influence cessation).</p> </li> <li> <p>Type of EC, e.g. cartridge; refillable; pod (as this could potentially influence all outcomes due to different delivery mechanisms). </p> </li> <li> <p>Instructions for EC use, e.g. study provision, length of provision, whether participants had a role in product choice (as this could potentially influence all outcomes, given variation in available devices and e‐liquids). </p> </li> <li> <p>Type of participants (this could potentially influence all outcomes, depending on, e.g. pre‐existing conditions, previous experience with EC). </p> </li> </ul> </p> <p>However, there were too few studies to conduct such analyses. Should further studies become available in future, we will follow this approach. For continuous outcomes, we subgroup data based on whether absolute values or change scores were available. For adverse events, we subgroup data by length of follow‐up for descriptive purposes. </p> <p>In the absence of sufficient data for subgroup analyses on EC type, in the text we specify the type of nicotine EC when reporting pooled results for cessation. </p> </section> <section id="CD010216-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>For both pairwise and network meta‐analyses, we conducted sensitivity analyses to detect whether pooled results were sensitive to the removal of studies judged to be at high risk of bias overall, and to the removal of studies reporting funding by the tobacco and/or vaping industry. We did this for all outcomes. </p> </section> <section id="CD010216-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Following standard Cochrane methodology, we created summary of findings tables for our three main comparisons using <a href="./references#CD010216-bbs2-0230" title="GRADEpro GDT. Version accessed 30 July 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2020. Available at gradepro.org.">GRADEpro GDT</a>: nicotine EC versus non‐nicotine EC; nicotine EC versus NRT; and nicotine EC versus behavioural support only/no support. We selected these comparisons a priori as being the most clinically relevant. </p> <p>In the summary of findings tables, we present data on our primary outcomes (cessation at longest follow‐up, at least six months from baseline, and adverse events and serious adverse events at one week or longer, at the longest follow‐up at which participants were still being provided or encouraged to use EC) for these main comparisons, from our pairwise meta‐analyses only. </p> <p>Following standard Cochrane methodology, we used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence for each outcome (also based on our pairwise meta‐analyses only), and to draw conclusions about the certainty of evidence within the text of the review. GRADE assessments were carried out by JHB and NL. If, in the future, results from NMA are inconsistent with those from our pairwise analyses, we will consider this as a possible justification for downgrading based on indirectness (as it would signal that direct and indirect evidence are incongruent). </p> <p>We did not conduct certainty assessments for the NMA outcomes, as our primary analyses of interest were the pair‐wise comparisons. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010216-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010216-sec-0041"></div> <section id="CD010216-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD010216-sec-0043"> <h4 class="title">Results of the search</h4> <p>For this update, our bibliographic database searches identified 624 non‐duplicate records (See <a href="#CD010216-fig-0001">Figure 1</a> for PRISMA flow diagram). We screened all records and retrieved the full‐text papers of 34 potentially relevant articles. After screening and checking the full texts, we included 26 records, representing two new studies for this update (<a href="./references#CD010216-bbs2-0066" title="NCT04854616. Cessation of Smoking Trial in the Emergency Department (CoSTED). clinicaltrials.gov/ct2/show/NCT04854616 (date first received 22 April 2021). NotleyC , ClarkL , BeldersonP , WardE , ClarkAB , ParrottS , et al. Cessation of smoking trial in the emergency department (CoSTED): protocol for a multicentre randomised controlled trial. BMJ Open2023;13(1):e064585. PopeI , ClarkLV , ClarkA , WardE , BeldersonP , Stirling S et al. Cessation of Smoking Trial in the Emergency Department (COSTED): a multicentre randomised controlled trial. Emergency Medicine Journal2024;41(5):276-82. [DOI: 10.1136/emermed-2023-213824]PopeI , NotleyC , BoyleA . Results of the cessation of smoking trial in the emergency department (COSTED). Emergency Medicine Journal2023;40(12):873-4. PopeI , NotleyC . Cessation of smoking trial in the emergency department. In: SRNT 29th Annual Meeting; 2023 Mar 1-4; San Antonio (TX), USA, POS2-14. 2023:119-20. ">Pope 2024</a>; <a href="./references#CD010216-bbs2-0089" title="XuY , GoldensonNI , Prakash S AugustsonEM , ShiffmanS . Randomized trial assessing the effect of the JUUL system on switching away from cigarettes and smoking reduction among U.S. adults who smoke cigarettes.. Experimental and Clinical Psychopharmacology2024;32(1):3-15. [DOI: 10.1037/pha0000698]">Xu 2023*</a>), 11 new articles linked to studies already identified, 11 new ongoing studies, and two records awaiting classification (see <a href="./references#CD010216-sec-0151" title="">Characteristics of ongoing studies</a>). Secondary study reports, commentaries, and correspondence relating to included studies are linked to studies in the reference section. </p> <div class="figure" id="CD010216-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA diagram for 2024 update" data-id="CD010216-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA diagram for 2024 update</p> </div> </div> </div> </section> <section id="CD010216-sec-0044"> <h4 class="title">Included studies</h4> <p>In total, we include 90 studies, with two new included studies and 88 studies included in the previous version of this review. Key features of these included studies are summarized below. Further details on each included study can be found in the <a href="./references#CD010216-sec-0148" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD010216-sec-0045"> <h4 class="title">Participants</h4> <p>The 90 included studies represented 29,044 participants. Thirty‐nine studies were conducted in the USA, 20 were conducted in the UK, nine in Italy, five in Australia, four in Greece, two each in New Zealand, Switzerland, and Canada, and one each in Belgium, Ireland, the Netherlands, Poland, the Republic of Korea, South Africa, and Turkey. All studies were conducted in adults who smoked. Twenty‐six studies exclusively recruited participants who were not motivated to quit smoking, and 45 studies exclusively recruited participants motivated to quit; motivation was not specified for the other studies. Thirty‐two studies recruited from specific population groups; these included nine studies that recruited participants based on physical health condition (heart attack, cancer, HIV, periodontitis, awaiting surgery, smoking‐related chronic disease), five studies that recruited participants with serious mental illness, four studies that recruited participants on treatment or having recently completed treatment for alcohol or other drug use, and three studies in dual users of EC and conventional cigarettes. Two studies recruited people accessing homeless centres or using supported temporary accommodation, and a further two recruited specifically within socially deprived areas. One study each recruited: people aged 55 or older, young adults, people who self‐identified as African‐American, pregnant women, people who had recently made a failed attempt to quit smoking, black and Latino participants, and people attending the emergency department. </p> </section> <section id="CD010216-sec-0046"> <h4 class="title">Interventions and comparators</h4> <p>Three studies recruited dual users of combustible cigarettes and EC at baseline, and instructed them to continue using their own EC devices (<a href="./references#CD010216-bbs2-0015" title='CzoliCD , FongGT , GoniewiczML , HammondD . Biomarkers of exposure among "dual users" of tobacco cigarettes and electronic cigarettes in Canada. Nicotine and Tobacco Research2019;21(9):1259-66. '>Czoli 2019</a>; <a href="./references#CD010216-bbs2-0047" title="ByrneM , SimmonsV , MartinezU , SuttonS , BrandonK , BrandonT . Cost effectiveness of a smoking cessation intervention for dual users of combustible and electronic cigarettes. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. March 2022. GoreLR , SuttonSK , MartinezU , BrandonKO , SimmonsVN , BrandonTH . Mediators of initial abstinence for an extended self help smoking cessation intervention with dual users of combustible and electronic cigarettes. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. Vol. PS3-7. March 2022. MartinezU , SimmonsVN , BrandonKO , QuinnGP , BrandonTH . Examining smoking and vaping behaviors, expectancies, and cessation outcomes between bisexual and heterosexual individuals. Behavioral Medicine 2023;49(4):392-401. [DOI: 10.1080/08964289.2022.2077295]MartinezU , SimmonsVN , SuttonSK , DrobesDJ , MeltzerLR , BrandonKO , et al. Targeted smoking cessation for dual users of combustible and electronic cigarettes: a randomised controlled trial. Lancet Public Health2021;6(7):e500-9. MeltzerLR , SimmonsVN , SuttonSK , DrobesDJ , QuinnGP , MeadeCD , et al. A randomized controlled trial of a smoking cessation self-help intervention for dual users of tobacco cigarettes and e-cigarettes: intervention development and research design. Contemporary Clinical Trials2017;60:56-62. NCT02416011. Smoking cessation self-help for dual users of tobacco cigarettes and e-cigarettes. clinicaltrials.gov/ct2/show/NCT02416011 (first received 18 August 2020). SuttonSK , BrandonKO , HarrellPT , Martínez Ú, SimmonsVN , Gore LR et al. Identifying prospective subpopulations of combustible and electronic cigarette dual users in the United States via finite mixture modeling. Addiction2022;117(9):2493-503. [DOI: 10.1111/add.15906]">Martinez 2021</a>; <a href="./references#CD010216-bbs2-0083" title="NCT03575468. Enhanced e-cigarette coaching intervention for dual users of cigarettes and e-cigarettes. clinicaltrials.gov/ct2/show/NCT03575468 (first received 2 July 2018). VickermanKA , CarpenterKM , MilesLN , HsuJM , WattKA , BrandonTH , et al. A randomized pilot of a tailored smoking cessation quitline intervention for individuals who smoke and vape. Nicotine &amp; Tobacco Research2022;24(11):1811-20. [DOI: 10.1093/ntr/ntac129]VickermanKA , CarpenterKM , WattK , MilesL , HsuJ , BrandonT , et al. A behavioral smoking cessation intervention for Quitline callers who also use e-cigarettes. In: Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting; February 24-27 2021 (virtual). 2021:POD14-1 p50. ">Vickerman 2022</a>). One study recruited users of combustible cigarettes only and provided information on using EC, but did not provide them with EC (<a href="./references#CD010216-bbs2-0021" title="EllingJM , CrutzenR , TalhoutR , DeVriesH . Effects of providing tailored information about e-cigarettes in a web-based smoking cessation intervention: protocol for a randomised control trial. Journal of Medical Internet Research, Research Protocols2021;10(5):e27088. [DOI: 10.2196/27088]EllingJM , CrutzenR , TalhoutR , deVriesH . Effects of providing tailored information about e-cigarettes in a digital smoking cessation intervention: randomized controlled trial. Health Education Research2023;38(2):150-62. [DOI: 10.1093/her/cyad004]NL8330. Communication about e-cigarettes in a digital smoking cessation intervention [Effect of communication about e-cigarettes in a digital smoking cessation intervention on smoking reduction, smoking cessation, and informed decision making]. trialsearch.who.int/?TrialID=NL8330 (first received 24 January 2020). ">Elling 2023</a>). The remaining studies all provided some form of nicotine EC. </p> <p>In two studies where nicotine ECs were provided on their own, nicotine levels were judged to be so low as to be clinically comparable to non‐nicotine EC (<a href="./references#CD010216-bbs2-0045" title="KCT0001277. Effect of an electronic cigarette for smoking reduction and cessation in Korean male smokers: a randomized, controlled study. KCT0001277 2014 (accessed 15 August 2016). LeeSH , AhnSH , CheongYS . Effect of electronic cigarettes on smoking reduction and cessation in Korean male smokers: a randomized controlled study. Journal of the American Board of Family Medicine2019;32(4):567-74. ">Lee 2019</a>; <a href="./references#CD010216-bbs2-0082" title="Van StadenSR , GroenewaldM , EngelbrechtR , BeckerPJ , HazelhurstLT . Carboxyhaemoglobin levels, health and lifestyle perceptions in smokers converting from tobacco cigarettes to electronic cigarettes. South African Medical Journal2013;103(11):865-8. ">Van Staden 2013*</a>); we include these studies in non‐nicotine EC comparisons. Twelve studies compared nicotine EC with non‐nicotine EC, 26 studies compared nicotine EC to behavioural support only or to no support, and 20 studies compared nicotine EC to NRT. Six studies compared high‐ versus low‐nicotine EC devices (<a href="./references#CD010216-bbs2-0007" title="CampagnaD , CibellaF , CaponnettoP , AmaradioMD , CarusoM , MorjariaJB , et al. Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. European Journal of Clinical Investigation2016;46(8):698-706. CaponnettoP , CampagnaD , CibellaF , MorjariaJB , CarusoM , RussoC , et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLOS One2013;8(6):e66317. CibellaF , CampagnaD , CaponnettoP , AmaradioMD , CarusoM , RussoC , et al. Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. Clinical Science2016;130(21):1929-37. FarsalinosK , CibellaF , CaponnettoP , CampagnaD , MorjariaJB , BattagliaE , et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Internal and Emergency Medicine2016;11(1):85-94. NCT01164072. Efficacy and safety of an electronic nicotine delivery device (e-cigarette). clinicaltrials.gov/ct2/show/NCT01164072 (first received 16 July 2010). NCT01188239. A structured protocol to evaluate efficacy and safety of a popular electronic nicotine delivery device (e-cigarette) efficacy and safety of a popular electronic nicotine delivery device (e-cigarette). https://clinicaltrials.gov/ct2/show/NCT01188239. NCT01194583. Efficacy and safety of an electronic nicotine delivery device (e-cigarette) without nicotine cartridges. clinicaltrials.gov/ct2/show/NCT01194583 (first received 3 September 2010). RussoC , CibellaF , CaponnettoP , CampagnaD , MagliaM , FrazzettoE , et al. Evaluation of post cessation weight gain in a 1-year randomized smoking cessation trial of electronic cigarettes. Scientific Reports2016;6:18763. ">Caponnetto 2013a*</a>; <a href="./references#CD010216-bbs2-0013" title="CobbCO , FouldsJ , Yen M-S, VeldheerS , LopezAA , Yingst JM et al. Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, controlled trial. Lancet Respiratory Medicine2021;9(8):840-50. [DOI: 10.1016/ S2213-2600(21)00022-9]FouldsJ , CobbC , Yen M-S, VeldheerS , BrosnanP , Yingst J et al. Effect of electronic nicotine delivery systems on cigarette abstinence in smokers with no plans to quit: exploratory analysis of a randomized placebo-controlled trial. Nicotine Tobacco Research2022;24(7):955-61. [DOI: 10.1093/ntr/ntab247]LopezAA , CobbCO , YingstJM , VeldheerS , HrabovskyS , YenMS , et al. A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation. BMC Public Health2016;16(1):217. [PMCID:: PMC4778292] [PMID: 26941050]NCT02342795. Randomized controlled trial methods for novel tobacco products evaluation. clinicaltrials.gov/show/NCT02342795 (accessed 17 February 2016). VeldheerS , YingstJ , MidyaV , HummerB , LesterC , KrebsN , . Pulmonary and other health effects of electronic cigarette use among adult smokers participating in a randomized controlled smoking reduction trial. Addictive Behaviors2019;91:95-101. YingstJ , FouldsJ , VeldheerS , CobbCO , YenM , HrabovskyS , et al. Measurement of electronic cigarette frequency of use among smokers participating in a randomized controlled trial. Nicotine &amp; Tobacco Research2020;22(5):699-704. [NCT02342795]YingstJ , WangX , AndersonA , BrelandA , SouleE , Barnes A et al. Evaluation of nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoke. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. March 2022. YingstJ , WangX , LopezAA , BrelandA , SouleE , Barnes A et al. Randomized Control Trial Methods Workgroup of the Center for the Study of Tobacco Products. Changes in nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoking in a randomized controlled trial. Nicotine Tobacco Research 2022 Jun 25 [Epub ahead of print]. [DOI: 10.1093/ntr/ntac153]YingstJ , Wang Xi, LopezAA , BrelandA , SouleE , BarnesA , et al. Randomized control trial methods workgroup of the center for the study of tobacco products, changes in nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoking in a randomized controlled trial. Nicotine &amp; Tobacco Research2023;25(3):372-8. [DOI: 10.1093/ntr/ntac153]">Cobb 2021</a>; <a href="./references#CD010216-bbs2-0039" title="KanobeMN , JonesBA , NelsonP , BrownBG , ChenP , MakenaP , et al. Part three: a randomized study to assess biomarker changes in cigarette smokers switched to Vuse Solo or abstinence. Scientific Reports2022;12:20658. [DOI: 10.1038/s41598-022-25054-z]KanobeMN , NelsonPR , BrownBG , ChenP , PatruduM , Caraway JW et al. Changes in biomarkers of exposure and potential harm in smokers switched to Vuse Vibe or Vuse Ciro electronic nicotine delivery systems. Toxics2023;11(7):564. [DOI: 10.3390/toxics11070564]NCT03170674. CSD170501: Study to assess biomarkers of tobacco exposure in smokers during in-clinic confinement switch to an electronic cigarette. clinicaltrials.gov/ct2/show/NCT03170674 (first received 31 May 2017). ">Kanobe 2022*</a><a href="./references#CD010216-bbs2-0041" title="KimberCF , SoarK , Dawkins LE. Changes in puffing topography and subjective effects over a 2-week period in e-cigarette naive smokers: effects of device type and nicotine concentrations. Addictive Behaviors2021;118:106909. [DOI: 10.1016/j.addbeh.2021.106909]">Kimber 2021</a>; <a href="./references#CD010216-bbs2-0053" title="MorrisP , McDermottS , ChapmanF , VerronT , CahoursX , StevensonM , et al. Reductions in biomarkers of exposure to selected harmful and potentially harmful constituents following exclusive and partial switching from combustible cigarettes to myblu TM electronic nicotine delivery systems (ENDS). Internal &amp; Emergency Medicine2022;17(2):397-410. [DOI: 10.1007/s11739-021-02813-w]NCT04429932. A study to evaluate nicotine uptake and biomarkers in adult smokers using mybluTM electronic cigarettes. clinicaltrials.gov/ct2/show/NCT04429932 (first received 7 June 2021). NCT04430634. A study to evaluate nicotine uptake and biomarkers in smokers using mybluTM electronic cigarettes [An open-label, randomized, crossover study to assess nicotine uptake, tobacco-related biomarkers of exposure, biomarkers of potential harm, and puff topography with use of mybluTM electronic cigarettes in adult smokers]. clinicaltrials.gov/ct2/show/NCT04430634 (first received 7 June 2021). ">Morris 2022*</a>; <a href="./references#CD010216-bbs2-0088" title="NCT03185546. Project 2 cigarette and e-cigarette nicotine content and e-liquid flavors. clinicaltrials.gov/ct2/show/NCT03185546 (first received 14 May 2021). WhiteCM , Denlinger-ApteRL , TessierKM , KoopmeinersJS , HatsukamiDK , StrasserAA . Cigarette nicotine reduction in the presence of an alternative: investigating how cigarette nicotine content and e-liquid content affect smoking. In: Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting February 24-27 2021 (virtual). 2021:SYM2C p2-3. WhiteCM , TessierKM , KoopmeinersJS , Denlinger-ApteRL , CobbCO , LaneT , et al. Preliminary evidence on cigarette nicotine reduction with concurrent access to an e-cigarette: manipulating cigarette nicotine content, e-liquid nicotine content, and e-liquid flavor availability. Preventive Medicine2022;165(Pt B):107213. [DOI: 10.1016/j.ypmed.2022.107213]">White 2021</a>), four studies included comparisons based on flavours (<a href="./references#CD010216-bbs2-0017" title="EdmistonJS , WebbKM , WangJ , OliveriD , LiangQ , SarkarM . Biomarkers of exposure and biomarkers of potential harm in adult smokers who switch to e-vapor products relative to cigarette smoking in a 24-week, randomized, clinical trial. Nicotine &amp; Tobacco Research2022;24(7):1047–54. [DOI: 10.1093/ntr/ntac029]">Edmiston 2022*</a>; <a href="./references#CD010216-bbs2-0053" title="MorrisP , McDermottS , ChapmanF , VerronT , CahoursX , StevensonM , et al. Reductions in biomarkers of exposure to selected harmful and potentially harmful constituents following exclusive and partial switching from combustible cigarettes to myblu TM electronic nicotine delivery systems (ENDS). Internal &amp; Emergency Medicine2022;17(2):397-410. [DOI: 10.1007/s11739-021-02813-w]NCT04429932. A study to evaluate nicotine uptake and biomarkers in adult smokers using mybluTM electronic cigarettes. clinicaltrials.gov/ct2/show/NCT04429932 (first received 7 June 2021). NCT04430634. A study to evaluate nicotine uptake and biomarkers in smokers using mybluTM electronic cigarettes [An open-label, randomized, crossover study to assess nicotine uptake, tobacco-related biomarkers of exposure, biomarkers of potential harm, and puff topography with use of mybluTM electronic cigarettes in adult smokers]. clinicaltrials.gov/ct2/show/NCT04430634 (first received 7 June 2021). ">Morris 2022*</a>; <a href="./references#CD010216-bbs2-0088" title="NCT03185546. Project 2 cigarette and e-cigarette nicotine content and e-liquid flavors. clinicaltrials.gov/ct2/show/NCT03185546 (first received 14 May 2021). WhiteCM , Denlinger-ApteRL , TessierKM , KoopmeinersJS , HatsukamiDK , StrasserAA . Cigarette nicotine reduction in the presence of an alternative: investigating how cigarette nicotine content and e-liquid content affect smoking. In: Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting February 24-27 2021 (virtual). 2021:SYM2C p2-3. WhiteCM , TessierKM , KoopmeinersJS , Denlinger-ApteRL , CobbCO , LaneT , et al. Preliminary evidence on cigarette nicotine reduction with concurrent access to an e-cigarette: manipulating cigarette nicotine content, e-liquid nicotine content, and e-liquid flavor availability. Preventive Medicine2022;165(Pt B):107213. [DOI: 10.1016/j.ypmed.2022.107213]">White 2021</a>; <a href="./references#CD010216-bbs2-0089" title="XuY , GoldensonNI , Prakash S AugustsonEM , ShiffmanS . Randomized trial assessing the effect of the JUUL system on switching away from cigarettes and smoking reduction among U.S. adults who smoke cigarettes.. Experimental and Clinical Psychopharmacology2024;32(1):3-15. [DOI: 10.1037/pha0000698]">Xu 2023*</a>), two studies directly compared device types (<a href="./references#CD010216-bbs2-0041" title="KimberCF , SoarK , Dawkins LE. Changes in puffing topography and subjective effects over a 2-week period in e-cigarette naive smokers: effects of device type and nicotine concentrations. Addictive Behaviors2021;118:106909. [DOI: 10.1016/j.addbeh.2021.106909]">Kimber 2021</a>; <a href="./references#CD010216-bbs2-0090" title="YingstJ , FouldsJ , ZurloJ , SteinbergMB , EissenbergT , DuP . Acceptability of electronic nicotine delivery systems (ENDS) among HIV positive smokers. AIDS Care2020;32(10):1224-8. ">Yingst 2020</a>), and two studies directly compared a freebase nicotine to a salt‐based nicotine device (<a href="./references#CD010216-bbs2-0053" title="MorrisP , McDermottS , ChapmanF , VerronT , CahoursX , StevensonM , et al. Reductions in biomarkers of exposure to selected harmful and potentially harmful constituents following exclusive and partial switching from combustible cigarettes to myblu TM electronic nicotine delivery systems (ENDS). Internal &amp; Emergency Medicine2022;17(2):397-410. [DOI: 10.1007/s11739-021-02813-w]NCT04429932. A study to evaluate nicotine uptake and biomarkers in adult smokers using mybluTM electronic cigarettes. clinicaltrials.gov/ct2/show/NCT04429932 (first received 7 June 2021). NCT04430634. A study to evaluate nicotine uptake and biomarkers in smokers using mybluTM electronic cigarettes [An open-label, randomized, crossover study to assess nicotine uptake, tobacco-related biomarkers of exposure, biomarkers of potential harm, and puff topography with use of mybluTM electronic cigarettes in adult smokers]. clinicaltrials.gov/ct2/show/NCT04430634 (first received 7 June 2021). ">Morris 2022*</a>; <a href="./references#CD010216-bbs2-0073" title="RussellC , McKeganeyN , KatsampourisE , SatchwellA , HaseenF . A randomised community-based trial of a closed-system pod e-vapour product and nicotine replacement therapy for cigarette abstinence and reduction. Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting February 24-27 2021 virtual:PH-353 p230. ">Russell 2021</a>). Results from these studies are reported by comparison in <a href="#CD010216-sec-0057">Effects of interventions</a>. Further details on the intervention and comparator groups (where applicable) for each study can be found in the <a href="./references#CD010216-sec-0148" title="">Characteristics of included studies</a> table. </p> <p>Where reported in the primary research publications, details of the devices tested can also be found in the <a href="./references#CD010216-sec-0148" title="">Characteristics of included studies</a> table. Of the studies with sufficient data with which to judge, 31 used cartridge devices, 34 used refillable devices, four used both types, 10 used a pod device, and the remainder did not report device type. </p> </section> <section id="CD010216-sec-0047"> <h4 class="title">Outcomes</h4> <p>Of the 90 included studies:</p> <p> <ul id="CD010216-list-0008"> <li> <p>40 reported data on abstinence at six months or longer;</p> </li> <li> <p>64 reported data on adverse events;</p> </li> <li> <p>46 reported data on serious adverse events;</p> </li> <li> <p>49 reported data on carbon monoxide;</p> </li> <li> <p>12 reported data on heart rate;</p> </li> <li> <p>14 reported data on blood pressure;</p> </li> <li> <p>4 reported data on blood oxygen saturation;</p> </li> <li> <p>16 reported data on at least one known toxin/carcinogen;</p> </li> <li> <p>8 reported data on at least one measure of lung function;</p> </li> <li> <p>20 reported data on study product use at six months or longer.</p> </li> </ul> </p> <p>One study measured safety outcomes but did not report them in the text available at the time of writing (they may be forthcoming); hence, this study currently does not contribute any data to this review (<a href="./references#CD010216-bbs2-0075" title="ACTRN12617000905369. Smoking reduction interventions for smoking cessation. ncbi.nlm.nih.gov/pmc/articles/PMC6953262/ (first received 9 June 2017). [DOI: 10.1002/14651858.CD013183.pub2]LumA , SkeltonE , RobinsonM , GuillaumierA , WynneO , GartnerC , et al. Barriers and facilitators to using vaporised nicotine products as smoking cessation aids among people receiving treatment for substance use disorder. Addictive Behaviors2021;124:107097. [DOI: 10.1016/j.addbeh.2021.107097]SkeltonE , LumA , RobinsonM , DunlopA , GuillaumierA , BakerA , et al. A pilot randomised controlled trial of abrupt versus gradual smoking cessation in combination with vaporised nicotine products for people receiving alcohol and other drug treatment. Addictive Behaviors2022;131:107328. [DOI: 10.1016/j.addbeh.2022.107328]">Skelton 2022</a>). </p> </section> <section id="CD010216-sec-0048"> <h4 class="title">Study types</h4> <p>Forty‐nine studies were RCTs, 28 of which contributed to cessation analyses. Eight studies used randomized cross‐over designs, and the remainder were uncontrolled cohort studies. </p> </section> <section id="CD010216-sec-0049"> <h4 class="title">Funding</h4> <p>Of the 83 studies that reported funding information, 68 had no tobacco or EC industry funding or support. Below, we detail the industry funding from the 15 studies that report tobacco or EC industry funding or support. An asterisk (*) has been added after the study name for all studies that received tobacco or EC industry funding. Where these studies contributed to meta‐analyses, we tested whether results were sensitive to their inclusion, and took account of this in our results and conclusions. </p> <p>Fifteen of the included studies reported support from the tobacco or vaping industry, or that authors had received tobacco or vaping industry support outside of the study being conducted. Six of these studies received funding from the Lega Italiana AntiFumo (<a href="./references#CD010216-bbs2-0007" title="CampagnaD , CibellaF , CaponnettoP , AmaradioMD , CarusoM , MorjariaJB , et al. Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. European Journal of Clinical Investigation2016;46(8):698-706. CaponnettoP , CampagnaD , CibellaF , MorjariaJB , CarusoM , RussoC , et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLOS One2013;8(6):e66317. CibellaF , CampagnaD , CaponnettoP , AmaradioMD , CarusoM , RussoC , et al. Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. Clinical Science2016;130(21):1929-37. FarsalinosK , CibellaF , CaponnettoP , CampagnaD , MorjariaJB , BattagliaE , et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Internal and Emergency Medicine2016;11(1):85-94. NCT01164072. Efficacy and safety of an electronic nicotine delivery device (e-cigarette). clinicaltrials.gov/ct2/show/NCT01164072 (first received 16 July 2010). NCT01188239. A structured protocol to evaluate efficacy and safety of a popular electronic nicotine delivery device (e-cigarette) efficacy and safety of a popular electronic nicotine delivery device (e-cigarette). https://clinicaltrials.gov/ct2/show/NCT01188239. NCT01194583. Efficacy and safety of an electronic nicotine delivery device (e-cigarette) without nicotine cartridges. clinicaltrials.gov/ct2/show/NCT01194583 (first received 3 September 2010). RussoC , CibellaF , CaponnettoP , CampagnaD , MagliaM , FrazzettoE , et al. Evaluation of post cessation weight gain in a 1-year randomized smoking cessation trial of electronic cigarettes. Scientific Reports2016;6:18763. ">Caponnetto 2013a*</a>; <a href="./references#CD010216-bbs2-0008" title="CaponnettoP , AuditoreR , RussoC , CappelloGC , PolosaR . Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. International Journal of Environmental Research and Public Health2013;10(2):446-61. MinutoloG , CaponnettoP , AuditoreR , RussoC , PolosaR . Management of smoking reduction and cessation in inpatients with schizophrenia: impact of electronic cigarettes. European Neuropsychopharmacology2013;23:S581-2. ">Caponnetto 2013b*</a>; <a href="./references#CD010216-bbs2-0009" title="CaponnettoP , DiPiazzaJ , KimJ , MagliaM , PolosaR . A single-arm, open-label pilot, and feasibility study of a high nicotine strength e-cigarette intervention for smoking cessation or reduction for people with schizophrenia spectrum disorders who smoke cigarettes. Nicotine &amp; Tobacco Research2021;23(7):1113-22. [DOI: 10.1093/ntr/ntab005]">Caponnetto 2021*</a>; <a href="./references#CD010216-bbs2-0063" title="NCT01195597. Smoking cessation and reduction with an electronic nicotine delivery device (ENDD). clinicaltrials.gov/ct2/show/NCT01195597 (first received 6 September 2010). PolosaR , CaponnettoP , MorjariaJB , PapaleG , CampagnaD , RussoC . Effect of an electronic nicotine delivery device (e-cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health2011;11:786. PolosaR , MorjariaJB , CaponnettoP , CampagnaD , RussoC , AlamoA , et al. Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. Internal and Emergency Medicine2014;9(5):537-46. ">Polosa 2011*</a>; <a href="./references#CD010216-bbs2-0064" title="NCT02124200. High cessation rates in smokers using personal vaporizers (VAPECIG). clinicaltrials.gov/ct2/show/NCT02124200 (first received 28 April 2014). PolosaR , CaponnettoP , MagliaM , MorjariaJB , RussoC . Success rates with nicotine personal vaporizers: a prospective 6-month pilot study of smokers not intending to quit. BMC Public Health2014;14:1159. ">Polosa 2014b*</a>; <a href="./references#CD010216-bbs2-0065" title="PolosaR , CaponnettoP , CibellaF , Le-HouezecJ . Quit and smoking reduction rates in vape shop consumers: a prospective 12-month survey. International Journal of Environmental Research and Public Health2015;12(4):3428-38. ">Polosa 2015*</a>). <a href="./references#CD010216-bbs2-0008" title="CaponnettoP , AuditoreR , RussoC , CappelloGC , PolosaR . Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. International Journal of Environmental Research and Public Health2013;10(2):446-61. MinutoloG , CaponnettoP , AuditoreR , RussoC , PolosaR . Management of smoking reduction and cessation in inpatients with schizophrenia: impact of electronic cigarettes. European Neuropsychopharmacology2013;23:S581-2. ">Caponnetto 2013b*</a> and <a href="./references#CD010216-bbs2-0063" title="NCT01195597. Smoking cessation and reduction with an electronic nicotine delivery device (ENDD). clinicaltrials.gov/ct2/show/NCT01195597 (first received 6 September 2010). PolosaR , CaponnettoP , MorjariaJB , PapaleG , CampagnaD , RussoC . Effect of an electronic nicotine delivery device (e-cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health2011;11:786. PolosaR , MorjariaJB , CaponnettoP , CampagnaD , RussoC , AlamoA , et al. Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. Internal and Emergency Medicine2014;9(5):537-46. ">Polosa 2011*</a> also received free “Categoria” EC kits from the Arbi Group Srl (Milano, Italy). <a href="./references#CD010216-bbs2-0009" title="CaponnettoP , DiPiazzaJ , KimJ , MagliaM , PolosaR . A single-arm, open-label pilot, and feasibility study of a high nicotine strength e-cigarette intervention for smoking cessation or reduction for people with schizophrenia spectrum disorders who smoke cigarettes. Nicotine &amp; Tobacco Research2021;23(7):1113-22. [DOI: 10.1093/ntr/ntab005]">Caponnetto 2021*</a> received free JUUL EC from the manufacturer, PAX Labs (became JUUL Labs in 2017). Altria Group (formerly, Philip Morris Companies) acquired a 35% stake in JUUL Labs on 20 December 2018; the study was completed before Altria invested in JUUL. <a href="./references#CD010216-bbs2-0064" title="NCT02124200. High cessation rates in smokers using personal vaporizers (VAPECIG). clinicaltrials.gov/ct2/show/NCT02124200 (first received 28 April 2014). PolosaR , CaponnettoP , MagliaM , MorjariaJB , RussoC . Success rates with nicotine personal vaporizers: a prospective 6-month pilot study of smokers not intending to quit. BMC Public Health2014;14:1159. ">Polosa 2014b*</a> thank FlavourArt (Oleggio, NO, Italy; <a href="http://www.flavourart.it" target="_blank">www.flavourart.it</a>), an EC flavour company. </p> <p><a href="./references#CD010216-bbs2-0010" title="CaponnettoP , CampagnaD , MagliaM , BenfattoF , EmmaR , CarusoM , et al. Comparing the effectiveness, tolerability, and acceptability of heated tobacco products and refillable electronic cigarettes for cigarette substitution (CEASEFIRE): randomized controlled trial. Public Health Surveillance2023;9:e42628. [DOI: 10.2196/42628]CaponnettoP , CarusoM , MagliaM , EmmaR , SaittaD , BusaB , et al. Non-inferiority trial comparing cigarette consumption, adoption rates, acceptability, tolerability, and tobacco harm reduction potential in smokers switching to Heated Tobacco Products or electronic cigarettes: study protocol for a randomized controlled trial. Contemporary Clinical Trials Communications2020;8:17. NCT03569748. Heated tobacco products vs electronic cigarettes. clinicaltrials.gov/ct2/show/NCT03569748 (first received 25 June 2021). ">Caponnetto 2023*</a> was funded by Philip Morris Product Société Anonyme. </p> <p><a href="./references#CD010216-bbs2-0017" title="EdmistonJS , WebbKM , WangJ , OliveriD , LiangQ , SarkarM . Biomarkers of exposure and biomarkers of potential harm in adult smokers who switch to e-vapor products relative to cigarette smoking in a 24-week, randomized, clinical trial. Nicotine &amp; Tobacco Research2022;24(7):1047–54. [DOI: 10.1093/ntr/ntac029]">Edmiston 2022*</a> was funded by Altria Client Services LLC. Altria is the parent company of Philip Morris USA (producer of Marlboro cigarettes), John Middleton, Inc., U.S. Smokeless Tobacco Company, Inc., and Philip Morris Capital Corporation. </p> <p><a href="./references#CD010216-bbs2-0039" title="KanobeMN , JonesBA , NelsonP , BrownBG , ChenP , MakenaP , et al. Part three: a randomized study to assess biomarker changes in cigarette smokers switched to Vuse Solo or abstinence. Scientific Reports2022;12:20658. [DOI: 10.1038/s41598-022-25054-z]KanobeMN , NelsonPR , BrownBG , ChenP , PatruduM , Caraway JW et al. Changes in biomarkers of exposure and potential harm in smokers switched to Vuse Vibe or Vuse Ciro electronic nicotine delivery systems. Toxics2023;11(7):564. [DOI: 10.3390/toxics11070564]NCT03170674. CSD170501: Study to assess biomarkers of tobacco exposure in smokers during in-clinic confinement switch to an electronic cigarette. clinicaltrials.gov/ct2/show/NCT03170674 (first received 31 May 2017). ">Kanobe 2022*</a> was funded by RAI Services Company. The parent company is Reynolds American. Reynolds American manufacture and market a variety of tobacco products, including cigarettes (Newport, Camel, Pall Mall, Kent, Doral, Misty, Capri, and Natural American Spirit brands), EC (Vuse brand), and moist snuff (Grizzly and Kodiak brands). </p> <p><a href="./references#CD010216-bbs2-0053" title="MorrisP , McDermottS , ChapmanF , VerronT , CahoursX , StevensonM , et al. Reductions in biomarkers of exposure to selected harmful and potentially harmful constituents following exclusive and partial switching from combustible cigarettes to myblu TM electronic nicotine delivery systems (ENDS). Internal &amp; Emergency Medicine2022;17(2):397-410. [DOI: 10.1007/s11739-021-02813-w]NCT04429932. A study to evaluate nicotine uptake and biomarkers in adult smokers using mybluTM electronic cigarettes. clinicaltrials.gov/ct2/show/NCT04429932 (first received 7 June 2021). NCT04430634. A study to evaluate nicotine uptake and biomarkers in smokers using mybluTM electronic cigarettes [An open-label, randomized, crossover study to assess nicotine uptake, tobacco-related biomarkers of exposure, biomarkers of potential harm, and puff topography with use of mybluTM electronic cigarettes in adult smokers]. clinicaltrials.gov/ct2/show/NCT04430634 (first received 7 June 2021). ">Morris 2022*</a> was funded entirely by Fontem US LLC, a subsidiary of Imperial Brands PLC. </p> <p><a href="./references#CD010216-bbs2-0058" title="NCT01898169. Evaluation of short-term safety and use patterns of an electronic nicotine delivery system. clinicaltrials.gov/ct2/show/NCT01898169 (first received 12 July 2013). NidesMA , LeischowSJ , BhatterM , SimmonsM . Nicotine blood levels and short-term smoking reduction with an electronic nicotine delivery system. American Journal of Health Behavior2014;38(2):265-74. ">Nides 2014*</a> was funded by NJOY, Inc., Scottsdale, AZ. Funded by the EC/alternative nicotine products industry. </p> <p><a href="./references#CD010216-bbs2-0072" title="NCT03492463. The role of nicotine dose and route of delivery in affecting adoption of e-cigarettes and reducing exposure to toxic combustion products (ENDS-Switch). clinicaltrials.gov/ct2/show/study/NCT03492463 (first received 10 April 2018). RoseJE , FrisbeeS , CampbellD , SalleyA , ClaerhoutS , DavisJM . Smoking reduction using electronic nicotine delivery systems in combination with nicotine skin patches. Psychopharmacology2023;240:1901-9. [DOI: 10.1007/s00213-023-06401-y]">Rose 2023*</a> was funded by the National Institute on Drug Abuse (NIDA). However, the lead author declared research support from Foundation for a Smoke‐Free World (which has links to the tobacco industry), Philip Morris International, Altria, Embera Neuro Therapeutics, Inc., Otsuka Pharmaceutical, JUUL Labs, consulting with Revive pharmaceuticals, and consulting and patent purchase agreements with Philip Morris International. </p> <p><a href="./references#CD010216-bbs2-0082" title="Van StadenSR , GroenewaldM , EngelbrechtR , BeckerPJ , HazelhurstLT . Carboxyhaemoglobin levels, health and lifestyle perceptions in smokers converting from tobacco cigarettes to electronic cigarettes. South African Medical Journal2013;103(11):865-8. ">Van Staden 2013*</a> was funded by eGo e‐cigarette packs by Twisp. </p> <p><a href="./references#CD010216-bbs2-0086" title="CravoAS , BushJ , SharmaG , SaviozR , MartinC , CraigeS , et al. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. Regulatory Toxicology and Pharmacology2016;81:S1-S14. NCT02029196. A randomised, parallel group, multi-centre study to evaluate the safety profile of the ITG EVP G1 product. clinicaltrials.gov/show/NCT02029196 (accessed 16 July 2014). NCT02143310. A multi-centre study to evaluate the safety of use of electronic vapour products for two years. clinicaltrials.gov/show/NCT02143310 (accessed 16 July 2014). WaleleT , BushJ , KochA , SaviozR , MartinC , O'ConnellG . Evaluation of the safety profile of an electronic vapour product used for two years by smokers in a real-life setting. Regulatory Toxicology and Pharmacology2018;92:226-38. ">Walele 2018*</a> was funded and supported by Fontem Ventures B.V. Imperial Brands plc (Imperial Tobacco plc) is the parent company of Fontem Ventures B.V., the manufacturer of the EC prototype used in their study. </p> <p><a href="./references#CD010216-bbs2-0089" title="XuY , GoldensonNI , Prakash S AugustsonEM , ShiffmanS . Randomized trial assessing the effect of the JUUL system on switching away from cigarettes and smoking reduction among U.S. adults who smoke cigarettes.. Experimental and Clinical Psychopharmacology2024;32(1):3-15. [DOI: 10.1037/pha0000698]">Xu 2023*</a> was funded by Juul Labs, Inc. </p> </section> <section id="CD010216-sec-0050"> <h4 class="title">Excluded studies</h4> <p>We list 32 studies excluded at full‐text stage, along with reasons for exclusion, in the <a href="./references#CD010216-sec-0149" title="">Characteristics of excluded studies</a> table. After the reference being a duplicate, the most common reason for exclusion was that studies did not include outcomes relevant to this review. </p> </section> </section> <section id="CD010216-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, we judged 10 studies to be at low risk of bias (<a href="./references#CD010216-bbs2-0006" title="BullenC , HoweC , LaugesenM , McRobbieH , ParagV , WillimanJ , et al. Electronic cigarettes and smoking cessation: a quandary? - Authors' reply. Lancet2014;383(9915):408-9. BullenC , HoweC , LaugesenM , McRobbieH , ParagV , WillimanJ , et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet2013;382(9905):1629-37. BullenC , HoweC , LaugesenM , McRobbieH , ParagV , WillimanJ . Do electronic cigarettes help smokers quit? Results from a randomised controlled trial [Abstract]. In: European Respiratory Society Annual Congress, 2013 September 7-11, Barcelona, Spain. Vol. 42. 2013:215s-[P1047]. BullenC , WillimanJ , HoweC , LaugesenM , McRobbieH , ParagV , et al. Study protocol for a randomised controlled trial of electronic cigarettes versus nicotine patch for smoking cessation. BMC Public Health2013;13:210. O'BrienB , Knight-WestO , WalkerN , ParagV , BullenC . E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial. Tobacco Induced Diseases2015;13(1):5. ">Bullen 2013</a>; <a href="./references#CD010216-bbs2-0013" title="CobbCO , FouldsJ , Yen M-S, VeldheerS , LopezAA , Yingst JM et al. Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, controlled trial. Lancet Respiratory Medicine2021;9(8):840-50. [DOI: 10.1016/ S2213-2600(21)00022-9]FouldsJ , CobbC , Yen M-S, VeldheerS , BrosnanP , Yingst J et al. Effect of electronic nicotine delivery systems on cigarette abstinence in smokers with no plans to quit: exploratory analysis of a randomized placebo-controlled trial. Nicotine Tobacco Research2022;24(7):955-61. [DOI: 10.1093/ntr/ntab247]LopezAA , CobbCO , YingstJM , VeldheerS , HrabovskyS , YenMS , et al. A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation. BMC Public Health2016;16(1):217. [PMCID:: PMC4778292] [PMID: 26941050]NCT02342795. Randomized controlled trial methods for novel tobacco products evaluation. clinicaltrials.gov/show/NCT02342795 (accessed 17 February 2016). VeldheerS , YingstJ , MidyaV , HummerB , LesterC , KrebsN , . Pulmonary and other health effects of electronic cigarette use among adult smokers participating in a randomized controlled smoking reduction trial. Addictive Behaviors2019;91:95-101. YingstJ , FouldsJ , VeldheerS , CobbCO , YenM , HrabovskyS , et al. Measurement of electronic cigarette frequency of use among smokers participating in a randomized controlled trial. Nicotine &amp; Tobacco Research2020;22(5):699-704. [NCT02342795]YingstJ , WangX , AndersonA , BrelandA , SouleE , Barnes A et al. Evaluation of nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoke. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. March 2022. YingstJ , WangX , LopezAA , BrelandA , SouleE , Barnes A et al. Randomized Control Trial Methods Workgroup of the Center for the Study of Tobacco Products. Changes in nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoking in a randomized controlled trial. Nicotine Tobacco Research 2022 Jun 25 [Epub ahead of print]. [DOI: 10.1093/ntr/ntac153]YingstJ , Wang Xi, LopezAA , BrelandA , SouleE , BarnesA , et al. Randomized control trial methods workgroup of the center for the study of tobacco products, changes in nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoking in a randomized controlled trial. Nicotine &amp; Tobacco Research2023;25(3):372-8. [DOI: 10.1093/ntr/ntac153]">Cobb 2021</a>; <a href="./references#CD010216-bbs2-0019" title="EisenbergMJ , Hébert-LosierM , WindleSB , GreenspoonT , BrandysT , FülöpT . Effect of e-cigarettes plus counseling vs counseling alone on smoking cessation: a randomized clinical trial. JAMA2020;324(18):1844-54. Hebert-LosierA , FilionKB , WindleSB , EisenbergMJ . A randomized controlled trial evaluating the efficacy of e-cigarette use for smoking cessation in the general population: E3 trial design. Canadian Journal of Cardiology Open2020;2(3):168-75. [NCT02417467]NCT02417467. Evaluating the efficacy of e-cigarette use for smoking cessation (E3) trial. clinicaltrials.gov/show/NCT02417467 (accessed 17 February 2016). PrellC , Hebert-LosierA , FilionKB , ReynierP , EisenbergMJ . Evaluating the impact of varying expired carbon monoxide thresholds on smoking relapse identification: insights from the E3 trial on e-cigarette efficacy for smoking cessation. BMJ Open2023;13(13):10. [DOI: 10.1136/bmjopen-2022-071099]">Eisenberg 2020</a>; <a href="./references#CD010216-bbs2-0028" title="HajekP , Phillips-WallerA , PrzuljD , PesolaF , Myers SmithK , BisalN , et al. A randomized trial of e-cigarettes versus nicotine-replacement therapy. New England Journal of Medicine2019;380(7):629-37. HajekP , Phillips-WallerA , PrzuljD , PesolaF , SmithKM , BisalN , et al. E-cigarettes compared with nicotine replacement therapy within the UK Stop Smoking Services: the TEC RCT. Health Technology Assessment2019;23(43):1-82. [ISRCTN60477608]ISRCTN60477608. The efficacy of e-cigarettes compared with nicotine replacement therapy, when used within the UK stop smoking service. www.isrctn.com/ISRCTN60477608 (first received 2 April 2015). LiJ , HajekP , PesolaF , WuQ , Phillips-WallerA , PrzuljD , et al. Cost-effectiveness of e-cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial. Addiction2020;115(3):507-17. ">Hajek 2019</a>; <a href="./references#CD010216-bbs2-0029" title="FordA , UnyI , LowesJ , NaughtonF , CooperS , ColemanT . A qualitative study of factors influencing adherence among pregnant women taking part in a trial of e-cigarettes for smoking cessation. International Journal of Environmental Research and Public Health2021;18(2):430. HajekP , PrzuljD , PesolaF , GriffithsC , WaltonR , McRobbieH , et al. Author Correction: Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial. Nature Medicine2023;29(11):2957. [DOI: 10.1038/s41591-022-02099-1]HajekP , PrzuljD , PesolaF , GriffithsC , WaltonR , McRobbieH , et al. Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial. Nature Medicine2022;28:958-64. [DOI: 10.1038/s41591-022-01808-0]ISRCTN62025374. Helping pregnant smokers quit: a multi-centre study of electronic cigarettes and nicotine patches. www.isrctn.com/ISRCTN62025374 (first received 21 March 2017). [DOI: 10.1186/ISRCTN62025374]PesolaF , SmithKM , Phillips-WallerA , PrzuljD , GriffithsC , Walton R et al. Safety of e-cigarettes and nicotine patches as stop-smoking aids in pregnancy: Secondary analysis of the Pregnancy Trial of E-cigarettes and Patches (PREP) randomized controlled trial. Addiction2024;119(5):875-84. [DOI: 10.1111/add.16422]PrzuljD , PesolaF , SmithKM , McRobbieH , ColemanT , Lewis S et al. Helping pregnant smokers quit: a multicentre randomised controlled trial of electronic cigarettes versus nicotine replacement therapy. Health Technology Assessment2023;27(13):1-53. [DOI: 10.3310/AGTH6901]">Hajek 2022</a>; <a href="./references#CD010216-bbs2-0040" title="KerrD . Chapter 5: A randomised controlled trial investigating the cardiovascular effects of e-cigaretttes in comparison to nicotine replacement patches [personal communication]. Studies into the Cardiovascular and Respiratory Effects of Electronic Cigarettes (PhD thesis), emailed to: A Butler 27 September 2020. NCT03358953. The cardiovascular impacts of electronic cigarettes in comparison to the use of nicotine replacement patches (VAPOUR). clinicaltrials.gov/ct2/show/NCT03358953 (first received 2 December 2017). ">Kerr 2020</a>; <a href="./references#CD010216-bbs2-0044" title="LeeSM , TenneyR , WallaceA , ArjojmandiM . The end perioperative smoking pilot study: a randomized trial comparing e-cigarettes versus nicotine patch. Canadian Journal of Anesthesia2017;64(1 Suppl 1):S48-9. LeeSM , TenneyR , WallaceA , ArjomandiM . Exploring the teachable moment: facilitators and barriers to perioperative smoking cessation, a qualitative study. Canadian Journal of Anesthesia 2017; Conference: 2017 Annual Meeting of the Canadian Anesthesiologists' Society, Canada 61;1 Suppl:S46-7. LeeSM , TenneyR , WallaceAW , ArjomandiM . E-cigarettes versus nicotine patches for perioperative smoking cessation: a pilot randomized trial. PeerJ2018;6(9):e5609. NCT02482233. A pilot randomized controlled clinical trial - &quot;Electronic nicotine delivery device (e-cigarette) for perioperative smoking cessation in veterans&quot;. clinicaltrials.gov/show/NCT02482233 (accessed 17 February 2016). ">Lee 2018</a>; <a href="./references#CD010216-bbs2-0045" title="KCT0001277. Effect of an electronic cigarette for smoking reduction and cessation in Korean male smokers: a randomized, controlled study. KCT0001277 2014 (accessed 15 August 2016). LeeSH , AhnSH , CheongYS . Effect of electronic cigarettes on smoking reduction and cessation in Korean male smokers: a randomized controlled study. Journal of the American Board of Family Medicine2019;32(4):567-74. ">Lee 2019</a>; <a href="./references#CD010216-bbs2-0047" title="ByrneM , SimmonsV , MartinezU , SuttonS , BrandonK , BrandonT . Cost effectiveness of a smoking cessation intervention for dual users of combustible and electronic cigarettes. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. March 2022. GoreLR , SuttonSK , MartinezU , BrandonKO , SimmonsVN , BrandonTH . Mediators of initial abstinence for an extended self help smoking cessation intervention with dual users of combustible and electronic cigarettes. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. Vol. PS3-7. March 2022. MartinezU , SimmonsVN , BrandonKO , QuinnGP , BrandonTH . Examining smoking and vaping behaviors, expectancies, and cessation outcomes between bisexual and heterosexual individuals. Behavioral Medicine 2023;49(4):392-401. [DOI: 10.1080/08964289.2022.2077295]MartinezU , SimmonsVN , SuttonSK , DrobesDJ , MeltzerLR , BrandonKO , et al. Targeted smoking cessation for dual users of combustible and electronic cigarettes: a randomised controlled trial. Lancet Public Health2021;6(7):e500-9. MeltzerLR , SimmonsVN , SuttonSK , DrobesDJ , QuinnGP , MeadeCD , et al. A randomized controlled trial of a smoking cessation self-help intervention for dual users of tobacco cigarettes and e-cigarettes: intervention development and research design. Contemporary Clinical Trials2017;60:56-62. NCT02416011. Smoking cessation self-help for dual users of tobacco cigarettes and e-cigarettes. clinicaltrials.gov/ct2/show/NCT02416011 (first received 18 August 2020). SuttonSK , BrandonKO , HarrellPT , Martínez Ú, SimmonsVN , Gore LR et al. Identifying prospective subpopulations of combustible and electronic cigarette dual users in the United States via finite mixture modeling. Addiction2022;117(9):2493-503. [DOI: 10.1111/add.15906]">Martinez 2021</a>; <a href="./references#CD010216-bbs2-0054" title="ISRCTN13288677. Can electronic cigarettes and nicotine replacement treatment help reduce smoking in smokers who struggle to quit?www.isrctn.com/ISRCTN13288677 (first received 17 March 2017). Myers SmithK , Phillips-WallerA , PesolaF , McRobbieH , PrzuljD , OrzolM , et al. E-cigarettes versus nicotine replacement treatment as harm reduction interventions for smokers who find quitting difficult: randomised controlled trial. Addiction2022;117(1):224-33. [DOI: 10.1111/add.15628]">Myers‐Smith 2022</a>), 19 to be at unclear risk, and the remaining 61 at high risk of bias (this includes the non‐randomized studies, which we deemed to be at high risk due to lack of randomization). </p> <p>Details of the risk of bias judgements for each domain of each included study can be found in the <a href="./references#CD010216-sec-0148" title="">Characteristics of included studies</a> table. <a href="#CD010216-fig-0002">Figure 2</a> and <a href="#CD010216-fig-0003">Figure 3</a> illustrate our judgements across the included studies. </p> <div class="figure" id="CD010216-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph" data-id="CD010216-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph</p> </div> </div> </div> <div class="figure" id="CD010216-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary" data-id="CD010216-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary</p> </div> </div> </div> <section id="CD010216-sec-0052"> <h4 class="title">Allocation</h4> <p>We judged 28 studies to be at high risk of selection bias; for the majority of cases, this is because the study was not randomized. We rated a pilot cluster‐randomized trial to be at high risk, as randomization was not carried out as intended for pragmatic reasons (<a href="./references#CD010216-bbs2-0016" title="DawkinsL , BauldL , FordA , RobsonD , HajekP , ParrottS , et al. A cluster feasibility trial to explore the uptake and use of e-cigarettes versus usual care offered to smokers attending homeless centres in Great Britain. PLOS One2020;15(10):e0240968. [ISRCTN14140672]ISRCTN14140672. Exploring the use and uptake of e-cigarettes for homeless smokers. www.isrctn.com/ISRCTN14140672 (first received 7 November 2018). ">Dawkins 2020</a>). We judged 31 studies to be at low risk of selection bias, and the remainder to be at unclear risk as there was insufficient information with which to judge. </p> </section> <section id="CD010216-sec-0053"> <h4 class="title">Blinding</h4> <p>In all, we assessed 65 studies for performance bias and detection bias. For performance bias, we rated 31 to be at low risk, 24 at high risk, and 10 at unclear risk. For detection bias, we rated 46 as low risk, 11 as high risk, and eight at unclear risk. </p> <p>In these studies, blinding was not used and different levels of support were provided; this alone, or in conjunction with the outcome measures being used (subjective rather than objective measures), meant that we thought there was a high risk of bias being introduced. We judged the rest to be at unclear risk, or ineligible for this domain due to single‐arm design. </p> </section> <section id="CD010216-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>We judged most studies (66 out of 90) to be at low risk of attrition bias. We rated 10 studies with substantial loss to follow‐up as being at high risk of attrition bias. The remainder did not provide sufficient data on which to judge, and hence we judged them to be at unclear risk. </p> </section> <section id="CD010216-sec-0055"> <h4 class="title">Selective reporting</h4> <p>Of the 90 studies, we considered 46 at low risk of reporting bias, as all prespecified or expected outcomes were reported. We rated 10 as being at high risk, as data were not available as specified in the original protocols (note in some cases these are recent studies, and judgement on these may change as more publications emerge). We judged the rest to be at unclear risk, due to insufficient information with which to make a judgement. </p> </section> <section id="CD010216-sec-0056"> <h4 class="title">Other potential sources of bias</h4> <p>We considered <a href="./references#CD010216-bbs2-0038" title="IoakeimidisN , VlachopoulosC , GeorgakopoulosC , AbdelrasoulM , SklirosN , KatsiV , et al. Smoking cessation rates with varenicline and electronic cigarettes in relapsed smokers with a history of acute coronary syndrome. European Heart Journal2018;39(Suppl 1):242. ">Ioakeimidis 2018</a> to be at high risk of other bias; data were from a conference poster and the associated abstract, and quit rates in the intervention arm differed between the two sources. We considered four further studies to be at unclear risk in this domain. </p> </section> </section> <section id="CD010216-sec-0057"> <h3 class="title" id="CD010216-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD010216-tbl-0001"><b>Summary of findings 1</b> Nicotine EC compared to NRT for smoking cessation</a>; <a href="./full#CD010216-tbl-0002"><b>Summary of findings 2</b> Nicotine EC compared to non‐nicotine EC for smoking cessation</a>; <a href="./full#CD010216-tbl-0003"><b>Summary of findings 3</b> Nicotine EC compared to behavioural support only/no support for smoking cessation</a> </p> <p>Data on our outcomes of interest are summarized below and in our <a href="./full#CD010216-tbl-0001">summary of findings Table 1</a>, <a href="./full#CD010216-tbl-0002">summary of findings Table 2</a>, and <a href="./full#CD010216-tbl-0003">summary of findings Table 3</a>. Due to the volume of data available, some relevant information is hosted on a companion repository; these data are open‐access and can be found at <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">http://dx.doi.org/10.5287/ora-jnvxbp7qr</a>. They are referred to below as supplemental tables. Forest plots are available through 'analysis' links; for some outcomes, benefit is plotted on the right; for others it is plotted on the left. This is due to direction of effect, e.g. an increase in cessation is a benefit, whereas an increase in a carcinogen is not. </p> <section id="CD010216-sec-0058"> <h4 class="title">Direct comparisons between nicotine EC and other pharmacotherapies</h4> <p>Comparisons reported here include nicotine ECs versus NRT, and nicotine ECs versus varenicline. Only randomized controlled trials contributed data. </p> <section id="CD010216-sec-0059"> <h5 class="title">Cessation</h5> <p>Pooled data from seven studies (two cartridges, four refillable, one pod), five of which were rated at low risk of bias (<a href="./references#CD010216-bbs2-0006" title="BullenC , HoweC , LaugesenM , McRobbieH , ParagV , WillimanJ , et al. Electronic cigarettes and smoking cessation: a quandary? - Authors' reply. Lancet2014;383(9915):408-9. BullenC , HoweC , LaugesenM , McRobbieH , ParagV , WillimanJ , et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet2013;382(9905):1629-37. BullenC , HoweC , LaugesenM , McRobbieH , ParagV , WillimanJ . Do electronic cigarettes help smokers quit? Results from a randomised controlled trial [Abstract]. In: European Respiratory Society Annual Congress, 2013 September 7-11, Barcelona, Spain. Vol. 42. 2013:215s-[P1047]. BullenC , WillimanJ , HoweC , LaugesenM , McRobbieH , ParagV , et al. Study protocol for a randomised controlled trial of electronic cigarettes versus nicotine patch for smoking cessation. BMC Public Health2013;13:210. O'BrienB , Knight-WestO , WalkerN , ParagV , BullenC . E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial. Tobacco Induced Diseases2015;13(1):5. ">Bullen 2013</a>; <a href="./references#CD010216-bbs2-0028" title="HajekP , Phillips-WallerA , PrzuljD , PesolaF , Myers SmithK , BisalN , et al. A randomized trial of e-cigarettes versus nicotine-replacement therapy. New England Journal of Medicine2019;380(7):629-37. HajekP , Phillips-WallerA , PrzuljD , PesolaF , SmithKM , BisalN , et al. E-cigarettes compared with nicotine replacement therapy within the UK Stop Smoking Services: the TEC RCT. Health Technology Assessment2019;23(43):1-82. [ISRCTN60477608]ISRCTN60477608. The efficacy of e-cigarettes compared with nicotine replacement therapy, when used within the UK stop smoking service. www.isrctn.com/ISRCTN60477608 (first received 2 April 2015). LiJ , HajekP , PesolaF , WuQ , Phillips-WallerA , PrzuljD , et al. Cost-effectiveness of e-cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial. Addiction2020;115(3):507-17. ">Hajek 2019</a>; <a href="./references#CD010216-bbs2-0029" title="FordA , UnyI , LowesJ , NaughtonF , CooperS , ColemanT . A qualitative study of factors influencing adherence among pregnant women taking part in a trial of e-cigarettes for smoking cessation. International Journal of Environmental Research and Public Health2021;18(2):430. HajekP , PrzuljD , PesolaF , GriffithsC , WaltonR , McRobbieH , et al. Author Correction: Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial. Nature Medicine2023;29(11):2957. [DOI: 10.1038/s41591-022-02099-1]HajekP , PrzuljD , PesolaF , GriffithsC , WaltonR , McRobbieH , et al. Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial. Nature Medicine2022;28:958-64. [DOI: 10.1038/s41591-022-01808-0]ISRCTN62025374. Helping pregnant smokers quit: a multi-centre study of electronic cigarettes and nicotine patches. www.isrctn.com/ISRCTN62025374 (first received 21 March 2017). [DOI: 10.1186/ISRCTN62025374]PesolaF , SmithKM , Phillips-WallerA , PrzuljD , GriffithsC , Walton R et al. Safety of e-cigarettes and nicotine patches as stop-smoking aids in pregnancy: Secondary analysis of the Pregnancy Trial of E-cigarettes and Patches (PREP) randomized controlled trial. Addiction2024;119(5):875-84. [DOI: 10.1111/add.16422]PrzuljD , PesolaF , SmithKM , McRobbieH , ColemanT , Lewis S et al. Helping pregnant smokers quit: a multicentre randomised controlled trial of electronic cigarettes versus nicotine replacement therapy. Health Technology Assessment2023;27(13):1-53. [DOI: 10.3310/AGTH6901]">Hajek 2022</a>; <a href="./references#CD010216-bbs2-0044" title="LeeSM , TenneyR , WallaceA , ArjojmandiM . The end perioperative smoking pilot study: a randomized trial comparing e-cigarettes versus nicotine patch. Canadian Journal of Anesthesia2017;64(1 Suppl 1):S48-9. LeeSM , TenneyR , WallaceA , ArjomandiM . Exploring the teachable moment: facilitators and barriers to perioperative smoking cessation, a qualitative study. Canadian Journal of Anesthesia 2017; Conference: 2017 Annual Meeting of the Canadian Anesthesiologists' Society, Canada 61;1 Suppl:S46-7. LeeSM , TenneyR , WallaceAW , ArjomandiM . E-cigarettes versus nicotine patches for perioperative smoking cessation: a pilot randomized trial. PeerJ2018;6(9):e5609. NCT02482233. A pilot randomized controlled clinical trial - &quot;Electronic nicotine delivery device (e-cigarette) for perioperative smoking cessation in veterans&quot;. clinicaltrials.gov/show/NCT02482233 (accessed 17 February 2016). ">Lee 2018</a>; <a href="./references#CD010216-bbs2-0054" title="ISRCTN13288677. Can electronic cigarettes and nicotine replacement treatment help reduce smoking in smokers who struggle to quit?www.isrctn.com/ISRCTN13288677 (first received 17 March 2017). Myers SmithK , Phillips-WallerA , PesolaF , McRobbieH , PrzuljD , OrzolM , et al. E-cigarettes versus nicotine replacement treatment as harm reduction interventions for smokers who find quitting difficult: randomised controlled trial. Addiction2022;117(1):224-33. [DOI: 10.1111/add.15628]">Myers‐Smith 2022</a>) and two as unclear (<a href="./references#CD010216-bbs2-0042" title="JonesG , McIntoshE , BroseLS , KlonizakisM . Participant experiences of a quit smoking attempt through either Nicotine Replacement Therapy (NRT) methods or the use of an e-cigarette. Journal of Addiction Medicine2022;16(3):272-7. KlonizakisM , CrankH , GumberA , BroseLS . Smokers making a quit attempt using e-cigarettes with or without nicotine or prescription nicotine replacement therapy: impact on cardiovascular function (ISME-NRT) - a study protocol. BMC Public Health2017;17(1):293. KlonizakisM , GumberA , McIntoshE , BroseLS . Medium-and longer-term cardiovascular effects of e-cigarettes in adults making a stop-smoking attempt: a randomized controlled trial. BMC Medicine2022;20(1):276. [DOI: 10.1186/s12916-022-02451-9]KlonizakisM , GumberA , McIntoshE , BroseLS . Short-term cardiovascular effects of e-cigarettes in adults making a stop-smoking attempt: a randomized controlled trial. Biology2021;10(11):1208. [DOI: 10.3390/biology10111208]NCT03061253. E-cigarettes and cardiovascular function (ISME-NRT). clinicaltrials.gov/ct2/show/NCT03061253 (first received 23 February 2017). ">Klonizakis 2022</a>; <a href="./references#CD010216-bbs2-0073" title="RussellC , McKeganeyN , KatsampourisE , SatchwellA , HaseenF . A randomised community-based trial of a closed-system pod e-vapour product and nicotine replacement therapy for cigarette abstinence and reduction. Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting February 24-27 2021 virtual:PH-353 p230. ">Russell 2021</a>), showed increased quit rates in people randomized to nicotine EC when compared to NRT (risk ratio (RR) 1.59, 95% confidence interval (CI) 1.30 to 1.93; I<sup>2</sup> = 0%; 2544 participants; <a href="./references#CD010216-fig-0012" title="">Analysis 1.1</a>). The certainty of evidence is high and has not been downgraded. One study included in this analysis, <a href="./references#CD010216-bbs2-0029" title="FordA , UnyI , LowesJ , NaughtonF , CooperS , ColemanT . A qualitative study of factors influencing adherence among pregnant women taking part in a trial of e-cigarettes for smoking cessation. International Journal of Environmental Research and Public Health2021;18(2):430. HajekP , PrzuljD , PesolaF , GriffithsC , WaltonR , McRobbieH , et al. Author Correction: Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial. Nature Medicine2023;29(11):2957. [DOI: 10.1038/s41591-022-02099-1]HajekP , PrzuljD , PesolaF , GriffithsC , WaltonR , McRobbieH , et al. Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial. Nature Medicine2022;28:958-64. [DOI: 10.1038/s41591-022-01808-0]ISRCTN62025374. Helping pregnant smokers quit: a multi-centre study of electronic cigarettes and nicotine patches. www.isrctn.com/ISRCTN62025374 (first received 21 March 2017). [DOI: 10.1186/ISRCTN62025374]PesolaF , SmithKM , Phillips-WallerA , PrzuljD , GriffithsC , Walton R et al. Safety of e-cigarettes and nicotine patches as stop-smoking aids in pregnancy: Secondary analysis of the Pregnancy Trial of E-cigarettes and Patches (PREP) randomized controlled trial. Addiction2024;119(5):875-84. [DOI: 10.1111/add.16422]PrzuljD , PesolaF , SmithKM , McRobbieH , ColemanT , Lewis S et al. Helping pregnant smokers quit: a multicentre randomised controlled trial of electronic cigarettes versus nicotine replacement therapy. Health Technology Assessment2023;27(13):1-53. [DOI: 10.3310/AGTH6901]">Hajek 2022</a>, was conducted in pregnant women. There was no evidence of a subgroup difference between this study and studies in participants not selected on the basis of pregnancy (P = 0.87, I<sup>2</sup> for subgroup differences = 0%). Follow‐up time was based on end of pregnancy, and our analysis included only those participants with follow‐up of at least six months. Results were not sensitive to the exclusion of the one study that received industry funding (<a href="./references#CD010216-bbs2-0073" title="RussellC , McKeganeyN , KatsampourisE , SatchwellA , HaseenF . A randomised community-based trial of a closed-system pod e-vapour product and nicotine replacement therapy for cigarette abstinence and reduction. Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting February 24-27 2021 virtual:PH-353 p230. ">Russell 2021</a>); when this study was removed, the point estimate increased to 1.72, but the CIs remained consistent with those from the main analysis. </p> <p>One study, <a href="./references#CD010216-bbs2-0038" title="IoakeimidisN , VlachopoulosC , GeorgakopoulosC , AbdelrasoulM , SklirosN , KatsiV , et al. Smoking cessation rates with varenicline and electronic cigarettes in relapsed smokers with a history of acute coronary syndrome. European Heart Journal2018;39(Suppl 1):242. ">Ioakeimidis 2018</a>, available as a conference presentation only and considered at high risk of bias due to inconsistencies in the data reported and an unclear definition of abstinence, favoured varenicline for quitting compared to nicotine EC (cartridge) (RR 0.31, 95% CI 0.11 to 0.82; 54 participants; <a href="./references#CD010216-fig-0030" title="">Analysis 2.1</a>). </p> </section> <section id="CD010216-sec-0060"> <h5 class="title">Adverse events</h5> <p>Pooled data from five studies (four considered at low risk of bias (<a href="./references#CD010216-bbs2-0006" title="BullenC , HoweC , LaugesenM , McRobbieH , ParagV , WillimanJ , et al. Electronic cigarettes and smoking cessation: a quandary? - Authors' reply. Lancet2014;383(9915):408-9. BullenC , HoweC , LaugesenM , McRobbieH , ParagV , WillimanJ , et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet2013;382(9905):1629-37. BullenC , HoweC , LaugesenM , McRobbieH , ParagV , WillimanJ . Do electronic cigarettes help smokers quit? Results from a randomised controlled trial [Abstract]. In: European Respiratory Society Annual Congress, 2013 September 7-11, Barcelona, Spain. Vol. 42. 2013:215s-[P1047]. BullenC , WillimanJ , HoweC , LaugesenM , McRobbieH , ParagV , et al. Study protocol for a randomised controlled trial of electronic cigarettes versus nicotine patch for smoking cessation. BMC Public Health2013;13:210. O'BrienB , Knight-WestO , WalkerN , ParagV , BullenC . E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial. Tobacco Induced Diseases2015;13(1):5. ">Bullen 2013</a>; <a href="./references#CD010216-bbs2-0029" title="FordA , UnyI , LowesJ , NaughtonF , CooperS , ColemanT . A qualitative study of factors influencing adherence among pregnant women taking part in a trial of e-cigarettes for smoking cessation. International Journal of Environmental Research and Public Health2021;18(2):430. HajekP , PrzuljD , PesolaF , GriffithsC , WaltonR , McRobbieH , et al. Author Correction: Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial. Nature Medicine2023;29(11):2957. [DOI: 10.1038/s41591-022-02099-1]HajekP , PrzuljD , PesolaF , GriffithsC , WaltonR , McRobbieH , et al. Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial. Nature Medicine2022;28:958-64. [DOI: 10.1038/s41591-022-01808-0]ISRCTN62025374. Helping pregnant smokers quit: a multi-centre study of electronic cigarettes and nicotine patches. www.isrctn.com/ISRCTN62025374 (first received 21 March 2017). [DOI: 10.1186/ISRCTN62025374]PesolaF , SmithKM , Phillips-WallerA , PrzuljD , GriffithsC , Walton R et al. Safety of e-cigarettes and nicotine patches as stop-smoking aids in pregnancy: Secondary analysis of the Pregnancy Trial of E-cigarettes and Patches (PREP) randomized controlled trial. Addiction2024;119(5):875-84. [DOI: 10.1111/add.16422]PrzuljD , PesolaF , SmithKM , McRobbieH , ColemanT , Lewis S et al. Helping pregnant smokers quit: a multicentre randomised controlled trial of electronic cigarettes versus nicotine replacement therapy. Health Technology Assessment2023;27(13):1-53. [DOI: 10.3310/AGTH6901]">Hajek 2022</a>; <a href="./references#CD010216-bbs2-0044" title="LeeSM , TenneyR , WallaceA , ArjojmandiM . The end perioperative smoking pilot study: a randomized trial comparing e-cigarettes versus nicotine patch. Canadian Journal of Anesthesia2017;64(1 Suppl 1):S48-9. LeeSM , TenneyR , WallaceA , ArjomandiM . Exploring the teachable moment: facilitators and barriers to perioperative smoking cessation, a qualitative study. Canadian Journal of Anesthesia 2017; Conference: 2017 Annual Meeting of the Canadian Anesthesiologists' Society, Canada 61;1 Suppl:S46-7. LeeSM , TenneyR , WallaceAW , ArjomandiM . E-cigarettes versus nicotine patches for perioperative smoking cessation: a pilot randomized trial. PeerJ2018;6(9):e5609. NCT02482233. A pilot randomized controlled clinical trial - &quot;Electronic nicotine delivery device (e-cigarette) for perioperative smoking cessation in veterans&quot;. clinicaltrials.gov/show/NCT02482233 (accessed 17 February 2016). ">Lee 2018</a>; <a href="./references#CD010216-bbs2-0054" title="ISRCTN13288677. Can electronic cigarettes and nicotine replacement treatment help reduce smoking in smokers who struggle to quit?www.isrctn.com/ISRCTN13288677 (first received 17 March 2017). Myers SmithK , Phillips-WallerA , PesolaF , McRobbieH , PrzuljD , OrzolM , et al. E-cigarettes versus nicotine replacement treatment as harm reduction interventions for smokers who find quitting difficult: randomised controlled trial. Addiction2022;117(1):224-33. [DOI: 10.1111/add.15628]">Myers‐Smith 2022</a>) and one at unclear risk (<a href="./references#CD010216-bbs2-0085" title="WagenerT , BeebeL , BusinelleM , CarpenterM , HintonA , HartJ , et al. E-cigarette versus combination nicotine replacement therapy delivered through state quitlines on smoking abstinence following a recent failed quit attempt: a randomized trial. In: Society for Research on Nicotine and Tobacco (SRNT) 29th Annual Meeting; 2023 Mar 1-4; San Antonio (TX), USA. SYM5-2. 2023. ">Wagener 2023</a>)) showed that there is probably no difference in the number of participants reporting adverse events (AEs) between nicotine EC and NRT arms (RR 1.03, 95% CI 0.91 to 1.17; I<sup>2</sup> = 0%; 2052 participants; <a href="./references#CD010216-fig-0013" title="">Analysis 1.2</a>). The certainty of evidence is moderate, downgraded one level due to imprecision; the CIs were consistent with benefit and harm. None of the studies contributing data to this analysis received funding from the vaping or tobacco industries. </p> <p><a href="./references#CD010216-bbs2-0028" title="HajekP , Phillips-WallerA , PrzuljD , PesolaF , Myers SmithK , BisalN , et al. A randomized trial of e-cigarettes versus nicotine-replacement therapy. New England Journal of Medicine2019;380(7):629-37. HajekP , Phillips-WallerA , PrzuljD , PesolaF , SmithKM , BisalN , et al. E-cigarettes compared with nicotine replacement therapy within the UK Stop Smoking Services: the TEC RCT. Health Technology Assessment2019;23(43):1-82. [ISRCTN60477608]ISRCTN60477608. The efficacy of e-cigarettes compared with nicotine replacement therapy, when used within the UK stop smoking service. www.isrctn.com/ISRCTN60477608 (first received 2 April 2015). LiJ , HajekP , PesolaF , WuQ , Phillips-WallerA , PrzuljD , et al. Cost-effectiveness of e-cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial. Addiction2020;115(3):507-17. ">Hajek 2019</a> and <a href="./references#CD010216-bbs2-0005" title="Bonafont ReyesBV , StevensE , NicholsonA , LeiL , VojjalaM , Sherman S. Understanding racial and ethnic differences in switching from combustible cigarettes to e-cigarettes in COPD patients. Journal of the American Geriatrics Society, Annual Scientific Meeting2022;170(S1):S1-S345. ">Bonafont Reyes 2022</a> did not contribute data to this analysis due to the way in which events were recorded. In <a href="./references#CD010216-bbs2-0028" title="HajekP , Phillips-WallerA , PrzuljD , PesolaF , Myers SmithK , BisalN , et al. A randomized trial of e-cigarettes versus nicotine-replacement therapy. New England Journal of Medicine2019;380(7):629-37. HajekP , Phillips-WallerA , PrzuljD , PesolaF , SmithKM , BisalN , et al. E-cigarettes compared with nicotine replacement therapy within the UK Stop Smoking Services: the TEC RCT. Health Technology Assessment2019;23(43):1-82. [ISRCTN60477608]ISRCTN60477608. The efficacy of e-cigarettes compared with nicotine replacement therapy, when used within the UK stop smoking service. www.isrctn.com/ISRCTN60477608 (first received 2 April 2015). LiJ , HajekP , PesolaF , WuQ , Phillips-WallerA , PrzuljD , et al. Cost-effectiveness of e-cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial. Addiction2020;115(3):507-17. ">Hajek 2019</a>'s prespecified adverse reactions of interest, nausea was more frequent in the NRT group, throat/mouth irritation was more frequent in the nicotine EC group, and there was little difference in other reactions (see <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 1</a> for more detail). <a href="./references#CD010216-bbs2-0005" title="Bonafont ReyesBV , StevensE , NicholsonA , LeiL , VojjalaM , Sherman S. Understanding racial and ethnic differences in switching from combustible cigarettes to e-cigarettes in COPD patients. Journal of the American Geriatrics Society, Annual Scientific Meeting2022;170(S1):S1-S345. ">Bonafont Reyes 2022</a> recruited participants with chronic obstructive pulmonary disease (COPD) and reported "a trend towards decreased dyspnoea and COPD symptoms ... in the EC arm compared to the NRT arm", but did not provide further detail. </p> <p>In <a href="./references#CD010216-bbs2-0038" title="IoakeimidisN , VlachopoulosC , GeorgakopoulosC , AbdelrasoulM , SklirosN , KatsiV , et al. Smoking cessation rates with varenicline and electronic cigarettes in relapsed smokers with a history of acute coronary syndrome. European Heart Journal2018;39(Suppl 1):242. ">Ioakeimidis 2018</a>, reports of sleep disorders were evenly distributed between groups, and nausea was more common in the varenicline arm than in the nicotine EC arm (see <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 1</a> for more detail). </p> </section> <section id="CD010216-sec-0061"> <h5 class="title">Serious adverse events</h5> <p>Six studies (five at low risk of bias (<a href="./references#CD010216-bbs2-0006" title="BullenC , HoweC , LaugesenM , McRobbieH , ParagV , WillimanJ , et al. Electronic cigarettes and smoking cessation: a quandary? - Authors' reply. Lancet2014;383(9915):408-9. BullenC , HoweC , LaugesenM , McRobbieH , ParagV , WillimanJ , et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet2013;382(9905):1629-37. BullenC , HoweC , LaugesenM , McRobbieH , ParagV , WillimanJ . Do electronic cigarettes help smokers quit? Results from a randomised controlled trial [Abstract]. In: European Respiratory Society Annual Congress, 2013 September 7-11, Barcelona, Spain. Vol. 42. 2013:215s-[P1047]. BullenC , WillimanJ , HoweC , LaugesenM , McRobbieH , ParagV , et al. Study protocol for a randomised controlled trial of electronic cigarettes versus nicotine patch for smoking cessation. BMC Public Health2013;13:210. O'BrienB , Knight-WestO , WalkerN , ParagV , BullenC . E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial. Tobacco Induced Diseases2015;13(1):5. ">Bullen 2013</a>; <a href="./references#CD010216-bbs2-0028" title="HajekP , Phillips-WallerA , PrzuljD , PesolaF , Myers SmithK , BisalN , et al. A randomized trial of e-cigarettes versus nicotine-replacement therapy. New England Journal of Medicine2019;380(7):629-37. HajekP , Phillips-WallerA , PrzuljD , PesolaF , SmithKM , BisalN , et al. E-cigarettes compared with nicotine replacement therapy within the UK Stop Smoking Services: the TEC RCT. Health Technology Assessment2019;23(43):1-82. [ISRCTN60477608]ISRCTN60477608. The efficacy of e-cigarettes compared with nicotine replacement therapy, when used within the UK stop smoking service. www.isrctn.com/ISRCTN60477608 (first received 2 April 2015). LiJ , HajekP , PesolaF , WuQ , Phillips-WallerA , PrzuljD , et al. Cost-effectiveness of e-cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial. Addiction2020;115(3):507-17. ">Hajek 2019</a>; <a href="./references#CD010216-bbs2-0029" title="FordA , UnyI , LowesJ , NaughtonF , CooperS , ColemanT . A qualitative study of factors influencing adherence among pregnant women taking part in a trial of e-cigarettes for smoking cessation. International Journal of Environmental Research and Public Health2021;18(2):430. HajekP , PrzuljD , PesolaF , GriffithsC , WaltonR , McRobbieH , et al. Author Correction: Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial. Nature Medicine2023;29(11):2957. [DOI: 10.1038/s41591-022-02099-1]HajekP , PrzuljD , PesolaF , GriffithsC , WaltonR , McRobbieH , et al. Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial. Nature Medicine2022;28:958-64. [DOI: 10.1038/s41591-022-01808-0]ISRCTN62025374. Helping pregnant smokers quit: a multi-centre study of electronic cigarettes and nicotine patches. www.isrctn.com/ISRCTN62025374 (first received 21 March 2017). [DOI: 10.1186/ISRCTN62025374]PesolaF , SmithKM , Phillips-WallerA , PrzuljD , GriffithsC , Walton R et al. Safety of e-cigarettes and nicotine patches as stop-smoking aids in pregnancy: Secondary analysis of the Pregnancy Trial of E-cigarettes and Patches (PREP) randomized controlled trial. Addiction2024;119(5):875-84. [DOI: 10.1111/add.16422]PrzuljD , PesolaF , SmithKM , McRobbieH , ColemanT , Lewis S et al. Helping pregnant smokers quit: a multicentre randomised controlled trial of electronic cigarettes versus nicotine replacement therapy. Health Technology Assessment2023;27(13):1-53. [DOI: 10.3310/AGTH6901]">Hajek 2022</a>; <a href="./references#CD010216-bbs2-0044" title="LeeSM , TenneyR , WallaceA , ArjojmandiM . The end perioperative smoking pilot study: a randomized trial comparing e-cigarettes versus nicotine patch. Canadian Journal of Anesthesia2017;64(1 Suppl 1):S48-9. LeeSM , TenneyR , WallaceA , ArjomandiM . Exploring the teachable moment: facilitators and barriers to perioperative smoking cessation, a qualitative study. Canadian Journal of Anesthesia 2017; Conference: 2017 Annual Meeting of the Canadian Anesthesiologists' Society, Canada 61;1 Suppl:S46-7. LeeSM , TenneyR , WallaceAW , ArjomandiM . E-cigarettes versus nicotine patches for perioperative smoking cessation: a pilot randomized trial. PeerJ2018;6(9):e5609. NCT02482233. A pilot randomized controlled clinical trial - &quot;Electronic nicotine delivery device (e-cigarette) for perioperative smoking cessation in veterans&quot;. clinicaltrials.gov/show/NCT02482233 (accessed 17 February 2016). ">Lee 2018</a>; <a href="./references#CD010216-bbs2-0054" title="ISRCTN13288677. Can electronic cigarettes and nicotine replacement treatment help reduce smoking in smokers who struggle to quit?www.isrctn.com/ISRCTN13288677 (first received 17 March 2017). Myers SmithK , Phillips-WallerA , PesolaF , McRobbieH , PrzuljD , OrzolM , et al. E-cigarettes versus nicotine replacement treatment as harm reduction interventions for smokers who find quitting difficult: randomised controlled trial. Addiction2022;117(1):224-33. [DOI: 10.1111/add.15628]">Myers‐Smith 2022</a>) and one at unclear risk (<a href="./references#CD010216-bbs2-0085" title="WagenerT , BeebeL , BusinelleM , CarpenterM , HintonA , HartJ , et al. E-cigarette versus combination nicotine replacement therapy delivered through state quitlines on smoking abstinence following a recent failed quit attempt: a randomized trial. In: Society for Research on Nicotine and Tobacco (SRNT) 29th Annual Meeting; 2023 Mar 1-4; San Antonio (TX), USA. SYM5-2. 2023. ">Wagener 2023</a>)) comparing nicotine ECs with NRT provided data on serious adverse events. In some studies, no events occurred. Pooled results showed that there may be a slight increase in serious adverse events in the nicotine EC arms compared to NRT. There is low certainty of evidence for this outcome, downgraded two levels due to imprecision; there were fewer than 300 events and wide CIs incorporating no difference, as well as clinically significant harm and clinically significant benefit (RR 1.20, 95% CI 0.90 to 1.60; I<sup>2</sup> = 32%; 2761 participants; <a href="./references#CD010216-fig-0014" title="">Analysis 1.3</a>). None of the studies contributing data to this analysis received funding from the vaping or tobacco industries. In <a href="./references#CD010216-bbs2-0029" title="FordA , UnyI , LowesJ , NaughtonF , CooperS , ColemanT . A qualitative study of factors influencing adherence among pregnant women taking part in a trial of e-cigarettes for smoking cessation. International Journal of Environmental Research and Public Health2021;18(2):430. HajekP , PrzuljD , PesolaF , GriffithsC , WaltonR , McRobbieH , et al. Author Correction: Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial. Nature Medicine2023;29(11):2957. [DOI: 10.1038/s41591-022-02099-1]HajekP , PrzuljD , PesolaF , GriffithsC , WaltonR , McRobbieH , et al. Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial. Nature Medicine2022;28:958-64. [DOI: 10.1038/s41591-022-01808-0]ISRCTN62025374. Helping pregnant smokers quit: a multi-centre study of electronic cigarettes and nicotine patches. www.isrctn.com/ISRCTN62025374 (first received 21 March 2017). [DOI: 10.1186/ISRCTN62025374]PesolaF , SmithKM , Phillips-WallerA , PrzuljD , GriffithsC , Walton R et al. Safety of e-cigarettes and nicotine patches as stop-smoking aids in pregnancy: Secondary analysis of the Pregnancy Trial of E-cigarettes and Patches (PREP) randomized controlled trial. Addiction2024;119(5):875-84. [DOI: 10.1111/add.16422]PrzuljD , PesolaF , SmithKM , McRobbieH , ColemanT , Lewis S et al. Helping pregnant smokers quit: a multicentre randomised controlled trial of electronic cigarettes versus nicotine replacement therapy. Health Technology Assessment2023;27(13):1-53. [DOI: 10.3310/AGTH6901]">Hajek 2022</a> (conducted in pregnant women), the authors reported no evidence of a difference in birth outcomes overall. However, low birthweight (&lt; 2500 g) was less frequent in the EC than the NRT arm (14.8% versus 9.6%; RR 0.65, 95% CI 0.47 to 0.90). </p> <p>No SAEs occurred in <a href="./references#CD010216-bbs2-0038" title="IoakeimidisN , VlachopoulosC , GeorgakopoulosC , AbdelrasoulM , SklirosN , KatsiV , et al. Smoking cessation rates with varenicline and electronic cigarettes in relapsed smokers with a history of acute coronary syndrome. European Heart Journal2018;39(Suppl 1):242. ">Ioakeimidis 2018</a> (<a href="./references#CD010216-fig-0031" title="">Analysis 2.2</a>). </p> </section> <section id="CD010216-sec-0062"> <h5 class="title">Carbon monoxide (CO)</h5> <p>Pooled data from four studies (<a href="./references#CD010216-bbs2-0031" title="HatsukamiD , MeierE , LindgrenBR , AndersonA , ReisingerS , NortonK , et al. A randomized clinical trial examining the effects of instructions for electronic cigarette use on smoking-related behaviors, and biomarkers of exposure. Nicotine &amp; Tobacco Research2020;22(9):1524-32. [DOI: 10.1093/ntr/ntz233]NCT03111537. Methods project 4: clinical trial - amended (COMET). https://clinicaltrials.gov/ct2/show/NCT03111537 (accessed 10 September 2022). ">Hatsukami 2020</a>; <a href="./references#CD010216-bbs2-0040" title="KerrD . Chapter 5: A randomised controlled trial investigating the cardiovascular effects of e-cigaretttes in comparison to nicotine replacement patches [personal communication]. Studies into the Cardiovascular and Respiratory Effects of Electronic Cigarettes (PhD thesis), emailed to: A Butler 27 September 2020. NCT03358953. The cardiovascular impacts of electronic cigarettes in comparison to the use of nicotine replacement patches (VAPOUR). clinicaltrials.gov/ct2/show/NCT03358953 (first received 2 December 2017). ">Kerr 2020</a>; <a href="./references#CD010216-bbs2-0042" title="JonesG , McIntoshE , BroseLS , KlonizakisM . Participant experiences of a quit smoking attempt through either Nicotine Replacement Therapy (NRT) methods or the use of an e-cigarette. Journal of Addiction Medicine2022;16(3):272-7. KlonizakisM , CrankH , GumberA , BroseLS . Smokers making a quit attempt using e-cigarettes with or without nicotine or prescription nicotine replacement therapy: impact on cardiovascular function (ISME-NRT) - a study protocol. BMC Public Health2017;17(1):293. KlonizakisM , GumberA , McIntoshE , BroseLS . Medium-and longer-term cardiovascular effects of e-cigarettes in adults making a stop-smoking attempt: a randomized controlled trial. BMC Medicine2022;20(1):276. [DOI: 10.1186/s12916-022-02451-9]KlonizakisM , GumberA , McIntoshE , BroseLS . Short-term cardiovascular effects of e-cigarettes in adults making a stop-smoking attempt: a randomized controlled trial. Biology2021;10(11):1208. [DOI: 10.3390/biology10111208]NCT03061253. E-cigarettes and cardiovascular function (ISME-NRT). clinicaltrials.gov/ct2/show/NCT03061253 (first received 23 February 2017). ">Klonizakis 2022</a>; <a href="./references#CD010216-bbs2-0044" title="LeeSM , TenneyR , WallaceA , ArjojmandiM . The end perioperative smoking pilot study: a randomized trial comparing e-cigarettes versus nicotine patch. Canadian Journal of Anesthesia2017;64(1 Suppl 1):S48-9. LeeSM , TenneyR , WallaceA , ArjomandiM . Exploring the teachable moment: facilitators and barriers to perioperative smoking cessation, a qualitative study. Canadian Journal of Anesthesia 2017; Conference: 2017 Annual Meeting of the Canadian Anesthesiologists' Society, Canada 61;1 Suppl:S46-7. LeeSM , TenneyR , WallaceAW , ArjomandiM . E-cigarettes versus nicotine patches for perioperative smoking cessation: a pilot randomized trial. PeerJ2018;6(9):e5609. NCT02482233. A pilot randomized controlled clinical trial - &quot;Electronic nicotine delivery device (e-cigarette) for perioperative smoking cessation in veterans&quot;. clinicaltrials.gov/show/NCT02482233 (accessed 17 February 2016). ">Lee 2018</a>), none of which received tobacco/vaping industry funding and none of which were considered at high risk of bias, comparing nicotine EC with NRT, found some evidence that CO levels decreased more in those randomized to nicotine EC; however, the CIs incorporated the possibility of no between‐group difference (mean difference (MD) ‐1.81 ppm, 95% CI ‐3.64 to 0.01; I<sup>2</sup> = 0%; 357 participants; <a href="./references#CD010216-fig-0015" title="">Analysis 1.4</a>). A fourth, small study (<a href="./references#CD010216-bbs2-0020" title="EisenhoferJ , MakanjuolaT , MartinezV , Thompson-LakeDG , RodgmanC , DeBruleDS , et al. Efficacy of electronic cigarettes for smoking cessation in veterans. Drug and Alcohol Dependence2015;156:e63-4. ">Eisenhofer 2015</a>; n = 11) was reported as a conference abstract and hence had limited data available. At three weeks, this study showed that both EC and NRT groups had "significantly reduced" CO, but between‐group differences were not reported. </p> </section> <section id="CD010216-sec-0063"> <h5 class="title">Heart rate, blood pressure, and oxygen saturation</h5> <p>Pooled data from two studies (166 participants; one study judged to be at unclear risk of bias (<a href="./references#CD010216-bbs2-0031" title="HatsukamiD , MeierE , LindgrenBR , AndersonA , ReisingerS , NortonK , et al. A randomized clinical trial examining the effects of instructions for electronic cigarette use on smoking-related behaviors, and biomarkers of exposure. Nicotine &amp; Tobacco Research2020;22(9):1524-32. [DOI: 10.1093/ntr/ntz233]NCT03111537. Methods project 4: clinical trial - amended (COMET). https://clinicaltrials.gov/ct2/show/NCT03111537 (accessed 10 September 2022). ">Hatsukami 2020</a>) and one at low risk (<a href="./references#CD010216-bbs2-0040" title="KerrD . Chapter 5: A randomised controlled trial investigating the cardiovascular effects of e-cigaretttes in comparison to nicotine replacement patches [personal communication]. Studies into the Cardiovascular and Respiratory Effects of Electronic Cigarettes (PhD thesis), emailed to: A Butler 27 September 2020. NCT03358953. The cardiovascular impacts of electronic cigarettes in comparison to the use of nicotine replacement patches (VAPOUR). clinicaltrials.gov/ct2/show/NCT03358953 (first received 2 December 2017). ">Kerr 2020</a>), neither in receipt of vaping/tobacco industry funding) showed no clear evidence of a clinically meaningful difference in heart rate (MD 0.53 bpm, 95% CI ‐1.76 to 2.83; I<sup>2</sup> = 0%; <a href="./references#CD010216-fig-0016" title="">Analysis 1.5</a>), systolic blood pressure (MD ‐1.62, 95% CI ‐3.59 to 0.36; I<sup>2</sup> = 0%; <a href="./references#CD010216-fig-0017" title="">Analysis 1.6</a>), or blood oxygen saturation (MD ‐0.14, 95% CI ‐0.59 to 0.30; I<sup>2</sup> = 0%; <a href="./references#CD010216-fig-0018" title="">Analysis 1.7</a>), although confidence intervals were wide. </p> </section> <section id="CD010216-sec-0064"> <h5 class="title">Toxicants</h5> <p>Only <a href="./references#CD010216-bbs2-0031" title="HatsukamiD , MeierE , LindgrenBR , AndersonA , ReisingerS , NortonK , et al. A randomized clinical trial examining the effects of instructions for electronic cigarette use on smoking-related behaviors, and biomarkers of exposure. Nicotine &amp; Tobacco Research2020;22(9):1524-32. [DOI: 10.1093/ntr/ntz233]NCT03111537. Methods project 4: clinical trial - amended (COMET). https://clinicaltrials.gov/ct2/show/NCT03111537 (accessed 10 September 2022). ">Hatsukami 2020</a> (unclear risk of bias, no tobacco/vaping industry funding, n = 111) contributed data for these outcomes. For 3‐HPMA, 2‐HPMA, and HMPMA, point estimates favoured EC but CIs included no difference (<a href="./references#CD010216-fig-0019" title="">Analysis 1.8</a>; <a href="./references#CD010216-fig-0021" title="">Analysis 1.10</a>; <a href="./references#CD010216-fig-0022" title="">Analysis 1.11</a>). There was no evidence of a difference for NNAL (nitrosamine 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐ butanol) but CIs were again wide (<a href="./references#CD010216-fig-0020" title="">Analysis 1.9</a>). For PheT, CEMA, and AAMA (<a href="./references#CD010216-fig-0023" title="">Analysis 1.12</a>; <a href="./references#CD010216-fig-0024" title="">Analysis 1.13</a>; <a href="./references#CD010216-fig-0025" title="">Analysis 1.14</a>), point estimates favoured NRT but CIs included no difference. </p> </section> <section id="CD010216-sec-0065"> <h5 class="title">Lung function</h5> <p><a href="./references#CD010216-bbs2-0044" title="LeeSM , TenneyR , WallaceA , ArjojmandiM . The end perioperative smoking pilot study: a randomized trial comparing e-cigarettes versus nicotine patch. Canadian Journal of Anesthesia2017;64(1 Suppl 1):S48-9. LeeSM , TenneyR , WallaceA , ArjomandiM . Exploring the teachable moment: facilitators and barriers to perioperative smoking cessation, a qualitative study. Canadian Journal of Anesthesia 2017; Conference: 2017 Annual Meeting of the Canadian Anesthesiologists' Society, Canada 61;1 Suppl:S46-7. LeeSM , TenneyR , WallaceAW , ArjomandiM . E-cigarettes versus nicotine patches for perioperative smoking cessation: a pilot randomized trial. PeerJ2018;6(9):e5609. NCT02482233. A pilot randomized controlled clinical trial - &quot;Electronic nicotine delivery device (e-cigarette) for perioperative smoking cessation in veterans&quot;. clinicaltrials.gov/show/NCT02482233 (accessed 17 February 2016). ">Lee 2018</a> and <a href="./references#CD010216-bbs2-0040" title="KerrD . Chapter 5: A randomised controlled trial investigating the cardiovascular effects of e-cigaretttes in comparison to nicotine replacement patches [personal communication]. Studies into the Cardiovascular and Respiratory Effects of Electronic Cigarettes (PhD thesis), emailed to: A Butler 27 September 2020. NCT03358953. The cardiovascular impacts of electronic cigarettes in comparison to the use of nicotine replacement patches (VAPOUR). clinicaltrials.gov/ct2/show/NCT03358953 (first received 2 December 2017). ">Kerr 2020</a> (no tobacco/vaping industry funding) measured change in FEV1 (forced expiratory volume) and FEV1/FVC (forced vital capacity) (both low risk of bias; n = 81). High statistical heterogeneity (I<sup>2</sup> = 89%) precluded pooling for FEV1 (<a href="./references#CD010216-fig-0026" title="">Analysis 1.15</a>). The point estimate for <a href="./references#CD010216-bbs2-0044" title="LeeSM , TenneyR , WallaceA , ArjojmandiM . The end perioperative smoking pilot study: a randomized trial comparing e-cigarettes versus nicotine patch. Canadian Journal of Anesthesia2017;64(1 Suppl 1):S48-9. LeeSM , TenneyR , WallaceA , ArjomandiM . Exploring the teachable moment: facilitators and barriers to perioperative smoking cessation, a qualitative study. Canadian Journal of Anesthesia 2017; Conference: 2017 Annual Meeting of the Canadian Anesthesiologists' Society, Canada 61;1 Suppl:S46-7. LeeSM , TenneyR , WallaceAW , ArjomandiM . E-cigarettes versus nicotine patches for perioperative smoking cessation: a pilot randomized trial. PeerJ2018;6(9):e5609. NCT02482233. A pilot randomized controlled clinical trial - &quot;Electronic nicotine delivery device (e-cigarette) for perioperative smoking cessation in veterans&quot;. clinicaltrials.gov/show/NCT02482233 (accessed 17 February 2016). ">Lee 2018</a> favoured EC and for <a href="./references#CD010216-bbs2-0040" title="KerrD . Chapter 5: A randomised controlled trial investigating the cardiovascular effects of e-cigaretttes in comparison to nicotine replacement patches [personal communication]. Studies into the Cardiovascular and Respiratory Effects of Electronic Cigarettes (PhD thesis), emailed to: A Butler 27 September 2020. NCT03358953. The cardiovascular impacts of electronic cigarettes in comparison to the use of nicotine replacement patches (VAPOUR). clinicaltrials.gov/ct2/show/NCT03358953 (first received 2 December 2017). ">Kerr 2020</a> favoured NRT; for <a href="./references#CD010216-bbs2-0040" title="KerrD . Chapter 5: A randomised controlled trial investigating the cardiovascular effects of e-cigaretttes in comparison to nicotine replacement patches [personal communication]. Studies into the Cardiovascular and Respiratory Effects of Electronic Cigarettes (PhD thesis), emailed to: A Butler 27 September 2020. NCT03358953. The cardiovascular impacts of electronic cigarettes in comparison to the use of nicotine replacement patches (VAPOUR). clinicaltrials.gov/ct2/show/NCT03358953 (first received 2 December 2017). ">Kerr 2020</a>, the CIs included no difference. There was no evidence of a difference for FEV1/FVC, but there was moderate unexplained statistical heterogeneity and, again, CIs were wide (MD ‐0.16%, 95% CI ‐1.83 to 1.50; I<sup>2</sup> = 51%; <a href="./references#CD010216-fig-0027" title="">Analysis 1.16</a>). For PEF (peak expiratory flow) only one study contributed to this analysis (<a href="./references#CD010216-bbs2-0040" title="KerrD . Chapter 5: A randomised controlled trial investigating the cardiovascular effects of e-cigaretttes in comparison to nicotine replacement patches [personal communication]. Studies into the Cardiovascular and Respiratory Effects of Electronic Cigarettes (PhD thesis), emailed to: A Butler 27 September 2020. NCT03358953. The cardiovascular impacts of electronic cigarettes in comparison to the use of nicotine replacement patches (VAPOUR). clinicaltrials.gov/ct2/show/NCT03358953 (first received 2 December 2017). ">Kerr 2020</a>, n = 55). The point estimate favoured NRT but CIs were wide and included no difference (MD ‐3.00, 95% CI ‐27.09 to 21.09) (<a href="./references#CD010216-fig-0028" title="">Analysis 1.17</a>). </p> </section> <section id="CD010216-sec-0066"> <h5 class="title">Study product use</h5> <p>Five studies (one, <a href="./references#CD010216-bbs2-0073" title="RussellC , McKeganeyN , KatsampourisE , SatchwellA , HaseenF . A randomised community-based trial of a closed-system pod e-vapour product and nicotine replacement therapy for cigarette abstinence and reduction. Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting February 24-27 2021 virtual:PH-353 p230. ">Russell 2021</a>, with vaping industry funding) reported study product use at six months or longer, but statistical heterogeneity precluded pooling (I<sup>2</sup> = 95%). Whereas <a href="./references#CD010216-bbs2-0073" title="RussellC , McKeganeyN , KatsampourisE , SatchwellA , HaseenF . A randomised community-based trial of a closed-system pod e-vapour product and nicotine replacement therapy for cigarette abstinence and reduction. Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting February 24-27 2021 virtual:PH-353 p230. ">Russell 2021</a> and <a href="./references#CD010216-bbs2-0044" title="LeeSM , TenneyR , WallaceA , ArjojmandiM . The end perioperative smoking pilot study: a randomized trial comparing e-cigarettes versus nicotine patch. Canadian Journal of Anesthesia2017;64(1 Suppl 1):S48-9. LeeSM , TenneyR , WallaceA , ArjomandiM . Exploring the teachable moment: facilitators and barriers to perioperative smoking cessation, a qualitative study. Canadian Journal of Anesthesia 2017; Conference: 2017 Annual Meeting of the Canadian Anesthesiologists' Society, Canada 61;1 Suppl:S46-7. LeeSM , TenneyR , WallaceAW , ArjomandiM . E-cigarettes versus nicotine patches for perioperative smoking cessation: a pilot randomized trial. PeerJ2018;6(9):e5609. NCT02482233. A pilot randomized controlled clinical trial - &quot;Electronic nicotine delivery device (e-cigarette) for perioperative smoking cessation in veterans&quot;. clinicaltrials.gov/show/NCT02482233 (accessed 17 February 2016). ">Lee 2018</a> found no difference between the EC and NRT arms, in the other three studies, people in the EC arm were more likely to continue to use the study product (EC) than those in the NRT arm (<a href="./references#CD010216-fig-0029" title="">Analysis 1.18</a>). A companion publication explored long‐term rates in more detail (<a href="./references#CD010216-bbs2-0207" title="ButlerAR , LindsonN , FanshaweTR , TheodoulouA , BeghR , HajekP , et al. Longer-term use of electronic cigarettes when provided as a stop smoking aid: systematic review with meta-analyses. Preventive Medicine2022;165(Pt B):107182. [DOI: 10.1016/j.ypmed.2022.107182] [PMID: 35933001]">Butler 2022</a>). </p> </section> </section> <section id="CD010216-sec-0067"> <h4 class="title">Nicotine EC versus other tobacco/nicotine products used for stopping combustible tobacco use </h4> <p>Currently, the only comparison reported here is nicotine EC compared to heated tobacco. One study (<a href="./references#CD010216-bbs2-0010" title="CaponnettoP , CampagnaD , MagliaM , BenfattoF , EmmaR , CarusoM , et al. Comparing the effectiveness, tolerability, and acceptability of heated tobacco products and refillable electronic cigarettes for cigarette substitution (CEASEFIRE): randomized controlled trial. Public Health Surveillance2023;9:e42628. [DOI: 10.2196/42628]CaponnettoP , CarusoM , MagliaM , EmmaR , SaittaD , BusaB , et al. Non-inferiority trial comparing cigarette consumption, adoption rates, acceptability, tolerability, and tobacco harm reduction potential in smokers switching to Heated Tobacco Products or electronic cigarettes: study protocol for a randomized controlled trial. Contemporary Clinical Trials Communications2020;8:17. NCT03569748. Heated tobacco products vs electronic cigarettes. clinicaltrials.gov/ct2/show/NCT03569748 (first received 25 June 2021). ">Caponnetto 2023*</a>; n = 220, tobacco/vaping industry‐funded), considered at high risk of bias due to a lack of blinding alongside strong participant product preferences, reported on AEs, SAEs, expired carbon monoxide (eCO), and VO<sub>2</sub> max as a measure of lung function, heart rate, and blood pressure at 12 weeks follow‐up. The effect estimate demonstrated no clear evidence of a difference in AEs between the nicotine EC and heated tobacco group (RR 0.86, 95% CI 0.68 to 1.10; 220 participants; <a href="./references#CD010216-fig-0032" title="">Analysis 3.1</a>). There were no SAEs reported in either arm, so an effect estimate could not be calculated for this outcome (<a href="./references#CD010216-fig-0033" title="">Analysis 3.2</a>). There was no clear evidence of a between‐group difference in eCO levels (MD 1.90, 95% CI ‐0.71 to 4.51; 217 participants; <a href="./references#CD010216-fig-0034" title="">Analysis 3.3</a>), or VO<sub>2</sub> max (MD 6.20, 95% CI ‐2.01 to 14.41; 211 participants; <a href="./references#CD010216-fig-0035" title="">Analysis 3.4</a>). </p> <p>The following was reported on heart rate and blood pressure and is reported in <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Tables 4 &amp; 5</a>: “No significant changes in the mean resting heart rate, blood pressure, and BMI during product use were observed between and within study groups.” </p> </section> <section id="CD010216-sec-0068"> <h4 class="title">Nicotine EC alone or versus control</h4> <p>Comparisons reported here include nicotine EC versus non‐nicotine EC, and nicotine EC compared to behavioural support only or to no support. In this section, we also reported results from studies in which all participants received nicotine EC (cohort studies and randomized studies that did not differ across arms in EC provision, device generation, or nicotine content). </p> <section id="CD010216-sec-0069"> <h5 class="title">Cessation</h5> <section id="CD010216-sec-0070"> <h6 class="title">Randomized controlled trials</h6> <p>At six months or longer, quit rates were higher in nicotine EC groups than in comparator groups. Compared to EC without nicotine (placebo EC), pooled results showed nicotine EC probably produced higher quit rates (RR 1.46, 95% CI 1.09 to 1.96; I<sup>2</sup> = 4%; 5 studies of cartridge and 1 study of refillable devices, 1613 participants; <a href="./references#CD010216-fig-0036" title="">Analysis 4.1</a>). There is moderate‐certainty evidence that nicotine EC probably increases quit rates compared to non‐nicotine EC. The certainty has been downgraded one level due to imprecision; there are fewer than 300 events overall. This has not been downgraded for risk of bias: removing the one study considered at high risk of bias increased the direction of the effect in favour of nicotine EC. The interpretation of the effect remained the same when we removed the one study at high risk of bias (<a href="./references#CD010216-bbs2-0046" title="LucchiariC , MasieroM , MazzoccoK , VeronesiG , MaisonneauveP , JemosC , et al. Benefits of e-cigarettes in smoking reduction and in pulmonary health among chronic smokers undergoing a lung cancer screening program at 6 months. Addictive Behaviours2020;103:106222. LucchiariC , MasieroM , MazzoccoK , VeronesiG , MaisonneuveP , JemosC , et al. Nicotine-free e-cigarettes might promote tobacco smoking reduction better than nicotine delivery devices: results of a double-blind randomized controlled trial at 1 year. Current Oncology2022;29(11):8579-90. [DOI: 10.3390/curroncol29110676]LucchiariC , MasieroM , VeronesiG , MaisonneuveP , SpinaS , JemosC , et al. Benefits of e-cigarettes among heavy smokers undergoing a lung cancer screening program: randomized controlled trial protocol. JMIR Research Protocols2016;5(1):e21. [PMID: 26842790]MasieroM , LucchiariC , MazzoccoK , VeronesiG , Maisonneuve P JemosC , et al. Corrigendum: E-cigarettes may support smokers with high smoking-related risk awareness to stop smoking in the short run: preliminary results by randomized controlled trial. Nicotine and Tobacco Research2020;22(4):594-5. [NCT02422914]MasieroM , LucchiariC , MazzoccoK , VeronesiG , MaisonneuveP , JemosC , et al. E-cigarettes may support smokers with high smoking-related risk awareness to stop smoking in the short run: preliminary results by randomized controlled trial. Nicotine and Tobacco Research2019;21(1):119-26. [NCT02422914]NCT02422914. Benefits of tobacco free cigarette among heavy smokers undergoing a lung cancer screening program: a randomized controlled study. clinicaltrials.gov/show/NCT02422914 (accessed 17 February 2016). PravettoniG , MasieroM , LucchiariC , MaisenneuveP , MazzoccoK , VeronesiG . The role of electronic cigarettes in smoking cessation among heavy smokers undergoing a lung cancer screening program: preliminary results of a randomized controlled study. Psycho-Oncology2016;25:72. [DOI: 10.1002/pon.4082]">Lucchiari 2022</a>) and when we removed the one study with tobacco/vaping industry funding (<a href="./references#CD010216-bbs2-0007" title="CampagnaD , CibellaF , CaponnettoP , AmaradioMD , CarusoM , MorjariaJB , et al. Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. European Journal of Clinical Investigation2016;46(8):698-706. CaponnettoP , CampagnaD , CibellaF , MorjariaJB , CarusoM , RussoC , et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLOS One2013;8(6):e66317. CibellaF , CampagnaD , CaponnettoP , AmaradioMD , CarusoM , RussoC , et al. Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. Clinical Science2016;130(21):1929-37. FarsalinosK , CibellaF , CaponnettoP , CampagnaD , MorjariaJB , BattagliaE , et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Internal and Emergency Medicine2016;11(1):85-94. NCT01164072. Efficacy and safety of an electronic nicotine delivery device (e-cigarette). clinicaltrials.gov/ct2/show/NCT01164072 (first received 16 July 2010). NCT01188239. A structured protocol to evaluate efficacy and safety of a popular electronic nicotine delivery device (e-cigarette) efficacy and safety of a popular electronic nicotine delivery device (e-cigarette). https://clinicaltrials.gov/ct2/show/NCT01188239. NCT01194583. Efficacy and safety of an electronic nicotine delivery device (e-cigarette) without nicotine cartridges. clinicaltrials.gov/ct2/show/NCT01194583 (first received 3 September 2010). RussoC , CibellaF , CaponnettoP , CampagnaD , MagliaM , FrazzettoE , et al. Evaluation of post cessation weight gain in a 1-year randomized smoking cessation trial of electronic cigarettes. Scientific Reports2016;6:18763. ">Caponnetto 2013a*</a>). The effect may be more pronounced when comparing nicotine EC to behavioural support only or to no support (RR 1.96, 95% CI 1.66 to 2.32; I<sup>2</sup> = 0%; 11 studies (5 refillable, 3 cartridge, 3 pod), 6819 participants; <a href="./references#CD010216-fig-0047" title="">Analysis 5.1</a>). As this involved unblinded comparisons with unequal levels of support, we judged all data contributing to this outcome to be at high risk of bias (the certainty of the evidence was low, downgraded two levels). One of the studies contributing data to this comparison reported tobacco/vaping industry funding (<a href="./references#CD010216-bbs2-0089" title="XuY , GoldensonNI , Prakash S AugustsonEM , ShiffmanS . Randomized trial assessing the effect of the JUUL system on switching away from cigarettes and smoking reduction among U.S. adults who smoke cigarettes.. Experimental and Clinical Psychopharmacology2024;32(1):3-15. [DOI: 10.1037/pha0000698]">Xu 2023*</a>). The removal of this study in a sensitivity analysis did not change the interpretation of the effect (<a href="#CD010216-tbl-0004">Table 1</a>). </p> <div class="table" id="CD010216-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis for all studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Analysis number</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sensitivity analysis removing studies at high risk of bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sensitivity analysis removing industry‐funded studies</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1‐1.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1‐2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1‐3.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.61 (1.15, 2.26) I<sup>2</sup> = 9% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.34 (0.98, 1.82) I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.01 (0.91, 1.11) I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.00 (0.56, 1.79) I<sup>2</sup> = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.95 (0.52, 1.72) I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5‐4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐0.03 (‐0.46, 0.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.83 (1.53, 2.18), I<sup>2</sup> = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 4.73 (0.56, 39.88) I<sup>2</sup> not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.29 (1.15, 1.45) I<sup>2</sup> not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.19 (1.05, 1.30) I<sup>2</sup> = 8% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.90 (0.65, 4.70) I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 1.11 (‐3.95, 6.18) I<sup>2</sup> = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ST MD ‐0.30 (‐0.74, 0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ST MD ‐0.30 (‐0.74, 0.13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ST MD 0.00 (‐0.44, 0.44)/N/A no overall value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.10‐5.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐0.14 (‐0.28, 0.00) I<sup>2</sup> not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.18‐5.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A the 1 study that is industry‐funded does not contribute to the RR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐0.90 (‐1.70, ‐0.10) I<sup>2</sup> = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐1.15 (‐2.05, ‐0.24) I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.5‐6.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.11‐6.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1‐7.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.1‐8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.1‐10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.86 (0.30, 27.10) I<sup>2</sup> not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.33, 4.33) No change as the study at high risk of bias was not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.1‐12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.1‐13.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.04 (0.89, 1.22) I<sup>2</sup> not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.2‐14.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.25 (0.78, 1.99) I<sup>2</sup> not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.09 (0.90, 1.31) I<sup>2</sup> not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.59 (0.11, 3.34) I<sup>2</sup> not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67 (0.37, 1.19) I<sup>2</sup> not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐9.10 (‐15.83, ‐2.37) I<sup>2</sup> not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐1.40 (‐4.26, 1.46) I<sup>2</sup> not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.5‐15.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.85 (1.91, 7.74) I<sup>2</sup> not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.2‐16.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.1‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>N/A 1 = no studies at high risk of bias/no industry‐funded studies</p> <p>N/A 2 = all studies at high risk of bias/industry‐funded</p> <p>N/A 3 = results not pooled</p> <p>MD: mean difference; RR: risk ratio; ST MD: standardized mean difference</p> </div> </div> <p><a href="./references#CD010216-bbs2-0071" title="ArnoldM , NollenN , MayoM , AhluwaliaJ , LeavensE , Zhang G et al. Dual use of cigarettes and e-cigarettes in African American and LatinX smokers: secondary analyses from a randomised controlled e-cigarettes switching trial. In: Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting. February 24-27 2021 virtual:POD4-2 p31. ArnoldMJ , NollenNL , MayoMS , AhluwaliaJS , LeavensEL , ZhangG , RiceM , et al. Harm reduction associated with dual use of cigarettes and e-cigarettes in Black and Latino smokers: secondary analyses from a randomized controlled e-cigarette switching trial. Nicotine &amp; Tobacco Research2021;23(11):1972-6. [DOI: 10.1093/ntr/ntab069]LeavensELS , NollenN , AhluwaliaJ , MayoM , RiceM , BrettE , et al. Changes in dependence, withdrawal, and craving among adult smokers who switch to nicotine salt pod-based e-cigarettes. In: Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting. February 24-27 2021 virtual:POD53-1 p96, C-6 p116. LeavensELS , NollenN , AhluwaliaJS , MayoMS , RiceM , Brett EI et al. Changes in dependence, withdrawal, and craving among adult smokers who switch to nicotine salt pod-based e-cigarettes. Addiction2021;117(1):207-15. [DOI: 10.1111/add.15597]LeeSC , MaglalangDD , AvilaJC , LeavensELS , Nollen NL PulversK , et al. Change in e-cigarette risk perception and smoking behavior of Black and Latinx individuals who smoke. Drug and Alcohol Dependence2023;245:109824. [DOI: 10.1016/j.drugalcdep.2023.109824]NCT03511001. Effects among smokers who use and do not use e-cigarettes. https://clinicaltrials.gov/ct2/show/NCT03511001. NollenN , LambertL , LeavensE , AhluwaliaJ , RiceM , PulversK . Does menthol flavoring help black and LatinX adult menthol combustible cigarette smokers switch to e-cigarettes?: secondary analyses from a randomized clinical trial. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. March 2022. NollenNL , LeavensELS , AhluwaliaJS , RiceM , MayoMS , PulversK . Menthol versus non-menthol flavouring and switching to e-cigarettes in black and Latinx adult menthol combustible cigarette smokers: secondary analyses from a randomised clinical trial. Tobacco Control Online 29 March 2022;EPub:Online version. [DOI: 10.1136/tobaccocontrol-2021-057180]PulversK , NollenNL , RiceM , SchmidCH , QuK , BenowitzNL , et al. Effect of pod e-cigarettes vs cigarettes on carcinogen exposure among African American and Latinx smokers: a randomized clinical trial. JAMA Network Open2020;3(11):e2026324. RiceM , NollenN , WoodcockA , BenowitzN , AhluwaliaJ , PulversK . Effect of marijuana use on smokers switching to e-cigarettes in a randomised control trial. In: Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting. February 24-27 2021 virtual:SRNT C-44, p125. RiceM , NollenNL , AhluwaliaJS , BenowitzN , WoodcockA , PulversK . Effects of marijuana use on smokers switching to e-cigarettes in a randomized clinical trial. Nicotine &amp; Tobacco Research2022;24(7):994-1002. [DOI: 10.1093/ntr/ntac008]RubensteinD , SokolovskyA , AstonE , NollenN , SchmidC , Pulvers K et al. Predictors of smoking reduction among African American and LatinX smokers in a randomised controlled trial of Juul e-cigarettes. In: Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting. Vol. C-56. February 24-27 2021 virtual:129. RubensteinD , SokolovskyAW , AstonER , NollenNL , SchmidCH , RiceM , et al. Predictors of smoking reduction among African American and Latinx smokers in a randomized controlled trial of JUUL e-cigarettes. Addictive Behaviors2021;122:107037. [DOI: 10.1016/j.addbeh.2021.107037]">Pulvers 2020</a> (pod device) measured cessation at six months in the intervention group only, using self‐report. As they did not measure cessation at six months in the comparator group, we could not include these data in our meta‐analysis. At six months, 23 (24%) intervention participants were exclusively using EC and 10 (10.4%) reported using neither EC nor combustible cigarettes (making a combined quit rate of 34.4% in the intervention arm at six months). </p> </section> <section id="CD010216-sec-0071"> <h6 class="title">Data from other studies</h6> <p>Ten studies provided all participants with nicotine EC and assessed abstinence at six months or longer (<a href="#CD010216-tbl-0005">Table 2</a>; 2 refillable, 6 cartridges, 1 pod, 1 not specified). The highest proportion of quitters at six months was observed in <a href="./references#CD010216-bbs2-0022" title="ElyJ . Evaluation of the use of electric cigarettes in a rural smoking cessation program. Available online at: digscholarship.unco.edu/cgi/viewcontent.cgi?article=1001&amp;context=capstones 2013 (accessed 1 November 2014). ">Ely 2013</a> (cartridge), in which all participants (n = 48) used EC and 18 used additional pharmacotherapy; 44% of participants were abstinent at six months. The lowest quit rates were seen in <a href="./references#CD010216-bbs2-0008" title="CaponnettoP , AuditoreR , RussoC , CappelloGC , PolosaR . Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. International Journal of Environmental Research and Public Health2013;10(2):446-61. MinutoloG , CaponnettoP , AuditoreR , RussoC , PolosaR . Management of smoking reduction and cessation in inpatients with schizophrenia: impact of electronic cigarettes. European Neuropsychopharmacology2013;23:S581-2. ">Caponnetto 2013b*</a>, where 14% of participants were abstinent at 12 months, and <a href="./references#CD010216-bbs2-0069" title="PriceAD , CoffeyM , HoustonL , CookPA . Evaluation of a pharmacy supported e-cigarette smoking cessation intervention in Northwest England. BMC Public Health2022;22:1326. [DOI: 10.1186/s12889-022-13711-x]">Price 2022</a>, where 5% of participants were abstinent at 12 months. In the former, participants were unmotivated to quit smoking and, in the latter, motivation was unclear and participants were recruited from a socially deprived area on the basis of receiving a free nicotine EC. </p> <div class="table" id="CD010216-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of proportion of participants abstinent from smoking at 6+ months follow‐up: cohort studies of nicotine EC</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Motivated or unmotivated to quit smoking?</b> </p> </th> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="bottom"> <p><b>% abstinent</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Cohort studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>6‐month</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>12‐month</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>18‐month</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>24‐month</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0001" title="AdriaensK , Van GuchtD , DeclerckP , BaeyensF . Effectiveness of the electronic cigarette: an eight-week Flemish study with six-month follow-up on smoking reduction, craving and experienced benefits and complaints. International Journal of Environmental Research and Public Health2014;11(11):11220-48. "><b>Adriaens 2014</b> </a><b><sup>a</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unmotivated to quit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.6% (10/51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data from 8‐month follow‐up</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0018" title="ACTRN12616001641482. Tobacco harm reduction with vaporised nicotine (THRiVe): feasibility study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12616001641482 (first received 28 November 2016). BellS , DeanJ , GilksC , BoydMA , FitzgeraldL , MutchA , et al. Tobacco harm reduction with vaporised nicotine (THRiVe): the study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with HIV who smoke. International Journal of Environmental Research and Public Health2017;14(7):799. EdwardsS , PuljevicC , DeanJA , GilksC , BoydMA , BakerP , et al. Tobacco harm reduction with vaporised nicotine (THRiVe): a feasibility trial of nicotine vaping products for smoking cessation among people living with HIV. AIDS and Behavior2023;27(2):618-27. [DOI: 10.1007/s10461-022-03797-0]"><b>Edwards 2023</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Willing to attempt to quit"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.6% (8/30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010216-bbs2-0008" title="CaponnettoP , AuditoreR , RussoC , CappelloGC , PolosaR . Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. International Journal of Environmental Research and Public Health2013;10(2):446-61. MinutoloG , CaponnettoP , AuditoreR , RussoC , PolosaR . Management of smoking reduction and cessation in inpatients with schizophrenia: impact of electronic cigarettes. European Neuropsychopharmacology2013;23:S581-2. "><b>Caponnetto 2013b*</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unmotivated to quit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14% (2/14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0009" title="CaponnettoP , DiPiazzaJ , KimJ , MagliaM , PolosaR . A single-arm, open-label pilot, and feasibility study of a high nicotine strength e-cigarette intervention for smoking cessation or reduction for people with schizophrenia spectrum disorders who smoke cigarettes. Nicotine &amp; Tobacco Research2021;23(7):1113-22. [DOI: 10.1093/ntr/ntab005]"><b>Caponnetto 2021*</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unmotivated to quit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35% (14/40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0022" title="ElyJ . Evaluation of the use of electric cigarettes in a rural smoking cessation program. Available online at: digscholarship.unco.edu/cgi/viewcontent.cgi?article=1001&amp;context=capstones 2013 (accessed 1 November 2014). "><b>Ely 2013</b> </a><b><sup>b</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Motivated to quit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44% (21/48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0062" title="PacificiR , PichiniS , GrazianoS , PellegriniM , MassaroG , BeatriceF . Successful nicotine intake in medical assisted use of e-cigarettes: a pilot study. International Journal of Environmental Research and Public Health2015;12(7):7638-46. "><b>Pacifici 2015</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unmotivated to quit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53% (18/34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010216-bbs2-0063" title="NCT01195597. Smoking cessation and reduction with an electronic nicotine delivery device (ENDD). clinicaltrials.gov/ct2/show/NCT01195597 (first received 6 September 2010). PolosaR , CaponnettoP , MorjariaJB , PapaleG , CampagnaD , RussoC . Effect of an electronic nicotine delivery device (e-cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health2011;11:786. PolosaR , MorjariaJB , CaponnettoP , CampagnaD , RussoC , AlamoA , et al. Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. Internal and Emergency Medicine2014;9(5):537-46. "><b>Polosa 2011*</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unmotivated to quit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23% (9/40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15% (6/40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13% (5/40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0064" title="NCT02124200. High cessation rates in smokers using personal vaporizers (VAPECIG). clinicaltrials.gov/ct2/show/NCT02124200 (first received 28 April 2014). PolosaR , CaponnettoP , MagliaM , MorjariaJB , RussoC . Success rates with nicotine personal vaporizers: a prospective 6-month pilot study of smokers not intending to quit. BMC Public Health2014;14:1159. "><b>Polosa 2014b*</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unmotivated to quit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36% (18/50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0065" title="PolosaR , CaponnettoP , CibellaF , Le-HouezecJ . Quit and smoking reduction rates in vape shop consumers: a prospective 12-month survey. International Journal of Environmental Research and Public Health2015;12(4):3428-38. "><b>Polosa 2015*</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42% (30/71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41% (29/71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0069" title="PriceAD , CoffeyM , HoustonL , CookPA . Evaluation of a pharmacy supported e-cigarette smoking cessation intervention in Northwest England. BMC Public Health2022;22:1326. [DOI: 10.1186/s12889-022-13711-x]"><b>Price 2022</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5% (42/871)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Technically an RCT but observational for purposes of EC analysis.<br/><sup>b</sup>All participants (N = 48) used an EC, but 16 also used bupropion and 2 used varenicline. </p> </div> </div> </section> </section> <section id="CD010216-sec-0072"> <h5 class="title">Adverse events</h5> <section id="CD010216-sec-0073"> <h6 class="title">Randomized controlled trials</h6> <p>Pooled data from five studies (none at high risk of bias, one reporting tobacco/vaping industry funding) showed that there is probably no difference in the number of participants experiencing adverse events when comparing nicotine EC to non‐nicotine EC (RR 1.01, 95% CI 0.91 to 1.11; I<sup>2</sup> = 0%; 840 participants; <a href="./references#CD010216-fig-0037" title="">Analysis 4.2</a>); this is moderate‐certainty evidence, downgraded one level due to imprecision (fewer than 300 events overall). Removing the one study linked to industry funding had no effect on the interpretation of the result (<a href="#CD010216-tbl-0004">Table 1</a>). When comparing nicotine EC to behavioural support only or to no support, evidence suggests more people in the groups randomized to nicotine EC experience adverse events (RR 1.18, 95% CI 1.10 to 1.27; I<sup>2</sup> = 6%; 6 studies, 2351 participants; <a href="./references#CD010216-fig-0048" title="">Analysis 5.2</a>). As this involved unblinded comparisons with unequal levels of support, we judged all data contributing to this outcome to be at high risk of bias (low‐certainty evidence downgraded two levels due to risk of bias). Interpretation of the outcome was not sensitive to the inclusion of the one study with tobacco/vaping industry support (<a href="./references#CD010216-bbs2-0086" title="CravoAS , BushJ , SharmaG , SaviozR , MartinC , CraigeS , et al. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. Regulatory Toxicology and Pharmacology2016;81:S1-S14. NCT02029196. A randomised, parallel group, multi-centre study to evaluate the safety profile of the ITG EVP G1 product. clinicaltrials.gov/show/NCT02029196 (accessed 16 July 2014). NCT02143310. A multi-centre study to evaluate the safety of use of electronic vapour products for two years. clinicaltrials.gov/show/NCT02143310 (accessed 16 July 2014). WaleleT , BushJ , KochA , SaviozR , MartinC , O'ConnellG . Evaluation of the safety profile of an electronic vapour product used for two years by smokers in a real-life setting. Regulatory Toxicology and Pharmacology2018;92:226-38. ">Walele 2018*</a>). </p> <p>A further 11 randomized controlled trials provided adverse event or related data for this comparison, but could not be included in the meta‐analysis due to the way in which data were presented (see <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 1</a>). In the studies comparing nicotine EC to non‐nicotine EC, one found similar event rates across arms (<a href="./references#CD010216-bbs2-0007" title="CampagnaD , CibellaF , CaponnettoP , AmaradioMD , CarusoM , MorjariaJB , et al. Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. European Journal of Clinical Investigation2016;46(8):698-706. CaponnettoP , CampagnaD , CibellaF , MorjariaJB , CarusoM , RussoC , et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLOS One2013;8(6):e66317. CibellaF , CampagnaD , CaponnettoP , AmaradioMD , CarusoM , RussoC , et al. Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. Clinical Science2016;130(21):1929-37. FarsalinosK , CibellaF , CaponnettoP , CampagnaD , MorjariaJB , BattagliaE , et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Internal and Emergency Medicine2016;11(1):85-94. NCT01164072. Efficacy and safety of an electronic nicotine delivery device (e-cigarette). clinicaltrials.gov/ct2/show/NCT01164072 (first received 16 July 2010). NCT01188239. A structured protocol to evaluate efficacy and safety of a popular electronic nicotine delivery device (e-cigarette) efficacy and safety of a popular electronic nicotine delivery device (e-cigarette). https://clinicaltrials.gov/ct2/show/NCT01188239. NCT01194583. Efficacy and safety of an electronic nicotine delivery device (e-cigarette) without nicotine cartridges. clinicaltrials.gov/ct2/show/NCT01194583 (first received 3 September 2010). RussoC , CibellaF , CaponnettoP , CampagnaD , MagliaM , FrazzettoE , et al. Evaluation of post cessation weight gain in a 1-year randomized smoking cessation trial of electronic cigarettes. Scientific Reports2016;6:18763. ">Caponnetto 2013a*</a>), and two reported more events in the nicotine EC arms (<a href="./references#CD010216-bbs2-0023" title="FelicioneNJ , EnlowP , ElswickD , LongD , SullivanCR , BlankMD . A pilot investigation of the effect of electronic cigarettes on smoking behavior among opioid-dependent smokers. Addictive Behaviors2019;91:45-50. ">Felicione 2019</a>; <a href="./references#CD010216-bbs2-0080" title='GuttentagA , Tuo-YenT , ShelleyD , ThomasK . Analyzing trajectories of acute cigarette reduction post-introduction of an e-cigarette using ecological momentary assessment data. International Journal of Environmental Research and Public Health2022;19(12):7452. [DOI: 10.3390/ijerph19127452]GuttentagA . Do e-cigarettes "Work" for smokers as a step on the way to cessation? An analysis of the temporal and spatial correlates of switching in a harm reduction trial among adult smokers. Dissertation Abstracts International: Section B: The Sciences and Engineering2021;82:8-B. NCT02628964. Assessing the use of electronic cigarettes (e-cigarettes) as a harm reduction strategy. clinicaltrials.gov/show/NCT02628964 (accessed 17 February 2016). TsengTY , OstroffJS , CampoA , GerardM , KirchnerT , RotrosenJ , et al. A randomized trial comparing the effect of nicotine versus placebo electronic cigarettes on smoking reduction among young adult smokers. Nicotine &amp; Tobacco Research2016;18(10):1937-43. '>Tseng 2016</a>). In a further study comparing nicotine to non‐nicotine EC, events were reported by type, with an increase in some seen in the nicotine group and an increase in others seen in the non‐nicotine group (<a href="./references#CD010216-bbs2-0046" title="LucchiariC , MasieroM , MazzoccoK , VeronesiG , MaisonneauveP , JemosC , et al. Benefits of e-cigarettes in smoking reduction and in pulmonary health among chronic smokers undergoing a lung cancer screening program at 6 months. Addictive Behaviours2020;103:106222. LucchiariC , MasieroM , MazzoccoK , VeronesiG , MaisonneuveP , JemosC , et al. Nicotine-free e-cigarettes might promote tobacco smoking reduction better than nicotine delivery devices: results of a double-blind randomized controlled trial at 1 year. Current Oncology2022;29(11):8579-90. [DOI: 10.3390/curroncol29110676]LucchiariC , MasieroM , VeronesiG , MaisonneuveP , SpinaS , JemosC , et al. Benefits of e-cigarettes among heavy smokers undergoing a lung cancer screening program: randomized controlled trial protocol. JMIR Research Protocols2016;5(1):e21. [PMID: 26842790]MasieroM , LucchiariC , MazzoccoK , VeronesiG , Maisonneuve P JemosC , et al. Corrigendum: E-cigarettes may support smokers with high smoking-related risk awareness to stop smoking in the short run: preliminary results by randomized controlled trial. Nicotine and Tobacco Research2020;22(4):594-5. [NCT02422914]MasieroM , LucchiariC , MazzoccoK , VeronesiG , MaisonneuveP , JemosC , et al. E-cigarettes may support smokers with high smoking-related risk awareness to stop smoking in the short run: preliminary results by randomized controlled trial. Nicotine and Tobacco Research2019;21(1):119-26. [NCT02422914]NCT02422914. Benefits of tobacco free cigarette among heavy smokers undergoing a lung cancer screening program: a randomized controlled study. clinicaltrials.gov/show/NCT02422914 (accessed 17 February 2016). PravettoniG , MasieroM , LucchiariC , MaisenneuveP , MazzoccoK , VeronesiG . The role of electronic cigarettes in smoking cessation among heavy smokers undergoing a lung cancer screening program: preliminary results of a randomized controlled study. Psycho-Oncology2016;25:72. [DOI: 10.1002/pon.4082]">Lucchiari 2022</a>). In the seven studies comparing nicotine EC to behavioural support only or traditional cigarettes, <a href="./references#CD010216-bbs2-0043" title="KumralTL , SaltürkZ , YildirimG , UyarY , BerkitenG , AtarY , et al. How does electronic cigarette smoking affect sinonasal symptoms and nasal mucociliary clearance?B-ENT2016;12(1):17-21. ">Kumral 2016</a> found an increase in sinonasal symptoms in the group receiving nicotine EC compared to behavioural support only, and <a href="./references#CD010216-bbs2-0061" title="Ozga-HessJE , FelicioneNJ , FergusonSG , DinoG , ElswickD , WhitworthC , et al. Piloting a clinical laboratory method to evaluate the influence of potential modified risk tobacco products on smokers' quit-related motivation, choice, and behaviour. Addictive Behaviors2019;99:106105. ">Ozga‐Hess 2019</a> found that throat irritation, cough, and dry mouth increased in the e‐cigarette group relative to the traditional cigarette group. By contrast, <a href="./references#CD010216-bbs2-0071" title="ArnoldM , NollenN , MayoM , AhluwaliaJ , LeavensE , Zhang G et al. Dual use of cigarettes and e-cigarettes in African American and LatinX smokers: secondary analyses from a randomised controlled e-cigarettes switching trial. In: Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting. February 24-27 2021 virtual:POD4-2 p31. ArnoldMJ , NollenNL , MayoMS , AhluwaliaJS , LeavensEL , ZhangG , RiceM , et al. Harm reduction associated with dual use of cigarettes and e-cigarettes in Black and Latino smokers: secondary analyses from a randomized controlled e-cigarette switching trial. Nicotine &amp; Tobacco Research2021;23(11):1972-6. [DOI: 10.1093/ntr/ntab069]LeavensELS , NollenN , AhluwaliaJ , MayoM , RiceM , BrettE , et al. Changes in dependence, withdrawal, and craving among adult smokers who switch to nicotine salt pod-based e-cigarettes. In: Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting. February 24-27 2021 virtual:POD53-1 p96, C-6 p116. LeavensELS , NollenN , AhluwaliaJS , MayoMS , RiceM , Brett EI et al. Changes in dependence, withdrawal, and craving among adult smokers who switch to nicotine salt pod-based e-cigarettes. Addiction2021;117(1):207-15. [DOI: 10.1111/add.15597]LeeSC , MaglalangDD , AvilaJC , LeavensELS , Nollen NL PulversK , et al. Change in e-cigarette risk perception and smoking behavior of Black and Latinx individuals who smoke. Drug and Alcohol Dependence2023;245:109824. [DOI: 10.1016/j.drugalcdep.2023.109824]NCT03511001. Effects among smokers who use and do not use e-cigarettes. https://clinicaltrials.gov/ct2/show/NCT03511001. NollenN , LambertL , LeavensE , AhluwaliaJ , RiceM , PulversK . Does menthol flavoring help black and LatinX adult menthol combustible cigarette smokers switch to e-cigarettes?: secondary analyses from a randomized clinical trial. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. March 2022. NollenNL , LeavensELS , AhluwaliaJS , RiceM , MayoMS , PulversK . Menthol versus non-menthol flavouring and switching to e-cigarettes in black and Latinx adult menthol combustible cigarette smokers: secondary analyses from a randomised clinical trial. Tobacco Control Online 29 March 2022;EPub:Online version. [DOI: 10.1136/tobaccocontrol-2021-057180]PulversK , NollenNL , RiceM , SchmidCH , QuK , BenowitzNL , et al. Effect of pod e-cigarettes vs cigarettes on carcinogen exposure among African American and Latinx smokers: a randomized clinical trial. JAMA Network Open2020;3(11):e2026324. RiceM , NollenN , WoodcockA , BenowitzN , AhluwaliaJ , PulversK . Effect of marijuana use on smokers switching to e-cigarettes in a randomised control trial. In: Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting. February 24-27 2021 virtual:SRNT C-44, p125. RiceM , NollenNL , AhluwaliaJS , BenowitzN , WoodcockA , PulversK . Effects of marijuana use on smokers switching to e-cigarettes in a randomized clinical trial. Nicotine &amp; Tobacco Research2022;24(7):994-1002. [DOI: 10.1093/ntr/ntac008]RubensteinD , SokolovskyA , AstonE , NollenN , SchmidC , Pulvers K et al. Predictors of smoking reduction among African American and LatinX smokers in a randomised controlled trial of Juul e-cigarettes. In: Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting. Vol. C-56. February 24-27 2021 virtual:129. RubensteinD , SokolovskyAW , AstonER , NollenNL , SchmidCH , RiceM , et al. Predictors of smoking reduction among African American and Latinx smokers in a randomized controlled trial of JUUL e-cigarettes. Addictive Behaviors2021;122:107037. [DOI: 10.1016/j.addbeh.2021.107037]">Pulvers 2020</a> found a reduction in respiratory symptoms in the EC compared to the traditional cigarette group, and <a href="./references#CD010216-bbs2-0066" title="NCT04854616. Cessation of Smoking Trial in the Emergency Department (CoSTED). clinicaltrials.gov/ct2/show/NCT04854616 (date first received 22 April 2021). NotleyC , ClarkL , BeldersonP , WardE , ClarkAB , ParrottS , et al. Cessation of smoking trial in the emergency department (CoSTED): protocol for a multicentre randomised controlled trial. BMJ Open2023;13(1):e064585. PopeI , ClarkLV , ClarkA , WardE , BeldersonP , Stirling S et al. Cessation of Smoking Trial in the Emergency Department (COSTED): a multicentre randomised controlled trial. Emergency Medicine Journal2024;41(5):276-82. [DOI: 10.1136/emermed-2023-213824]PopeI , NotleyC , BoyleA . Results of the cessation of smoking trial in the emergency department (COSTED). Emergency Medicine Journal2023;40(12):873-4. PopeI , NotleyC . Cessation of smoking trial in the emergency department. In: SRNT 29th Annual Meeting; 2023 Mar 1-4; San Antonio (TX), USA, POS2-14. 2023:119-20. ">Pope 2024</a> found no clear difference in the number of participants reporting dry cough and throat and mouth irritation between the EC arm and the referral information arm. <a href="./references#CD010216-bbs2-0004" title="AlburyC , BarnesR , FerreyA , ColemanT , GilbertH , NaughtonF , et al. The old and familiar meets the new and unknown: patient and clinician perceptions on e-cigarettes for smoking reduction in UK general practice, a qualitative interview study. Addiction 20212022;117(5):1427-37. [DOI: 10.1111/add.15760]BeghR , BatemanP , WilliamsN , GrabeyJ , StevensR . Examining the effectiveness of general practitioner and nurse promotion of electronic cigarettes versus standard care for smoking reduction and abstinence in hardcore smokers with smoking-related chronic disease: a randomised controlled trial. Statistical Analysis Report, Version 2.02021:1-56. BeghR , ColemanT , YardleyL , BarnesR , NaughtonF , GilbertH , et al. Examining the effectiveness of general practitioner and nurse promotion of electronic cigarettes versus standard care for smoking reduction and abstinence in hardcore smokers with smoking-related chronic disease: protocol for a randomised controlled trial. Trials2019;20(1):659. BeghR . Training general practitioners and nurses to deliver brief advice about e-cigarettes for smoking reduction: lessons learned from a randomised controlled trial. In: SRNT E-Conference, SY3-04 . 2021. ISRCTN59404712. GP/nurse promotion of e-cigarettes in supporting reduced smoking and cessation in smokers. www.isrctn.com/ISRCTN59404712 (first received 28 November 2017). ">Begh 2021</a> found an increase in throat irritation, palpitations, and dizziness in the EC group, but decreases in cough, headache, nausea, dry mouth, shortness of breath, and stomach pain. <a href="./references#CD010216-bbs2-0017" title="EdmistonJS , WebbKM , WangJ , OliveriD , LiangQ , SarkarM . Biomarkers of exposure and biomarkers of potential harm in adult smokers who switch to e-vapor products relative to cigarette smoking in a 24-week, randomized, clinical trial. Nicotine &amp; Tobacco Research2022;24(7):1047–54. [DOI: 10.1093/ntr/ntac029]">Edmiston 2022*</a> did not break down AEs by group but reported that three participants experienced a non‐serious adverse event definitely related to the study product. <a href="./references#CD010216-bbs2-0068" title="NCT03050853. The appeal and impact of e-cigarettes in smokers with SMI. clinicaltrials.gov/ct2/show/NCT03050853 (first received 13 February 2017). PrattS , FerronJ , SargentJ , BrunetteM . Assessing the effect of e-cigarettes versus usual smoking on NNAL among chronic smokers with serious mental illness. In: Society for Research on Nicotine and Tobacco (SRNT) 29th Annual Meeting 1-4 March 2023 . Vol. PPS22-5. 2023:73. PrattSI , BrunetteMF , FerronJC , SantosM , SargentJ , XieH . E-cigarette provision to promote switching in cigarette smokers with serious mental illness - a randomized trial. Nicotine &amp; Tobacco Research2022;6(24):1405-12. [DOI: 10.1093/ntr/ntac082]">Pratt 2022</a> reported no statistically significant between‐group difference in AEs. </p> </section> <section id="CD010216-sec-0074"> <h6 class="title">Data from other studies</h6> <p>Eighteen studies provided all participants with nicotine EC and assessed adverse events at one week or longer and one RCT reported AEs reported in the nicotine EC group only (see <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 1</a>). In the eight studies that tracked event rates over time, six showed adverse events reducing over time (<a href="./references#CD010216-bbs2-0008" title="CaponnettoP , AuditoreR , RussoC , CappelloGC , PolosaR . Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. International Journal of Environmental Research and Public Health2013;10(2):446-61. MinutoloG , CaponnettoP , AuditoreR , RussoC , PolosaR . Management of smoking reduction and cessation in inpatients with schizophrenia: impact of electronic cigarettes. European Neuropsychopharmacology2013;23:S581-2. ">Caponnetto 2013b*</a>; <a href="./references#CD010216-bbs2-0018" title="ACTRN12616001641482. Tobacco harm reduction with vaporised nicotine (THRiVe): feasibility study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12616001641482 (first received 28 November 2016). BellS , DeanJ , GilksC , BoydMA , FitzgeraldL , MutchA , et al. Tobacco harm reduction with vaporised nicotine (THRiVe): the study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with HIV who smoke. International Journal of Environmental Research and Public Health2017;14(7):799. EdwardsS , PuljevicC , DeanJA , GilksC , BoydMA , BakerP , et al. Tobacco harm reduction with vaporised nicotine (THRiVe): a feasibility trial of nicotine vaping products for smoking cessation among people living with HIV. AIDS and Behavior2023;27(2):618-27. [DOI: 10.1007/s10461-022-03797-0]">Edwards 2023</a>; <a href="./references#CD010216-bbs2-0025" title="GoniewiczML , GawronM , SmithDM , PengM , Jacob P 3rd, BenowitzNL . Exposure to nicotine and selected toxicants in cigarette smokers who switched to electronic cigarettes: a longitudinal within-subjects observational study. Nicotine &amp; Tobacco Research2017;19(2):160-7. ">Goniewicz 2017</a>; <a href="./references#CD010216-bbs2-0063" title="NCT01195597. Smoking cessation and reduction with an electronic nicotine delivery device (ENDD). clinicaltrials.gov/ct2/show/NCT01195597 (first received 6 September 2010). PolosaR , CaponnettoP , MorjariaJB , PapaleG , CampagnaD , RussoC . Effect of an electronic nicotine delivery device (e-cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health2011;11:786. PolosaR , MorjariaJB , CaponnettoP , CampagnaD , RussoC , AlamoA , et al. Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. Internal and Emergency Medicine2014;9(5):537-46. ">Polosa 2011*</a>; <a href="./references#CD010216-bbs2-0064" title="NCT02124200. High cessation rates in smokers using personal vaporizers (VAPECIG). clinicaltrials.gov/ct2/show/NCT02124200 (first received 28 April 2014). PolosaR , CaponnettoP , MagliaM , MorjariaJB , RussoC . Success rates with nicotine personal vaporizers: a prospective 6-month pilot study of smokers not intending to quit. BMC Public Health2014;14:1159. ">Polosa 2014b*</a>; <a href="./references#CD010216-bbs2-0067" title="PrattSI , SargentJ , DanielsL , SantosMM , BrunetteM . Appeal of electronic cigarettes in smokers with serious mental illness. Addictive Behaviors2016;59:30-4. ">Pratt 2016</a>). <a href="./references#CD010216-bbs2-0032" title="HicklingLM , Perez-IglesiasR , McNeillA , DawkinsL , MoxhamJ , RuffellT , et al. A pre-post pilot study of electronic cigarettes to reduce smoking in people with severe mental illness. Psychological Medicine2019;49(6):1033-40. NCT02212041. Acceptability, patterns of use and safety of electronic cigarette in people with mental illness: a pilot study. clinicaltrials.gov/show/NCT02212041 (accessed 17 February 2016). ">Hickling 2019</a> showed no change. The most commonly reported adverse events were throat/mouth irritation, headache, cough, and nausea. </p> </section> </section> <section id="CD010216-sec-0075"> <h5 class="title">Serious adverse events</h5> <section id="CD010216-sec-0076"> <h6 class="title">Randomized controlled trials</h6> <p>Nine studies compared nicotine EC with non‐nicotine EC and reported data on SAEs; in five of these (including one tobacco/vaping industry study, <a href="./references#CD010216-bbs2-0007" title="CampagnaD , CibellaF , CaponnettoP , AmaradioMD , CarusoM , MorjariaJB , et al. Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. European Journal of Clinical Investigation2016;46(8):698-706. CaponnettoP , CampagnaD , CibellaF , MorjariaJB , CarusoM , RussoC , et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLOS One2013;8(6):e66317. CibellaF , CampagnaD , CaponnettoP , AmaradioMD , CarusoM , RussoC , et al. Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. Clinical Science2016;130(21):1929-37. FarsalinosK , CibellaF , CaponnettoP , CampagnaD , MorjariaJB , BattagliaE , et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Internal and Emergency Medicine2016;11(1):85-94. NCT01164072. Efficacy and safety of an electronic nicotine delivery device (e-cigarette). clinicaltrials.gov/ct2/show/NCT01164072 (first received 16 July 2010). NCT01188239. A structured protocol to evaluate efficacy and safety of a popular electronic nicotine delivery device (e-cigarette) efficacy and safety of a popular electronic nicotine delivery device (e-cigarette). https://clinicaltrials.gov/ct2/show/NCT01188239. NCT01194583. Efficacy and safety of an electronic nicotine delivery device (e-cigarette) without nicotine cartridges. clinicaltrials.gov/ct2/show/NCT01194583 (first received 3 September 2010). RussoC , CibellaF , CaponnettoP , CampagnaD , MagliaM , FrazzettoE , et al. Evaluation of post cessation weight gain in a 1-year randomized smoking cessation trial of electronic cigarettes. Scientific Reports2016;6:18763. ">Caponnetto 2013a*</a>), no events occurred, so results could not contribute to the meta‐analysis, although they are included in the forest plots for descriptive purposes. In the four studies (three low risk of bias, one unclear) where events occurred, there may be little to no difference between groups, but CIs were wide (RR 1.00, 95% CI 0.56 to 1.79; I<sup>2</sup> = 0%; 1412 participants; <a href="./references#CD010216-fig-0038" title="">Analysis 4.3</a>). The evidence was of low certainty; this was downgraded two levels due to imprecision: the confidence intervals encompassed clinically significant harm as well as clinically significant benefit, and there were fewer than 300 events overall. One of these studies had links to industry funding (<a href="./references#CD010216-bbs2-0072" title="NCT03492463. The role of nicotine dose and route of delivery in affecting adoption of e-cigarettes and reducing exposure to toxic combustion products (ENDS-Switch). clinicaltrials.gov/ct2/show/study/NCT03492463 (first received 10 April 2018). RoseJE , FrisbeeS , CampbellD , SalleyA , ClaerhoutS , DavisJM . Smoking reduction using electronic nicotine delivery systems in combination with nicotine skin patches. Psychopharmacology2023;240:1901-9. [DOI: 10.1007/s00213-023-06401-y]">Rose 2023*</a>); removing it from the analysis changed the effect estimate to 0.95 but the 95% CI remained wide (0.52 to 1.72) and so the interpretation of the result remained the same. </p> <p>Twelve studies compared nicotine EC with behavioural support only or no support and reported data on SAEs; in five of these, no events occurred. Pooled results from the seven studies in which events occurred showed very uncertain evidence about the difference between arms, but CIs were wide (RR 0.93, 95% CI 0.68 to 1.28; I<sup>2</sup> = 0%; 4561 participants; <a href="./references#CD010216-fig-0049" title="">Analysis 5.3</a>). Here the certainty of evidence was very low; this was downgraded two levels due to risk of bias (lack of blinding and differential support between arms, judged to be at high risk of bias). Removing the one study with tobacco/vaping industry support did not affect the interpretation of the results (<a href="./references#CD010216-bbs2-0086" title="CravoAS , BushJ , SharmaG , SaviozR , MartinC , CraigeS , et al. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. Regulatory Toxicology and Pharmacology2016;81:S1-S14. NCT02029196. A randomised, parallel group, multi-centre study to evaluate the safety profile of the ITG EVP G1 product. clinicaltrials.gov/show/NCT02029196 (accessed 16 July 2014). NCT02143310. A multi-centre study to evaluate the safety of use of electronic vapour products for two years. clinicaltrials.gov/show/NCT02143310 (accessed 16 July 2014). WaleleT , BushJ , KochA , SaviozR , MartinC , O'ConnellG . Evaluation of the safety profile of an electronic vapour product used for two years by smokers in a real-life setting. Regulatory Toxicology and Pharmacology2018;92:226-38. ">Walele 2018*</a>). </p> <p>In a study in people experiencing homelessness (<a href="./references#CD010216-bbs2-0016" title="DawkinsL , BauldL , FordA , RobsonD , HajekP , ParrottS , et al. A cluster feasibility trial to explore the uptake and use of e-cigarettes versus usual care offered to smokers attending homeless centres in Great Britain. PLOS One2020;15(10):e0240968. [ISRCTN14140672]ISRCTN14140672. Exploring the use and uptake of e-cigarettes for homeless smokers. www.isrctn.com/ISRCTN14140672 (first received 7 November 2018). ">Dawkins 2020</a>), SAEs were not reported, but authors reported that four to seven participants in the usual care arm and five to seven participants in the nicotine EC arm visited Accident &amp; Emergency services at a hospital. The authors reported that these visits were unrelated to study treatment and were assessed to gather data for future economic evaluation. Further detail can be found in <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 2</a>. </p> </section> <section id="CD010216-sec-0077"> <h6 class="title">Data from other studies</h6> <p>Nine studies provided all participants with nicotine EC and reported SAEs at a week or longer (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 2</a>). In six of these, authors reported that no SAEs occurred (<a href="./references#CD010216-bbs2-0008" title="CaponnettoP , AuditoreR , RussoC , CappelloGC , PolosaR . Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. International Journal of Environmental Research and Public Health2013;10(2):446-61. MinutoloG , CaponnettoP , AuditoreR , RussoC , PolosaR . Management of smoking reduction and cessation in inpatients with schizophrenia: impact of electronic cigarettes. European Neuropsychopharmacology2013;23:S581-2. ">Caponnetto 2013b*</a>; <a href="./references#CD010216-bbs2-0009" title="CaponnettoP , DiPiazzaJ , KimJ , MagliaM , PolosaR . A single-arm, open-label pilot, and feasibility study of a high nicotine strength e-cigarette intervention for smoking cessation or reduction for people with schizophrenia spectrum disorders who smoke cigarettes. Nicotine &amp; Tobacco Research2021;23(7):1113-22. [DOI: 10.1093/ntr/ntab005]">Caponnetto 2021*</a>; <a href="./references#CD010216-bbs2-0018" title="ACTRN12616001641482. Tobacco harm reduction with vaporised nicotine (THRiVe): feasibility study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12616001641482 (first received 28 November 2016). BellS , DeanJ , GilksC , BoydMA , FitzgeraldL , MutchA , et al. Tobacco harm reduction with vaporised nicotine (THRiVe): the study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with HIV who smoke. International Journal of Environmental Research and Public Health2017;14(7):799. EdwardsS , PuljevicC , DeanJA , GilksC , BoydMA , BakerP , et al. Tobacco harm reduction with vaporised nicotine (THRiVe): a feasibility trial of nicotine vaping products for smoking cessation among people living with HIV. AIDS and Behavior2023;27(2):618-27. [DOI: 10.1007/s10461-022-03797-0]">Edwards 2023</a>; <a href="./references#CD010216-bbs2-0034" title="Humair J-P, TangoR . Can e-cigarette help patients to reduce or stop smoking in primary care practice?Journal of General Internal Medicine2014;29:S480. ">Humair 2014</a>; <a href="./references#CD010216-bbs2-0039" title="KanobeMN , JonesBA , NelsonP , BrownBG , ChenP , MakenaP , et al. Part three: a randomized study to assess biomarker changes in cigarette smokers switched to Vuse Solo or abstinence. Scientific Reports2022;12:20658. [DOI: 10.1038/s41598-022-25054-z]KanobeMN , NelsonPR , BrownBG , ChenP , PatruduM , Caraway JW et al. Changes in biomarkers of exposure and potential harm in smokers switched to Vuse Vibe or Vuse Ciro electronic nicotine delivery systems. Toxics2023;11(7):564. [DOI: 10.3390/toxics11070564]NCT03170674. CSD170501: Study to assess biomarkers of tobacco exposure in smokers during in-clinic confinement switch to an electronic cigarette. clinicaltrials.gov/ct2/show/NCT03170674 (first received 31 May 2017). ">Kanobe 2022*</a>; <a href="./references#CD010216-bbs2-0063" title="NCT01195597. Smoking cessation and reduction with an electronic nicotine delivery device (ENDD). clinicaltrials.gov/ct2/show/NCT01195597 (first received 6 September 2010). PolosaR , CaponnettoP , MorjariaJB , PapaleG , CampagnaD , RussoC . Effect of an electronic nicotine delivery device (e-cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health2011;11:786. PolosaR , MorjariaJB , CaponnettoP , CampagnaD , RussoC , AlamoA , et al. Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. Internal and Emergency Medicine2014;9(5):537-46. ">Polosa 2011*</a>; <a href="./references#CD010216-bbs2-0081" title="ValentineGW , HefnerK , JatlowPI , RosenheckRA , GueorguievaR , SofuogluM . Impact of e-cigarettes on smoking and related outcomes in veteran smokers with psychiatric comorbidity. Journal of Dual Diagnosis2018;14(1):2-13. ">Valentine 2018</a>). In <a href="./references#CD010216-bbs2-0055" title="NCT02648178. Evaluation of appeal and impact of e-cigarettes among chronic smokers with smoking-related cancers. clinicaltrials.gov/show/NCT02648178 (accessed 17 February 2016). ">NCT02648178</a> (19 participants), one death occurred (no further detail provided). <a href="./references#CD010216-bbs2-0032" title="HicklingLM , Perez-IglesiasR , McNeillA , DawkinsL , MoxhamJ , RuffellT , et al. A pre-post pilot study of electronic cigarettes to reduce smoking in people with severe mental illness. Psychological Medicine2019;49(6):1033-40. NCT02212041. Acceptability, patterns of use and safety of electronic cigarette in people with mental illness: a pilot study. clinicaltrials.gov/show/NCT02212041 (accessed 17 February 2016). ">Hickling 2019</a> (50 participants) recruited participants from mental health settings; five SAEs were recorded during the study, all of which were psychiatric hospitalizations. None were considered related to study treatment. </p> </section> </section> <section id="CD010216-sec-0078"> <h5 class="title">Carbon monoxide</h5> <section id="CD010216-sec-0079"> <h6 class="title">Randomized controlled trials</h6> <p>High statistical heterogeneity (I<sup>2</sup> = 80%) precluded pooling CO data from the six trials (n = 677, none considered at high risk of bias) comparing nicotine EC with non‐nicotine EC (<a href="./references#CD010216-fig-0039" title="">Analysis 4.4</a>). Point estimates from four studies (one reporting links to industry funding; <a href="./references#CD010216-bbs2-0072" title="NCT03492463. The role of nicotine dose and route of delivery in affecting adoption of e-cigarettes and reducing exposure to toxic combustion products (ENDS-Switch). clinicaltrials.gov/ct2/show/study/NCT03492463 (first received 10 April 2018). RoseJE , FrisbeeS , CampbellD , SalleyA , ClaerhoutS , DavisJM . Smoking reduction using electronic nicotine delivery systems in combination with nicotine skin patches. Psychopharmacology2023;240:1901-9. [DOI: 10.1007/s00213-023-06401-y]">Rose 2023*</a>) favoured nicotine EC and from two (one reporting industry funding; <a href="./references#CD010216-bbs2-0007" title="CampagnaD , CibellaF , CaponnettoP , AmaradioMD , CarusoM , MorjariaJB , et al. Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. European Journal of Clinical Investigation2016;46(8):698-706. CaponnettoP , CampagnaD , CibellaF , MorjariaJB , CarusoM , RussoC , et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLOS One2013;8(6):e66317. CibellaF , CampagnaD , CaponnettoP , AmaradioMD , CarusoM , RussoC , et al. Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. Clinical Science2016;130(21):1929-37. FarsalinosK , CibellaF , CaponnettoP , CampagnaD , MorjariaJB , BattagliaE , et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Internal and Emergency Medicine2016;11(1):85-94. NCT01164072. Efficacy and safety of an electronic nicotine delivery device (e-cigarette). clinicaltrials.gov/ct2/show/NCT01164072 (first received 16 July 2010). NCT01188239. A structured protocol to evaluate efficacy and safety of a popular electronic nicotine delivery device (e-cigarette) efficacy and safety of a popular electronic nicotine delivery device (e-cigarette). https://clinicaltrials.gov/ct2/show/NCT01188239. NCT01194583. Efficacy and safety of an electronic nicotine delivery device (e-cigarette) without nicotine cartridges. clinicaltrials.gov/ct2/show/NCT01194583 (first received 3 September 2010). RussoC , CibellaF , CaponnettoP , CampagnaD , MagliaM , FrazzettoE , et al. Evaluation of post cessation weight gain in a 1-year randomized smoking cessation trial of electronic cigarettes. Scientific Reports2016;6:18763. ">Caponnetto 2013a*</a>) favoured non‐nicotine EC, but in all cases CIs were consistent with no clinically meaningful difference. Three further randomized studies measured CO levels in those assigned to nicotine EC and those assigned to non‐nicotine EC, but did not present data in a way that could be pooled: <a href="./references#CD010216-bbs2-0024" title="GeorgeJ , HussainM , VadivelooT , IrelandS , HopkinsonP , StruthersAD , et al. Cardiovascular effects of switching from tobacco cigarettes to electronic cigarettes. Journal of the American College of Cardiology2019;74(25):3112-20. NCT02878421. Vascular EffectS of regUlar cigarettes Versus electronIc cigarette USe (VESUVIUS). clinicaltrials.gov/ct2/show/NCT02878421 (first received 25 August 2016). ">George 2019</a> did not compare data by group; <a href="./references#CD010216-bbs2-0080" title='GuttentagA , Tuo-YenT , ShelleyD , ThomasK . Analyzing trajectories of acute cigarette reduction post-introduction of an e-cigarette using ecological momentary assessment data. International Journal of Environmental Research and Public Health2022;19(12):7452. [DOI: 10.3390/ijerph19127452]GuttentagA . Do e-cigarettes "Work" for smokers as a step on the way to cessation? An analysis of the temporal and spatial correlates of switching in a harm reduction trial among adult smokers. Dissertation Abstracts International: Section B: The Sciences and Engineering2021;82:8-B. NCT02628964. Assessing the use of electronic cigarettes (e-cigarettes) as a harm reduction strategy. clinicaltrials.gov/show/NCT02628964 (accessed 17 February 2016). TsengTY , OstroffJS , CampoA , GerardM , KirchnerT , RotrosenJ , et al. A randomized trial comparing the effect of nicotine versus placebo electronic cigarettes on smoking reduction among young adult smokers. Nicotine &amp; Tobacco Research2016;18(10):1937-43. '>Tseng 2016</a> reported no between‐group differences; and <a href="./references#CD010216-bbs2-0050" title="MeierE , WahlquistAE , HeckmanBW , CummingsKM , FroeligerB , CarpenterMJ . A pilot randomized crossover trial of electronic cigarette sampling among smokers. Nicotine &amp; Tobacco Research2017;19(2):176-82. ">Meier 2017</a> found a slightly higher CO reading in those using nicotine EC, but the clinical and statistical significance of this difference was not clear (see <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 3</a> for more detail). These data were from all study participants based on group randomized, not on subsequent EC or cigarette use. </p> <p>Pooled data from 11 studies comparing nicotine EC to behavioural support alone or to no support resulted in a high I<sup>2</sup> value (89%); thus, pooled results were not presented here (see <a href="./references#CD010216-fig-0050" title="">Analysis 5.4</a> for individual study data). None of these studies reported tobacco/vaping industry funding. A funnel plot did not show asymmetry (<a href="#CD010216-fig-0004">Figure 4</a>). Heterogeneity was primarily driven by magnitude rather than direction of effect, with results in 10 of 11 studies favouring nicotine EC. Three further trials reported data that could not be included in a meta‐analysis. <a href="./references#CD010216-bbs2-0086" title="CravoAS , BushJ , SharmaG , SaviozR , MartinC , CraigeS , et al. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. Regulatory Toxicology and Pharmacology2016;81:S1-S14. NCT02029196. A randomised, parallel group, multi-centre study to evaluate the safety profile of the ITG EVP G1 product. clinicaltrials.gov/show/NCT02029196 (accessed 16 July 2014). NCT02143310. A multi-centre study to evaluate the safety of use of electronic vapour products for two years. clinicaltrials.gov/show/NCT02143310 (accessed 16 July 2014). WaleleT , BushJ , KochA , SaviozR , MartinC , O'ConnellG . Evaluation of the safety profile of an electronic vapour product used for two years by smokers in a real-life setting. Regulatory Toxicology and Pharmacology2018;92:226-38. ">Walele 2018*</a> compared nicotine EC to cigarettes and found that CO levels declined in the EC group and remained similar to baseline in the cigarette group. <a href="./references#CD010216-bbs2-0015" title='CzoliCD , FongGT , GoniewiczML , HammondD . Biomarkers of exposure among "dual users" of tobacco cigarettes and electronic cigarettes in Canada. Nicotine and Tobacco Research2019;21(9):1259-66. '>Czoli 2019</a> instructed baseline dual users to spend periods only using EC or only using traditional cigarettes; CO measured during sole EC use was lower than baseline and lower than during cigarette‐only periods. Further details can be found in <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 3</a>. </p> <div class="figure" id="CD010216-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot. Comparison: Nicotine EC vs behavioural/no support. Outcome: Carbon monoxide (ppm)" data-id="CD010216-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot. Comparison: Nicotine EC vs behavioural/no support. Outcome: Carbon monoxide (ppm) </p> </div> </div> </div> </section> <section id="CD010216-sec-0080"> <h6 class="title">Data from other studies</h6> <p>Twenty studies provided all participants with nicotine EC and reported data on CO at one week or longer. In the 19 studies that presented change over time, CO declined from baseline, although in <a href="./references#CD010216-bbs2-0035" title="IkonomidisI , VlastosD , KoureaK , KostelliG , VaroudiM , PavlidisG , et al. Electronic cigarette smoking increases arterial stiffness and oxidative stress to a lesser extent than a single conventional cigarette: an acute and chronic study. Circulation2018;137(3):303-6. NCT03039920. The effects of electronic cigarette smoking on the arterial wall and endothelial glycocalyx properties of smokers. clinicaltrials.gov/ct2/show/NCT03039920 (first received 1 February 2017). ">Ikonomidis 2018</a> CO levels were equivalent to baseline again at 24 weeks, and in <a href="./references#CD010216-bbs2-0064" title="NCT02124200. High cessation rates in smokers using personal vaporizers (VAPECIG). clinicaltrials.gov/ct2/show/NCT02124200 (first received 28 April 2014). PolosaR , CaponnettoP , MagliaM , MorjariaJB , RussoC . Success rates with nicotine personal vaporizers: a prospective 6-month pilot study of smokers not intending to quit. BMC Public Health2014;14:1159. ">Polosa 2014b*</a> a decline was observed in people who quit smoking or reduced cigarette consumption by at least half, but not in those who continued smoking at least half as many cigarettes as they had from baseline. </p> </section> </section> <section id="CD010216-sec-0081"> <h5 class="title">Heart rate</h5> <section id="CD010216-sec-0082"> <h6 class="title">Randomized controlled trials</h6> <p>One RCT (<a href="./references#CD010216-bbs2-0007" title="CampagnaD , CibellaF , CaponnettoP , AmaradioMD , CarusoM , MorjariaJB , et al. Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. European Journal of Clinical Investigation2016;46(8):698-706. CaponnettoP , CampagnaD , CibellaF , MorjariaJB , CarusoM , RussoC , et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLOS One2013;8(6):e66317. CibellaF , CampagnaD , CaponnettoP , AmaradioMD , CarusoM , RussoC , et al. Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. Clinical Science2016;130(21):1929-37. FarsalinosK , CibellaF , CaponnettoP , CampagnaD , MorjariaJB , BattagliaE , et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Internal and Emergency Medicine2016;11(1):85-94. NCT01164072. Efficacy and safety of an electronic nicotine delivery device (e-cigarette). clinicaltrials.gov/ct2/show/NCT01164072 (first received 16 July 2010). NCT01188239. A structured protocol to evaluate efficacy and safety of a popular electronic nicotine delivery device (e-cigarette) efficacy and safety of a popular electronic nicotine delivery device (e-cigarette). https://clinicaltrials.gov/ct2/show/NCT01188239. NCT01194583. Efficacy and safety of an electronic nicotine delivery device (e-cigarette) without nicotine cartridges. clinicaltrials.gov/ct2/show/NCT01194583 (first received 3 September 2010). RussoC , CibellaF , CaponnettoP , CampagnaD , MagliaM , FrazzettoE , et al. Evaluation of post cessation weight gain in a 1-year randomized smoking cessation trial of electronic cigarettes. Scientific Reports2016;6:18763. ">Caponnetto 2013a*</a>, unclear risk of bias, n = 141) provided data on heart rate and compared nicotine EC with non‐nicotine EC; there was no evidence of a clinically significant between‐group difference (MD ‐2.3, 95% CI ‐6.10 to 1.50) (<a href="./references#CD010216-fig-0040" title="">Analysis 4.5</a>). This was comparable with findings from the one RCT (<a href="./references#CD010216-bbs2-0031" title="HatsukamiD , MeierE , LindgrenBR , AndersonA , ReisingerS , NortonK , et al. A randomized clinical trial examining the effects of instructions for electronic cigarette use on smoking-related behaviors, and biomarkers of exposure. Nicotine &amp; Tobacco Research2020;22(9):1524-32. [DOI: 10.1093/ntr/ntz233]NCT03111537. Methods project 4: clinical trial - amended (COMET). https://clinicaltrials.gov/ct2/show/NCT03111537 (accessed 10 September 2022). ">Hatsukami 2020</a>, unclear risk of bias, n = 90) comparing nicotine EC with no pharmacotherapy, which also found no evidence of a clinically significant difference (MD 1.17, 95% CI ‐4.17 to 6.61) (<a href="./references#CD010216-fig-0051" title="">Analysis 5.5</a>). </p> <p>A further three RCTs provided data on heart rate that could not be used to calculate effect estimates. <a href="./references#CD010216-bbs2-0024" title="GeorgeJ , HussainM , VadivelooT , IrelandS , HopkinsonP , StruthersAD , et al. Cardiovascular effects of switching from tobacco cigarettes to electronic cigarettes. Journal of the American College of Cardiology2019;74(25):3112-20. NCT02878421. Vascular EffectS of regUlar cigarettes Versus electronIc cigarette USe (VESUVIUS). clinicaltrials.gov/ct2/show/NCT02878421 (first received 25 August 2016). ">George 2019</a> compared nicotine to non‐nicotine EC and found no difference in heart rate between arms; <a href="./references#CD010216-bbs2-0086" title="CravoAS , BushJ , SharmaG , SaviozR , MartinC , CraigeS , et al. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. Regulatory Toxicology and Pharmacology2016;81:S1-S14. NCT02029196. A randomised, parallel group, multi-centre study to evaluate the safety profile of the ITG EVP G1 product. clinicaltrials.gov/show/NCT02029196 (accessed 16 July 2014). NCT02143310. A multi-centre study to evaluate the safety of use of electronic vapour products for two years. clinicaltrials.gov/show/NCT02143310 (accessed 16 July 2014). WaleleT , BushJ , KochA , SaviozR , MartinC , O'ConnellG . Evaluation of the safety profile of an electronic vapour product used for two years by smokers in a real-life setting. Regulatory Toxicology and Pharmacology2018;92:226-38. ">Walele 2018*</a> compared a nicotine EC with a traditional cigarette and reported "no clinically significant changes", and <a href="./references#CD010216-bbs2-0013" title="CobbCO , FouldsJ , Yen M-S, VeldheerS , LopezAA , Yingst JM et al. Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, controlled trial. Lancet Respiratory Medicine2021;9(8):840-50. [DOI: 10.1016/ S2213-2600(21)00022-9]FouldsJ , CobbC , Yen M-S, VeldheerS , BrosnanP , Yingst J et al. Effect of electronic nicotine delivery systems on cigarette abstinence in smokers with no plans to quit: exploratory analysis of a randomized placebo-controlled trial. Nicotine Tobacco Research2022;24(7):955-61. [DOI: 10.1093/ntr/ntab247]LopezAA , CobbCO , YingstJM , VeldheerS , HrabovskyS , YenMS , et al. A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation. BMC Public Health2016;16(1):217. [PMCID:: PMC4778292] [PMID: 26941050]NCT02342795. Randomized controlled trial methods for novel tobacco products evaluation. clinicaltrials.gov/show/NCT02342795 (accessed 17 February 2016). VeldheerS , YingstJ , MidyaV , HummerB , LesterC , KrebsN , . Pulmonary and other health effects of electronic cigarette use among adult smokers participating in a randomized controlled smoking reduction trial. Addictive Behaviors2019;91:95-101. YingstJ , FouldsJ , VeldheerS , CobbCO , YenM , HrabovskyS , et al. Measurement of electronic cigarette frequency of use among smokers participating in a randomized controlled trial. Nicotine &amp; Tobacco Research2020;22(5):699-704. [NCT02342795]YingstJ , WangX , AndersonA , BrelandA , SouleE , Barnes A et al. Evaluation of nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoke. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. March 2022. YingstJ , WangX , LopezAA , BrelandA , SouleE , Barnes A et al. Randomized Control Trial Methods Workgroup of the Center for the Study of Tobacco Products. Changes in nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoking in a randomized controlled trial. Nicotine Tobacco Research 2022 Jun 25 [Epub ahead of print]. [DOI: 10.1093/ntr/ntac153]YingstJ , Wang Xi, LopezAA , BrelandA , SouleE , BarnesA , et al. Randomized control trial methods workgroup of the center for the study of tobacco products, changes in nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoking in a randomized controlled trial. Nicotine &amp; Tobacco Research2023;25(3):372-8. [DOI: 10.1093/ntr/ntac153]">Cobb 2021</a> found decreases in both the EC and QuitSmart cigarette substitute groups, with the decrease being slightly greater in the latter group. See <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 4</a> for further information. </p> </section> <section id="CD010216-sec-0083"> <h6 class="title">Data from other studies</h6> <p>Six studies in which all participants received a nicotine EC also reported data on heart rate; for five, changes were minimal and directions of effect were mixed, and for <a href="./references#CD010216-bbs2-0009" title="CaponnettoP , DiPiazzaJ , KimJ , MagliaM , PolosaR . A single-arm, open-label pilot, and feasibility study of a high nicotine strength e-cigarette intervention for smoking cessation or reduction for people with schizophrenia spectrum disorders who smoke cigarettes. Nicotine &amp; Tobacco Research2021;23(7):1113-22. [DOI: 10.1093/ntr/ntab005]">Caponnetto 2021*</a> (n = 40), the rate reduced by 9 bpm at 12 weeks (see <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 4</a>). </p> </section> </section> <section id="CD010216-sec-0084"> <h5 class="title">Blood pressure</h5> <p><a href="./references#CD010216-bbs2-0007" title="CampagnaD , CibellaF , CaponnettoP , AmaradioMD , CarusoM , MorjariaJB , et al. Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. European Journal of Clinical Investigation2016;46(8):698-706. CaponnettoP , CampagnaD , CibellaF , MorjariaJB , CarusoM , RussoC , et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLOS One2013;8(6):e66317. CibellaF , CampagnaD , CaponnettoP , AmaradioMD , CarusoM , RussoC , et al. Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. Clinical Science2016;130(21):1929-37. FarsalinosK , CibellaF , CaponnettoP , CampagnaD , MorjariaJB , BattagliaE , et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Internal and Emergency Medicine2016;11(1):85-94. NCT01164072. Efficacy and safety of an electronic nicotine delivery device (e-cigarette). clinicaltrials.gov/ct2/show/NCT01164072 (first received 16 July 2010). NCT01188239. A structured protocol to evaluate efficacy and safety of a popular electronic nicotine delivery device (e-cigarette) efficacy and safety of a popular electronic nicotine delivery device (e-cigarette). https://clinicaltrials.gov/ct2/show/NCT01188239. NCT01194583. Efficacy and safety of an electronic nicotine delivery device (e-cigarette) without nicotine cartridges. clinicaltrials.gov/ct2/show/NCT01194583 (first received 3 September 2010). RussoC , CibellaF , CaponnettoP , CampagnaD , MagliaM , FrazzettoE , et al. Evaluation of post cessation weight gain in a 1-year randomized smoking cessation trial of electronic cigarettes. Scientific Reports2016;6:18763. ">Caponnetto 2013a*</a> found no evidence of a difference in the change in systolic blood pressure (BP) between nicotine EC and non‐nicotine EC arms (unclear risk of bias, 141 participants, MD 1.2, 95% CI ‐3.99 to 6.39; <a href="./references#CD010216-fig-0041" title="">Analysis 4.6</a>). Three studies (two at high risk of bias, one at unclear risk of bias, none reporting tobacco/vaping industry funding) compared nicotine EC to behavioural support only and reported data on systolic blood pressure; there was a small difference favouring the EC arms (MD ‐2.3, 95% CI ‐3.9 to ‐0.7, I<sup>2</sup> = 24%; 298 participants; <a href="./references#CD010216-fig-0052" title="">Analysis 5.6</a>). Three further RCTs measured change in blood pressure but presented results in such a way that they could not be pooled. <a href="./references#CD010216-bbs2-0024" title="GeorgeJ , HussainM , VadivelooT , IrelandS , HopkinsonP , StruthersAD , et al. Cardiovascular effects of switching from tobacco cigarettes to electronic cigarettes. Journal of the American College of Cardiology2019;74(25):3112-20. NCT02878421. Vascular EffectS of regUlar cigarettes Versus electronIc cigarette USe (VESUVIUS). clinicaltrials.gov/ct2/show/NCT02878421 (first received 25 August 2016). ">George 2019</a> compared nicotine EC and non‐nicotine EC and combined data from both groups; BP declined over time. Compared to a QuitSmart cigarette substitute, <a href="./references#CD010216-bbs2-0013" title="CobbCO , FouldsJ , Yen M-S, VeldheerS , LopezAA , Yingst JM et al. Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, controlled trial. Lancet Respiratory Medicine2021;9(8):840-50. [DOI: 10.1016/ S2213-2600(21)00022-9]FouldsJ , CobbC , Yen M-S, VeldheerS , BrosnanP , Yingst J et al. Effect of electronic nicotine delivery systems on cigarette abstinence in smokers with no plans to quit: exploratory analysis of a randomized placebo-controlled trial. Nicotine Tobacco Research2022;24(7):955-61. [DOI: 10.1093/ntr/ntab247]LopezAA , CobbCO , YingstJM , VeldheerS , HrabovskyS , YenMS , et al. A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation. BMC Public Health2016;16(1):217. [PMCID:: PMC4778292] [PMID: 26941050]NCT02342795. Randomized controlled trial methods for novel tobacco products evaluation. clinicaltrials.gov/show/NCT02342795 (accessed 17 February 2016). VeldheerS , YingstJ , MidyaV , HummerB , LesterC , KrebsN , . Pulmonary and other health effects of electronic cigarette use among adult smokers participating in a randomized controlled smoking reduction trial. Addictive Behaviors2019;91:95-101. YingstJ , FouldsJ , VeldheerS , CobbCO , YenM , HrabovskyS , et al. Measurement of electronic cigarette frequency of use among smokers participating in a randomized controlled trial. Nicotine &amp; Tobacco Research2020;22(5):699-704. [NCT02342795]YingstJ , WangX , AndersonA , BrelandA , SouleE , Barnes A et al. Evaluation of nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoke. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. March 2022. YingstJ , WangX , LopezAA , BrelandA , SouleE , Barnes A et al. Randomized Control Trial Methods Workgroup of the Center for the Study of Tobacco Products. Changes in nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoking in a randomized controlled trial. Nicotine Tobacco Research 2022 Jun 25 [Epub ahead of print]. [DOI: 10.1093/ntr/ntac153]YingstJ , Wang Xi, LopezAA , BrelandA , SouleE , BarnesA , et al. Randomized control trial methods workgroup of the center for the study of tobacco products, changes in nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoking in a randomized controlled trial. Nicotine &amp; Tobacco Research2023;25(3):372-8. [DOI: 10.1093/ntr/ntac153]">Cobb 2021</a> found that EC led to a greater reduction in BP. <a href="./references#CD010216-bbs2-0086" title="CravoAS , BushJ , SharmaG , SaviozR , MartinC , CraigeS , et al. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. Regulatory Toxicology and Pharmacology2016;81:S1-S14. NCT02029196. A randomised, parallel group, multi-centre study to evaluate the safety profile of the ITG EVP G1 product. clinicaltrials.gov/show/NCT02029196 (accessed 16 July 2014). NCT02143310. A multi-centre study to evaluate the safety of use of electronic vapour products for two years. clinicaltrials.gov/show/NCT02143310 (accessed 16 July 2014). WaleleT , BushJ , KochA , SaviozR , MartinC , O'ConnellG . Evaluation of the safety profile of an electronic vapour product used for two years by smokers in a real-life setting. Regulatory Toxicology and Pharmacology2018;92:226-38. ">Walele 2018*</a> found "no clinically significant changes" when comparing nicotine EC to a conventional cigarette at two weeks. </p> <p>Five studies, which provided nicotine EC to all participants, reported change in blood pressure; results were clinically insignificant except for <a href="./references#CD010216-bbs2-0009" title="CaponnettoP , DiPiazzaJ , KimJ , MagliaM , PolosaR . A single-arm, open-label pilot, and feasibility study of a high nicotine strength e-cigarette intervention for smoking cessation or reduction for people with schizophrenia spectrum disorders who smoke cigarettes. Nicotine &amp; Tobacco Research2021;23(7):1113-22. [DOI: 10.1093/ntr/ntab005]">Caponnetto 2021*</a> in which systolic BP reduced by 12 (from 134 to 122) at 12 weeks (see <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 5</a> for further details on all studies reporting this outcome). </p> </section> <section id="CD010216-sec-0085"> <h5 class="title">Oxygen saturation</h5> <p><a href="./references#CD010216-bbs2-0031" title="HatsukamiD , MeierE , LindgrenBR , AndersonA , ReisingerS , NortonK , et al. A randomized clinical trial examining the effects of instructions for electronic cigarette use on smoking-related behaviors, and biomarkers of exposure. Nicotine &amp; Tobacco Research2020;22(9):1524-32. [DOI: 10.1093/ntr/ntz233]NCT03111537. Methods project 4: clinical trial - amended (COMET). https://clinicaltrials.gov/ct2/show/NCT03111537 (accessed 10 September 2022). ">Hatsukami 2020</a> found no evidence of a difference in blood oxygen saturation when comparing nicotine EC to cigarettes (89 participants, MD 0.20, 95% CI ‐0.30 to 0.70; <a href="./references#CD010216-fig-0053" title="">Analysis 5.7</a>). <a href="./references#CD010216-bbs2-0082" title="Van StadenSR , GroenewaldM , EngelbrechtR , BeckerPJ , HazelhurstLT . Carboxyhaemoglobin levels, health and lifestyle perceptions in smokers converting from tobacco cigarettes to electronic cigarettes. South African Medical Journal2013;103(11):865-8. ">Van Staden 2013*</a>, a short‐term pre‐post study, which measured outcomes after two weeks of EC use, found that people who smoked and switched to ECs had significant improvement in blood oxygen saturation (96.2% (standard deviation (SD) 1.8) to 97.5% (SD 1.3); 1.3% increase, 95% CI 0.6 to 2.1; P = 0.002). </p> </section> <section id="CD010216-sec-0086"> <h5 class="title">Toxicants</h5> <p>Unless stated otherwise, all randomized controlled trials measuring these outcomes compared nicotine EC with no pharmacotherapy. </p> <p>Two trials measured change in 3‐HPMA (one at high risk of bias). In both, the point estimate favoured the EC arm, but pooling was precluded due to differences in measurement methods (<a href="./references#CD010216-fig-0054" title="">Analysis 5.8</a>). Five further studies, in which all participants were given nicotine EC, measured 3‐HPMA; all found reductions over time (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 6</a>). </p> <p>Five trials measured change in NNAL and provided sufficient data to calculate summary effects (four at high risk of bias; <a href="./references#CD010216-fig-0055" title="">Analysis 5.9</a>). Three of the five studies found results favouring nicotine EC, but the final two indicated no difference; statistical heterogeneity was high (I<sup>2</sup> = 96%), so pooled results were not presented. One study comparing nicotine EC to no treatment described their findings narratively and stated that "NNAL decreased more over time in the e‐cigarette group ... the e‐cigarette group had significantly lower NNAL at 4 weeks (estimate = 0.54; SE = 0.23; t = 2.37; P &lt; 0.02), but the group difference was attenuated at 8 weeks (estimate = 0.42; SE = 0.23; t = 1.83; P &lt; 0.07)" (<a href="./references#CD010216-bbs2-0068" title="NCT03050853. The appeal and impact of e-cigarettes in smokers with SMI. clinicaltrials.gov/ct2/show/NCT03050853 (first received 13 February 2017). PrattS , FerronJ , SargentJ , BrunetteM . Assessing the effect of e-cigarettes versus usual smoking on NNAL among chronic smokers with serious mental illness. In: Society for Research on Nicotine and Tobacco (SRNT) 29th Annual Meeting 1-4 March 2023 . Vol. PPS22-5. 2023:73. PrattSI , BrunetteMF , FerronJC , SantosM , SargentJ , XieH . E-cigarette provision to promote switching in cigarette smokers with serious mental illness - a randomized trial. Nicotine &amp; Tobacco Research2022;6(24):1405-12. [DOI: 10.1093/ntr/ntac082]">Pratt 2022</a>). <a href="./references#CD010216-bbs2-0070" title="PulversK , EmamiAS , NollenNL , RomeroDR , StrongDR , BenowitzNL , et al. Tobacco consumption and toxicant exposure of cigarette smokers using electronic cigarettes. Nicotine &amp; Tobacco Research2018;20(2):206-14. ">Pulvers 2018</a> and <a href="./references#CD010216-bbs2-0053" title="MorrisP , McDermottS , ChapmanF , VerronT , CahoursX , StevensonM , et al. Reductions in biomarkers of exposure to selected harmful and potentially harmful constituents following exclusive and partial switching from combustible cigarettes to myblu TM electronic nicotine delivery systems (ENDS). Internal &amp; Emergency Medicine2022;17(2):397-410. [DOI: 10.1007/s11739-021-02813-w]NCT04429932. A study to evaluate nicotine uptake and biomarkers in adult smokers using mybluTM electronic cigarettes. clinicaltrials.gov/ct2/show/NCT04429932 (first received 7 June 2021). NCT04430634. A study to evaluate nicotine uptake and biomarkers in smokers using mybluTM electronic cigarettes [An open-label, randomized, crossover study to assess nicotine uptake, tobacco-related biomarkers of exposure, biomarkers of potential harm, and puff topography with use of mybluTM electronic cigarettes in adult smokers]. clinicaltrials.gov/ct2/show/NCT04430634 (first received 7 June 2021). ">Morris 2022*</a>, which provided all participants with nicotine EC, found a reduction in NNAL over time and <a href="./references#CD010216-bbs2-0015" title='CzoliCD , FongGT , GoniewiczML , HammondD . Biomarkers of exposure among "dual users" of tobacco cigarettes and electronic cigarettes in Canada. Nicotine and Tobacco Research2019;21(9):1259-66. '>Czoli 2019</a>, which was a cross‐over trial, found NNAL decreased when using nicotine EC compared to using traditional cigarettes (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 6</a>). An additional two RCTs (one unclear and one low risk of bias; none reporting tobacco/vaping industry funding) compared nicotine EC versus non‐nicotine EC and found no evidence of difference, with wide CIs and moderate statistical heterogeneity (‐0.02 pmol/mg creatinine, 95% CI ‐0.45 to 0.41; I<sup>2</sup> = 54%; 363 participants; <a href="./references#CD010216-fig-0045" title="">Analysis 4.10</a>). </p> <p>One trial (n = 90, unclear risk of bias) found non‐statistically significant lower levels of 2‐HPMA, HMPMA, PhET, and AAMA in nicotine EC arms compared to control (<a href="./references#CD010216-fig-0056" title="">Analysis 5.10</a>; <a href="./references#CD010216-fig-0057" title="">Analysis 5.11</a>; <a href="./references#CD010216-fig-0058" title="">Analysis 5.12</a>; <a href="./references#CD010216-fig-0060" title="">Analysis 5.14</a>). A further two studies, in which all participants received nicotine EC, found reductions in 2‐HPMA and AAMA measures over time (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 6</a>). No difference was found in the one trial (n = 90, unclear risk of bias) evaluating CEMA (<a href="./references#CD010216-fig-0059" title="">Analysis 5.13</a>). </p> <p>One trial (n = 384, unclear risk of bias) found reductions in S‐PMA compared to control (MD ‐1371.00 nanograms, 95% CI ‐1995.23 to ‐746.88) (<a href="./references#CD010216-fig-0061" title="">Analysis 5.15</a>); this was consistent with the two studies in which all participants received nicotine EC that measured S‐PMA, where levels declined over time (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 6</a>). </p> <p>Of the 33 remaining measurements in single studies where all participants received a nicotine EC, 28 reduced over time and five increased (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 6</a>). </p> </section> <section id="CD010216-sec-0087"> <h5 class="title">Lung function</h5> <p><a href="./references#CD010216-bbs2-0007" title="CampagnaD , CibellaF , CaponnettoP , AmaradioMD , CarusoM , MorjariaJB , et al. Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. European Journal of Clinical Investigation2016;46(8):698-706. CaponnettoP , CampagnaD , CibellaF , MorjariaJB , CarusoM , RussoC , et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLOS One2013;8(6):e66317. CibellaF , CampagnaD , CaponnettoP , AmaradioMD , CarusoM , RussoC , et al. Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. Clinical Science2016;130(21):1929-37. FarsalinosK , CibellaF , CaponnettoP , CampagnaD , MorjariaJB , BattagliaE , et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Internal and Emergency Medicine2016;11(1):85-94. NCT01164072. Efficacy and safety of an electronic nicotine delivery device (e-cigarette). clinicaltrials.gov/ct2/show/NCT01164072 (first received 16 July 2010). NCT01188239. A structured protocol to evaluate efficacy and safety of a popular electronic nicotine delivery device (e-cigarette) efficacy and safety of a popular electronic nicotine delivery device (e-cigarette). https://clinicaltrials.gov/ct2/show/NCT01188239. NCT01194583. Efficacy and safety of an electronic nicotine delivery device (e-cigarette) without nicotine cartridges. clinicaltrials.gov/ct2/show/NCT01194583 (first received 3 September 2010). RussoC , CibellaF , CaponnettoP , CampagnaD , MagliaM , FrazzettoE , et al. Evaluation of post cessation weight gain in a 1-year randomized smoking cessation trial of electronic cigarettes. Scientific Reports2016;6:18763. ">Caponnetto 2013a*</a> measured a number of lung function parameters. FeNO increased more in the nicotine EC than the non‐nicotine EC group (MD 2.35, 95% CI 1.78 to 2.92; 90 participants; <a href="./references#CD010216-fig-0042" title="">Analysis 4.7</a>). No difference was found between nicotine and non‐nicotine EC for FEV1 or FEV1/FVC (<a href="./references#CD010216-fig-0043" title="">Analysis 4.8</a>; <a href="./references#CD010216-fig-0044" title="">Analysis 4.9</a>). </p> <p>In the comparison of nicotine EC to behavioural support only/no support, pooled results from two studies (both high risk of bias, both tobacco/vaping industry funded) found improvements in FEV1 but with moderate statistical heterogeneity and CIs including no difference (standardized mean difference (SMD) 0.15, 95% CI ‐0.01 to 0.31, I<sup>2</sup> = 70%; 714 participants; <a href="./references#CD010216-fig-0062" title="">Analysis 5.16</a>). Pooled data from two studies (both high risk of bias, one reporting tobacco/vaping industry funding (<a href="./references#CD010216-bbs2-0086" title="CravoAS , BushJ , SharmaG , SaviozR , MartinC , CraigeS , et al. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. Regulatory Toxicology and Pharmacology2016;81:S1-S14. NCT02029196. A randomised, parallel group, multi-centre study to evaluate the safety profile of the ITG EVP G1 product. clinicaltrials.gov/show/NCT02029196 (accessed 16 July 2014). NCT02143310. A multi-centre study to evaluate the safety of use of electronic vapour products for two years. clinicaltrials.gov/show/NCT02143310 (accessed 16 July 2014). WaleleT , BushJ , KochA , SaviozR , MartinC , O'ConnellG . Evaluation of the safety profile of an electronic vapour product used for two years by smokers in a real-life setting. Regulatory Toxicology and Pharmacology2018;92:226-38. ">Walele 2018*</a>)) showed no difference in FEF (forced expiratory flow) 25‐75, with substantial levels of statistical heterogeneity (MD ‐0.06, 95% CI ‐0.18 to 0.06, I<sup>2</sup> = 73%; 2 studies, 555 participants; <a href="./references#CD010216-fig-0063" title="">Analysis 5.17</a>). In a sensitivity analysis removing Walele, the result was still consistent with no difference, though the point estimate was greater in magnitude. Data from one study at high risk of bias showed no difference in PEF (peak expiratory flow 25‐75 (litres/minute)) (387 participants, MD ‐7.10, 95% CI ‐29.14 to 14.94; <a href="./references#CD010216-fig-0064" title="">Analysis 5.18</a>). The one study reporting FEV1/FVC (327 participants, MD 1.72, 95% CI 0.74 to 2.70, high risk of bias) favoured nicotine EC (<a href="./references#CD010216-bbs2-0017" title="EdmistonJS , WebbKM , WangJ , OliveriD , LiangQ , SarkarM . Biomarkers of exposure and biomarkers of potential harm in adult smokers who switch to e-vapor products relative to cigarette smoking in a 24-week, randomized, clinical trial. Nicotine &amp; Tobacco Research2022;24(7):1047–54. [DOI: 10.1093/ntr/ntac029]">Edmiston 2022*</a>) (<a href="./references#CD010216-fig-0065" title="">Analysis 5.19</a>). </p> <p><a href="./references#CD010216-bbs2-0013" title="CobbCO , FouldsJ , Yen M-S, VeldheerS , LopezAA , Yingst JM et al. Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, controlled trial. Lancet Respiratory Medicine2021;9(8):840-50. [DOI: 10.1016/ S2213-2600(21)00022-9]FouldsJ , CobbC , Yen M-S, VeldheerS , BrosnanP , Yingst J et al. Effect of electronic nicotine delivery systems on cigarette abstinence in smokers with no plans to quit: exploratory analysis of a randomized placebo-controlled trial. Nicotine Tobacco Research2022;24(7):955-61. [DOI: 10.1093/ntr/ntab247]LopezAA , CobbCO , YingstJM , VeldheerS , HrabovskyS , YenMS , et al. A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation. BMC Public Health2016;16(1):217. [PMCID:: PMC4778292] [PMID: 26941050]NCT02342795. Randomized controlled trial methods for novel tobacco products evaluation. clinicaltrials.gov/show/NCT02342795 (accessed 17 February 2016). VeldheerS , YingstJ , MidyaV , HummerB , LesterC , KrebsN , . Pulmonary and other health effects of electronic cigarette use among adult smokers participating in a randomized controlled smoking reduction trial. Addictive Behaviors2019;91:95-101. YingstJ , FouldsJ , VeldheerS , CobbCO , YenM , HrabovskyS , et al. Measurement of electronic cigarette frequency of use among smokers participating in a randomized controlled trial. Nicotine &amp; Tobacco Research2020;22(5):699-704. [NCT02342795]YingstJ , WangX , AndersonA , BrelandA , SouleE , Barnes A et al. Evaluation of nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoke. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. March 2022. YingstJ , WangX , LopezAA , BrelandA , SouleE , Barnes A et al. Randomized Control Trial Methods Workgroup of the Center for the Study of Tobacco Products. Changes in nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoking in a randomized controlled trial. Nicotine Tobacco Research 2022 Jun 25 [Epub ahead of print]. [DOI: 10.1093/ntr/ntac153]YingstJ , Wang Xi, LopezAA , BrelandA , SouleE , BarnesA , et al. Randomized control trial methods workgroup of the center for the study of tobacco products, changes in nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoking in a randomized controlled trial. Nicotine &amp; Tobacco Research2023;25(3):372-8. [DOI: 10.1093/ntr/ntac153]">Cobb 2021</a>, which randomized participants to EC or the QuitSmart cigarette substitute, measured change in a number of lung function parameters: direction of effect was mixed across these, with no statistically or clinically significant between‐group differences at 12 weeks (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 7</a>). </p> <p>Two studies, which provided all participants with nicotine EC, measured change in lung function over time: <a href="./references#CD010216-bbs2-0032" title="HicklingLM , Perez-IglesiasR , McNeillA , DawkinsL , MoxhamJ , RuffellT , et al. A pre-post pilot study of electronic cigarettes to reduce smoking in people with severe mental illness. Psychological Medicine2019;49(6):1033-40. NCT02212041. Acceptability, patterns of use and safety of electronic cigarette in people with mental illness: a pilot study. clinicaltrials.gov/show/NCT02212041 (accessed 17 February 2016). ">Hickling 2019</a> found an increase in peak flow, and <a href="./references#CD010216-bbs2-0060" title="NCT01775787. Effects of electronic cigarettes on nicotine concentrations (ECIG). clinicaltrials.gov/ct2/show/NCT01775787 (first received 25 January 2013). OnckenCA , LittMD , McLaughlinLD , BurkiNA . Nicotine concentrations with electronic cigarette use: effects of sex and flavor. Nicotine &amp; Tobacco Research2015;17(4):473-8. SwedehMA , OnckenC , BurkiNK . Acute effects of electronic cigarettes on airway function in human subjects. In: American Thoracic Society International Conference Abstracts. Vol. 189. 2014:A4089. ">Oncken 2015</a> found "no significant differences" in airway function (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 7</a>). </p> </section> <section id="CD010216-sec-0088"> <h5 class="title">Study product use</h5> <p>Three trials (all low risk), comparing nicotine EC with non‐nicotine EC, reported the number of participants still using EC at six months or longer. Slightly more participants were still using EC in the nicotine EC arms, but CIs were wide and included no difference (RR 1.15, 95% CI 0.94 to 1.41, I<sup>2</sup> = 30%; 874 participants; <a href="./references#CD010216-fig-0046" title="">Analysis 4.11</a>). Data on this outcome from single‐arm studies or RCTs where a study product (i.e. EC) was only provided in one arm can be found in a companion publication (<a href="./references#CD010216-bbs2-0207" title="ButlerAR , LindsonN , FanshaweTR , TheodoulouA , BeghR , HajekP , et al. Longer-term use of electronic cigarettes when provided as a stop smoking aid: systematic review with meta-analyses. Preventive Medicine2022;165(Pt B):107182. [DOI: 10.1016/j.ypmed.2022.107182] [PMID: 35933001]">Butler 2022</a>) and <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 8</a>. </p> </section> </section> <section id="CD010216-sec-0089"> <h4 class="title">Direct comparisons between nicotine EC</h4> <p>Note, studies reported in this section are only those where participants were randomized to different nicotine EC conditions. </p> <section id="CD010216-sec-0090"> <h5 class="title">Comparisons based on nicotine dose</h5> <p>Six trials provided data comparing different doses of nicotine in EC (although other studies provided a range of doses, these were not randomly assigned). Only one study provided data on abstinence; in <a href="./references#CD010216-bbs2-0013" title="CobbCO , FouldsJ , Yen M-S, VeldheerS , LopezAA , Yingst JM et al. Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, controlled trial. Lancet Respiratory Medicine2021;9(8):840-50. [DOI: 10.1016/ S2213-2600(21)00022-9]FouldsJ , CobbC , Yen M-S, VeldheerS , BrosnanP , Yingst J et al. Effect of electronic nicotine delivery systems on cigarette abstinence in smokers with no plans to quit: exploratory analysis of a randomized placebo-controlled trial. Nicotine Tobacco Research2022;24(7):955-61. [DOI: 10.1093/ntr/ntab247]LopezAA , CobbCO , YingstJM , VeldheerS , HrabovskyS , YenMS , et al. A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation. BMC Public Health2016;16(1):217. [PMCID:: PMC4778292] [PMID: 26941050]NCT02342795. Randomized controlled trial methods for novel tobacco products evaluation. clinicaltrials.gov/show/NCT02342795 (accessed 17 February 2016). VeldheerS , YingstJ , MidyaV , HummerB , LesterC , KrebsN , . Pulmonary and other health effects of electronic cigarette use among adult smokers participating in a randomized controlled smoking reduction trial. Addictive Behaviors2019;91:95-101. YingstJ , FouldsJ , VeldheerS , CobbCO , YenM , HrabovskyS , et al. Measurement of electronic cigarette frequency of use among smokers participating in a randomized controlled trial. Nicotine &amp; Tobacco Research2020;22(5):699-704. [NCT02342795]YingstJ , WangX , AndersonA , BrelandA , SouleE , Barnes A et al. Evaluation of nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoke. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. March 2022. YingstJ , WangX , LopezAA , BrelandA , SouleE , Barnes A et al. Randomized Control Trial Methods Workgroup of the Center for the Study of Tobacco Products. Changes in nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoking in a randomized controlled trial. Nicotine Tobacco Research 2022 Jun 25 [Epub ahead of print]. [DOI: 10.1093/ntr/ntac153]YingstJ , Wang Xi, LopezAA , BrelandA , SouleE , BarnesA , et al. Randomized control trial methods workgroup of the center for the study of tobacco products, changes in nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoking in a randomized controlled trial. Nicotine &amp; Tobacco Research2023;25(3):372-8. [DOI: 10.1093/ntr/ntac153]">Cobb 2021</a> (low risk of bias), quit rates were higher in the higher‐dose arm but the 95% CI included no difference (RR 2.50, 95% CI 0.80 to 7.77; 260 participants; <a href="./references#CD010216-fig-0066" title="">Analysis 6.1</a>). </p> <p>Three of the four studies that provided data on adverse events and contributed to this comparison provided them in such a way that the studies could not be pooled. <a href="./references#CD010216-bbs2-0041" title="KimberCF , SoarK , Dawkins LE. Changes in puffing topography and subjective effects over a 2-week period in e-cigarette naive smokers: effects of device type and nicotine concentrations. Addictive Behaviors2021;118:106909. [DOI: 10.1016/j.addbeh.2021.106909]">Kimber 2021</a> reported "no changes over time or differences between condition", and <a href="./references#CD010216-bbs2-0068" title="NCT03050853. The appeal and impact of e-cigarettes in smokers with SMI. clinicaltrials.gov/ct2/show/NCT03050853 (first received 13 February 2017). PrattS , FerronJ , SargentJ , BrunetteM . Assessing the effect of e-cigarettes versus usual smoking on NNAL among chronic smokers with serious mental illness. In: Society for Research on Nicotine and Tobacco (SRNT) 29th Annual Meeting 1-4 March 2023 . Vol. PPS22-5. 2023:73. PrattSI , BrunetteMF , FerronJC , SantosM , SargentJ , XieH . E-cigarette provision to promote switching in cigarette smokers with serious mental illness - a randomized trial. Nicotine &amp; Tobacco Research2022;6(24):1405-12. [DOI: 10.1093/ntr/ntac082]">Pratt 2022</a> and <a href="./references#CD010216-bbs2-0053" title="MorrisP , McDermottS , ChapmanF , VerronT , CahoursX , StevensonM , et al. Reductions in biomarkers of exposure to selected harmful and potentially harmful constituents following exclusive and partial switching from combustible cigarettes to myblu TM electronic nicotine delivery systems (ENDS). Internal &amp; Emergency Medicine2022;17(2):397-410. [DOI: 10.1007/s11739-021-02813-w]NCT04429932. A study to evaluate nicotine uptake and biomarkers in adult smokers using mybluTM electronic cigarettes. clinicaltrials.gov/ct2/show/NCT04429932 (first received 7 June 2021). NCT04430634. A study to evaluate nicotine uptake and biomarkers in smokers using mybluTM electronic cigarettes [An open-label, randomized, crossover study to assess nicotine uptake, tobacco-related biomarkers of exposure, biomarkers of potential harm, and puff topography with use of mybluTM electronic cigarettes in adult smokers]. clinicaltrials.gov/ct2/show/NCT04430634 (first received 7 June 2021). ">Morris 2022*</a> did not compare AEs by nicotine strength (see <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 1</a>). <a href="./references#CD010216-bbs2-0039" title="KanobeMN , JonesBA , NelsonP , BrownBG , ChenP , MakenaP , et al. Part three: a randomized study to assess biomarker changes in cigarette smokers switched to Vuse Solo or abstinence. Scientific Reports2022;12:20658. [DOI: 10.1038/s41598-022-25054-z]KanobeMN , NelsonPR , BrownBG , ChenP , PatruduM , Caraway JW et al. Changes in biomarkers of exposure and potential harm in smokers switched to Vuse Vibe or Vuse Ciro electronic nicotine delivery systems. Toxics2023;11(7):564. [DOI: 10.3390/toxics11070564]NCT03170674. CSD170501: Study to assess biomarkers of tobacco exposure in smokers during in-clinic confinement switch to an electronic cigarette. clinicaltrials.gov/ct2/show/NCT03170674 (first received 31 May 2017). ">Kanobe 2022*</a> found slightly more participants in the lower‐dose group reported AEs; however, 95% CI incorporated the null and also the possibility that more people experienced AEs in the higher‐dose arm (RR 0.90, 95% CI 0.58 to 1.40; 68 participants; <a href="./references#CD010216-fig-0067" title="">Analysis 6.2</a>). </p> <p>In <a href="./references#CD010216-bbs2-0007" title="CampagnaD , CibellaF , CaponnettoP , AmaradioMD , CarusoM , MorjariaJB , et al. Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. European Journal of Clinical Investigation2016;46(8):698-706. CaponnettoP , CampagnaD , CibellaF , MorjariaJB , CarusoM , RussoC , et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLOS One2013;8(6):e66317. CibellaF , CampagnaD , CaponnettoP , AmaradioMD , CarusoM , RussoC , et al. Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. Clinical Science2016;130(21):1929-37. FarsalinosK , CibellaF , CaponnettoP , CampagnaD , MorjariaJB , BattagliaE , et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Internal and Emergency Medicine2016;11(1):85-94. NCT01164072. Efficacy and safety of an electronic nicotine delivery device (e-cigarette). clinicaltrials.gov/ct2/show/NCT01164072 (first received 16 July 2010). NCT01188239. A structured protocol to evaluate efficacy and safety of a popular electronic nicotine delivery device (e-cigarette) efficacy and safety of a popular electronic nicotine delivery device (e-cigarette). https://clinicaltrials.gov/ct2/show/NCT01188239. NCT01194583. Efficacy and safety of an electronic nicotine delivery device (e-cigarette) without nicotine cartridges. clinicaltrials.gov/ct2/show/NCT01194583 (first received 3 September 2010). RussoC , CibellaF , CaponnettoP , CampagnaD , MagliaM , FrazzettoE , et al. Evaluation of post cessation weight gain in a 1-year randomized smoking cessation trial of electronic cigarettes. Scientific Reports2016;6:18763. ">Caponnetto 2013a*</a>, no serious adverse events were reported in either arm; in <a href="./references#CD010216-bbs2-0013" title="CobbCO , FouldsJ , Yen M-S, VeldheerS , LopezAA , Yingst JM et al. Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, controlled trial. Lancet Respiratory Medicine2021;9(8):840-50. [DOI: 10.1016/ S2213-2600(21)00022-9]FouldsJ , CobbC , Yen M-S, VeldheerS , BrosnanP , Yingst J et al. Effect of electronic nicotine delivery systems on cigarette abstinence in smokers with no plans to quit: exploratory analysis of a randomized placebo-controlled trial. Nicotine Tobacco Research2022;24(7):955-61. [DOI: 10.1093/ntr/ntab247]LopezAA , CobbCO , YingstJM , VeldheerS , HrabovskyS , YenMS , et al. A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation. BMC Public Health2016;16(1):217. [PMCID:: PMC4778292] [PMID: 26941050]NCT02342795. Randomized controlled trial methods for novel tobacco products evaluation. clinicaltrials.gov/show/NCT02342795 (accessed 17 February 2016). VeldheerS , YingstJ , MidyaV , HummerB , LesterC , KrebsN , . Pulmonary and other health effects of electronic cigarette use among adult smokers participating in a randomized controlled smoking reduction trial. Addictive Behaviors2019;91:95-101. YingstJ , FouldsJ , VeldheerS , CobbCO , YenM , HrabovskyS , et al. Measurement of electronic cigarette frequency of use among smokers participating in a randomized controlled trial. Nicotine &amp; Tobacco Research2020;22(5):699-704. [NCT02342795]YingstJ , WangX , AndersonA , BrelandA , SouleE , Barnes A et al. Evaluation of nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoke. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. March 2022. YingstJ , WangX , LopezAA , BrelandA , SouleE , Barnes A et al. Randomized Control Trial Methods Workgroup of the Center for the Study of Tobacco Products. Changes in nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoking in a randomized controlled trial. Nicotine Tobacco Research 2022 Jun 25 [Epub ahead of print]. [DOI: 10.1093/ntr/ntac153]YingstJ , Wang Xi, LopezAA , BrelandA , SouleE , BarnesA , et al. Randomized control trial methods workgroup of the center for the study of tobacco products, changes in nicotine dependence among smokers using electronic cigarettes to reduce cigarette smoking in a randomized controlled trial. Nicotine &amp; Tobacco Research2023;25(3):372-8. [DOI: 10.1093/ntr/ntac153]">Cobb 2021</a>, there were more events in the higher‐dose arm but CIs were wide (RR 1.51, 95% CI 0.51 to 4.42; 239 participants; <a href="./references#CD010216-fig-0068" title="">Analysis 6.3</a>). In <a href="./references#CD010216-bbs2-0053" title="MorrisP , McDermottS , ChapmanF , VerronT , CahoursX , StevensonM , et al. Reductions in biomarkers of exposure to selected harmful and potentially harmful constituents following exclusive and partial switching from combustible cigarettes to myblu TM electronic nicotine delivery systems (ENDS). Internal &amp; Emergency Medicine2022;17(2):397-410. [DOI: 10.1007/s11739-021-02813-w]NCT04429932. A study to evaluate nicotine uptake and biomarkers in adult smokers using mybluTM electronic cigarettes. clinicaltrials.gov/ct2/show/NCT04429932 (first received 7 June 2021). NCT04430634. A study to evaluate nicotine uptake and biomarkers in smokers using mybluTM electronic cigarettes [An open-label, randomized, crossover study to assess nicotine uptake, tobacco-related biomarkers of exposure, biomarkers of potential harm, and puff topography with use of mybluTM electronic cigarettes in adult smokers]. clinicaltrials.gov/ct2/show/NCT04430634 (first received 7 June 2021). ">Morris 2022*</a>, no serious adverse events occurred (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 2</a>). </p> <p>Point estimates favoured higher‐dose EC and CIs excluded no difference for carbon monoxide and FEV1/FVC (MD ‐0.92, 95% CI ‐1.71 to ‐0.13; 348 participants, 3 studies) (<a href="./references#CD010216-fig-0069" title="">Analysis 6.4</a>), (MD 0.91, 95% CI 0.15, 1.67; 90 participants, 1 industry‐funded study) (<a href="./references#CD010216-fig-0075" title="">Analysis 6.10</a>). Interpretation of <a href="./references#CD010216-fig-0069" title="">Analysis 6.4</a> did not change when excluding the one study with tobacco/vaping industry funding (<a href="./references#CD010216-bbs2-0007" title="CampagnaD , CibellaF , CaponnettoP , AmaradioMD , CarusoM , MorjariaJB , et al. Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. European Journal of Clinical Investigation2016;46(8):698-706. CaponnettoP , CampagnaD , CibellaF , MorjariaJB , CarusoM , RussoC , et al. EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLOS One2013;8(6):e66317. CibellaF , CampagnaD , CaponnettoP , AmaradioMD , CarusoM , RussoC , et al. Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. Clinical Science2016;130(21):1929-37. FarsalinosK , CibellaF , CaponnettoP , CampagnaD , MorjariaJB , BattagliaE , et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Internal and Emergency Medicine2016;11(1):85-94. NCT01164072. Efficacy and safety of an electronic nicotine delivery device (e-cigarette). clinicaltrials.gov/ct2/show/NCT01164072 (first received 16 July 2010). NCT01188239. A structured protocol to evaluate efficacy and safety of a popular electronic nicotine delivery device (e-cigarette) efficacy and safety of a popular electronic nicotine delivery device (e-cigarette). https://clinicaltrials.gov/ct2/show/NCT01188239. NCT01194583. Efficacy and safety of an electronic nicotine delivery device (e-cigarette) without nicotine cartridges. clinicaltrials.gov/ct2/show/NCT01194583 (first received 3 September 2010). RussoC , CibellaF , CaponnettoP , CampagnaD , MagliaM , FrazzettoE , et al. Evaluation of post cessation weight gain in a 1-year randomized smoking cessation trial of electronic cigarettes. Scientific Reports2016;6:18763. ">Caponnetto 2013a*</a>); <a href="./references#CD010216-fig-0075" title="">Analysis 6.10</a> includes only this study. There were no clear differences between arms for heart rate, blood pressure, other lung function measures, or NNAL (<a href="./references#CD010216-fig-0070" title="">Analysis 6.5</a>; <a href="./references#CD010216-fig-0071" title="">Analysis 6.6</a>; <a href="./references#CD010216-fig-0072" title="">Analysis 6.7</a>; <a href="./references#CD010216-fig-0073" title="">Analysis 6.8</a>; <a href="./references#CD010216-fig-0074" title="">Analysis 6.9</a>; <a href="./references#CD010216-fig-0076" title="">Analysis 6.11</a>; all include only one study). More participants in the higher‐dose nicotine group were still using EC at six months or longer, but data were from one study and CIs were wide and included no difference (RR 1.27, 95% CI 0.95 to 1.68; 260 participants; <a href="./references#CD010216-fig-0077" title="">Analysis 6.12</a>). In <a href="./references#CD010216-bbs2-0090" title="YingstJ , FouldsJ , ZurloJ , SteinbergMB , EissenbergT , DuP . Acceptability of electronic nicotine delivery systems (ENDS) among HIV positive smokers. AIDS Care2020;32(10):1224-8. ">Yingst 2020</a> (cross‐over, comparing different doses and different devices), exhaled CO and reported nausea did not differ between devices; self‐reported dizziness was low overall but slightly higher in the higher‐dose arm. Further details can be found in <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 1</a> and <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 3</a>. <a href="./references#CD010216-bbs2-0053" title="MorrisP , McDermottS , ChapmanF , VerronT , CahoursX , StevensonM , et al. Reductions in biomarkers of exposure to selected harmful and potentially harmful constituents following exclusive and partial switching from combustible cigarettes to myblu TM electronic nicotine delivery systems (ENDS). Internal &amp; Emergency Medicine2022;17(2):397-410. [DOI: 10.1007/s11739-021-02813-w]NCT04429932. A study to evaluate nicotine uptake and biomarkers in adult smokers using mybluTM electronic cigarettes. clinicaltrials.gov/ct2/show/NCT04429932 (first received 7 June 2021). NCT04430634. A study to evaluate nicotine uptake and biomarkers in smokers using mybluTM electronic cigarettes [An open-label, randomized, crossover study to assess nicotine uptake, tobacco-related biomarkers of exposure, biomarkers of potential harm, and puff topography with use of mybluTM electronic cigarettes in adult smokers]. clinicaltrials.gov/ct2/show/NCT04430634 (first received 7 June 2021). ">Morris 2022*</a> measured a range of toxicants but did not compare these based on nicotine level assignments (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 6</a>). </p> <p>One further study, <a href="./references#CD010216-bbs2-0088" title="NCT03185546. Project 2 cigarette and e-cigarette nicotine content and e-liquid flavors. clinicaltrials.gov/ct2/show/NCT03185546 (first received 14 May 2021). WhiteCM , Denlinger-ApteRL , TessierKM , KoopmeinersJS , HatsukamiDK , StrasserAA . Cigarette nicotine reduction in the presence of an alternative: investigating how cigarette nicotine content and e-liquid content affect smoking. In: Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting February 24-27 2021 (virtual). 2021:SYM2C p2-3. WhiteCM , TessierKM , KoopmeinersJS , Denlinger-ApteRL , CobbCO , LaneT , et al. Preliminary evidence on cigarette nicotine reduction with concurrent access to an e-cigarette: manipulating cigarette nicotine content, e-liquid nicotine content, and e-liquid flavor availability. Preventive Medicine2022;165(Pt B):107213. [DOI: 10.1016/j.ypmed.2022.107213]">White 2021</a>, also included comparisons based on nicotine levels (1.8% free‐base nicotine, designated by the authors as 'moderate', and 0.3% free‐base nicotine, designated by the authors as 'low'). This was a factorial trial (unpublished at the time of writing) which, in addition to e‐liquid nicotine content, also manipulated cigarette nicotine content and e‐liquid flavour availability. The authors reported no significant main effects for nicotine content on CO or CEMA, and no statistically significant interactions for these conditions. There also appear to have been no differences in the proportions of people experiencing adverse events, but the study terminated early and was likely underpowered to detect differences. </p> </section> <section id="CD010216-sec-0091"> <h5 class="title">Comparisons based on flavour</h5> <p>One study randomized participants to different flavour conditions (1. tobacco flavour only; 2. a choice of flavours) and followed up participants for six months or longer (<a href="./references#CD010216-bbs2-0089" title="XuY , GoldensonNI , Prakash S AugustsonEM , ShiffmanS . Randomized trial assessing the effect of the JUUL system on switching away from cigarettes and smoking reduction among U.S. adults who smoke cigarettes.. Experimental and Clinical Psychopharmacology2024;32(1):3-15. [DOI: 10.1037/pha0000698]">Xu 2023*</a>, n = 566, industry‐funded, high risk of bias). Quit rates were lower in the choice compared to the tobacco arm, but the CIs were wide and incorporated no difference and a clinically significant increase relative to tobacco flavour (choice versus tobacco, RR 0.80, 95% CI 0.54 to 1.16; <a href="./references#CD010216-fig-0078" title="">Analysis 7.1</a>). <a href="./references#CD010216-bbs2-0089" title="XuY , GoldensonNI , Prakash S AugustsonEM , ShiffmanS . Randomized trial assessing the effect of the JUUL system on switching away from cigarettes and smoking reduction among U.S. adults who smoke cigarettes.. Experimental and Clinical Psychopharmacology2024;32(1):3-15. [DOI: 10.1037/pha0000698]">Xu 2023*</a> also reported on product use at six months or longer; again, there was no clear evidence of a difference, but the CIs were wide (choice versus tobacco, RR 1.10, 95% CI 0.86 to 1.40; <a href="./references#CD010216-fig-0079" title="">Analysis 7.2</a>). </p> <p>One study (<a href="./references#CD010216-bbs2-0017" title="EdmistonJS , WebbKM , WangJ , OliveriD , LiangQ , SarkarM . Biomarkers of exposure and biomarkers of potential harm in adult smokers who switch to e-vapor products relative to cigarette smoking in a 24-week, randomized, clinical trial. Nicotine &amp; Tobacco Research2022;24(7):1047–54. [DOI: 10.1093/ntr/ntac029]">Edmiston 2022*</a>, n = 300, high risk of bias, vaping/tobacco industry funding) randomized participants to different flavours (tobacco versus menthol) and provided SAE data in a way that could have been used to compute risk ratios, although no SAEs occurred in either arm (<a href="./references#CD010216-fig-0080" title="">Analysis 8.1</a>). NNAL and FEV1/FVC were lower in the tobacco flavour group but CIs were wide and included no difference (MD ‐26.10, 95% CI ‐66.73 to 14.53; <a href="./references#CD010216-fig-0081" title="">Analysis 8.2</a>; MD ‐0.46, 95% CI ‐1.67 to 0.75; <a href="./references#CD010216-fig-0083" title="">Analysis 8.4</a>). There was no evidence of a difference in FEV1 (MD ‐0.67, 95% CI ‐2.34 to 1.00; <a href="./references#CD010216-fig-0082" title="">Analysis 8.3</a>). No other outcomes from this paper were eligible for inclusion in our review. </p> <p><a href="./references#CD010216-bbs2-0053" title="MorrisP , McDermottS , ChapmanF , VerronT , CahoursX , StevensonM , et al. Reductions in biomarkers of exposure to selected harmful and potentially harmful constituents following exclusive and partial switching from combustible cigarettes to myblu TM electronic nicotine delivery systems (ENDS). Internal &amp; Emergency Medicine2022;17(2):397-410. [DOI: 10.1007/s11739-021-02813-w]NCT04429932. A study to evaluate nicotine uptake and biomarkers in adult smokers using mybluTM electronic cigarettes. clinicaltrials.gov/ct2/show/NCT04429932 (first received 7 June 2021). NCT04430634. A study to evaluate nicotine uptake and biomarkers in smokers using mybluTM electronic cigarettes [An open-label, randomized, crossover study to assess nicotine uptake, tobacco-related biomarkers of exposure, biomarkers of potential harm, and puff topography with use of mybluTM electronic cigarettes in adult smokers]. clinicaltrials.gov/ct2/show/NCT04430634 (first received 7 June 2021). ">Morris 2022*</a>, an industry‐funded, randomized, cross‐over trial, tested the effect of 10 different flavours (as well as nicotine strengths and salt versus free‐base nicotine). Only their data on AE and SAE were eligible for inclusion in our review, but analyses were not reported by flavour (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 1</a>; <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 2</a>). </p> <p><a href="./references#CD010216-bbs2-0088" title="NCT03185546. Project 2 cigarette and e-cigarette nicotine content and e-liquid flavors. clinicaltrials.gov/ct2/show/NCT03185546 (first received 14 May 2021). WhiteCM , Denlinger-ApteRL , TessierKM , KoopmeinersJS , HatsukamiDK , StrasserAA . Cigarette nicotine reduction in the presence of an alternative: investigating how cigarette nicotine content and e-liquid content affect smoking. In: Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting February 24-27 2021 (virtual). 2021:SYM2C p2-3. WhiteCM , TessierKM , KoopmeinersJS , Denlinger-ApteRL , CobbCO , LaneT , et al. Preliminary evidence on cigarette nicotine reduction with concurrent access to an e-cigarette: manipulating cigarette nicotine content, e-liquid nicotine content, and e-liquid flavor availability. Preventive Medicine2022;165(Pt B):107213. [DOI: 10.1016/j.ypmed.2022.107213]">White 2021</a> also contributed data to this comparison, with conditions being tobacco flavours only, or tobacco, fruit, dessert, and mint flavours. No significant main effects or interactions were found for flavours on the outcomes relevant to this review, namely CO and CEMA, and no difference was discernable in the occurrence of AEs. However, as noted above, the study terminated early and hence was underpowered to detect differences. </p> <p>More information on flavour choices across the studies in this review can be found in a companion publication (<a href="./references#CD010216-bbs2-0254" title="LindsonN , ButlerAR , LiberA , LevyD , BarnettP , TheodoulouA , et al. An exploration of flavours in studies of e-cigarettes for smoking cessation: secondary analyses of a systematic review with meta-analyses. Addiction 2022 Nov 18 [Epub ahead of print]. [DOI: 10.1111/add.16091]">Lindson 2022</a>). </p> </section> <section id="CD010216-sec-0092"> <h5 class="title">Comparisons based on device type</h5> <p><a href="./references#CD010216-bbs2-0041" title="KimberCF , SoarK , Dawkins LE. Changes in puffing topography and subjective effects over a 2-week period in e-cigarette naive smokers: effects of device type and nicotine concentrations. Addictive Behaviors2021;118:106909. [DOI: 10.1016/j.addbeh.2021.106909]">Kimber 2021</a> (high risk of bias) is the only study to directly compare device types (cartridge versus refillable). Outcomes eligible for this review were CO and AE. There was no difference between arms for CO, but CIs were wide (MD 0.70, 95% CI ‐4.98 to 6.38; 32 participants; <a href="./references#CD010216-fig-0084" title="">Analysis 9.1</a>). The authors reported "no changes over time or differences between condition" for AEs (see <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 1</a>). </p> </section> <section id="CD010216-sec-0093"> <h5 class="title">Nicotine salt versus free‐base nicotine</h5> <p>One study (<a href="./references#CD010216-bbs2-0073" title="RussellC , McKeganeyN , KatsampourisE , SatchwellA , HaseenF . A randomised community-based trial of a closed-system pod e-vapour product and nicotine replacement therapy for cigarette abstinence and reduction. Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting February 24-27 2021 virtual:PH-353 p230. ">Russell 2021</a>, unclear risk of bias, tobacco/vaping industry funding) contributed data to this comparison. Quit rates and study product use were both similar between arms (RR 1.25, 95% CI 0.85 to 1.83, n = 285; <a href="./references#CD010216-fig-0085" title="">Analysis 10.1</a>; and RR 1.07, 95% CI 0.82 to 1.41, n = 227; <a href="./references#CD010216-fig-0086" title="">Analysis 10.2</a>, respectively). </p> <p>As described above, <a href="./references#CD010216-bbs2-0053" title="MorrisP , McDermottS , ChapmanF , VerronT , CahoursX , StevensonM , et al. Reductions in biomarkers of exposure to selected harmful and potentially harmful constituents following exclusive and partial switching from combustible cigarettes to myblu TM electronic nicotine delivery systems (ENDS). Internal &amp; Emergency Medicine2022;17(2):397-410. [DOI: 10.1007/s11739-021-02813-w]NCT04429932. A study to evaluate nicotine uptake and biomarkers in adult smokers using mybluTM electronic cigarettes. clinicaltrials.gov/ct2/show/NCT04429932 (first received 7 June 2021). NCT04430634. A study to evaluate nicotine uptake and biomarkers in smokers using mybluTM electronic cigarettes [An open-label, randomized, crossover study to assess nicotine uptake, tobacco-related biomarkers of exposure, biomarkers of potential harm, and puff topography with use of mybluTM electronic cigarettes in adult smokers]. clinicaltrials.gov/ct2/show/NCT04430634 (first received 7 June 2021). ">Morris 2022*</a> also tested salt versus free‐base nicotine, but did not provide data broken down by these characteristics for our outcomes of interest (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 1</a>; <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 2</a>). </p> </section> </section> <section id="CD010216-sec-0094"> <h4 class="title">Non‐nicotine EC</h4> <p>Although non‐nicotine ECs serve as a 'control group' in our primary analysis, due to their behavioural properties, they can also be considered an intervention in and of themselves. Comparisons included here are: non‐nicotine EC versus NRT; non‐nicotine EC versus behavioural support/not treatment; and non‐nicotine EC as an adjunct to NRT. All contributing data were from randomized controlled trials. None of these studies reported data on change in heart rate, blood pressure, oxygen saturation, toxicants, or lung function. </p> <section id="CD010216-sec-0095"> <h5 class="title">Cessation</h5> <p>When comparing non‐nicotine EC to behavioural support only, pooled results from two studies (n = 388; one at high risk of bias, neither reporting tobacco/vaping industry funding) found higher quit rates in participants randomized to non‐nicotine EC, but the confidence interval included the possibility of no difference (RR 1.63, 95% CI 0.81 to 3.25; I<sup>2</sup> = 0%; <a href="./references#CD010216-fig-0087" title="">Analysis 11.1</a>). When evaluating non‐nicotine EC as an adjunct to NRT, <a href="./references#CD010216-bbs2-0087" title="NCT02521662. A randomised-controlled clinical trial to evaluate the effectiveness and safety of combining nicotine patches with e-cigarettes (with and without nicotine) plus behavioural support, on smoking abstinence. clinicaltrials.gov/show/NCT02521662 (accessed 17 February 2016). WalkerN , ParagV , VerbiestM , LakingG , LaugesenM , BullenC . Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial. Lancet. Respiratory Medicine2020;8(1):54-64. WalkerN , VerbiestM , KurdzielT , LakingG , LaugesenM , ParagV , et al. Effectiveness and safety of nicotine patches combined with e-cigarettes (with and without nicotine) for smoking cessation: study protocol for a randomised controlled trial. BMJ Open2019;9(2):e023659. ">Walker 2020</a> also found higher quit rates in participants randomized to non‐nicotine EC, although again the confidence interval included no difference (RR 1.67 95% CI 0.50 to 5.53; 624 participants; <a href="./references#CD010216-fig-0090" title="">Analysis 12.1</a>). </p> <p>Two studies (n = 314, neither at high risk of bias, neither reporting tobacco/vaping industry funding) compared non‐nicotine EC with NRT (<a href="./references#CD010216-bbs2-0042" title="JonesG , McIntoshE , BroseLS , KlonizakisM . Participant experiences of a quit smoking attempt through either Nicotine Replacement Therapy (NRT) methods or the use of an e-cigarette. Journal of Addiction Medicine2022;16(3):272-7. KlonizakisM , CrankH , GumberA , BroseLS . Smokers making a quit attempt using e-cigarettes with or without nicotine or prescription nicotine replacement therapy: impact on cardiovascular function (ISME-NRT) - a study protocol. BMC Public Health2017;17(1):293. KlonizakisM , GumberA , McIntoshE , BroseLS . Medium-and longer-term cardiovascular effects of e-cigarettes in adults making a stop-smoking attempt: a randomized controlled trial. BMC Medicine2022;20(1):276. [DOI: 10.1186/s12916-022-02451-9]KlonizakisM , GumberA , McIntoshE , BroseLS . Short-term cardiovascular effects of e-cigarettes in adults making a stop-smoking attempt: a randomized controlled trial. Biology2021;10(11):1208. [DOI: 10.3390/biology10111208]NCT03061253. E-cigarettes and cardiovascular function (ISME-NRT). clinicaltrials.gov/ct2/show/NCT03061253 (first received 23 February 2017). ">Klonizakis 2022</a>; <a href="./references#CD010216-bbs2-0045" title="KCT0001277. Effect of an electronic cigarette for smoking reduction and cessation in Korean male smokers: a randomized, controlled study. KCT0001277 2014 (accessed 15 August 2016). LeeSH , AhnSH , CheongYS . Effect of electronic cigarettes on smoking reduction and cessation in Korean male smokers: a randomized controlled study. Journal of the American Board of Family Medicine2019;32(4):567-74. ">Lee 2019</a>). The pooled estimate showed no clear evidence of a difference in quit rates between the two interventions (RR 0.99, 95% CI 0.64 to 1.54; I<sup>2</sup> = 36%; <a href="./references#CD010216-fig-0093" title="">Analysis 13.1</a>). </p> </section> <section id="CD010216-sec-0096"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD010216-bbs2-0019" title="EisenbergMJ , Hébert-LosierM , WindleSB , GreenspoonT , BrandysT , FülöpT . Effect of e-cigarettes plus counseling vs counseling alone on smoking cessation: a randomized clinical trial. JAMA2020;324(18):1844-54. Hebert-LosierA , FilionKB , WindleSB , EisenbergMJ . A randomized controlled trial evaluating the efficacy of e-cigarette use for smoking cessation in the general population: E3 trial design. Canadian Journal of Cardiology Open2020;2(3):168-75. [NCT02417467]NCT02417467. Evaluating the efficacy of e-cigarette use for smoking cessation (E3) trial. clinicaltrials.gov/show/NCT02417467 (accessed 17 February 2016). PrellC , Hebert-LosierA , FilionKB , ReynierP , EisenbergMJ . Evaluating the impact of varying expired carbon monoxide thresholds on smoking relapse identification: insights from the E3 trial on e-cigarette efficacy for smoking cessation. BMJ Open2023;13(13):10. [DOI: 10.1136/bmjopen-2022-071099]">Eisenberg 2020</a> found a higher rate of adverse events in the non‐nicotine EC arm than in behavioural support only, with the confidence interval excluding no difference (RR 1.28, 95% CI 1.13 to 1.44; 248 participants; <a href="./references#CD010216-fig-0088" title="">Analysis 11.2</a>). Also comparing non‐nicotine EC to behavioural support, <a href="./references#CD010216-bbs2-0046" title="LucchiariC , MasieroM , MazzoccoK , VeronesiG , MaisonneauveP , JemosC , et al. Benefits of e-cigarettes in smoking reduction and in pulmonary health among chronic smokers undergoing a lung cancer screening program at 6 months. Addictive Behaviours2020;103:106222. LucchiariC , MasieroM , MazzoccoK , VeronesiG , MaisonneuveP , JemosC , et al. Nicotine-free e-cigarettes might promote tobacco smoking reduction better than nicotine delivery devices: results of a double-blind randomized controlled trial at 1 year. Current Oncology2022;29(11):8579-90. [DOI: 10.3390/curroncol29110676]LucchiariC , MasieroM , VeronesiG , MaisonneuveP , SpinaS , JemosC , et al. Benefits of e-cigarettes among heavy smokers undergoing a lung cancer screening program: randomized controlled trial protocol. JMIR Research Protocols2016;5(1):e21. [PMID: 26842790]MasieroM , LucchiariC , MazzoccoK , VeronesiG , Maisonneuve P JemosC , et al. Corrigendum: E-cigarettes may support smokers with high smoking-related risk awareness to stop smoking in the short run: preliminary results by randomized controlled trial. Nicotine and Tobacco Research2020;22(4):594-5. [NCT02422914]MasieroM , LucchiariC , MazzoccoK , VeronesiG , MaisonneuveP , JemosC , et al. E-cigarettes may support smokers with high smoking-related risk awareness to stop smoking in the short run: preliminary results by randomized controlled trial. Nicotine and Tobacco Research2019;21(1):119-26. [NCT02422914]NCT02422914. Benefits of tobacco free cigarette among heavy smokers undergoing a lung cancer screening program: a randomized controlled study. clinicaltrials.gov/show/NCT02422914 (accessed 17 February 2016). PravettoniG , MasieroM , LucchiariC , MaisenneuveP , MazzoccoK , VeronesiG . The role of electronic cigarettes in smoking cessation among heavy smokers undergoing a lung cancer screening program: preliminary results of a randomized controlled study. Psycho-Oncology2016;25:72. [DOI: 10.1002/pon.4082]">Lucchiari 2022</a> reported that some AEs were lower in the non‐nicotine EC arm, some higher, and others reported at similar rates to the behavioural support arm (overall AE rates were not reported) (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 1</a>). </p> <p><a href="./references#CD010216-bbs2-0087" title="NCT02521662. A randomised-controlled clinical trial to evaluate the effectiveness and safety of combining nicotine patches with e-cigarettes (with and without nicotine) plus behavioural support, on smoking abstinence. clinicaltrials.gov/show/NCT02521662 (accessed 17 February 2016). WalkerN , ParagV , VerbiestM , LakingG , LaugesenM , BullenC . Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial. Lancet. Respiratory Medicine2020;8(1):54-64. WalkerN , VerbiestM , KurdzielT , LakingG , LaugesenM , ParagV , et al. Effectiveness and safety of nicotine patches combined with e-cigarettes (with and without nicotine) for smoking cessation: study protocol for a randomised controlled trial. BMJ Open2019;9(2):e023659. ">Walker 2020</a> found fewer adverse events in participants receiving non‐nicotine EC + NRT compared to NRT alone, with the confidence interval excluding no difference (RR 0.70, 95% CI 0.53 to 0.91; <a href="./references#CD010216-fig-0091" title="">Analysis 12.2</a>). <a href="./references#CD010216-bbs2-0045" title="KCT0001277. Effect of an electronic cigarette for smoking reduction and cessation in Korean male smokers: a randomized, controlled study. KCT0001277 2014 (accessed 15 August 2016). LeeSH , AhnSH , CheongYS . Effect of electronic cigarettes on smoking reduction and cessation in Korean male smokers: a randomized controlled study. Journal of the American Board of Family Medicine2019;32(4):567-74. ">Lee 2019</a> also found that fewer participants receiving non‐nicotine EC reported adverse events than those receiving NRT, with the confidence interval excluding no difference (RR 0.33, 95% CI 0.12 to 0.87; 132 participants; <a href="./references#CD010216-fig-0094" title="">Analysis 13.2</a>). </p> </section> <section id="CD010216-sec-0097"> <h5 class="title">Serious adverse events</h5> <p>Two studies reported on rates of SAEs when comparing non‐nicotine EC with behavioural support. <a href="./references#CD010216-bbs2-0046" title="LucchiariC , MasieroM , MazzoccoK , VeronesiG , MaisonneauveP , JemosC , et al. Benefits of e-cigarettes in smoking reduction and in pulmonary health among chronic smokers undergoing a lung cancer screening program at 6 months. Addictive Behaviours2020;103:106222. LucchiariC , MasieroM , MazzoccoK , VeronesiG , MaisonneuveP , JemosC , et al. Nicotine-free e-cigarettes might promote tobacco smoking reduction better than nicotine delivery devices: results of a double-blind randomized controlled trial at 1 year. Current Oncology2022;29(11):8579-90. [DOI: 10.3390/curroncol29110676]LucchiariC , MasieroM , VeronesiG , MaisonneuveP , SpinaS , JemosC , et al. Benefits of e-cigarettes among heavy smokers undergoing a lung cancer screening program: randomized controlled trial protocol. JMIR Research Protocols2016;5(1):e21. [PMID: 26842790]MasieroM , LucchiariC , MazzoccoK , VeronesiG , Maisonneuve P JemosC , et al. Corrigendum: E-cigarettes may support smokers with high smoking-related risk awareness to stop smoking in the short run: preliminary results by randomized controlled trial. Nicotine and Tobacco Research2020;22(4):594-5. [NCT02422914]MasieroM , LucchiariC , MazzoccoK , VeronesiG , MaisonneuveP , JemosC , et al. E-cigarettes may support smokers with high smoking-related risk awareness to stop smoking in the short run: preliminary results by randomized controlled trial. Nicotine and Tobacco Research2019;21(1):119-26. [NCT02422914]NCT02422914. Benefits of tobacco free cigarette among heavy smokers undergoing a lung cancer screening program: a randomized controlled study. clinicaltrials.gov/show/NCT02422914 (accessed 17 February 2016). PravettoniG , MasieroM , LucchiariC , MaisenneuveP , MazzoccoK , VeronesiG . The role of electronic cigarettes in smoking cessation among heavy smokers undergoing a lung cancer screening program: preliminary results of a randomized controlled study. Psycho-Oncology2016;25:72. [DOI: 10.1002/pon.4082]">Lucchiari 2022</a> reported no SAEs in either arm (RR not estimable), whereas <a href="./references#CD010216-bbs2-0019" title="EisenbergMJ , Hébert-LosierM , WindleSB , GreenspoonT , BrandysT , FülöpT . Effect of e-cigarettes plus counseling vs counseling alone on smoking cessation: a randomized clinical trial. JAMA2020;324(18):1844-54. Hebert-LosierA , FilionKB , WindleSB , EisenbergMJ . A randomized controlled trial evaluating the efficacy of e-cigarette use for smoking cessation in the general population: E3 trial design. Canadian Journal of Cardiology Open2020;2(3):168-75. [NCT02417467]NCT02417467. Evaluating the efficacy of e-cigarette use for smoking cessation (E3) trial. clinicaltrials.gov/show/NCT02417467 (accessed 17 February 2016). PrellC , Hebert-LosierA , FilionKB , ReynierP , EisenbergMJ . Evaluating the impact of varying expired carbon monoxide thresholds on smoking relapse identification: insights from the E3 trial on e-cigarette efficacy for smoking cessation. BMJ Open2023;13(13):10. [DOI: 10.1136/bmjopen-2022-071099]">Eisenberg 2020</a> found a higher rate of SAEs in the non‐nicotine EC arm than in the behavioural support‐only arm. However, confidence intervals were wide and incorporated clinically significant benefit and clinically significant harm (n = 388; RR 1.19, 95% CI 0.33 to 4.33; <a href="./references#CD010216-fig-0089" title="">Analysis 11.3</a>). In <a href="./references#CD010216-bbs2-0087" title="NCT02521662. A randomised-controlled clinical trial to evaluate the effectiveness and safety of combining nicotine patches with e-cigarettes (with and without nicotine) plus behavioural support, on smoking abstinence. clinicaltrials.gov/show/NCT02521662 (accessed 17 February 2016). WalkerN , ParagV , VerbiestM , LakingG , LaugesenM , BullenC . Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial. Lancet. Respiratory Medicine2020;8(1):54-64. WalkerN , VerbiestM , KurdzielT , LakingG , LaugesenM , ParagV , et al. Effectiveness and safety of nicotine patches combined with e-cigarettes (with and without nicotine) for smoking cessation: study protocol for a randomised controlled trial. BMJ Open2019;9(2):e023659. ">Walker 2020</a>, more SAEs occurred in the group randomized to non‐nicotine EC + NRT than in the NRT‐alone group, but the confidence interval included no difference as well as the potential for a clinically significant difference in favour of the intervention (RR 1.69, 95% CI 0.60 to 4.74; <a href="./references#CD010216-fig-0092" title="">Analysis 12.3</a>). No SAEs were reported in either arm of <a href="./references#CD010216-bbs2-0045" title="KCT0001277. Effect of an electronic cigarette for smoking reduction and cessation in Korean male smokers: a randomized, controlled study. KCT0001277 2014 (accessed 15 August 2016). LeeSH , AhnSH , CheongYS . Effect of electronic cigarettes on smoking reduction and cessation in Korean male smokers: a randomized controlled study. Journal of the American Board of Family Medicine2019;32(4):567-74. ">Lee 2019</a> (non‐nicotine EC versus NRT) (<a href="./references#CD010216-fig-0095" title="">Analysis 13.3</a>). </p> </section> <section id="CD010216-sec-0098"> <h5 class="title">Carbon monoxide</h5> <p>One study investigating the comparison between non‐nicotine EC and NRT reported change in CO between baseline and six‐month follow‐up. The point estimate favoured NRT; however, the CI encompassed both benefit and harm of the intervention (RR 2.00, 95% CI ‐0.50 to 4.50; n = 164; <a href="./references#CD010216-fig-0096" title="">Analysis 13.4</a>). </p> </section> </section> <section id="CD010216-sec-0099"> <h4 class="title">Advice to use EC to quit</h4> <p>Three studies did not provide EC, but instead provided participants with advice on how to use EC to stop smoking; none reported tobacco/vaping industry funding. <a href="./references#CD010216-bbs2-0015" title='CzoliCD , FongGT , GoniewiczML , HammondD . Biomarkers of exposure among "dual users" of tobacco cigarettes and electronic cigarettes in Canada. Nicotine and Tobacco Research2019;21(9):1259-66. '>Czoli 2019</a> and <a href="./references#CD010216-bbs2-0083" title="NCT03575468. Enhanced e-cigarette coaching intervention for dual users of cigarettes and e-cigarettes. clinicaltrials.gov/ct2/show/NCT03575468 (first received 2 July 2018). VickermanKA , CarpenterKM , MilesLN , HsuJM , WattKA , BrandonTH , et al. A randomized pilot of a tailored smoking cessation quitline intervention for individuals who smoke and vape. Nicotine &amp; Tobacco Research2022;24(11):1811-20. [DOI: 10.1093/ntr/ntac129]VickermanKA , CarpenterKM , WattK , MilesL , HsuJ , BrandonT , et al. A behavioral smoking cessation intervention for Quitline callers who also use e-cigarettes. In: Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting; February 24-27 2021 (virtual). 2021:POD14-1 p50. ">Vickerman 2022</a> were short‐term studies and contributed data to <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">supplemental tables</a> only. However, <a href="./references#CD010216-bbs2-0047" title="ByrneM , SimmonsV , MartinezU , SuttonS , BrandonK , BrandonT . Cost effectiveness of a smoking cessation intervention for dual users of combustible and electronic cigarettes. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. March 2022. GoreLR , SuttonSK , MartinezU , BrandonKO , SimmonsVN , BrandonTH . Mediators of initial abstinence for an extended self help smoking cessation intervention with dual users of combustible and electronic cigarettes. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. Vol. PS3-7. March 2022. MartinezU , SimmonsVN , BrandonKO , QuinnGP , BrandonTH . Examining smoking and vaping behaviors, expectancies, and cessation outcomes between bisexual and heterosexual individuals. Behavioral Medicine 2023;49(4):392-401. [DOI: 10.1080/08964289.2022.2077295]MartinezU , SimmonsVN , SuttonSK , DrobesDJ , MeltzerLR , BrandonKO , et al. Targeted smoking cessation for dual users of combustible and electronic cigarettes: a randomised controlled trial. Lancet Public Health2021;6(7):e500-9. MeltzerLR , SimmonsVN , SuttonSK , DrobesDJ , QuinnGP , MeadeCD , et al. A randomized controlled trial of a smoking cessation self-help intervention for dual users of tobacco cigarettes and e-cigarettes: intervention development and research design. Contemporary Clinical Trials2017;60:56-62. NCT02416011. Smoking cessation self-help for dual users of tobacco cigarettes and e-cigarettes. clinicaltrials.gov/ct2/show/NCT02416011 (first received 18 August 2020). SuttonSK , BrandonKO , HarrellPT , Martínez Ú, SimmonsVN , Gore LR et al. Identifying prospective subpopulations of combustible and electronic cigarette dual users in the United States via finite mixture modeling. Addiction2022;117(9):2493-503. [DOI: 10.1111/add.15906]">Martinez 2021</a> (low risk of bias) and <a href="./references#CD010216-bbs2-0021" title="EllingJM , CrutzenR , TalhoutR , DeVriesH . Effects of providing tailored information about e-cigarettes in a web-based smoking cessation intervention: protocol for a randomised control trial. Journal of Medical Internet Research, Research Protocols2021;10(5):e27088. [DOI: 10.2196/27088]EllingJM , CrutzenR , TalhoutR , deVriesH . Effects of providing tailored information about e-cigarettes in a digital smoking cessation intervention: randomized controlled trial. Health Education Research2023;38(2):150-62. [DOI: 10.1093/her/cyad004]NL8330. Communication about e-cigarettes in a digital smoking cessation intervention [Effect of communication about e-cigarettes in a digital smoking cessation intervention on smoking reduction, smoking cessation, and informed decision making]. trialsearch.who.int/?TrialID=NL8330 (first received 24 January 2020). ">Elling 2023</a> (high risk of bias) provided sufficient data from long‐term follow‐up to include them in meta‐analysis. In both cases, people received self‐help smoking cessation interventions with information on how to use EC to quit smoking compared to a smoking cessation intervention without the recommendation to use EC. However, <a href="./references#CD010216-bbs2-0047" title="ByrneM , SimmonsV , MartinezU , SuttonS , BrandonK , BrandonT . Cost effectiveness of a smoking cessation intervention for dual users of combustible and electronic cigarettes. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. March 2022. GoreLR , SuttonSK , MartinezU , BrandonKO , SimmonsVN , BrandonTH . Mediators of initial abstinence for an extended self help smoking cessation intervention with dual users of combustible and electronic cigarettes. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. Vol. PS3-7. March 2022. MartinezU , SimmonsVN , BrandonKO , QuinnGP , BrandonTH . Examining smoking and vaping behaviors, expectancies, and cessation outcomes between bisexual and heterosexual individuals. Behavioral Medicine 2023;49(4):392-401. [DOI: 10.1080/08964289.2022.2077295]MartinezU , SimmonsVN , SuttonSK , DrobesDJ , MeltzerLR , BrandonKO , et al. Targeted smoking cessation for dual users of combustible and electronic cigarettes: a randomised controlled trial. Lancet Public Health2021;6(7):e500-9. MeltzerLR , SimmonsVN , SuttonSK , DrobesDJ , QuinnGP , MeadeCD , et al. A randomized controlled trial of a smoking cessation self-help intervention for dual users of tobacco cigarettes and e-cigarettes: intervention development and research design. Contemporary Clinical Trials2017;60:56-62. NCT02416011. Smoking cessation self-help for dual users of tobacco cigarettes and e-cigarettes. clinicaltrials.gov/ct2/show/NCT02416011 (first received 18 August 2020). SuttonSK , BrandonKO , HarrellPT , Martínez Ú, SimmonsVN , Gore LR et al. Identifying prospective subpopulations of combustible and electronic cigarette dual users in the United States via finite mixture modeling. Addiction2022;117(9):2493-503. [DOI: 10.1111/add.15906]">Martinez 2021</a> specifically recruited people using both combustible cigarettes and EC (dual users) at baseline and <a href="./references#CD010216-bbs2-0021" title="EllingJM , CrutzenR , TalhoutR , DeVriesH . Effects of providing tailored information about e-cigarettes in a web-based smoking cessation intervention: protocol for a randomised control trial. Journal of Medical Internet Research, Research Protocols2021;10(5):e27088. [DOI: 10.2196/27088]EllingJM , CrutzenR , TalhoutR , deVriesH . Effects of providing tailored information about e-cigarettes in a digital smoking cessation intervention: randomized controlled trial. Health Education Research2023;38(2):150-62. [DOI: 10.1093/her/cyad004]NL8330. Communication about e-cigarettes in a digital smoking cessation intervention [Effect of communication about e-cigarettes in a digital smoking cessation intervention on smoking reduction, smoking cessation, and informed decision making]. trialsearch.who.int/?TrialID=NL8330 (first received 24 January 2020). ">Elling 2023</a> only required participants to be combustible cigarette users at baseline. Pooled quit rates provided no clear evidence of a difference between the two types of intervention provided (RR 1.02, 95% CI 0.88 to 1.19; 2652 participants; <a href="./references#CD010216-fig-0097" title="">Analysis 14.1</a>). In <a href="./references#CD010216-bbs2-0083" title="NCT03575468. Enhanced e-cigarette coaching intervention for dual users of cigarettes and e-cigarettes. clinicaltrials.gov/ct2/show/NCT03575468 (first received 2 July 2018). VickermanKA , CarpenterKM , MilesLN , HsuJM , WattKA , BrandonTH , et al. A randomized pilot of a tailored smoking cessation quitline intervention for individuals who smoke and vape. Nicotine &amp; Tobacco Research2022;24(11):1811-20. [DOI: 10.1093/ntr/ntac129]VickermanKA , CarpenterKM , WattK , MilesL , HsuJ , BrandonT , et al. A behavioral smoking cessation intervention for Quitline callers who also use e-cigarettes. In: Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting; February 24-27 2021 (virtual). 2021:POD14-1 p50. ">Vickerman 2022</a> more AEs occurred in the group receiving advice to use EC to quit; however, confidence intervals included no difference (RR 1.27, 95% CI 0.72 to 2.26; 52 participants; <a href="./references#CD010216-fig-0098" title="">Analysis 14.2</a>). No SAEs were reported, so RRs were not estimable (<a href="./references#CD010216-fig-0099" title="">Analysis 14.3</a>). <a href="./references#CD010216-bbs2-0021" title="EllingJM , CrutzenR , TalhoutR , DeVriesH . Effects of providing tailored information about e-cigarettes in a web-based smoking cessation intervention: protocol for a randomised control trial. Journal of Medical Internet Research, Research Protocols2021;10(5):e27088. [DOI: 10.2196/27088]EllingJM , CrutzenR , TalhoutR , deVriesH . Effects of providing tailored information about e-cigarettes in a digital smoking cessation intervention: randomized controlled trial. Health Education Research2023;38(2):150-62. [DOI: 10.1093/her/cyad004]NL8330. Communication about e-cigarettes in a digital smoking cessation intervention [Effect of communication about e-cigarettes in a digital smoking cessation intervention on smoking reduction, smoking cessation, and informed decision making]. trialsearch.who.int/?TrialID=NL8330 (first received 24 January 2020). ">Elling 2023</a> and <a href="./references#CD010216-bbs2-0047" title="ByrneM , SimmonsV , MartinezU , SuttonS , BrandonK , BrandonT . Cost effectiveness of a smoking cessation intervention for dual users of combustible and electronic cigarettes. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. March 2022. GoreLR , SuttonSK , MartinezU , BrandonKO , SimmonsVN , BrandonTH . Mediators of initial abstinence for an extended self help smoking cessation intervention with dual users of combustible and electronic cigarettes. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. Vol. PS3-7. March 2022. MartinezU , SimmonsVN , BrandonKO , QuinnGP , BrandonTH . Examining smoking and vaping behaviors, expectancies, and cessation outcomes between bisexual and heterosexual individuals. Behavioral Medicine 2023;49(4):392-401. [DOI: 10.1080/08964289.2022.2077295]MartinezU , SimmonsVN , SuttonSK , DrobesDJ , MeltzerLR , BrandonKO , et al. Targeted smoking cessation for dual users of combustible and electronic cigarettes: a randomised controlled trial. Lancet Public Health2021;6(7):e500-9. MeltzerLR , SimmonsVN , SuttonSK , DrobesDJ , QuinnGP , MeadeCD , et al. A randomized controlled trial of a smoking cessation self-help intervention for dual users of tobacco cigarettes and e-cigarettes: intervention development and research design. Contemporary Clinical Trials2017;60:56-62. NCT02416011. Smoking cessation self-help for dual users of tobacco cigarettes and e-cigarettes. clinicaltrials.gov/ct2/show/NCT02416011 (first received 18 August 2020). SuttonSK , BrandonKO , HarrellPT , Martínez Ú, SimmonsVN , Gore LR et al. Identifying prospective subpopulations of combustible and electronic cigarette dual users in the United States via finite mixture modeling. Addiction2022;117(9):2493-503. [DOI: 10.1111/add.15906]">Martinez 2021</a> also reported on EC use at six‐month follow‐up. Data from <a href="./references#CD010216-bbs2-0021" title="EllingJM , CrutzenR , TalhoutR , DeVriesH . Effects of providing tailored information about e-cigarettes in a web-based smoking cessation intervention: protocol for a randomised control trial. Journal of Medical Internet Research, Research Protocols2021;10(5):e27088. [DOI: 10.2196/27088]EllingJM , CrutzenR , TalhoutR , deVriesH . Effects of providing tailored information about e-cigarettes in a digital smoking cessation intervention: randomized controlled trial. Health Education Research2023;38(2):150-62. [DOI: 10.1093/her/cyad004]NL8330. Communication about e-cigarettes in a digital smoking cessation intervention [Effect of communication about e-cigarettes in a digital smoking cessation intervention on smoking reduction, smoking cessation, and informed decision making]. trialsearch.who.int/?TrialID=NL8330 (first received 24 January 2020). ">Elling 2023</a> suggested higher rates of long‐term EC use in the EC advice arm; however, the 95% CI also encompassed the possibility of lower long‐term EC use in the intervention arm (RR 1.77, 95% CI 0.83 to 3.79; <a href="./references#CD010216-fig-0100" title="">Analysis 14.4</a>). <a href="./references#CD010216-bbs2-0047" title="ByrneM , SimmonsV , MartinezU , SuttonS , BrandonK , BrandonT . Cost effectiveness of a smoking cessation intervention for dual users of combustible and electronic cigarettes. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. March 2022. GoreLR , SuttonSK , MartinezU , BrandonKO , SimmonsVN , BrandonTH . Mediators of initial abstinence for an extended self help smoking cessation intervention with dual users of combustible and electronic cigarettes. In: Society for Research on Nicotine and Tobacco, Annual Meeting, Baltimore USA. Vol. PS3-7. March 2022. MartinezU , SimmonsVN , BrandonKO , QuinnGP , BrandonTH . Examining smoking and vaping behaviors, expectancies, and cessation outcomes between bisexual and heterosexual individuals. Behavioral Medicine 2023;49(4):392-401. [DOI: 10.1080/08964289.2022.2077295]MartinezU , SimmonsVN , SuttonSK , DrobesDJ , MeltzerLR , BrandonKO , et al. Targeted smoking cessation for dual users of combustible and electronic cigarettes: a randomised controlled trial. Lancet Public Health2021;6(7):e500-9. MeltzerLR , SimmonsVN , SuttonSK , DrobesDJ , QuinnGP , MeadeCD , et al. A randomized controlled trial of a smoking cessation self-help intervention for dual users of tobacco cigarettes and e-cigarettes: intervention development and research design. Contemporary Clinical Trials2017;60:56-62. NCT02416011. Smoking cessation self-help for dual users of tobacco cigarettes and e-cigarettes. clinicaltrials.gov/ct2/show/NCT02416011 (first received 18 August 2020). SuttonSK , BrandonKO , HarrellPT , Martínez Ú, SimmonsVN , Gore LR et al. Identifying prospective subpopulations of combustible and electronic cigarette dual users in the United States via finite mixture modeling. Addiction2022;117(9):2493-503. [DOI: 10.1111/add.15906]">Martinez 2021</a> reported that 64% in the targeted booklet arm, and 66% in the generic booklet arm were still using EC. The latter data could not be incorporated into a meta‐analysis due to uncertainty about the denominator used to calculate percentages. </p> </section> <section id="CD010216-sec-0100"> <h4 class="title">Combination therapy</h4> <section id="CD010216-sec-0101"> <h5 class="title">Nicotine EC and NRT</h5> <p>This section covers two comparisons: studies in which all arms received NRT and participants were randomized to nicotine EC or non‐nicotine EC, and studies in which all participants received NRT and one arm was randomized to nicotine EC, in addition. All studies contributing data were randomized controlled trials. No studies in this group reported data on heart rate, blood pressure, oxygen, or toxicants. </p> <section id="CD010216-sec-0102"> <h6 class="title">Cessation</h6> <p>Two trials (both at high risk of bias, both testing refillable devices, neither reporting tobacco/vaping industry funding) in which all participants received NRT compared nicotine EC to non‐nicotine EC. The pooled results favoured nicotine EC, with the CI excluding no difference (RR 1.77, 95% CI 1.07 to 2.94; I<sup>2</sup> = 0%; 1039 participants; <a href="./references#CD010216-fig-0101" title="">Analysis 15.1</a>). </p> <p>Three studies (two high risk of bias, one unclear risk; two refillable, one cartridge; none reporting tobacco/vaping industry funding) also compared nicotine EC + NRT to NRT alone. Pooling results from all three studies resulted in high statistical heterogeneity, precluding meta‐analysis (I<sup>2</sup> = 83%). This heterogeneity was driven by the study of a cartridge device (RR 1.00, 95% CI 0.64 to 1.55, 1712 participants) (<a href="./references#CD010216-bbs2-0051" title="ACTRN12612001210864. Can using nicotine as a long-term substitute enhance smoking cessation over using it only as a cessation aid? [An open-label randomised pragmatic policy trial examining effectiveness of short-term use of Nicotine Replacement Therapy (NRT) vs short- or long-term use of NRT vs short- or long-term use of NRT or electronic nicotine delivery systems for smoking cessation in cigarette smokers.]. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12612001210864 (first received 15 November 2012). FraserD , BorlandR , GartnerC . Protocol for a randomised pragmatic policy trial of nicotine products for quitting or long-term substitution in smokers. BMC Public Health2015;15:1026. MorphettK , FraserD , BorlandR , HallW , WalkerN , BullenC , et al. A pragmatic randomized comparative trial of e-cigarettes and other nicotine products for quitting or long-term substitution in smokers. Nicotine &amp; Tobacco Research2022;24(7):1079-88. [DOI: 10.1093/ntr/ntab266]">Morphett 2022a</a>); historically, cartridge devices have had poorer nicotine delivery than refillables. Once this study was removed, heterogeneity disappeared (I<sup>2</sup> = 0%), but only two studies remained. In these two studies, pooled results showed more people quit in the refillable nicotine EC + NRT arm than in the NRT alone arm (RR 3.53, 95% CI 1.93 to 6.44; 980 participants; <a href="./references#CD010216-fig-0109" title="">Analysis 16.1</a>). In two of these studies, participants in both groups received nicotine patches but, in <a href="./references#CD010216-bbs2-0052" title="ACTRN12618000408280. Cessation And Relapse Prevention (CARP) trial: nicotine vaporisers compared to standard nicotine replacement therapy for smoking cessation among people with co-morbidities. www.anzctr.org.au/ACTRN12618000408280.aspx (first received 21 March 2018). MorphettK , BoydM , PuljevicC , GilksC , BonevskiB , BorlandR , et al. Do nicotine vaping products increase quitting among priority population groups over standard smoking cessation therapy? A pragmatic randomised partial cross-over trial. In: Society for Research on Nicotine and Tobacco (SRNT), Annual Meeting 2022. Vol. SYM17-4. 2022. ">Morphett 2022b</a>, participants in the NRT‐only arm also received a short‐acting form of NRT. </p> </section> <section id="CD010216-sec-0103"> <h6 class="title">Adverse events</h6> <p>Three trials in which nicotine ECs were compared to non‐nicotine ECs (both with NRT as an adjunct) reported data on AEs. <a href="./references#CD010216-bbs2-0003" title="BaldassarriSR , BernsteinSL , ChuppGL , SladeMD , FucitoLM , TollBA . Electronic cigarettes for adults with tobacco dependence enrolled in a tobacco treatment program: a pilot study. Addictive Behaviors2018;80:1-5. BaldassarriSR , BernsteinSL , ChuppGL , Toll BA. Electronic cigarettes for adults with tobacco dependence undergoing a tobacco treatment program: a pilot prospective study. American Journal of Respiratory and Critical Care Medicine, Meeting Abstracts2016;193:A6511. NCT02498145. Short term effects of electronic cigarettes in tobacco dependent adults. clinicaltrials.gov/show/NCT02498145 (accessed 17 February 2016). ">Baldassarri 2018</a> reported results combined across groups but noted "no significant differences by treatment group" (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 1</a>). Pooled data from the other two studies (one reporting tobacco/vaping industry funding; <a href="./references#CD010216-bbs2-0072" title="NCT03492463. The role of nicotine dose and route of delivery in affecting adoption of e-cigarettes and reducing exposure to toxic combustion products (ENDS-Switch). clinicaltrials.gov/ct2/show/study/NCT03492463 (first received 10 April 2018). RoseJE , FrisbeeS , CampbellD , SalleyA , ClaerhoutS , DavisJM . Smoking reduction using electronic nicotine delivery systems in combination with nicotine skin patches. Psychopharmacology2023;240:1901-9. [DOI: 10.1007/s00213-023-06401-y]">Rose 2023*</a>) also showed no clear evidence of difference (RR 1.11, 95% CI 0.93 to 1.32, I<sup>2</sup> = 0%; 677 participants; <a href="./references#CD010216-fig-0102" title="">Analysis 15.2</a>). As expected due to the low statistical heterogeneity, the two contributing study results had similar interpretations and so removing <a href="./references#CD010216-bbs2-0072" title="NCT03492463. The role of nicotine dose and route of delivery in affecting adoption of e-cigarettes and reducing exposure to toxic combustion products (ENDS-Switch). clinicaltrials.gov/ct2/show/study/NCT03492463 (first received 10 April 2018). RoseJE , FrisbeeS , CampbellD , SalleyA , ClaerhoutS , DavisJM . Smoking reduction using electronic nicotine delivery systems in combination with nicotine skin patches. Psychopharmacology2023;240:1901-9. [DOI: 10.1007/s00213-023-06401-y]">Rose 2023*</a> due to industry funding had no impact. </p> <p>The three trials comparing nicotine EC + NRT to NRT alone that contributed data to this outcome were all at high risk of bias; none reported tobacco/vaping industry funding. Pooled results showed no evidence of a difference in AEs between arms, but with moderate statistical heterogeneity (RR 0.96, 95% CI 0.83 to 1.11; I<sup>2</sup> = 64%; 1984 participants; <a href="./references#CD010216-fig-0110" title="">Analysis 16.2</a>). A further trial currently has only very limited information available from a conference abstract and trial registry (<a href="./references#CD010216-bbs2-0057" title="NCT04084210. Impact of alternative nicotine-delivery products on combustible cigarette use [Understanding the real-world impact of the use of three alternate nicotine-delivery products on combustible cigarette use]. clinicaltrials.gov/ct2/show/NCT04084210 (first received 10 September 2019). PiperM , SchlamT , DonnyE , JorenbyD . The real-world impact of three alternative nicotine delivery products on combustible cigarette use. In: Society for Research on Nicotine and Tobacco (SRNT) 29th Annual Meeting 1-4 March 2023. Vol. SYM17-2. 2023:22. ">NCT04084210</a>). This study appears to have trial arms that will allow comparison between nicotine EC + NRT and NRT alone. Data on AEs are reported in the trial registry; however, the way this is currently reported makes it hard to incorporate the data into our meta‐analysis; therefore, data available thus far are reported in <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 1</a>. </p> </section> <section id="CD010216-sec-0104"> <h6 class="title">Serious adverse events</h6> <p>Pooled data from two studies (one high risk, one unclear; one reporting tobacco/vaping industry funding) comparing nicotine EC with non‐nicotine EC as adjuncts to NRT showed fewer SAEs in the nicotine EC group than in the non‐nicotine EC group, but the CI included no difference (RR 0.66, 95% CI 0.38 to 1.14; I<sup>2</sup> = 0%; 1069 participants; <a href="./references#CD010216-fig-0103" title="">Analysis 15.3</a>). Removing the study with industry funding (<a href="./references#CD010216-bbs2-0072" title="NCT03492463. The role of nicotine dose and route of delivery in affecting adoption of e-cigarettes and reducing exposure to toxic combustion products (ENDS-Switch). clinicaltrials.gov/ct2/show/study/NCT03492463 (first received 10 April 2018). RoseJE , FrisbeeS , CampbellD , SalleyA , ClaerhoutS , DavisJM . Smoking reduction using electronic nicotine delivery systems in combination with nicotine skin patches. Psychopharmacology2023;240:1901-9. [DOI: 10.1007/s00213-023-06401-y]">Rose 2023*</a>) had no effect on interpretation. </p> <p>Four studies (all high risk of bias; none reporting tobacco/vaping industry funding) provided data on SAEs and compared nicotine EC + NRT to NRT alone. The pooled estimate favoured the NRT‐alone group, but the CI was wide and included no difference (RR 1.26, 95% CI 0.46 to 3.42: I<sup>2</sup> = 0; 2245 participants; <a href="./references#CD010216-fig-0111" title="">Analysis 16.3</a>). </p> <p>As noted above, there is currently very limited data available for <a href="./references#CD010216-bbs2-0057" title="NCT04084210. Impact of alternative nicotine-delivery products on combustible cigarette use [Understanding the real-world impact of the use of three alternate nicotine-delivery products on combustible cigarette use]. clinicaltrials.gov/ct2/show/NCT04084210 (first received 10 September 2019). PiperM , SchlamT , DonnyE , JorenbyD . The real-world impact of three alternative nicotine delivery products on combustible cigarette use. In: Society for Research on Nicotine and Tobacco (SRNT) 29th Annual Meeting 1-4 March 2023. Vol. SYM17-2. 2023:22. ">NCT04084210</a>. SAE data available thus far are reported in <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 2</a>. </p> </section> <section id="CD010216-sec-0105"> <h6 class="title">Carbon monoxide</h6> <p><a href="./references#CD010216-bbs2-0087" title="NCT02521662. A randomised-controlled clinical trial to evaluate the effectiveness and safety of combining nicotine patches with e-cigarettes (with and without nicotine) plus behavioural support, on smoking abstinence. clinicaltrials.gov/show/NCT02521662 (accessed 17 February 2016). WalkerN , ParagV , VerbiestM , LakingG , LaugesenM , BullenC . Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial. Lancet. Respiratory Medicine2020;8(1):54-64. WalkerN , VerbiestM , KurdzielT , LakingG , LaugesenM , ParagV , et al. Effectiveness and safety of nicotine patches combined with e-cigarettes (with and without nicotine) for smoking cessation: study protocol for a randomised controlled trial. BMJ Open2019;9(2):e023659. ">Walker 2020</a> (which compared nicotine EC + NRT, non‐nicotine EC + NRT, and NRT alone) measured change in CO levels but did not report data in a way that could be pooled. CO declined over time, with the greatest reduction seen in the nicotine EC group (see <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 3</a>). Pooled data from two studies (one high risk of bias, one unclear; one reporting tobacco/vaping industry funding) comparing nicotine and non‐nicotine EC as adjuncts to NRT found a greater reduction in CO in the nicotine EC group, but the CI included no clear evidence of a clinically significant difference (MD ‐2.58 ppm, 95% CI ‐5.21 to 0.05, I<sup>2</sup> = 77%; 70 participants; <a href="./references#CD010216-fig-0104" title="">Analysis 15.4</a>) between groups and there was substantial statistical heterogeneity. We have pooled these studies despite the high I<sup>2</sup> as the individual study effects both showed a benefit of nicotine EC with the difference being in the magnitude of effect. Removing the study at high risk of bias (<a href="./references#CD010216-bbs2-0003" title="BaldassarriSR , BernsteinSL , ChuppGL , SladeMD , FucitoLM , TollBA . Electronic cigarettes for adults with tobacco dependence enrolled in a tobacco treatment program: a pilot study. Addictive Behaviors2018;80:1-5. BaldassarriSR , BernsteinSL , ChuppGL , Toll BA. Electronic cigarettes for adults with tobacco dependence undergoing a tobacco treatment program: a pilot prospective study. American Journal of Respiratory and Critical Care Medicine, Meeting Abstracts2016;193:A6511. NCT02498145. Short term effects of electronic cigarettes in tobacco dependent adults. clinicaltrials.gov/show/NCT02498145 (accessed 17 February 2016). ">Baldassarri 2018</a>) left only <a href="./references#CD010216-bbs2-0072" title="NCT03492463. The role of nicotine dose and route of delivery in affecting adoption of e-cigarettes and reducing exposure to toxic combustion products (ENDS-Switch). clinicaltrials.gov/ct2/show/study/NCT03492463 (first received 10 April 2018). RoseJE , FrisbeeS , CampbellD , SalleyA , ClaerhoutS , DavisJM . Smoking reduction using electronic nicotine delivery systems in combination with nicotine skin patches. Psychopharmacology2023;240:1901-9. [DOI: 10.1007/s00213-023-06401-y]">Rose 2023*</a>, with the following effect estimate: RR ‐9.10, 95% CI ‐15.83 to ‐2.37; whereas removing the study with industry funding (<a href="./references#CD010216-bbs2-0072" title="NCT03492463. The role of nicotine dose and route of delivery in affecting adoption of e-cigarettes and reducing exposure to toxic combustion products (ENDS-Switch). clinicaltrials.gov/ct2/show/study/NCT03492463 (first received 10 April 2018). RoseJE , FrisbeeS , CampbellD , SalleyA , ClaerhoutS , DavisJM . Smoking reduction using electronic nicotine delivery systems in combination with nicotine skin patches. Psychopharmacology2023;240:1901-9. [DOI: 10.1007/s00213-023-06401-y]">Rose 2023*</a>) left only <a href="./references#CD010216-bbs2-0003" title="BaldassarriSR , BernsteinSL , ChuppGL , SladeMD , FucitoLM , TollBA . Electronic cigarettes for adults with tobacco dependence enrolled in a tobacco treatment program: a pilot study. Addictive Behaviors2018;80:1-5. BaldassarriSR , BernsteinSL , ChuppGL , Toll BA. Electronic cigarettes for adults with tobacco dependence undergoing a tobacco treatment program: a pilot prospective study. American Journal of Respiratory and Critical Care Medicine, Meeting Abstracts2016;193:A6511. NCT02498145. Short term effects of electronic cigarettes in tobacco dependent adults. clinicaltrials.gov/show/NCT02498145 (accessed 17 February 2016). ">Baldassarri 2018</a>, with the following effect estimate (RR ‐1.40, 95% CI ‐4.26 to 1.46). </p> </section> <section id="CD010216-sec-0106"> <h6 class="title">Lung function</h6> <p><a href="./references#CD010216-bbs2-0003" title="BaldassarriSR , BernsteinSL , ChuppGL , SladeMD , FucitoLM , TollBA . Electronic cigarettes for adults with tobacco dependence enrolled in a tobacco treatment program: a pilot study. Addictive Behaviors2018;80:1-5. BaldassarriSR , BernsteinSL , ChuppGL , Toll BA. Electronic cigarettes for adults with tobacco dependence undergoing a tobacco treatment program: a pilot prospective study. American Journal of Respiratory and Critical Care Medicine, Meeting Abstracts2016;193:A6511. NCT02498145. Short term effects of electronic cigarettes in tobacco dependent adults. clinicaltrials.gov/show/NCT02498145 (accessed 17 February 2016). ">Baldassarri 2018</a>, which compared nicotine EC to non‐nicotine EC, in which both groups received NRT, found no between‐group differences in FeNO, FEV1, or FVC (<a href="./references#CD010216-fig-0105" title="">Analysis 15.5</a>; <a href="./references#CD010216-fig-0106" title="">Analysis 15.6</a>; <a href="./references#CD010216-fig-0107" title="">Analysis 15.7</a>); confidence intervals were wide for all outcomes. </p> </section> <section id="CD010216-sec-0107"> <h6 class="title">Study product use</h6> <p>In <a href="./references#CD010216-bbs2-0087" title="NCT02521662. A randomised-controlled clinical trial to evaluate the effectiveness and safety of combining nicotine patches with e-cigarettes (with and without nicotine) plus behavioural support, on smoking abstinence. clinicaltrials.gov/show/NCT02521662 (accessed 17 February 2016). WalkerN , ParagV , VerbiestM , LakingG , LaugesenM , BullenC . Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial. Lancet. Respiratory Medicine2020;8(1):54-64. WalkerN , VerbiestM , KurdzielT , LakingG , LaugesenM , ParagV , et al. Effectiveness and safety of nicotine patches combined with e-cigarettes (with and without nicotine) for smoking cessation: study protocol for a randomised controlled trial. BMJ Open2019;9(2):e023659. ">Walker 2020</a>, at six months, 40% of the patches‐only arm (n = 52) were still using patches and, in the patches + nicotine EC group (n = 317), 22% were using patches only, 45% were using EC only, and 11% were using both patch and EC. In the patches + non‐nicotine EC group (n = 308), 29% were still using patches, 36% were using EC only, and 13% were using both patches and EC. In <a href="./references#CD010216-bbs2-0003" title="BaldassarriSR , BernsteinSL , ChuppGL , SladeMD , FucitoLM , TollBA . Electronic cigarettes for adults with tobacco dependence enrolled in a tobacco treatment program: a pilot study. Addictive Behaviors2018;80:1-5. BaldassarriSR , BernsteinSL , ChuppGL , Toll BA. Electronic cigarettes for adults with tobacco dependence undergoing a tobacco treatment program: a pilot prospective study. American Journal of Respiratory and Critical Care Medicine, Meeting Abstracts2016;193:A6511. NCT02498145. Short term effects of electronic cigarettes in tobacco dependent adults. clinicaltrials.gov/show/NCT02498145 (accessed 17 February 2016). ">Baldassarri 2018</a>, there was no difference between arms in product use, but only nine participants contributed data (RR 1.25, 95% CI 0.29 to 5.53; <a href="./references#CD010216-fig-0108" title="">Analysis 15.8</a>). </p> </section> </section> <section id="CD010216-sec-0108"> <h5 class="title">Nicotine EC and varenicline</h5> <p>One study, <a href="./references#CD010216-bbs2-0079" title="ISRCTN16931827. A trial to assess the benefit of offering an e-cigarette starter kit to smokers attempting to stop smoking with varenicline. isrctn.com/ISRCTN16931827 (first received 23 August 2018). Tattan-BirchH , KockL , BrownJ , BeardE , BauldL , WestR , et al. E-cigarettes to augment stop smoking in-person support and treatment with varenicline (E-ASSIST): a pragmatic randomised controlled trial. Nicotine &amp; Tobacco Research2023;25(3):395-403. [DOI: 10.1093/ntr/ntac149]">Tattan‐Birch 2023</a> (high risk of bias, 92 participants), evaluated nicotine EC and varenicline compared to varenicline alone. The study terminated early due to varenicline supply issues (an international recall), and the only data eligible for inclusion in this review related to AEs and SAEs. There was no evidence of a difference in AEs, though CIs were wide (RR 1.18, 95% CI 0.84 to 1.67; 92 participants; <a href="./references#CD010216-fig-0112" title="">Analysis 17.1</a>), and no SAEs occurred (<a href="./references#CD010216-fig-0113" title="">Analysis 17.2</a>). </p> </section> </section> <section id="CD010216-sec-0109"> <h4 class="title">Results from network meta‐analyses</h4> <p>We used fixed‐effect models for all three outcomes. For the cessation and SAE outcomes there was no indication of heterogeneity or inconsistency. The models fit well. The difference between the mean residual deviance and the number of data points was, at most, 2.2 (see <a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 9</a> for comparisons across models). Node‐splitting models raised no concerns over local inconsistency, resulting in P values greater than 0.05. </p> <p>For the AE outcome, there was inconsistency in the treatment effect comparing no e‐cigarettes or pharmacotherapy to non‐nicotine e‐cigarettes, as indicated by a node‐splitting model. Only one trial, <a href="./references#CD010216-bbs2-0019" title="EisenbergMJ , Hébert-LosierM , WindleSB , GreenspoonT , BrandysT , FülöpT . Effect of e-cigarettes plus counseling vs counseling alone on smoking cessation: a randomized clinical trial. JAMA2020;324(18):1844-54. Hebert-LosierA , FilionKB , WindleSB , EisenbergMJ . A randomized controlled trial evaluating the efficacy of e-cigarette use for smoking cessation in the general population: E3 trial design. Canadian Journal of Cardiology Open2020;2(3):168-75. [NCT02417467]NCT02417467. Evaluating the efficacy of e-cigarette use for smoking cessation (E3) trial. clinicaltrials.gov/show/NCT02417467 (accessed 17 February 2016). PrellC , Hebert-LosierA , FilionKB , ReynierP , EisenbergMJ . Evaluating the impact of varying expired carbon monoxide thresholds on smoking relapse identification: insights from the E3 trial on e-cigarette efficacy for smoking cessation. BMJ Open2023;13(13):10. [DOI: 10.1136/bmjopen-2022-071099]">Eisenberg 2020</a>, contributed direct evidence to this comparison. In this trial, the percentage of patients experiencing at least one AE was large, at 87%. This was the highest percentage in a very wide range (9% to 87%, mean 44%, standard deviation 24%). Percentages that are close to 100 can result in large effect sizes even when the absolute differences between the treatment groups are comparatively small. We believe that the inconsistency was caused by there being only one trial providing direct evidence, which had a high level of AEs, especially in the non‐nicotine e‐cigarette arm at 93%. </p> <p>Overall, results from NMAs were consistent with those from pairwise analyses. They are summarized below, and further details on all can be found in the relevant figures and supplemental files. </p> <p>The comparator for all odds ratios was the reference treatment: no e‐cigarettes or pharmacotherapy. </p> <section id="CD010216-sec-0110"> <h5 class="title">Cessation</h5> <p>See <a href="#CD010216-fig-0005">Figure 5</a> for the network map of the cessation outcome. </p> <div class="figure" id="CD010216-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Network map for cessation" data-id="CD010216-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Network map for cessation</p> </div> </div> </div> <p>Point estimates were highest for nicotine EC combined with NRT and non‐nicotine EC combined with NRT, though 95% credibility intervals (CrI) were wide for both nodes and overlapped with those of nicotine EC. Overall, data were consistent with those from pairwise meta‐analyses, showing higher quit rates with nicotine EC than with non‐nicotine EC or NRT. Risk ratios (RRs) and corresponding credibility intervals (CrI) for each node are as follows (and illustrated in <a href="#CD010216-fig-0006">Figure 6</a>): </p> <div class="figure" id="CD010216-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Cessation network meta‐analysis" data-id="CD010216-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Cessation network meta‐analysis</p> </div> </div> </div> <p> <ul id="CD010216-list-0009"> <li> <p>Nicotine EC: RR 1.95, 95% CrI 1.66 to 2.31</p> </li> <li> <p>Nicotine EC plus single‐form NRT: RR 4.18, 95% CrI 2.20 to 8.55</p> </li> <li> <p>Non‐nicotine EC: RR 1.34, 95% CrI 0.99 to 1.80</p> </li> <li> <p>Non‐nicotine EC plus single‐form NRT: RR 2.35, 95% CrI 1.06 to 5.37</p> </li> <li> <p>Combined NRT: RR 1.07, 95% CrI 0.73 to 1.54</p> </li> <li> <p>Single‐form NRT: RR 1.37, 95% CrI 1.04 to 1.80</p> </li> <li> <p>Advice on using EC: RR 1.02, 95% CrI 0.88 to 1.19</p> </li> </ul> </p> <p>When removing studies at high risk of bias, there were insufficient data to generate a point estimate for non‐nicotine EC combined with NRT. The risk ratio of single‐form NRT against no e‐cigarettes or pharmacotherapy changed from 1.37 to 2.25, and became significant, where it had been borderline‐significant in the main analysis. All other interpretations remained unchanged (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 10</a>). Results were not sensitive to the exclusion of studies with tobacco or vaping industry funding (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 10</a>). </p> </section> <section id="CD010216-sec-0111"> <h5 class="title">Adverse events</h5> <p>See <a href="#CD010216-fig-0007">Figure 7</a> for the network map of the AE outcome. </p> <div class="figure" id="CD010216-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Network map for adverse events" data-id="CD010216-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Network map for adverse events</p> </div> </div> </div> <p>As can be seen in <a href="#CD010216-fig-0008">Figure 8</a>, CrIs overlapped for all nodes. All interventions tested showed an increase in AEs (non‐serious) compared to control (no e‐cigarette or pharmaceutical intervention), with CrIs excluding no difference for nicotine ECs, non‐nicotine ECs, and single‐form NRTs. The RRs and corresponding CrI for each node are as follows (and illustrated in <a href="#CD010216-fig-0008">Figure 8</a>): </p> <div class="figure" id="CD010216-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Adverse events network meta‐analysis" data-id="CD010216-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Adverse events network meta‐analysis</p> </div> </div> </div> <p> <ul id="CD010216-list-0010"> <li> <p>Nicotine EC: RR 1.19, 95% CrI 1.12 to 1.27</p> </li> <li> <p>Nicotine EC plus single‐form NRT: RR 1.17, 95% CrI 0.92 to 1.48</p> </li> <li> <p>Non‐nicotine EC: RR 1.20, 95% CrI 1.11 to 1.30</p> </li> <li> <p>Non‐nicotine EC plus single‐form NRT: RR 1.02, 95% CrI 0.77 to 1.35</p> </li> <li> <p>Combined NRT: RR 1.07, 95% CrI 0.87 to 1.31</p> </li> <li> <p>Single‐form NRT: RR 1.24, 95% CrI 1.03 to 1.50</p> </li> </ul> </p> <p>Sensitivity analyses removing studies at high risk of bias and removing studies with tobacco or vaping industry funding did not affect interpretation of the results (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 10</a>). </p> </section> <section id="CD010216-sec-0112"> <h5 class="title">Serious adverse events</h5> <p>See <a href="#CD010216-fig-0009">Figure 9</a> for the network map of the SAE outcome. </p> <div class="figure" id="CD010216-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Network map for serious adverse events" data-id="CD010216-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Network map for serious adverse events</p> </div> </div> </div> <p>As illustrated in <a href="#CD010216-fig-0010">Figure 10</a>, CrIs were wide, overlapped, and included the possibility of no difference for all nodes, though point estimates were lowest for NRT. Only the point estimate for non‐nicotine EC combined with NRT was consistent with an increase in SAEs compared to the control condition, but here CrI were very wide and also encompassed a clinically significant reduction in SAEs in those receiving the intervention. The RRs and corresponding CrI for each node are as follows (and illustrated in <a href="#CD010216-fig-0010">Figure 10</a>): </p> <div class="figure" id="CD010216-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Serious adverse events network meta‐analysis" data-id="CD010216-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Serious adverse events network meta‐analysis</p> </div> </div> </div> <p> <ul id="CD010216-list-0011"> <li> <p>Nicotine EC: RR 0.98, 95% CrI 0.72 to 1.35</p> </li> <li> <p>Nicotine EC plus single‐form NRT: RR 1.01, 95% CrI 0.30 to 4.12</p> </li> <li> <p>Non‐nicotine EC: RR 1.01, 95% CrI 0.53 to 1.86</p> </li> <li> <p>Non‐nicotine EC plus single‐form NRT: RR 1.43, 95% CrI 0.43 to 5.78</p> </li> <li> <p>Combined NRT: RR 0.64, 95% CrI 0.36 to 1.10</p> </li> <li> <p>Single‐form NRT: RR 0.71, 95% CrI 0.35 to 1.40</p> </li> </ul> </p> <p>When removing studies at high risk of bias, only nicotine EC, non‐nicotine EC, combined NRT, and single‐form NRT had sufficient data to generate point estimates; these were consistent with those from the main model (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 10</a>). When removing studies with tobacco or vaping industry funding, there was still sufficient data for all nodes to be displayed; results were consistent with those from the main analysis (<a href="http://dx.doi.org/10.5287/ora-jnvxbp7qr" target="_blank">Supplemental Table 10</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010216-sec-0113" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010216-sec-0113"></div> <section id="CD010216-sec-0114"> <h3 class="title" id="CD010216-sec-0114">Summary of main results</h3> <p>This update includes a further two studies published since the last version (January 2024). Our three main comparisons, nicotine EC compared to NRT, nicotine EC compared to non‐nicotine EC, and nicotine EC compared to behavioural support only/no support continue to show increased quit rates in people assigned to nicotine EC arms. This is high‐certainty for the comparison with NRT, moderate‐certainty for the comparison with non‐nicotine EC, and low‐certainty for the comparison with behavioural support only/no support (<a href="./full#CD010216-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD010216-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD010216-tbl-0003">summary of findings Table 3</a>). In absolute terms, pooled data suggest an additional two to six people for every 100 would quit smoking with nicotine EC compared to NRT, an additional one to seven people for every 100 would quit smoking with nicotine EC compared to non‐nicotine EC, and an additional three to five people for every 100 would quit smoking with nicotine EC compared to behavioural support only or no support for smoking cessation. Most data come from studies of cartridges and refillable devices, although the number of studies investigating pod devices is increasing, with the two new included studies providing pod devices. </p> <p>There remains moderate certainty of no evidence of a difference in rates of adverse events (AEs) with nicotine EC compared to non‐nicotine EC, and moderate certainty of no evidence of a difference in rates of AEs with nicotine EC compared to NRT. Evidence on AEs and serious adverse events (SAEs) was of low to very low certainty across all other comparisons, due to a paucity of data. Many of the studies that measured SAEs reported no such events in either study arm. For nicotine EC compared to non‐nicotine EC, pooled data suggest no evidence of a difference in the number of people experiencing AEs or SAEs. Conversely, data from comparisons between nicotine EC and behavioural support alone or no support suggest an additional 9 people per 100 assigned to nicotine EC may experience AEs, but with no evidence of a difference in SAEs; this evidence was of low and very low certainty, respectively. As with AEs from other smoking cessation treatments (e.g. NRT, <a href="./references#CD010216-bbs2-0238" title="Hartmann-BoyceJ , ChepkinSC , YeW , BullenC , LancasterT . Nicotine replacement therapy versus control for smoking cessation. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD000146. [DOI: 10.1002/14651858.CD000146.pub5]">Hartmann‐Boyce 2018a</a>), AEs in these studies typically related to irritation at site (e.g. dry mouth, cough) and resolved over time. No studies in any of the different comparison conditions detected serious harms considered to be related to EC use. </p> <p>Beyond AEs and SAEs, we consider data on a range of safety‐ and health‐related outcomes, including carbon monoxide and other toxins, lung function, blood pressure, pulse, and oxygen levels. Data on all of these outcome measures were limited; for most outcomes within most comparisons, only one or two studies currently contribute data. A companion paper provides more data on the measured toxicants, analyzing studies based on actual use of ECs and combustible cigarettes (<a href="./references#CD010216-bbs2-0241" title="Hartmann-BoyceJ , ButlerAR , TheodoulouA , OnakpoyaIJ , HajekP , BullenC , et al. Biomarkers of potential harm in people switching from smoking tobacco to exclusive e-cigarette use, dual use, or abstinence: secondary analysis of Cochrane systematic review of trials of e-cigarettes for smoking cessation. Addiction2023;118(3):539-45. [DOI: 10.1111/add.16063]">Hartmann‐Boyce 2022a</a>). Consistent with findings from this review, the companion paper found that most measured toxicants were lower in people exclusively using EC than those exclusively smoking or those both smoking and using EC. Most measured toxicants were lower in people using both EC and smoking compared to smoking only. </p> <p>We also have data from studies testing nicotine EC as adjuncts to other stop‐smoking treatments. Pooled data from two studies in which all participants received NRT showed that nicotine EC led to higher quit rates than non‐nicotine EC, but we judged both studies to be at high risk of bias, meaning the effect remains uncertain. Three studies compare nicotine EC + NRT to NRT alone. Pooling cessation results from all three studies resulted in high statistical heterogeneity, precluding meta‐analysis, but this heterogeneity was driven by the one study of a cartridge device. When restricting the analyses to refillable devices, heterogeneity disappeared (I<sup>2</sup> = 0%), and results showed more people quit in the nicotine EC + NRT arm than in the NRT alone arm. These results should be treated with caution as one of the two studies was judged to be at high risk of bias, but it does suggest that this is an area where further research is warranted. It is well‐established that combining short‐ and long‐acting forms of NRT ('combined NRT') leads to greater success than single‐form NRT (<a href="./references#CD010216-bbs2-0294" title="TheodoulouA , ChepkinSC , YeW , FanshaweTR , BullenC , Hartmann-BoyceJ , et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews2023, Issue 6. Art. No: CD013308. [DOI: 10.1002/14651858.CD013308.pub2]">Theodoulou 2023</a>) but, of note, one of the studies showing a benefit of nicotine EC in this comparison compared nicotine EC + patch to short‐acting NRT + patch, suggesting that it is not just the 'combined NRT' effect that is driving increased effectiveness. </p> <p>This review also includes data on the proportion of participants still using the study product (EC or pharmacotherapy) at six months or longer. There remains no clear evidence of a between‐group difference for this outcome, which is also now explored further in a companion publication (<a href="./references#CD010216-bbs2-0207" title="ButlerAR , LindsonN , FanshaweTR , TheodoulouA , BeghR , HajekP , et al. Longer-term use of electronic cigarettes when provided as a stop smoking aid: systematic review with meta-analyses. Preventive Medicine2022;165(Pt B):107182. [DOI: 10.1016/j.ypmed.2022.107182] [PMID: 35933001]">Butler 2022</a>). We also searched for information investigating any association between withdrawal and smoking cessation, but no studies met our inclusion criteria for this outcome. </p> <p>Findings from the exploratory network meta‐analysis were consistent with those from pairwise meta‐analyses. </p> </section> <section id="CD010216-sec-0115"> <h3 class="title" id="CD010216-sec-0115">Overall completeness and applicability of evidence</h3> <p>This field of research and EC devices themselves continue to evolve rapidly. This is the fourth update conducted as part of our 'living systematic review' approach, with which we will proceed until at least the end of 2025, meaning we can continue to rapidly incorporate new evidence (see <a href="./appendices#CD010216-sec-0128">Appendix 1</a>). This is important, as all but two of our analyses currently demonstrate imprecision. </p> <p>This update incorporates data from 2 July 2023 to 1 February 2024. Subsequent monthly searches will keep the evidence in this review current. Although studies predominantly came from the USA and UK, overall this review covers data from 15 countries. Geographical range in studies may be particularly important in this area, due to the marked differences in EC regulation between countries; for example, studies conducted in countries that limit nicotine dose in EC, or allow only certain EC devices to be tested, may observe less pronounced effects on quitting. This review includes studies on some under‐researched populations, including people not motivated to quit smoking, people with substance misuse disorders, people with serious mental health conditions, people living in socially deprived areas and people experiencing homelessness. Quit rates in these groups are traditionally lower, which may make it more difficult to detect the effects of interventions. However, it could be that these groups may particularly stand to benefit from EC if they are effective because, in absolute terms, conventional cessation methods are often not as effective for them. </p> <p>As well as the rapid pace of research in this field, evolutions in EC technology pose a challenge when considering the applicability of our evidence to the present. We had downgraded the certainty of our data in the 2016 update, as the devices tested in the trials were first‐generation 'cig‐a‐like' devices which did not deliver nicotine well, meaning the studies may have yielded more conservative estimates than would be seen with newer models, as newer devices and models have tended towards improved nicotine delivery. Nicotine delivery is also relevant to the comparator NRT arms tested; use of both a shorter‐ and a longer‐acting form of NRT show the highest success, and it is important that, where possible, this be the comparator chosen for such trials (<a href="./references#CD010216-bbs2-0294" title="TheodoulouA , ChepkinSC , YeW , FanshaweTR , BullenC , Hartmann-BoyceJ , et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews2023, Issue 6. Art. No: CD013308. [DOI: 10.1002/14651858.CD013308.pub2]">Theodoulou 2023</a>). We no longer downgrade the evidence on this basis as studies with newer device types are now included, although there will always be a time lag between current devices and the research evidence available. Within our primary comparisons, none of the analyses of our primary outcomes signified substantial levels of statistical heterogeneity, despite the fact that different devices were used in the included studies. However, this could be because confidence intervals were wide for individual studies, and does not rule out clinically significant differences in effects between EC types. As further data emerge, we hope to be able to formally test for differences in subgroup analyses, and in head‐to‐head comparisons of different device types. As of this 2024 update, we have only three studies of pod devices contributing to our cessation analyses (<a href="./references#CD010216-bbs2-0066" title="NCT04854616. Cessation of Smoking Trial in the Emergency Department (CoSTED). clinicaltrials.gov/ct2/show/NCT04854616 (date first received 22 April 2021). NotleyC , ClarkL , BeldersonP , WardE , ClarkAB , ParrottS , et al. Cessation of smoking trial in the emergency department (CoSTED): protocol for a multicentre randomised controlled trial. BMJ Open2023;13(1):e064585. PopeI , ClarkLV , ClarkA , WardE , BeldersonP , Stirling S et al. Cessation of Smoking Trial in the Emergency Department (COSTED): a multicentre randomised controlled trial. Emergency Medicine Journal2024;41(5):276-82. [DOI: 10.1136/emermed-2023-213824]PopeI , NotleyC , BoyleA . Results of the cessation of smoking trial in the emergency department (COSTED). Emergency Medicine Journal2023;40(12):873-4. PopeI , NotleyC . Cessation of smoking trial in the emergency department. In: SRNT 29th Annual Meeting; 2023 Mar 1-4; San Antonio (TX), USA, POS2-14. 2023:119-20. ">Pope 2024</a>; <a href="./references#CD010216-bbs2-0073" title="RussellC , McKeganeyN , KatsampourisE , SatchwellA , HaseenF . A randomised community-based trial of a closed-system pod e-vapour product and nicotine replacement therapy for cigarette abstinence and reduction. Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting February 24-27 2021 virtual:PH-353 p230. ">Russell 2021</a>; <a href="./references#CD010216-bbs2-0089" title="XuY , GoldensonNI , Prakash S AugustsonEM , ShiffmanS . Randomized trial assessing the effect of the JUUL system on switching away from cigarettes and smoking reduction among U.S. adults who smoke cigarettes.. Experimental and Clinical Psychopharmacology2024;32(1):3-15. [DOI: 10.1037/pha0000698]">Xu 2023*</a>). No studies tested newer disposable devices, which data show are growing in popularity (<a href="./references#CD010216-bbs2-0291" title="Tattan-BirchH , JacksonSE , KockL , DockrellM , BrownJ . Rapid growth in disposable e-cigarette vaping among young adults in Great Britain from 2021 to 2022: a repeat cross-sectional survey. Addiction2023;118(2):382-6. [DOI: 10.1111/add.16044]">Tattan‐Birch 2022</a>; <a href="./references#CD010216-bbs2-0292" title="Tattan-BirchH , BrownJ , ShahabL , BeardE , JacksonS . Trends in vaping and smoking following the rise of disposable e-cigarettes: a repeat cross-sectional study in England between 2016 and 2023. The Lancet Regional Health – Europe2024;42:100924. [DOI: 10.1016/j.lanepe.2024.100924]">Tattan‐Birch 2024</a>). There also continues to be little evidence on the impact of different devices, flavours, and nicotine delivery profiles when directly compared to one another, although this update includes the first study that both randomized participants to different flavour conditions and measured smoking cessation at a follow‐up of six months or more. A companion paper explores available data on flavours in more detail but is not as up‐to‐date as this review (<a href="./references#CD010216-bbs2-0254" title="LindsonN , ButlerAR , LiberA , LevyD , BarnettP , TheodoulouA , et al. An exploration of flavours in studies of e-cigarettes for smoking cessation: secondary analyses of a systematic review with meta-analyses. Addiction 2022 Nov 18 [Epub ahead of print]. [DOI: 10.1111/add.16091]">Lindson 2022</a>). </p> <p>The AEs described in both the RCT and cohort studies continue to look similar, regardless of the brand of EC used or nicotine content, with placebo and nicotine‐containing ECs showing similar numbers and types of AEs in direct comparisons. They also reflect what is reported in survey data (<a href="./references#CD010216-bbs2-0215" title="DawkinsL , TurnerJ , RobertsA , SoarK . 'Vaping' profiles and preferences: an online survey of electronic cigarette users. Addiction2013;108(6):1115-25.">Dawkins 2013b</a>; <a href="./references#CD010216-bbs2-0224" title="EtterJF , BullenC . Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction2011;106(11):2017-28.">Etter 2011</a>). </p> <p>The structure of our analyses follows the standard practice of the Cochrane Tobacco Addiction Group, i.e. evaluating outcomes on an intention‐to‐treat basis, meaning our pooled results represent the effect of <i>offering an EC intervention.</i> This is different from evaluating the per‐protocol effect, or the effect only on those who use the EC to quit smoking entirely, or continue to smoke whilst also using EC. Although pragmatic and hopefully of use to those designing and delivering interventions, we acknowledge that our intention‐to‐treat approach limits the ability to use the data presented here to draw conclusions about biomarkers in subgroups of participants based on subsequent EC use/smoking profiles. A companion publication attempts to address this deficit (<a href="./references#CD010216-bbs2-0241" title="Hartmann-BoyceJ , ButlerAR , TheodoulouA , OnakpoyaIJ , HajekP , BullenC , et al. Biomarkers of potential harm in people switching from smoking tobacco to exclusive e-cigarette use, dual use, or abstinence: secondary analysis of Cochrane systematic review of trials of e-cigarettes for smoking cessation. Addiction2023;118(3):539-45. [DOI: 10.1111/add.16063]">Hartmann‐Boyce 2022a</a>). </p> <section id="CD010216-sec-0116"> <h4 class="title">Cessation</h4> <p>All three comparisons found effect estimates favouring nicotine EC for smoking cessation. For nicotine EC versus NRT, we continue to judge the evidence to be of high certainty, meaning we are very confident that the true effect lies close to the estimate of the effect. For nicotine EC versus non‐nicotine EC, we continue to judge the evidence to be of moderate certainty, meaning we think the true effect is likely to be close to the estimate of effect. For nicotine EC versus behavioural support only/no support, we continue to judge the evidence to be of low certainty, meaning we have limited confidence in the effect estimate. Nicotine EC versus non‐nicotine EC comparisons isolate the effect of nicotine as provided by an EC, and nicotine EC versus NRT comparisons isolate the effect of the sensorimotor elements provided by an EC. Both of these comparisons find a benefit of nicotine EC for smoking cessation. Therefore, it might logically follow that the comparison between nicotine EC and behavioural support only/no support would find a benefit in favour of nicotine EC, since this comparison would capture both pharmacological and sensorimotor mechanisms of effect. This increases our confidence in the effect of nicotine EC when compared to behavioural support alone or to no support. NRT has also been shown to be more effective than behavioural support alone, further supporting the likelihood that nicotine EC would be more effective than behavioural support alone (<a href="./references#CD010216-bbs2-0238" title="Hartmann-BoyceJ , ChepkinSC , YeW , BullenC , LancasterT . Nicotine replacement therapy versus control for smoking cessation. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD000146. [DOI: 10.1002/14651858.CD000146.pub5]">Hartmann‐Boyce 2018a</a>). </p> </section> <section id="CD010216-sec-0117"> <h4 class="title">Adverse and serious adverse events</h4> <p>We have moderate certainty of no evidence of a difference in adverse events for nicotine EC compared to NRT as well as for non‐nicotine EC. For all other outcomes in this category, evidence is of low or very low certainty. Imprecision remains a key issue for these outcomes, and particularly for SAEs. None of the analyses signalled serious harm, nor did complementary data from cohort studies but, unlike our cessation analyses, many of the confidence intervals encompassed the possibility of both clinically significant harm and clinically significant benefit. This uncertainty should reduce as more studies become available. </p> </section> </section> <section id="CD010216-sec-0118"> <h3 class="title" id="CD010216-sec-0118">Quality of the evidence</h3> <p>We consider the certainty of the evidence as it relates to primary outcomes for our three main comparisons: nicotine EC versus NRT; nicotine EC versus non‐nicotine EC; nicotine EC versus behavioural support only/no support (<a href="./full#CD010216-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD010216-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD010216-tbl-0003">summary of findings Table 3</a>). The certainty of evidence for all other comparisons and outcomes should be considered very low due to a paucity of data and issues with risk of bias. </p> <p>Our summary of findings tables and assessments of certainty are based on the evidence from randomized controlled trials (RCTs). The cohort studies that we include are all deemed to have high risks of bias, which is inherent in the study design. Data presented from these studies need to be interpreted with caution. However, data from cohort studies were reassuringly consistent with data from RCTs. </p> <p>Risk of bias did not impact on the certainty of evidence for comparisons between nicotine and non‐nicotine EC, or between nicotine EC and NRT. For the latter, we judged all seven studies to be at low or unclear risk of bias overall. For the former, removing one study at high risk of bias increased the effect estimate for our efficacy outcome. Risk of bias decreased our certainty in the effect estimates for our nicotine EC versus behavioural support only/no support comparison as, due to the nature of the comparison, blinding was not possible and different levels of support could lead to bias. </p> <p>All but three of our primary outcomes for our main comparisons were downgraded for imprecision, due to wide confidence intervals and few events. Other than the risk of bias and imprecision, we identified no other issues that decreased the certainty of the primary outcomes for our main comparisons. </p> <p>Due to the small number of studies contributing to individual analyses, we were unable to formally test for publication bias in most cases and cannot rule this out. For the comparison nicotine EC versus behavioural/no support, two of our outcomes had more than 10 studies contributing to meta‐analysis and therefore we did generate funnel plots. The funnel plot for the exhaled carbon monoxide outcome did not show any evidence of publication bias (<a href="#CD010216-fig-0004">Figure 4</a>). However, the funnel plot for smoking cessation showed evidence of asymmetry (<a href="#CD010216-fig-0011">Figure 11</a>), suggesting that smaller studies showing no benefit of nicotine EC may remain unpublished. We carried out a sensitivity analysis removing the two outlying studies (i.e. the smallest studies showing the most marked effects of EC; <a href="./references#CD010216-bbs2-0016" title="DawkinsL , BauldL , FordA , RobsonD , HajekP , ParrottS , et al. A cluster feasibility trial to explore the uptake and use of e-cigarettes versus usual care offered to smokers attending homeless centres in Great Britain. PLOS One2020;15(10):e0240968. [ISRCTN14140672]ISRCTN14140672. Exploring the use and uptake of e-cigarettes for homeless smokers. www.isrctn.com/ISRCTN14140672 (first received 7 November 2018). ">Dawkins 2020</a>; <a href="./references#CD010216-bbs2-0030" title="HalpernSD , HarhayMO , SaulsgiverK , BrophyC , TroxelAB , VolppKG . A pragmatic trial of e-cigarettes, incentives, and drugs for smoking cessation. New England Journal of Medicine2018;378(24):2302-10. HarhayMO , TroxelAB , BrophyC , SaulsgiverK , VolppKG , HalpernSD , . Financial incentives promote smoking cessation directly, not by increasing use of cessation aids. Annals of the American Thoracic Society2019;16(2):280-2. [DOI: 10.1513/AnnalsATS.201808-574RL]NCT02328794. Randomized clinical trial to reduce harm from tobacco. clinicaltrials.gov/show/NCT02357173 (accessed 17 February 2016). ">Halpern 2018</a>) and this did not change the interpretation of the pooled result. Therefore, we did not downgrade the certainty of the evidence for publication bias; however, we will continue to monitor this as the evidence is updated. </p> <div class="figure" id="CD010216-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Funnel plot. Comparison: Nicotine EC vs behavioural/no support. Outcome: smoking cessation" data-id="CD010216-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot. Comparison: Nicotine EC vs behavioural/no support. Outcome: smoking cessation</p> </div> </div> </div> </section> <section id="CD010216-sec-0119"> <h3 class="title" id="CD010216-sec-0119">Potential biases in the review process</h3> <p>We consider the review process we used to be robust. For outcome assessment, we followed the standard methods used for Cochrane Tobacco Addiction Review Group cessation reviews. Our search strategy included CENTRAL, which incorporates findings from trial registries, and we were able to capture a number of ongoing studies. However, there may be unpublished data that our searches did not uncover. We also considered participants lost to follow‐up as continuing to smoke, which is standard practice in this field. There are concerns that frequently updating meta‐analyses can lead to issues with multiple testing; we followed Cochrane guidance in conducting this living systematic review and hence do not adjust for multiple testing (<a href="./references#CD010216-bbs2-0204" title="BrookerJ , SynnotA , McDonaldS , ElliottJ , TurnerT , et al. Guidance for the production and publication of Cochrane living systematic reviews: Cochrane Reviews in living mode; December 2019. community.cochrane.org/sites/default/files/uploads/inline-files/Transform/201912_LSR_Revised_Guidance.pdf (accessed 30 July 2020).">Brooker 2019</a>). </p> <p>Six of our review authors are authors of the included studies. These authors were not involved in the decisions about inclusion of their studies, or in risk of bias assessment for these studies; this approach is standard across all Cochrane reviews (regardless of subject area) and has been approved by the Cochrane editorial office as sufficient to avoid bias. </p> <p>Our review includes studies funded by the tobacco/vaping industry ‐ Cochrane guidelines (not tobacco addiction‐specific) mandate that studies be included regardless of funder, in order that the reviews remain transparent and rigorous. As noted throughout the results section, we removed studies with tobacco or vaping industry funding in sensitivity analyses; our conclusions were unchanged when we did this. This means that studies funded by tobacco or vaping industries <i>do not influence</i> our conclusions. We do not receive any funding from tobacco or vaping industries, and maintain a firm stance of independence. </p> </section> <section id="CD010216-sec-0120"> <h3 class="title" id="CD010216-sec-0120">Agreements and disagreements with other studies or reviews</h3> <p>This Cochrane review aligns with but updates the conclusions of the 2018 US National Academies of Science, Engineering, and Medicine Consensus Study Report, <i>Public Health Consequences of E‐cigarettes</i> (<a href="./references#CD010216-bbs2-0264" title="National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice. Public Health Consequences of E-Cigarettes. Washington (DC): National Academies Press (US), 2018.">NASEM 2018</a>)<i>,</i> which reviewed literature published through August 2017 to address the question, “Do e‐cigarettes help smokers quit smoking combustible tobacco cigarettes?”. Focusing on RCTs and existing systematic reviews, it used a prespecified 'Level of Evidence' framework to develop conclusions. The report’s overall conclusion was that there was “limited evidence that e‐cigarettes may be effective aids to promote smoking cessation.” Based on the RCTs available, it concluded that there was “moderate evidence” that e‐cigarettes containing nicotine were more effective for cessation than e‐cigarettes without nicotine, but “insufficient evidence” about the effectiveness of e‐cigarettes compared to no treatment or to FDA‐approved smoking cessation treatments. Our review differs on this latter point, as we find high‐certainty evidence of benefit when comparing nicotine EC with NRT; this is due to the inclusion of studies published after <a href="./references#CD010216-bbs2-0264" title="National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice. Public Health Consequences of E-Cigarettes. Washington (DC): National Academies Press (US), 2018.">NASEM 2018</a>. Reviews from the Office for Health Improvement and Disparities (formerly Public Health England) conclude that, compared to their 2018 review, there is now stronger evidence that nicotine vaping products are effective for smoking cessation (<a href="./references#CD010216-bbs2-0260" title="McNeillA , BroseLS , CalderR , BauldL , RobsonD . Vaping in England: an evidence update including vaping for smoking cessation, February 2021: a report commissioned by Public Health England London, UK: Public Health England. assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/962221/Vaping_in_England_evidence_update_February_2021.pdf (accessed prior to 3 November 2022).">McNeill 2021</a>; <a href="./references#CD010216-bbs2-0261" title="McNeillA , SimonavičiusE , BroseLS , TaylorE , EastK , ZuikovaE , et al. Nicotine vaping in England: an evidence update including health risks and perceptions. A report commissioned by the Office for Health Improvement and Disparities. London: Office for Health Improvement and Disparities. assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1107701/Nicotine-vaping-in-England-2022-report.pdf (accessed prior to 3 November 2022).">McNeill 2022</a>). </p> <p><a href="./references#CD010216-bbs2-0309" title="ZhangYY , BuFL , DongF , WangJH , ZhuSJ , ZhangXW , et al. The effect of e-cigarettes on smoking cessation and cigarette smoking initiation: an evidence-based rapid review and meta-analysis. Tobacco Induced Diseases2021;19:04. [DOI: 10.18332/tid/131624]">Zhang 2021</a> conducted a rapid review; while their pooled analysis also suggested that EC increased quit rates compared to NRT or non‐nicotine EC, they judged the evidence to be of low certainty according to GRADE, driven by imprecision and inconsistency. <a href="./references#CD010216-bbs2-0309" title="ZhangYY , BuFL , DongF , WangJH , ZhuSJ , ZhangXW , et al. The effect of e-cigarettes on smoking cessation and cigarette smoking initiation: an evidence-based rapid review and meta-analysis. Tobacco Induced Diseases2021;19:04. [DOI: 10.18332/tid/131624]">Zhang 2021</a> combined studies with NRT comparators and those with non‐nicotine EC comparators in the same analysis and found moderate statistical heterogeneity; we evaluated these two comparisons separately and did not find evidence of statistical heterogeneity. We include more studies than <a href="./references#CD010216-bbs2-0309" title="ZhangYY , BuFL , DongF , WangJH , ZhuSJ , ZhangXW , et al. The effect of e-cigarettes on smoking cessation and cigarette smoking initiation: an evidence-based rapid review and meta-analysis. Tobacco Induced Diseases2021;19:04. [DOI: 10.18332/tid/131624]">Zhang 2021</a>. <a href="./references#CD010216-bbs2-0270" title="PatnodeCD , HendersonJT , CoppolaEL , MelnikowJ , DurbinS , ThomasRG . Interventions for tobacco cessation in adults, including pregnant persons: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA2021;325(3):280-98.">Patnode 2021</a> reviewed evidence on tobacco cessation interventions for the US Preventive Services Task Force (<a href="./references#CD010216-bbs2-0297" title="US Preventive Services Task Force. Interventions for tobacco smoking cessation in adults,including pregnant persons. www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions (accessed prior to 3 November 2022).">USPFTS 2021</a>). The authors stated that none of their included EC trials suggested higher rates of serious adverse events; this is in line with our analyses. However, they reported that findings across EC trials were inconsistent for effectiveness, with some finding statistically significant evidence of benefit and some finding no statistically significant difference. They did not conduct statistical meta‐analyses and included five trials, all of which are included in our cessation meta‐analyses. None of our cessation meta‐analyses, which include these trials, detected levels of heterogeneity beyond what would be expected from chance alone. <a href="./references#CD010216-bbs2-0303" title="WangRJ , BhadrirajuS , GlantzSA . E-cigarette use and adult cigarette smoking cessation: a meta-analysis. American Journal of Public Health2021;111:230-46.">Wang 2021</a> reviewed data both from observational studies and from randomized controlled trials; in the trials, e‐cigarettes were associated with increased smoking cessation (as with our review). In observational studies, ECs were not associated with increased smoking cessation. As discussed in <a href="#CD010216-sec-0014">Methods</a>, although we included non‐randomized studies in which an EC intervention is provided in this review, we did not include observational studies in which no EC intervention is provided, due to known issues with confounding. </p> <p><a href="./references#CD010216-bbs2-0210" title="ChanGCK , StepanovicD , LimC , SunT , Shanmuga AnandanAS , ConnorJP , et al. A systematic review of randomised controlled trials and network meta-analysis of e-cigarettes for smoking cessation. Addictive Behaviours2021;119:106912. [DOI: 10.1016/j.addbeh.2021.106912]">Chan 2021</a>, <a href="./references#CD010216-bbs2-0229" title="GrabovacI , OberndorferM , FischerJ , WiesingerW , HaiderS , DornerTE . Effectiveness of electronic cigarettes in smoking cessation: a systematic review and meta-analysis. Nicotine &amp; Tobacco Research2021;23(4):625-34. [DOI: 10.1093/ntr/ntaa181]">Grabovac 2021</a>, <a href="./references#CD010216-bbs2-0298" title="VanderkamP , BonneauA , KinouaniS , DzeraviashkaP , CasteraP , BesnierM , et al. Duration of the effectiveness of nicotine electronic cigarettes on smoking cessation and reduction: systematic review and meta-analysis. Front Psychiatry2022;4(13):915946.">Vanderkam 2022</a> and <a href="./references#CD010216-bbs2-0251" title="LevettJY , FilionKB , ReynierP , PrellC , EisenbergMJ . Efficacy and safety of e-cigarette use for smoking cessation: a systematic review and meta-analysis of randomized controlled trials. American Journal of Medicine2023;136(8):804-13.">Levett 2023</a> also reviewed evidence from randomized controlled trials and found higher quit rates in people assigned to nicotine EC than to NRT or non‐nicotine EC, although <a href="./references#CD010216-bbs2-0229" title="GrabovacI , OberndorferM , FischerJ , WiesingerW , HaiderS , DornerTE . Effectiveness of electronic cigarettes in smoking cessation: a systematic review and meta-analysis. Nicotine &amp; Tobacco Research2021;23(4):625-34. [DOI: 10.1093/ntr/ntaa181]">Grabovac 2021</a> noted that evidence was less clear at longer follow‐up when comparing nicotine EC to counselling alone. <a href="./references#CD010216-bbs2-0273" title="PoundCM , ZhangJZ , KoduaAT , SampsonM . Smoking cessation in individuals who use vaping as compared with traditional nicotine replacement therapies: a systematic review and meta-analysis. BMJ Open2021;11(2):e044222. [DOI: 10.1136/bmjopen-2020-044222]">Pound 2021</a> only compared nicotine EC with NRT; their pooled estimate showed a higher quit rate with nicotine EC (RR 1.42), but 95% CIs were wide and included the possibility of no difference. They included two studies in their comparison that we do not: one which measured cessation at less than six months and hence was not eligible for inclusion in our cessation analysis, and one in which the nicotine level was so low that we have classified the study as assessing non‐nicotine (<a href="./references#CD010216-bbs2-0045" title="KCT0001277. Effect of an electronic cigarette for smoking reduction and cessation in Korean male smokers: a randomized, controlled study. KCT0001277 2014 (accessed 15 August 2016). LeeSH , AhnSH , CheongYS . Effect of electronic cigarettes on smoking reduction and cessation in Korean male smokers: a randomized controlled study. Journal of the American Board of Family Medicine2019;32(4):567-74. ">Lee 2019</a>). The latter introduced statistical heterogeneity to their pooled results. We also include additional studies not available at the time of their analyses. </p> <p>Findings are also broadly consistent with those from other recent reviews regarding safety and markers of harm, with some exceptions. <a href="./references#CD010216-bbs2-0190" title="AmatoL , CrucianiF , SoliminiR , BarcaA , PacificiR , DavoliM . Effects of electronic cigarettes on health: a systematic review of the available evidence. Recenti Progressi in Medicina2020;111(1):30-43.">Amato 2020</a> focused only on safety; consistent with our review, they found very low‐ to moderate‐certainty evidence of a range of possible adverse effects, with the most frequently reported being cough, dry mouth, shortness of breath, irritation of the mouth and throat, and headache. Consistent with our review, the studies reviewed by <a href="./references#CD010216-bbs2-0261" title="McNeillA , SimonavičiusE , BroseLS , TaylorE , EastK , ZuikovaE , et al. Nicotine vaping in England: an evidence update including health risks and perceptions. A report commissioned by the Office for Health Improvement and Disparities. London: Office for Health Improvement and Disparities. assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1107701/Nicotine-vaping-in-England-2022-report.pdf (accessed prior to 3 November 2022).">McNeill 2022</a> showed that, compared to combustible cigarettes, using ECs led to a substantial reduction in biomarkers of toxicant exposure associated with cigarette smoking; <a href="./references#CD010216-bbs2-0278" title="Royal College of Physicians. E-cigarettes and harm reduction: An evidence review, 2024. https://www.rcp.ac.uk/policy-and-campaigns/policy-documents/e-cigarettes-and-harm-reduction-an-evidence-review (accessed 1 August 2024).">RCP 2024</a> and <a href="./references#CD010216-bbs2-0306" title="WilsonN , SummersJA , Ait OuakrimD , HoekJ , EdwardsR , BlakelyT . Improving on estimates of the potential relative harm to health from using modern ENDS (vaping) compared to tobacco smoking. BMC Public Health2021;21(1):2038.">Wilson 2021</a> also agree with this finding. <a href="./references#CD010216-bbs2-0189" title="AkiyamaY , SherwoodN . Systematic review of biomarker findings from clinical studies of electronic cigarettes and heated tobacco products. Toxicology Reports2021;8:282-94.">Akiyama 2021</a> reviewed biomarker findings from clinical studies and also concluded that the use of EC could lead to a significant reduction in exposure to harmful substances compared to traditional cigarettes; this is again consistent with findings from our review. A systematic review of 22 studies found that several carcinogens with a known link to bladder cancer were present in the urine of EC users and recommended further study on the urological safety of ECs (<a href="./references#CD010216-bbs2-0202" title="BjurlinMA , MatulewiczRS , RobertsTR , DearingBA , SchatzD , ShermanS , et al. Carcinogen biomarkers in the urine of electronic cigarette users and implications for the development of bladder cancer: a systematic review. European Urology Oncology2021;4(5):766-83.">Bjurlin 2021</a>). <a href="./references#CD010216-bbs2-0293" title="TaylorE , SimonaviciusE , McNeillA , BroseLS , EastK , MarczyloT , et al. Exposure to tobacco specific nitrosamines among people who vape, smoke or do neither. A systematic review and meta analysis. Nicotine and Tobacco Research 2023 24 Aug [Epub ahead of print]. [DOI: 10.1093/ntr/ntad156]">Taylor 2023</a> systematically reviewed tobacco‐specific nitrosamine exposure between people smoking, vaping, and doing neither. Exposure to all tobacco‐specific nitrosamines was lower amongst people who vaped compared to people who smoked. Levels were higher amongst people who vaped compared to people who neither vaped nor smoked. </p> <p><a href="./references#CD010216-bbs2-0258" title="Martinez-MorataI , SanchezTR , ShimboD , Navas-AcienA . Electronic cigarette use and blood pressure endpoints: a systematic review. Current Hypertension Reports2021;23(1):1.">Martinez‐Morata 2021</a> reviewed blood pressure findings and concluded that EC may result in short‐term elevations, but that more data are needed; our review also lacks sufficient data to draw any conclusions about blood pressure at one week or longer. A scoping review by <a href="./references#CD010216-bbs2-0231" title="GugalaE , OkohCM , GhoshS , MoczygembaLR . Pulmonary health effects of electronic cigarettes: a scoping review. Health Promotion Practice2022;23(3):388-96.">Gugala 2022</a> looked at the pulmonary health effects of EC and found an association between EC use and negative pulmonary symptoms. EC use resulted in worse outcomes than non‐smoking, but resulted in improved outcomes when compared with combustible cigarette use or dual use of combustible cigarettes and EC. The review by <a href="./references#CD010216-bbs2-0261" title="McNeillA , SimonavičiusE , BroseLS , TaylorE , EastK , ZuikovaE , et al. Nicotine vaping in England: an evidence update including health risks and perceptions. A report commissioned by the Office for Health Improvement and Disparities. London: Office for Health Improvement and Disparities. assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1107701/Nicotine-vaping-in-England-2022-report.pdf (accessed prior to 3 November 2022).">McNeill 2022</a> found acute and short‐to‐medium exposure to most potential respiratory toxicants from ECs to be significantly lower than combustible cigarettes, with substantial reductions in some biomarkers. For the respiratory toxicants assessed at long‐term exposure, evidence was moderate. <a href="./references#CD010216-bbs2-0261" title="McNeillA , SimonavičiusE , BroseLS , TaylorE , EastK , ZuikovaE , et al. Nicotine vaping in England: an evidence update including health risks and perceptions. A report commissioned by the Office for Health Improvement and Disparities. London: Office for Health Improvement and Disparities. assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1107701/Nicotine-vaping-in-England-2022-report.pdf (accessed prior to 3 November 2022).">McNeill 2022</a> found moderate evidence that exposure to most respiratory toxicants from ECs was similar to non‐use of tobacco or nicotine products. <a href="./references#CD010216-bbs2-0195" title="BanksE , YazidjoglouA , BrownS , NguyenM , MartinM , BeckwithK . Electronic Cigarettes and Health Outcomes: Systematic Review of Global Evidence. National Centre for Epidemiology and Population Health, ANU, 2022.">Banks 2022</a> focused on the absolute risks of EC; in this review, we are interested in both their absolute and relative risks in comparison to smoking. <a href="./references#CD010216-bbs2-0287" title="SiddiqiTJ , RashidAM , SiddiqiAK , AnwerA , UsmanMS , SakhiH , et al. Association of electronic cigarette exposure on cardiovascular health: a systematic review and meta-analysis. Current Problems in Cardiology2023;48(9):101748. [DOI: 10.1016/j.cpcardiol.2023.101748]">Siddiqi 2023</a> carried out a systematic review of randomized and observational studies on the association between EC and cardiovascular health and concluded that EC use was associated with a significant increase in cardiovascular haemodynamic measures and biomarkers. A systematic review by <a href="./references#CD010216-bbs2-0263" title="MengXC , GuoXX , PengZY , WangC , LiuR . Acute effects of electronic cigarettes on vascular endothelial function: a systematic review and meta-analysis of randomized controlled trials. European Journal of Preventive Cardiology2023;30(5):425-35. [DOI: 10.1093/eurjpc/zwac248]">Meng 2023</a> on the acute effects of EC on vascular endothelial function included eight RCTs. Evidence from their pooled analyses indicated that acute inhalation of EC led to negative changes in vascular endothelial function. <a href="./references#CD010216-bbs2-0295" title="ThiemDGE , DonkiewiczP , RejaeyR , Wiesmann-ImilowskiN , DeschnerJ , Al-Nawas B et al. The impact of electronic and conventional cigarettes on periodontal health-a systematic review and meta-analysis. Clinical Oral Investigations2023;27(9):4911-28. [DOI: 10.1007/s00784-023-05162-4]">Thiem 2023</a> carried out a systematic review of EC and CC on periodontal health; findings suggested that EC use might be considered a healthier alternative to CC concerning periodontal health. However, harmful effects of EC usage on periodontal health were observed. </p> <p>A network meta‐analysis, with searches up‐to‐date until February 2019, used direct and indirect evidence to compare the effectiveness and safety of ECs to placebo, bupropion, NRT, and varenicline (<a href="./references#CD010216-bbs2-0296" title="ThomasKH , DaliliMN , López‐LópezJA , KeeneyE , PhillippoDM , MunafòMR , et al. Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta‐analysis of randomized controlled trials. Addiction2022;117(4):861-76.">Thomas 2022</a>). The evidence was imprecise; however, there was evidence of a benefit of ECs with a nicotine level of 15 mg over placebo. The effect estimate also suggested a benefit of ECs with a 10 mg nicotine level, but the credibility interval indicated the possibility of both benefit and harm. Similarly, when EC was compared with individual pharmacotherapies, the direction of effect was in favour of ECs; however, imprecision means further evidence may change the interpretation of the effect. The safety data for ECs was inconclusive. A second network meta‐analysis also suffered from imprecision when comparing EC and NRT, though CIs were consistent with our results (<a href="./references#CD010216-bbs2-0276" title="QuigleyJM , WalshC , LeeC , LongJ , KennellyH , McCarthyA , et al. Efficacy and safety of electronic cigarettes as a smoking cessation intervention: a systematic review and network meta-analysis. Tobacco Prevention &amp; Cessation2021;7(69):1-14. [DOI: 10.18332/tpc/143077]">Quigley 2021</a>). A component network analysis updating this evidence and investigating additional components of the interventions and studies reports findings consistent with our review. Compared to placebo/no treatment, nicotine e‐cigarettes were associated with an approximate doubling of the odds of successfully quitting smoking at six months or longer (OR 2.37, 95% CrI 1.73 to 3.24; 16 RCTs, 3828 participants), placing them in the top three most effective treatments (alongside varenicline and cytisine). Evidence suggested combination NRT may also be as effective, but the point estimate was lower and this evidence was less certain (<a href="./references#CD010216-bbs2-0255" title="LindsonN , TheodoulouA , Ordóñez-MenaJM , FanshaweTR , SuttonAJ , Livingstone-BanksJ , et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta‐analyses. Cochrane Database of Systematic Reviews2023, Issue 9. Art. No: CD015226. [DOI: 10.1002/14651858.CD015226.pub2]">Lindson 2023a</a>). SAEs were rare and there was no clear evidence of a difference in the proportion of people experiencing SAEs between those randomized to nicotine e‐cigarettes and to no treatment, or to nicotine replacement therapies or nicotine receptor partial agonists. </p> <p>A systematic review by <a href="./references#CD010216-bbs2-0253" title="LiberAC , KnollM , CadhamCJ , IssabakhshM , OhH , CookS . The role of flavored electronic nicotine delivery systems in smoking cessation: a systematic review. Drug and Alcohol Dependence Reports2023;7:100143. [DOI: 10.1016/j.dadr.2023.100143]">Liber 2023</a> examined the evidence on the role of EC flavours in quit rates and concluded that the evidence was inconclusive, reflecting highly heterogeneous study definitions and methodological limitations, and called for more high‐quality evidence, ideally from RCTs. </p> <p>Reviews of ECs for policymaking (e.g. <a href="./references#CD010216-bbs2-0196" title="BanksE , YazidjoglouA , BrownS , NguyenM , MartinM , Beckwith K et al. Electronic cigarettes and health outcomes: umbrella and systematic review of the global evidence. Medical Journal of Australia2023;218(6):267-75. [DOI: 10.5694/mja2.51890]">Banks 2023</a>) are often broader in scope than our review, which focuses exclusively on their role in supporting smoking cessation in people who smoke. Outside of smoking cessation, there remain unanswered questions about the impact of EC availability and use, including in young people; we are evaluating this in a separate review (<a href="./references#CD010216-bbs2-0242" title="Hartmann-BoyceJ , BeghR , LindsonN , Livingstone-BanksJ , FanshaweTR , McNeillA , et al. Electronic cigarettes and subsequent cigarette smoking in young people. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD015170. [DOI: 10.1002/14651858.CD015170]">Hartmann‐Boyce 2022b</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010216-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA diagram for 2024 update" data-id="CD010216-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA diagram for 2024 update</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph" data-id="CD010216-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary" data-id="CD010216-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot. Comparison: Nicotine EC vs behavioural/no support. Outcome: Carbon monoxide (ppm)" data-id="CD010216-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot. Comparison: Nicotine EC vs behavioural/no support. Outcome: Carbon monoxide (ppm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Network map for cessation" data-id="CD010216-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Network map for cessation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Cessation network meta‐analysis" data-id="CD010216-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-07.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Cessation network meta‐analysis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Network map for adverse events" data-id="CD010216-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-08.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Network map for adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Adverse events network meta‐analysis" data-id="CD010216-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-09.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Adverse events network meta‐analysis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Network map for serious adverse events" data-id="CD010216-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-10.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Network map for serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Serious adverse events network meta‐analysis" data-id="CD010216-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-11.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Serious adverse events network meta‐analysis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot. Comparison: Nicotine EC vs behavioural/no support. Outcome: smoking cessation" data-id="CD010216-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Funnel plot. Comparison: Nicotine EC vs behavioural/no support. Outcome: smoking cessation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 1: Smoking cessation" data-id="CD010216-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 1: Smoking cessation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 2: Adverse events" data-id="CD010216-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 2: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 3: Serious adverse events" data-id="CD010216-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 3: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 4: Carbon monoxide (ppm)" data-id="CD010216-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 4: Carbon monoxide (ppm)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 5: Heart rate (bpm)" data-id="CD010216-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 5: Heart rate (bpm)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 6: Systolic blood pressure" data-id="CD010216-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 6: Systolic blood pressure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 7: Blood oxygen saturation" data-id="CD010216-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 7: Blood oxygen saturation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 8: 3‐HPMA (pmol/mg creatinine)" data-id="CD010216-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 8: 3‐HPMA (pmol/mg creatinine)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 9: NNAL (pmol/mg creatinine))" data-id="CD010216-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 9: NNAL (pmol/mg creatinine))</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 10: 2‐HPMA (pmol/mg creatinine)" data-id="CD010216-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 10: 2‐HPMA (pmol/mg creatinine)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 11: HMPMA (pmol/mg creatinine)" data-id="CD010216-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 11: HMPMA (pmol/mg creatinine)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 12: PheT (pmol/mg creatinine)" data-id="CD010216-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 12: PheT (pmol/mg creatinine)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 13: CEMA (pmol/mg creatinine)" data-id="CD010216-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 13: CEMA (pmol/mg creatinine)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 14: AAMA (pmol/mg creatinine)" data-id="CD010216-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 14: AAMA (pmol/mg creatinine)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 15: FEV1" data-id="CD010216-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 15: FEV1</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 16: FEV1/FVC (%)" data-id="CD010216-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 16: FEV1/FVC (%)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 17: PEF (L/min)" data-id="CD010216-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 17: PEF (L/min)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nicotine EC versus NRT, Outcome 18: Product use at 6+ months" data-id="CD010216-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Nicotine EC versus NRT, Outcome 18: Product use at 6+ months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nicotine EC versus varenicline, Outcome 1: Smoking cessation" data-id="CD010216-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Nicotine EC versus varenicline, Outcome 1: Smoking cessation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Nicotine EC versus varenicline, Outcome 2: Serious adverse events" data-id="CD010216-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Nicotine EC versus varenicline, Outcome 2: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nicotine EC versus heated tobacco, Outcome 1: Adverse events at 12 weeks" data-id="CD010216-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Nicotine EC versus heated tobacco, Outcome 1: Adverse events at 12 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nicotine EC versus heated tobacco, Outcome 2: SAEs at 12 weeks" data-id="CD010216-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Nicotine EC versus heated tobacco, Outcome 2: SAEs at 12 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nicotine EC versus heated tobacco, Outcome 3: Carbon monoxide (ppm) absolute values at 12 weeks" data-id="CD010216-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Nicotine EC versus heated tobacco, Outcome 3: Carbon monoxide (ppm) absolute values at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Nicotine EC versus heated tobacco, Outcome 4: VO2 Max at 12 weeks" data-id="CD010216-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Nicotine EC versus heated tobacco, Outcome 4: VO<sub>2</sub> Max at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 1: Smoking cessation" data-id="CD010216-fig-0036" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 1: Smoking cessation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 2: Adverse events" data-id="CD010216-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 2: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 3: Serious adverse events" data-id="CD010216-fig-0038" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 3: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 4: Carbon monoxide (ppm)" data-id="CD010216-fig-0039" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 4: Carbon monoxide (ppm)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 5: Heart rate" data-id="CD010216-fig-0040" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 5: Heart rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 6: Systolic blood pressure" data-id="CD010216-fig-0041" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 6: Systolic blood pressure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 7: FeNO (ppb)" data-id="CD010216-fig-0042" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 7: FeNO (ppb)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 8: FEV1 (l)" data-id="CD010216-fig-0043" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 8: FEV1 (l)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 9: FEV1/FVC" data-id="CD010216-fig-0044" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 9: FEV1/FVC</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 10: NNAL (pmol/mg creatinine)" data-id="CD010216-fig-0045" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 10: NNAL (pmol/mg creatinine)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-004.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 11: Product use at 6+ months" data-id="CD010216-fig-0046" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-004.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: Nicotine EC versus non‐nicotine EC, Outcome 11: Product use at 6+ months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-004.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 1: Smoking cessation" data-id="CD010216-fig-0047" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 1: Smoking cessation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 2: Adverse events" data-id="CD010216-fig-0048" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 3: Serious adverse events" data-id="CD010216-fig-0049" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 3: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 4: Carbon monoxide (ppm)" data-id="CD010216-fig-0050" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 4: Carbon monoxide (ppm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 5: Heart rate (bpm)" data-id="CD010216-fig-0051" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 5: Heart rate (bpm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 6: Systolic blood pressure" data-id="CD010216-fig-0052" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 6: Systolic blood pressure </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 7: Blood oxygen saturation" data-id="CD010216-fig-0053" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 7: Blood oxygen saturation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 8: 3‐HPMA (SMD)" data-id="CD010216-fig-0054" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 8: 3‐HPMA (SMD) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 9: NNAL (SMD)" data-id="CD010216-fig-0055" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 9: NNAL (SMD) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 10: 2‐HPMA (pmol/mg creatinine)" data-id="CD010216-fig-0056" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 10: 2‐HPMA (pmol/mg creatinine) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 11: HMPMA (pmol/mg creatinine)" data-id="CD010216-fig-0057" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 11: HMPMA (pmol/mg creatinine) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 12: PheT (pmol/mg creatinine)" data-id="CD010216-fig-0058" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 12: PheT (pmol/mg creatinine) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 13: CEMA (pmol/mg creatinine)" data-id="CD010216-fig-0059" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 13: CEMA (pmol/mg creatinine) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 14: AAMA (pmol/mg creatinine)" data-id="CD010216-fig-0060" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 14: AAMA (pmol/mg creatinine) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 15: S‐PMA (nanograms)" data-id="CD010216-fig-0061" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 15: S‐PMA (nanograms) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 16: FEV1 (SMD)" data-id="CD010216-fig-0062" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 16: FEV1 (SMD) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 17: FEF 25‐75 (litres/second))" data-id="CD010216-fig-0063" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 17: FEF 25‐75 (litres/second)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 18: PEF 25‐75 (litres/minute)" data-id="CD010216-fig-0064" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 18: PEF 25‐75 (litres/minute) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-005.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 19: FEV1/FVC" data-id="CD010216-fig-0065" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-005.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.19</div> <div class="figure-caption"> <p>Comparison 5: Nicotine EC versus behavioural support only/no support, Outcome 19: FEV1/FVC </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-005.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Higher versus lower nicotine content, Outcome 1: Smoking cessation" data-id="CD010216-fig-0066" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Higher versus lower nicotine content, Outcome 1: Smoking cessation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Higher versus lower nicotine content, Outcome 2: Adverse events at 1 week" data-id="CD010216-fig-0067" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Higher versus lower nicotine content, Outcome 2: Adverse events at 1 week </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Higher versus lower nicotine content, Outcome 3: Serious adverse events" data-id="CD010216-fig-0068" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Higher versus lower nicotine content, Outcome 3: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Higher versus lower nicotine content, Outcome 4: Carbon monoxide (ppm)" data-id="CD010216-fig-0069" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Higher versus lower nicotine content, Outcome 4: Carbon monoxide (ppm)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Higher versus lower nicotine content, Outcome 5: Heart rate" data-id="CD010216-fig-0070" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Higher versus lower nicotine content, Outcome 5: Heart rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Higher versus lower nicotine content, Outcome 6: Systolic blood pressure" data-id="CD010216-fig-0071" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Higher versus lower nicotine content, Outcome 6: Systolic blood pressure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Higher versus lower nicotine content, Outcome 7: FeNO (ppb)" data-id="CD010216-fig-0072" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Higher versus lower nicotine content, Outcome 7: FeNO (ppb)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-006.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Higher versus lower nicotine content, Outcome 8: FEV1 (l)" data-id="CD010216-fig-0073" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-006.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: Higher versus lower nicotine content, Outcome 8: FEV1 (l)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-006.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Higher versus lower nicotine content, Outcome 9: FVC (l)" data-id="CD010216-fig-0074" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-006.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6: Higher versus lower nicotine content, Outcome 9: FVC (l)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-006.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Higher versus lower nicotine content, Outcome 10: FEV1/FVC" data-id="CD010216-fig-0075" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-006.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6: Higher versus lower nicotine content, Outcome 10: FEV1/FVC</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-006.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Higher versus lower nicotine content, Outcome 11: NNAL (pg/mg creatinine) at 24 weeks" data-id="CD010216-fig-0076" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-006.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6: Higher versus lower nicotine content, Outcome 11: NNAL (pg/mg creatinine) at 24 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-006.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Higher versus lower nicotine content, Outcome 12: Product use at 6+ months" data-id="CD010216-fig-0077" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-006.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6: Higher versus lower nicotine content, Outcome 12: Product use at 6+ months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-006.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Choice of flavours vs. tobacco flavour only, Outcome 1: Smoking cessation" data-id="CD010216-fig-0078" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Choice of flavours vs. tobacco flavour only, Outcome 1: Smoking cessation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Choice of flavours vs. tobacco flavour only, Outcome 2: Product use at 6+ months" data-id="CD010216-fig-0079" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Choice of flavours vs. tobacco flavour only, Outcome 2: Product use at 6+ months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Tobacco vs. menthol flavour, Outcome 1: Serious adverse events" data-id="CD010216-fig-0080" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Tobacco vs. menthol flavour, Outcome 1: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Tobacco vs. menthol flavour, Outcome 2: NNAL (ng/g)" data-id="CD010216-fig-0081" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Tobacco vs. menthol flavour, Outcome 2: NNAL (ng/g)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Tobacco vs. menthol flavour, Outcome 3: FEV1 (% predicted)" data-id="CD010216-fig-0082" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Tobacco vs. menthol flavour, Outcome 3: FEV1 (% predicted)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Tobacco vs. menthol flavour, Outcome 4: FEV1/FVC" data-id="CD010216-fig-0083" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Tobacco vs. menthol flavour, Outcome 4: FEV1/FVC</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Refillable versus cartridge, Outcome 1: Exhaled CO" data-id="CD010216-fig-0084" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Refillable versus cartridge, Outcome 1: Exhaled CO</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Nicotine salt EC versus free‐base nicotine EC, Outcome 1: Smoking cessation" data-id="CD010216-fig-0085" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Nicotine salt EC versus free‐base nicotine EC, Outcome 1: Smoking cessation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Nicotine salt EC versus free‐base nicotine EC, Outcome 2: Product use at 6+ months" data-id="CD010216-fig-0086" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Nicotine salt EC versus free‐base nicotine EC, Outcome 2: Product use at 6+ months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Non‐nicotine EC versus behavioural support only/no support, Outcome 1: Smoking cessation" data-id="CD010216-fig-0087" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Non‐nicotine EC versus behavioural support only/no support, Outcome 1: Smoking cessation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Non‐nicotine EC versus behavioural support only/no support, Outcome 2: Adverse events at 12 weeks" data-id="CD010216-fig-0088" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Non‐nicotine EC versus behavioural support only/no support, Outcome 2: Adverse events at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Non‐nicotine EC versus behavioural support only/no support, Outcome 3: Serious adverse events at 24 weeks" data-id="CD010216-fig-0089" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Non‐nicotine EC versus behavioural support only/no support, Outcome 3: Serious adverse events at 24 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Non‐nicotine EC + NRT versus NRT, Outcome 1: Smoking cessation" data-id="CD010216-fig-0090" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Non‐nicotine EC + NRT versus NRT, Outcome 1: Smoking cessation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Non‐nicotine EC + NRT versus NRT, Outcome 2: Adverse events" data-id="CD010216-fig-0091" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Non‐nicotine EC + NRT versus NRT, Outcome 2: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Non‐nicotine EC + NRT versus NRT, Outcome 3: Serious adverse events" data-id="CD010216-fig-0092" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Non‐nicotine EC + NRT versus NRT, Outcome 3: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Non‐nicotine EC versus NRT, Outcome 1: Smoking cessation" data-id="CD010216-fig-0093" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Non‐nicotine EC versus NRT, Outcome 1: Smoking cessation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Non‐nicotine EC versus NRT, Outcome 2: Adverse events" data-id="CD010216-fig-0094" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Non‐nicotine EC versus NRT, Outcome 2: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Non‐nicotine EC versus NRT, Outcome 3: Serious adverse events" data-id="CD010216-fig-0095" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Non‐nicotine EC versus NRT, Outcome 3: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-013.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Non‐nicotine EC versus NRT, Outcome 4: Change in carbon monoxide (ppm) at 6 months" data-id="CD010216-fig-0096" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-013.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-013.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: Non‐nicotine EC versus NRT, Outcome 4: Change in carbon monoxide (ppm) at 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-013.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Advice to use e‐cigarettes compared to no advice to use e‐cigarettes, Outcome 1: Smoking cessation" data-id="CD010216-fig-0097" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Advice to use e‐cigarettes compared to no advice to use e‐cigarettes, Outcome 1: Smoking cessation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Advice to use e‐cigarettes compared to no advice to use e‐cigarettes, Outcome 2: Adverse events at 3 months" data-id="CD010216-fig-0098" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: Advice to use e‐cigarettes compared to no advice to use e‐cigarettes, Outcome 2: Adverse events at 3 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Advice to use e‐cigarettes compared to no advice to use e‐cigarettes, Outcome 3: Serious adverse events at 3 months" data-id="CD010216-fig-0099" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: Advice to use e‐cigarettes compared to no advice to use e‐cigarettes, Outcome 3: Serious adverse events at 3 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-014.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Advice to use e‐cigarettes compared to no advice to use e‐cigarettes, Outcome 4: Product use at 6+ months" data-id="CD010216-fig-0100" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-014.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-014.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14: Advice to use e‐cigarettes compared to no advice to use e‐cigarettes, Outcome 4: Product use at 6+ months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-014.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 1: Smoking cessation" data-id="CD010216-fig-0101" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 1: Smoking cessation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 2: Adverse events" data-id="CD010216-fig-0102" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-015.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 3: Serious adverse events" data-id="CD010216-fig-0103" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-015.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 3: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-015.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 4: Carbon monoxide (ppm)" data-id="CD010216-fig-0104" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-015.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 4: Carbon monoxide (ppm) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-015.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 5: FeNO (ppb)" data-id="CD010216-fig-0105" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-015.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.5</div> <div class="figure-caption"> <p>Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 5: FeNO (ppb)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-015.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 6: FEV1 (%)" data-id="CD010216-fig-0106" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-015.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.6</div> <div class="figure-caption"> <p>Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 6: FEV1 (%)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-015.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 7: FVC (%)" data-id="CD010216-fig-0107" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-015.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.7</div> <div class="figure-caption"> <p>Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 7: FVC (%)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-015.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 8: Study product use at 6+ months" data-id="CD010216-fig-0108" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-015.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.8</div> <div class="figure-caption"> <p>Comparison 15: Nicotine EC + NRT versus non‐nicotine EC + NRT, Outcome 8: Study product use at 6+ months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-015.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Nicotine EC + NRT versus NRT, Outcome 1: Smoking cessation" data-id="CD010216-fig-0109" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: Nicotine EC + NRT versus NRT, Outcome 1: Smoking cessation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-016.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Nicotine EC + NRT versus NRT, Outcome 2: Adverse events" data-id="CD010216-fig-0110" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-016.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-016.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16: Nicotine EC + NRT versus NRT, Outcome 2: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-016.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-016.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Nicotine EC + NRT versus NRT, Outcome 3: Serious adverse events" data-id="CD010216-fig-0111" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-016.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-016.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16: Nicotine EC + NRT versus NRT, Outcome 3: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-016.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-017.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Nicotine EC + varenicline vs. varenicline, Outcome 1: Adverse events at 12 weeks" data-id="CD010216-fig-0112" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-017.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-017.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17: Nicotine EC + varenicline vs. varenicline, Outcome 1: Adverse events at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-017.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010216-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/urn:x-wiley:14651858:media:CD010216:CD010216-CMP-017.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Nicotine EC + varenicline vs. varenicline, Outcome 2: Serious adverse events at 12 weeks" data-id="CD010216-fig-0113" src="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-017.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_t/tCD010216-CMP-017.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17: Nicotine EC + varenicline vs. varenicline, Outcome 2: Serious adverse events at 12 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/media/CDSR/CD010216/image_n/nCD010216-CMP-017.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010216-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Nicotine EC compared to NRT for smoking cessation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Nicotine EC compared to NRT for smoking cessation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke cigarettes, aged 18 or older<br/><b>Setting:</b> various settings in New Zealand, UK, USA<br/><b>Intervention:</b> nicotine EC<br/><b>Comparison:</b> NRT </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events with NRT</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events with Nicotine EC</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Smoking cessation at 6 months to 1 year</p> <p>Assessed with biochemical validation</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.59<br/>(1.30 to 1.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2544<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 100<br/>(8 to 12) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events at 4 weeks to 6 to 9 months</p> <p>Assessed by self‐report</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/>(0.91 to 1.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2052<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 100<br/>(21 to 27) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events at 4 weeks to 1 year</p> <p>Assessed via self‐report and medical records</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.20<br/>(0.90 to 1.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2761<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2 studies reported no events; effect estimate based on the 4 studies in which events were reported </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100<br/>(4 to 6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The estimated number of events in the intervention group</b> (and its 95% confidence interval) is based on the assumed number of events in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). For cessation, the assumed number of events in the control group is based on assumed quit rates for NRT assuming receipt of limited behavioural stop‐smoking support (as per <a href="./references#CD010216-bbs2-0238" title="Hartmann-BoyceJ , ChepkinSC , YeW , BullenC , LancasterT . Nicotine replacement therapy versus control for smoking cessation. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD000146. [DOI: 10.1002/14651858.CD000146.pub5]">Hartmann‐Boyce 2018a</a>). The assumed risk for adverse events and serious adverse events is a weighted mean average of quit rates across control groups in contributing studies.<br/><br/><b>CI:</b> confidence interval; <b>EC</b> : electronic cigarette; <b>NRT</b> : nicotine replacement therapy; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to imprecision; CIs consistent with benefit and harm.<br/><sup>b</sup>Downgraded two levels due to imprecision; fewer than 300 events and CIs encompass clinically important harm and clinically important benefit. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Nicotine EC compared to NRT for smoking cessation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010216-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Nicotine EC compared to non‐nicotine EC for smoking cessation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Nicotine EC compared to non‐nicotine EC for smoking cessation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke cigarettes, aged 18 or older<br/><b>Setting:</b> various settings in Canada, Italy, New Zealand, UK, USA<br/><b>Intervention:</b> nicotine EC<br/><b>Comparison:</b> non‐nicotine EC </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events with non‐nicotine EC</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events with nicotine EC</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Smoking cessation at 6 to 12 months</p> <p>Assessed with biochemical validation</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.46<br/>(1.09 to 1.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1613<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 100<br/>(8 to 14) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events at 1 week to 6 months</p> <p>Assessed via self‐report</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.91 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>840<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100<br/>(8 to 10) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events at 1 week to 1 year</p> <p>Assessed via self‐report and medical records</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.00<br/>(0.56 to 1.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1412<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5 studies reported no events; effect estimate based on the 4 studies in which events were reported </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100<br/>(2 to 6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The estimated number of events in the intervention group</b> (and its 95% confidence interval) is based on the assumed number of events in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). For cessation, the assumed number of events in the control group is based on assumed quit rates for NRT assuming receipt of limited behavioural stop‐smoking support (as per <a href="./references#CD010216-bbs2-0238" title="Hartmann-BoyceJ , ChepkinSC , YeW , BullenC , LancasterT . Nicotine replacement therapy versus control for smoking cessation. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD000146. [DOI: 10.1002/14651858.CD000146.pub5]">Hartmann‐Boyce 2018a</a>). The assumed risk for adverse events and serious adverse events is a weighted mean average of quit rates across control groups in contributing studies.<br/><br/><b>CI:</b> confidence interval; <b>EC</b> : electronic cigarette; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for risk of bias. One of four studies considered high risk of bias; removing this study increased the direction of the effect in favour of the intervention.<br/><sup>b</sup>Downgraded one level due to imprecision; &lt; 300 events overall.<br/><sup>c</sup>Downgraded two levels due to imprecision: confidence intervals encompass clinically significant harm as well as clinically significant benefit; &lt; 300 events overall. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Nicotine EC compared to non‐nicotine EC for smoking cessation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010216-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Nicotine EC compared to behavioural support only/no support for smoking cessation</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Nicotine EC compared to behavioural support only/no support for smoking cessation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people who smoke cigarettes, aged 18 or older<br/><b>Setting:</b> various settings in Canada, Italy, Switzerland, UK, USA<br/><b>Intervention:</b> nicotine EC<br/><b>Comparison:</b> behavioural support only/no support </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events with behavioural support only/no support</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Events with nicotine EC</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Smoking cessation at 6 to 12 months</p> <p>Assessed using biochemical validation</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.96<br/>(1.66 to 2.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6819<br/>(11 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 100<br/>(7 to 9) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events at 12 weeks to 6 months</p> <p>Assessed via self‐report</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.18<br/>(1.10 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2351<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 100<br/>(54 to 62) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events at 4 weeks to 8 months</p> <p>Assessed via self‐report and medical records</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/>(0.68 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4561<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5 of the 12 studies reported no SAEs; MA is based on pooled results from 7 studies.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100<br/>(3 to 5) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The estimated number of events in the intervention group</b> (and its 95% confidence interval) is based on the assumed number of events in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). For cessation, the assumed number of events in the control group is based on assumed quit rates assuming receipt of limited behavioural stop‐smoking support (as per <a href="./references#CD010216-bbs2-0238" title="Hartmann-BoyceJ , ChepkinSC , YeW , BullenC , LancasterT . Nicotine replacement therapy versus control for smoking cessation. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD000146. [DOI: 10.1002/14651858.CD000146.pub5]">Hartmann‐Boyce 2018a</a>). The assumed risk for adverse events and serious adverse events is a weighted mean average of quit rates across control groups in contributing studies.<br/><br/><b>CI:</b> confidence interval; <b>EC</b> : electronic cigarette; <b>MA:</b> meta‐analysis; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels due to risk of bias. Due to lack of blinding and differential support between arms, judged to be at high risk of bias.<br/><sup>b</sup>Downgraded two levels due to imprecision. Confidence intervals incorporate clinically significant benefit and clinically significant harm; &lt; 300 events overall. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Nicotine EC compared to behavioural support only/no support for smoking cessation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010216-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis for all studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Analysis number</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sensitivity analysis removing studies at high risk of bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sensitivity analysis removing industry‐funded studies</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.1‐1.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1‐2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1‐3.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.61 (1.15, 2.26) I<sup>2</sup> = 9% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.34 (0.98, 1.82) I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.01 (0.91, 1.11) I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.00 (0.56, 1.79) I<sup>2</sup> = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.95 (0.52, 1.72) I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5‐4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐0.03 (‐0.46, 0.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.83 (1.53, 2.18), I<sup>2</sup> = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 4.73 (0.56, 39.88) I<sup>2</sup> not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.29 (1.15, 1.45) I<sup>2</sup> not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.19 (1.05, 1.30) I<sup>2</sup> = 8% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.90 (0.65, 4.70) I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 1.11 (‐3.95, 6.18) I<sup>2</sup> = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ST MD ‐0.30 (‐0.74, 0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ST MD ‐0.30 (‐0.74, 0.13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ST MD 0.00 (‐0.44, 0.44)/N/A no overall value</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.10‐5.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐0.14 (‐0.28, 0.00) I<sup>2</sup> not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.18‐5.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A the 1 study that is industry‐funded does not contribute to the RR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐0.90 (‐1.70, ‐0.10) I<sup>2</sup> = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐1.15 (‐2.05, ‐0.24) I<sup>2</sup> = 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.5‐6.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.11‐6.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.1‐7.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.1‐8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.1‐10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.86 (0.30, 27.10) I<sup>2</sup> not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.33, 4.33) No change as the study at high risk of bias was not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.1‐12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.1‐13.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.04 (0.89, 1.22) I<sup>2</sup> not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.2‐14.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.25 (0.78, 1.99) I<sup>2</sup> not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.09 (0.90, 1.31) I<sup>2</sup> not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.59 (0.11, 3.34) I<sup>2</sup> not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67 (0.37, 1.19) I<sup>2</sup> not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐9.10 (‐15.83, ‐2.37) I<sup>2</sup> not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD ‐1.40 (‐4.26, 1.46) I<sup>2</sup> not estimable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.5‐15.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.85 (1.91, 7.74) I<sup>2</sup> not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.2‐16.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.1‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A 1</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>N/A 1 = no studies at high risk of bias/no industry‐funded studies</p> <p>N/A 2 = all studies at high risk of bias/industry‐funded</p> <p>N/A 3 = results not pooled</p> <p>MD: mean difference; RR: risk ratio; ST MD: standardized mean difference</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Sensitivity analysis for all studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010216-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of proportion of participants abstinent from smoking at 6+ months follow‐up: cohort studies of nicotine EC</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Motivated or unmotivated to quit smoking?</b> </p> </th> <th align="" class="headercell" colspan="5" rowspan="1" scope="col" valign="bottom"> <p><b>% abstinent</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Cohort studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>6‐month</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>12‐month</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>18‐month</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>24‐month</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Notes</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0001" title="AdriaensK , Van GuchtD , DeclerckP , BaeyensF . Effectiveness of the electronic cigarette: an eight-week Flemish study with six-month follow-up on smoking reduction, craving and experienced benefits and complaints. International Journal of Environmental Research and Public Health2014;11(11):11220-48. "><b>Adriaens 2014</b> </a><b><sup>a</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unmotivated to quit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.6% (10/51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data from 8‐month follow‐up</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0018" title="ACTRN12616001641482. Tobacco harm reduction with vaporised nicotine (THRiVe): feasibility study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12616001641482 (first received 28 November 2016). BellS , DeanJ , GilksC , BoydMA , FitzgeraldL , MutchA , et al. Tobacco harm reduction with vaporised nicotine (THRiVe): the study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with HIV who smoke. International Journal of Environmental Research and Public Health2017;14(7):799. EdwardsS , PuljevicC , DeanJA , GilksC , BoydMA , BakerP , et al. Tobacco harm reduction with vaporised nicotine (THRiVe): a feasibility trial of nicotine vaping products for smoking cessation among people living with HIV. AIDS and Behavior2023;27(2):618-27. [DOI: 10.1007/s10461-022-03797-0]"><b>Edwards 2023</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Willing to attempt to quit"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.6% (8/30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010216-bbs2-0008" title="CaponnettoP , AuditoreR , RussoC , CappelloGC , PolosaR . Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. International Journal of Environmental Research and Public Health2013;10(2):446-61. MinutoloG , CaponnettoP , AuditoreR , RussoC , PolosaR . Management of smoking reduction and cessation in inpatients with schizophrenia: impact of electronic cigarettes. European Neuropsychopharmacology2013;23:S581-2. "><b>Caponnetto 2013b*</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unmotivated to quit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14% (2/14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0009" title="CaponnettoP , DiPiazzaJ , KimJ , MagliaM , PolosaR . A single-arm, open-label pilot, and feasibility study of a high nicotine strength e-cigarette intervention for smoking cessation or reduction for people with schizophrenia spectrum disorders who smoke cigarettes. Nicotine &amp; Tobacco Research2021;23(7):1113-22. [DOI: 10.1093/ntr/ntab005]"><b>Caponnetto 2021*</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unmotivated to quit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35% (14/40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0022" title="ElyJ . Evaluation of the use of electric cigarettes in a rural smoking cessation program. Available online at: digscholarship.unco.edu/cgi/viewcontent.cgi?article=1001&amp;context=capstones 2013 (accessed 1 November 2014). "><b>Ely 2013</b> </a><b><sup>b</sup> </b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Motivated to quit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44% (21/48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0062" title="PacificiR , PichiniS , GrazianoS , PellegriniM , MassaroG , BeatriceF . Successful nicotine intake in medical assisted use of e-cigarettes: a pilot study. International Journal of Environmental Research and Public Health2015;12(7):7638-46. "><b>Pacifici 2015</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unmotivated to quit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53% (18/34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD010216-bbs2-0063" title="NCT01195597. Smoking cessation and reduction with an electronic nicotine delivery device (ENDD). clinicaltrials.gov/ct2/show/NCT01195597 (first received 6 September 2010). PolosaR , CaponnettoP , MorjariaJB , PapaleG , CampagnaD , RussoC . Effect of an electronic nicotine delivery device (e-cigarette) on smoking reduction and cessation: a prospective 6-month pilot study. BMC Public Health2011;11:786. PolosaR , MorjariaJB , CaponnettoP , CampagnaD , RussoC , AlamoA , et al. Effectiveness and tolerability of electronic cigarette in real-life: a 24-month prospective observational study. Internal and Emergency Medicine2014;9(5):537-46. "><b>Polosa 2011*</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unmotivated to quit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23% (9/40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15% (6/40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13% (5/40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0064" title="NCT02124200. High cessation rates in smokers using personal vaporizers (VAPECIG). clinicaltrials.gov/ct2/show/NCT02124200 (first received 28 April 2014). PolosaR , CaponnettoP , MagliaM , MorjariaJB , RussoC . Success rates with nicotine personal vaporizers: a prospective 6-month pilot study of smokers not intending to quit. BMC Public Health2014;14:1159. "><b>Polosa 2014b*</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unmotivated to quit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36% (18/50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0065" title="PolosaR , CaponnettoP , CibellaF , Le-HouezecJ . Quit and smoking reduction rates in vape shop consumers: a prospective 12-month survey. International Journal of Environmental Research and Public Health2015;12(4):3428-38. "><b>Polosa 2015*</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42% (30/71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41% (29/71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD010216-bbs2-0069" title="PriceAD , CoffeyM , HoustonL , CookPA . Evaluation of a pharmacy supported e-cigarette smoking cessation intervention in Northwest England. BMC Public Health2022;22:1326. [DOI: 10.1186/s12889-022-13711-x]"><b>Price 2022</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5% (42/871)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Technically an RCT but observational for purposes of EC analysis.<br/><sup>b</sup>All participants (N = 48) used an EC, but 16 also used bupropion and 2 used varenicline. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of proportion of participants abstinent from smoking at 6+ months follow‐up: cohort studies of nicotine EC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/full#CD010216-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Nicotine EC versus NRT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Smoking cessation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.30, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Not selected on pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.29, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Pregnant population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.45, 6.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.91, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.31, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.87, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.82, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 3 months after end of pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.84, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2761</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.90, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.86, 3.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.81, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.77, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.5 3 months after end of pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.52, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Carbon monoxide (ppm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.81 [‐3.64, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.87 [‐5.15, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.79 [‐3.98, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Heart rate (bpm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [‐1.76, 2.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.74 [‐5.17, 3.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐1.69, 3.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.62 [‐3.59, 0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐4.54, 6.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.00 [‐4.11, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Blood oxygen saturation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.59, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.72, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.83, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 3‐HPMA (pmol/mg creatinine) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 NNAL (pmol/mg creatinine)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 2‐HPMA (pmol/mg creatinine) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 HMPMA (pmol/mg creatinine) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 PheT (pmol/mg creatinine) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 CEMA (pmol/mg creatinine) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 AAMA (pmol/mg creatinine) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 FEV1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 FEV1/FVC (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐1.83, 1.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐1.83, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 PEF (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Product use at 6+ months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Nicotine EC versus NRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Nicotine EC versus varenicline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Smoking cessation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Nicotine EC versus varenicline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Nicotine EC versus heated tobacco</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Adverse events at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 SAEs at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Carbon monoxide (ppm) absolute values at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 VO<sub>2</sub> Max at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Nicotine EC versus heated tobacco</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Nicotine EC versus non‐nicotine EC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Smoking cessation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.09, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.91, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.27, 8.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.38, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.4 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.71, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.56, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 1 week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [0.16, 78.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.4 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.52, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.5 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Carbon monoxide (ppm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Heart rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 FeNO (ppb) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 FEV1 (l) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 FEV1/FVC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 NNAL (pmol/mg creatinine) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.45, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.27 [‐4.98, 35.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.2 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.46, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 Product use at 6+ months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.94, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Nicotine EC versus non‐nicotine EC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Nicotine EC versus behavioural support only/no support</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Smoking cessation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.66, 2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.10, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.11, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.67, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [1.05, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4561</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.68, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 4 to 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.06, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.69 [0.21, 66.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.5 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2875</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.62, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.6 8 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.68, 4.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Carbon monoxide (ppm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Heart rate (bpm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.30 [‐3.91, ‐0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.68 [‐4.38, ‐0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.2 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [‐3.95, 6.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Blood oxygen saturation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 3‐HPMA (SMD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.2 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 NNAL (SMD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.2 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 2‐HPMA (pmol/mg creatinine) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.11 HMPMA (pmol/mg creatinine) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.12 PheT (pmol/mg creatinine) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.12.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.13 CEMA (pmol/mg creatinine) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.13.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.14 AAMA (pmol/mg creatinine) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.14.1 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.15 S‐PMA (nanograms) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.15.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.16 FEV1 (SMD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.01, 0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.16.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.01, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.17 FEF 25‐75 (litres/second)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.18, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.17.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.18, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.18 PEF 25‐75 (litres/minute) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.18.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.19 FEV1/FVC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.19.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Nicotine EC versus behavioural support only/no support</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Higher versus lower nicotine content</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Smoking cessation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Adverse events at 1 week <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Carbon monoxide (ppm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.92 [‐1.71, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.70, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.2 Absolute values at follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.66 [‐6.65, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Heart rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Systolic blood pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 FeNO (ppb) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 FEV1 (l) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.9 FVC (l) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.10 FEV1/FVC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.10.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.11 NNAL (pg/mg creatinine) at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.12 Product use at 6+ months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Higher versus lower nicotine content</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Choice of flavours vs. tobacco flavour only</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Smoking cessation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.54, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Product use at 6+ months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.86, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Choice of flavours vs. tobacco flavour only</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Tobacco vs. menthol flavour</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 NNAL (ng/g) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 FEV1 (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 FEV1/FVC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.1 Change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Tobacco vs. menthol flavour</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Refillable versus cartridge</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Exhaled CO <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Refillable versus cartridge</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Nicotine salt EC versus free‐base nicotine EC</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Smoking cessation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Product use at 6+ months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Nicotine salt EC versus free‐base nicotine EC</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Non‐nicotine EC versus behavioural support only/no support</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Smoking cessation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.81, 3.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Adverse events at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Serious adverse events at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Non‐nicotine EC versus behavioural support only/no support</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Non‐nicotine EC + NRT versus NRT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Smoking cessation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Non‐nicotine EC + NRT versus NRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Non‐nicotine EC versus NRT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Smoking cessation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.64, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Change in carbon monoxide (ppm) at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Non‐nicotine EC versus NRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Advice to use e‐cigarettes compared to no advice to use e‐cigarettes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Smoking cessation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.88, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Adverse events at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Serious adverse events at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.4 Product use at 6+ months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Advice to use e‐cigarettes compared to no advice to use e‐cigarettes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Nicotine EC + NRT versus non‐nicotine EC + NRT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Smoking cessation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.07, 2.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.93, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.1 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.78, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.2 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.90, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1069</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.38, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.1 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.11, 3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.2 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.37, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.4 Carbon monoxide (ppm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.58 [‐5.21, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4.1 change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.58 [‐5.21, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.5 FeNO (ppb) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.6 FEV1 (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.7 FVC (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.7.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.8 Study product use at 6+ months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Nicotine EC + NRT versus non‐nicotine EC + NRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Nicotine EC + NRT versus NRT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 Smoking cessation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>980</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.53 [1.93, 6.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.83, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.69, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.2 7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.82, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.46, 3.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.1 5 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.2 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.13, 70.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.3 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.39, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.4 7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Nicotine EC + NRT versus NRT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010216-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Nicotine EC + varenicline vs. varenicline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.1 Adverse events at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.2 Serious adverse events at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Nicotine EC + varenicline vs. varenicline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010216.pub9/references#CD010216-tbl-0022">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010216.pub9&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010216-note-0010">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010216-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fr#CD010216-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010216-note-0011">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010216\x2epub9"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010216\x2epub9"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010216\x2epub9"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010216\x2epub9\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010216\x2epub9"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010216.pub9&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010216.pub9';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010216.pub9/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010216.pub9/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010216.pub9%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716000377"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010216.pub9/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716000381"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010216.pub9/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d94ce697b9368',t:'MTc0MDcxNjAwMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 